{"AllianceGenome": "6407", "HGNC": "6407", "MIM": "190070", "_id": "3845", "_version": 4, "accession": {"genomic": ["AC087239.18", "AC092794.10", "AF285779.1", "AH001529.2", "AH005283.2", "CH471094.1", "CP068266.2", "EF471933.1", "EF471950.1", "EF471954.1", "EF471956.1", "EF685661.1", "EF685662.1", "EU332849.1", "HC464412.1", "HC464568.1", "HD032929.1", "HM459605.1", "JC006857.1", "JQ248012.1", "JX512447.1", "KF459678.1", "KX302153.1", "KY752515.1", "KY828926.1", "LC090171.1", "LC090172.1", "LC090174.1", "LC090175.1", "LC090177.1", "LC090179.1", "LC090180.1", "LC090181.1", "LC090182.1", "LC090184.1", "LC090187.1", "LC090191.1", "LC090192.1", "LC090193.1", "LC090194.1", "M26261.1", "M34904.1", "MF083614.1", "MN503305.1", "MZ230613.1", "MZ230614.1", "MZ230615.1", "NC_000012.12", "NC_060936.1", "NG_007524.2", "S64261.1", "X01669.1", "X02825.1"], "protein": ["AAA35689.1", "AAA35690.1", "AAA36148.1", "AAA36149.1", "AAA36554.1", "AAA36555.1", "AAB41942.1", "AAB59444.1", "AAB59445.1", "AAD13953.1", "AAF91482.1", "AAH13572.1", "AAM12631.1", "AAP35817.1", "ABP96992.1", "ABP97009.1", "ABP97013.1", "ABP97015.1", "ABS10683.1", "ABS10684.1", "ABY87538.1", "ADQ00188.1", "AFF18187.1", "AGC09594.1", "ASO66780.1", "ASO66781.1", "ASO66782.1", "BAF85199.1", "CAA25828.1", "CAA26593.1", "CBK51852.1", "CBK51925.1", "CBV35640.1", "CDL93479.1", "EAW96511.1", "EAW96512.1", "EAW96513.1", "EAW96514.1", "NP_001356715.1", "NP_001356716.1", "NP_004976.2", "NP_203524.1", "P01116.1", "QDA95515.1", "QDA95516.1", "QDA95517.1", "QFQ66249.1", "UBF41787.1", "UBF41788.1", "UBF41789.1", "UJY53486.1", "UJY53487.1", "UJY53488.1", "UJY53489.1", "UJY53490.1", "UJY53491.1", "UJY53492.1", "UJY53493.1", "UJY53494.1", "UJY53495.1", "UJY53496.1", "UJY53497.1", "UJY53498.1", "UJY53499.1", "WPW61478.1", "XP_047284782.1", "XP_054227990.1"], "rna": ["AA812162.1", "AF493917.1", "AI539465.1", "AK292510.1", "AW117295.1", "BC010502.1", "BC013572.2", "BC029545.1", "BG258021.1", "BT007153.1", "CD245555.1", "M17087.1", "M35504.1", "M35505.1", "M54968.1", "MK570060.1", "MK570061.1", "MK570062.1", "MK570063.1", "MK570064.1", "MK570065.1", "MK570066.1", "MK570067.1", "MK570068.1", "MZ068300.1", "MZ068301.1", "MZ068302.1", "MZ068303.1", "MZ068304.1", "MZ068305.1", "MZ068306.1", "MZ068307.1", "MZ068308.1", "MZ068309.1", "MZ068310.1", "MZ068311.1", "MZ068312.1", "MZ068313.1", "MZ068314.1", "MZ068315.1", "NM_001369786.1", "NM_001369787.1", "NM_004985.5", "NM_033360.4", "OR946359.1", "XM_047428826.1", "XM_054372015.1"], "translation": [{"protein": "QDA95517.1", "rna": "MK570064.1"}, {"protein": "NP_004976.2", "rna": "NM_004985.5"}, {"protein": "XP_054227990.1", "rna": "XM_054372015.1"}, {"protein": "NP_203524.1", "rna": "NM_033360.4"}, {"protein": "UJY53493.1", "rna": "MZ068307.1"}, {"protein": "UJY53488.1", "rna": "MZ068302.1"}, {"protein": "UJY53494.1", "rna": "MZ068308.1"}, {"protein": "UJY53499.1", "rna": "MZ068313.1"}, {"protein": "UJY53495.1", "rna": "MZ068309.1"}, {"protein": "UJY53491.1", "rna": "MZ068305.1"}, {"protein": "QDA95515.1", "rna": "MK570060.1"}, {"protein": "UJY53489.1", "rna": "MZ068303.1"}, {"protein": "XP_047284782.1", "rna": "XM_047428826.1"}, {"protein": "AAA35689.1", "rna": "M35504.1"}, {"protein": "UJY53492.1", "rna": "MZ068306.1"}, {"protein": "WPW61478.1", "rna": "OR946359.1"}, {"protein": "UJY53490.1", "rna": "MZ068304.1"}, {"protein": "BAF85199.1", "rna": "AK292510.1"}, {"protein": "UJY53497.1", "rna": "MZ068311.1"}, {"protein": "AAH13572.1", "rna": "BC013572.2"}, {"protein": "AAM12631.1", "rna": "AF493917.1"}, {"protein": "NP_001356716.1", "rna": "NM_001369787.1"}, {"protein": "AAA35690.1", "rna": "M35505.1"}, {"protein": "AAA36555.1", "rna": "M17087.1"}, {"protein": "NP_001356715.1", "rna": "NM_001369786.1"}, {"protein": "UJY53498.1", "rna": "MZ068312.1"}, {"protein": "QDA95516.1", "rna": "MK570063.1"}, {"protein": "AAB41942.1", "rna": "M54968.1"}, {"protein": "UJY53487.1", "rna": "MZ068301.1"}, {"protein": "AAP35817.1", "rna": "BT007153.1"}, {"protein": "UJY53496.1", "rna": "MZ068310.1"}, {"protein": "UJY53486.1", "rna": "MZ068300.1"}]}, "alias": ["'C-K-RAS", "C-K-RAS", "CFC2", "K-RAS2A", "K-RAS2B", "K-RAS4A", "K-RAS4B", "K-Ras", "K-Ras 2", "KI-RAS", "KRAS1", "KRAS2", "NS", "NS3", "OES", "RALD", "RASK2", "c-Ki-ras", "c-Ki-ras2"], "clingen": {"_license": "https://www.clinicalgenome.org/docs/terms-of-use/", "clinical_validity": [{"classification": "disputed", "classification_date": "2018-07-24T16:00:00.000Z", "disease_label": "Costello syndrome", "gcep": "RASopathy Gene Curation Expert Panel", "moi": "AD", "mondo": "MONDO:0009026", "online_report": "https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_bc9a82d0-8447-454c-8d54-def792d20e1d-2018-07-24T160000.000Z", "sop": "SOP5"}, {"classification": "strong", "classification_date": "2018-07-24T16:00:00.000Z", "disease_label": "cardiofaciocutaneous syndrome", "gcep": "RASopathy Gene Curation Expert Panel", "moi": "AD", "mondo": "MONDO:0015280", "online_report": "https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_248e0d6b-9300-4d17-a350-f742fa92c82c-2018-07-24T160000.000Z", "sop": "SOP5"}, {"classification": "definitive", "classification_date": "2018-07-24T16:00:00.000Z", "disease_label": "Noonan syndrome", "gcep": "RASopathy Gene Curation Expert Panel", "moi": "AD", "mondo": "MONDO:0018997", "online_report": "https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_6476a5fd-8f66-462b-b17a-43540dad3c1f-2018-07-24T160000.000Z", "sop": "SOP5"}]}, "ec": "3.6.5.2", "ensembl": {"gene": "ENSG00000133703", "protein": ["ENSP00000256078", "ENSP00000308495", "ENSP00000451856", "ENSP00000452512", "ENSP00000508568", "ENSP00000508921", "ENSP00000509223", "ENSP00000509238", "ENSP00000509798", "ENSP00000510254", "ENSP00000510431", "ENSP00000510479", "ENSP00000510511"], "transcript": ["ENST00000256078", "ENST00000311936", "ENST00000556131", "ENST00000557334", "ENST00000685328", "ENST00000686877", "ENST00000686969", "ENST00000687356", "ENST00000688228", "ENST00000688940", "ENST00000690406", "ENST00000690804", "ENST00000692768", "ENST00000693229"], "translation": [{"protein": "ENSP00000509798", "rna": "ENST00000690406"}, {"protein": "ENSP00000256078", "rna": "ENST00000256078"}, {"protein": "ENSP00000308495", "rna": "ENST00000311936"}, {"protein": "ENSP00000510431", "rna": "ENST00000686877"}, {"protein": "ENSP00000508921", "rna": "ENST00000685328"}, {"protein": "ENSP00000509223", "rna": "ENST00000693229"}, {"protein": "ENSP00000510511", "rna": "ENST00000687356"}, {"protein": "ENSP00000510254", "rna": "ENST00000692768"}, {"protein": "ENSP00000509238", "rna": "ENST00000688940"}, {"protein": "ENSP00000508568", "rna": "ENST00000690804"}, {"protein": "ENSP00000452512", "rna": "ENST00000557334"}, {"protein": "ENSP00000510479", "rna": "ENST00000686969"}, {"protein": "ENSP00000451856", "rna": "ENST00000556131"}], "type_of_gene": "protein_coding"}, "entrezgene": "3845", "exac": {"_license": "http://bit.ly/2H9c4hg", "all": {"exp_lof": 6.35962525468, "exp_mis": 49.5116387428, "exp_syn": 20.6726924996, "lof_z": 0.534063822599928, "mis_z": 1.35630257198828, "mu_lof": 4.35870949242e-07, "mu_mis": 4.49157304904e-06, "mu_syn": 1.8132911624e-06, "n_lof": 5.0, "n_mis": 30.0, "n_syn": 17.0, "p_li": 0.00106119304255182, "p_null": 0.395790550839053, "p_rec": 0.603148256118395, "syn_z": 0.500766452320494}, "bp": 570, "cds_end": 25398318, "cds_start": 25368374, "n_exons": 4, "nonpsych": {"exp_lof": 5.67821205546, "exp_mis": 44.7349496472, "exp_syn": 18.6329193881, "lof_z": 0.279519212746055, "mis_z": 1.33742104669444, "mu_lof": 4.35870949242e-07, "mu_mis": 4.49157304904e-06, "mu_syn": 1.8132911624e-06, "n_lof": 5.0, "n_mis": 27.0, "n_syn": 17.0, "p_li": 0.000800455744248145, "p_null": 0.486672476932022, "p_rec": 0.51252706732373, "syn_z": 0.238170527160918}, "nontcga": {"exp_lof": 5.84326588382, "exp_mis": 45.5431213526, "exp_syn": 19.0112885823, "lof_z": 0.75221397111016, "mis_z": 1.29510591732072, "mu_lof": 4.35870949242e-07, "mu_mis": 4.49157304904e-06, "mu_syn": 1.8132911624e-06, "n_lof": 4.0, "n_mis": 28.0, "n_syn": 16.0, "p_li": 0.00567377477963463, "p_null": 0.27242033515203, "p_rec": 0.721905890068335, "syn_z": 0.437289556277205}, "transcript": "ENST00000256078.4"}, "exons": [{"cdsend": 25245384, "cdsstart": 25215440, "chr": "12", "position": [[25205245, 25209911], [25215436, 25215560], [25225613, 25225773], [25227233, 25227412], [25245273, 25245395], [25250763, 25250929]], "strand": -1, "transcript": "NM_001369786", "txend": 25250929, "txstart": 25205245}, {"cdsend": 25245384, "cdsstart": 25209794, "chr": "12", "position": [[25205245, 25209911], [25225613, 25225773], [25227233, 25227412], [25245273, 25245395], [25250763, 25250929]], "strand": -1, "transcript": "NM_001369787", "txend": 25250929, "txstart": 25205245}, {"cdsend": 25245384, "cdsstart": 25209794, "chr": "12", "position": [[25205245, 25209911], [25225613, 25225773], [25227233, 25227412], [25245273, 25245395], [25250750, 25250929]], "strand": -1, "transcript": "NM_004985", "txend": 25250929, "txstart": 25205245}, {"cdsend": 25245384, "cdsstart": 25215440, "chr": "12", "position": [[25205245, 25209911], [25215436, 25215560], [25225613, 25225773], [25227233, 25227412], [25245273, 25245395], [25250750, 25250929]], "strand": -1, "transcript": "NM_033360", "txend": 25250929, "txstart": 25205245}], "exons_hg19": [{"cdsend": 25398318, "cdsstart": 25368374, "chr": "12", "position": [[25358179, 25362845], [25368370, 25368494], [25378547, 25378707], [25380167, 25380346], [25398207, 25398329], [25403697, 25403863]], "strand": -1, "transcript": "NM_001369786", "txend": 25403863, "txstart": 25358179}, {"cdsend": 25398318, "cdsstart": 25362728, "chr": "12", "position": [[25358179, 25362845], [25378547, 25378707], [25380167, 25380346], [25398207, 25398329], [25403697, 25403863]], "strand": -1, "transcript": "NM_001369787", "txend": 25403863, "txstart": 25358179}, {"cdsend": 25398318, "cdsstart": 25362728, "chr": "12", "position": [[25358179, 25362845], [25378547, 25378707], [25380167, 25380346], [25398207, 25398329], [25403684, 25403863]], "strand": -1, "transcript": "NM_004985", "txend": 25403863, "txstart": 25358179}, {"cdsend": 25398318, "cdsstart": 25368374, "chr": "12", "position": [[25358179, 25362845], [25368370, 25368494], [25378547, 25378707], [25380167, 25380346], [25398207, 25398329], [25403684, 25403863]], "strand": -1, "transcript": "NM_033360", "txend": 25403863, "txstart": 25358179}], "generif": [{"pubmed": 10398103, "text": "It is proposed that lowering the affinity for GTP allows G12D Ras an escape from the oncogenic GTP-bound state, whereas GTP tightly bound to G12V mutant Ras generates a more persistent, potentially oncogenic, signal."}, {"pubmed": 11016621, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 11524732, "text": "Mutations were detected by using allele-specific amplification method."}, {"pubmed": 11668624, "text": "oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC"}, {"pubmed": 11745690, "text": "valine-12 Ki-Ras mutants demonstrated a greater ability to invade Matrigel than cells expressing the aspartate-12 mutant or wild-type Ki-Ras proteins."}, {"pubmed": 11746970, "text": "KRAS2 mutations have been detected in laser-capture microdissected atypical endometrial hyperplasia specimens arising concurrently with endometrial carcinoma."}, {"pubmed": 11822784, "text": "Ras modulates the proliferative response of RSF to TNF-alpha and TGF-alpha"}, {"pubmed": 11836595, "text": "mutations in K-ras have been detected in primary carcinoma of small intestine"}, {"pubmed": 12006650, "text": "Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis"}, {"pubmed": 12032847, "text": "K-ras mutations and RASSF1A promoter methylation in colorectal cancer"}, {"pubmed": 12082617, "text": "Multiple K-RAS mutations are frequent both in PC with associated PanIN and in biliary cancers, and indicate that clonally distinct precursor lesions of PC might variably contribute to tumor development."}, {"pubmed": 12085227, "text": "Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells"}, {"pubmed": 12093899, "text": "Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. The most common combination of mutations was p53 and APC (27.1%), whereas mutations in both p53 and K-ras were extremely rare."}, {"pubmed": 12135058, "text": "Uncommon mutation types of K-ras may contribute to long term patient survival in pancreatic adenocarcinoma."}, {"pubmed": 12211074, "text": "study performed to determine the status of K-ras-2 in liver angiosarcomas (LAS) from workers occupationally exposed to vinyl chloride"}, {"pubmed": 12372883, "text": "Immunohistochemical staining of p21 appears to be of prognostic value in patients receiving systemic adjuvant chemotherapy for locally advanced bladder cancer."}, {"pubmed": 12452332, "text": "the constitutive activation of Ras might have induced the persistent expression of p21cip1 and p27kip1, and that this induction of p21cip1 and p27kip1 expression possibly caused the cell cycle arrest at the G1 phase."}, {"pubmed": 12557259, "text": "Review: Exploring environmental causes of altered ras effects: fragmentation plus integration?"}, {"pubmed": 12592366, "text": "Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers."}, {"pubmed": 12606501, "text": "acute hyperglycemia-mediated mononuclear cell activation is dependent on activation of ras, p42/p44 mitogen-activated protein kinase phosphorylation, and subsequent NF-kappaB activation"}, {"pubmed": 12606951, "text": "LOH of chromosome 12p was seen in about 50% of human lung adenocarcinomas & large cell carcinomas. Kras2 mutations were seen at codon 12 in about 40% of adenocarcinomas & large cell carcinomas. The wild-type Kras2 is a tumor suppressor of lung cancer."}, {"pubmed": 12644542, "text": "results demonstrate that the mutational status of BRAF and KRAS is distinctly different among histologic types of ovarian serous carcinoma, occurring most frequently in invasive micropapillary serous carcinomas and its precursors, serous borderline tumors"}, {"pubmed": 12651912, "text": "Ki-ras mutations and HGF signaling cooperate to enhance tumor growth by increased duration of MAPK activation and decreased apoptosis in human carcinoma cells."}, {"pubmed": 12720172, "text": "results suggest that carcinogenesis in the biliary tract epithelium in anomalous pancreaticobiliary ductal union (APBDU) is accompanied by multistep genetic mutational events; K-ras gene mutation occurs early in epithelial hyperplasia or metaplasia"}, {"pubmed": 12727204, "text": "The results suggest a potential role for Ca2+/calmodulin in the regulation of K-RasB function."}, {"pubmed": 12766905, "text": "No somatic mutations were identified in either TP53 or KRAS, indicating that disregulation of these genes is not required for leiomyomas development"}, {"pubmed": 12824925, "text": "types of mutations in sinonasal NK/T cell lymphoma in northeast district of China"}, {"pubmed": 12826308, "text": "codon 12 K-ras mutations in lung tumors or sputum samples from 102 lung cancer patients"}, {"pubmed": 12871370, "text": "p21Ras activation is instrumental in FVIIa signal transduction and the FVIIa-dependent activation of p21Ras involves either PKC or Src-dependent mechanisms, depending on the cell type investigated."}, {"pubmed": 12882980, "text": "K-Ras4B polybasic domain or an alternatively prenylated CAAX renders Ras prenylation, Ras-induced Elk-1 activation, and anchorage-independent cell growth farnesyltransferase inhibitor-resistant."}, {"pubmed": 12908779, "text": "Point mutations in Ki-ras gene is associated with colorectal cancers in mexican patients"}, {"pubmed": 12972432, "text": "signaling initiated by activated Ki-ras interferes with the IFN/STAT signaling pathway and modulates the responsiveness of cancer cells to interferons"}, {"pubmed": 14508142, "text": "K-ras mutations may have an effect on proliferation in pancreatic ductal adenocarcinoma"}, {"pubmed": 14511407, "text": "there is an inverse relationship between Kras2 activation and RASSF1A promoter methylation in the majority of human lung adenocarcinomas and large cell carcinomas"}, {"pubmed": 14513361, "text": "BRAF mutations, which are present in a variety of other human cancers, do not seem to be involved in gastric cancer development"}, {"pubmed": 14520703, "text": "Observational study of gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 14534542, "text": "KRAS2 mutations were seen in stomach neoplasms."}, {"pubmed": 14601056, "text": "findings indicate the wild-type KRAS allele is occasionally lost in lung cancer and the oncogenic activation of mutant KRAS is more frequently associated with overexpression of the mutant allele than with loss of the wild-type allele in NSCLC development"}, {"pubmed": 14612290, "text": "The positive expression rates of p21 and p53 proteins were 75.0% and 57.3% respectively in pancreatic carcinoma, which were significantly different from those in the normal tissue (P<0.05). p21 and p53 proteins were positively correlated (P<0.05)."}, {"pubmed": 14654903, "text": "Oncogene Protein p21(ras) accumulation was confined to the upper layer of esophageal squamous cell carcinoma."}, {"pubmed": 14688017, "text": "Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 14724583, "text": "RAS or BRAF mutations are detected in about 32% of all Barrett's adenocarcinomas; the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma"}, {"pubmed": 14761400, "text": "Detection of P21 may be used as the screening marker for diagnosis of polycyclic aromatic hydrocarbons (PAHs)-related lung cancer related lung cancer, and may supplement the diagnostic value of conventional cytology."}, {"pubmed": 14961576, "text": "Mutations in K-ras gene is associated with malignant melanomas"}, {"pubmed": 14966563, "text": "These studies identify isoprenylcysteine carboxyl methyltransferase as a potential target for reducing the growth of K-Ras- and B-Raf-induced malignancies."}, {"pubmed": 14989985, "text": "Mutant-type [(12)Asp]K-ras4B can enhance the expression of estrogen receptor alpha and beta proteins and their transcriptional activity as a transcription factor in endometrial carcinoma HEC-1A cell line."}, {"pubmed": 15010862, "text": "p21Ras, hSOS1, and p120GAP are not involved in polycystic ovary disease"}, {"pubmed": 15037631, "text": "k-ras has a role in cell death through the p38 MAP kinase pathway in human colonic cancer cells"}, {"pubmed": 15040037, "text": "K-ras mutation may play a role in the malignant transformation of pancreatic ductal cell."}, {"pubmed": 15077125, "text": "ovarian serous cystadenomas do not contain mutations in either BRAF or KRAS genes"}, {"pubmed": 15112277, "text": "K-ras mutations are frequently found in surgical margins in non-small-cell lung carcinoma patients."}, {"pubmed": 15112354, "text": "Results suggest that changes in telomerase activity and K-ras point mutation at codon 12 may be an early event of malignant progression in pancreatic cancer."}, {"pubmed": 15213223, "text": "k-Ras has a role in promoting butyrate-induced apoptosis by inhibiting gelsolin expression"}, {"pubmed": 15221969, "text": "Sensitivity of PNA clamp PCR assay in identifying occult micrometastases in the sentinal lymph nodes of colorectal cancer patients by single-base mutation analysis."}, {"pubmed": 15262995, "text": "H-Ras mediates FucT-VII induction in Jurkat T cells via the activation of the Raf, PI3K, and a distinct, H-Ras-specific effector signaling pathway."}, {"pubmed": 15367885, "text": "K-Ras mutations were found in 80% of pancreatic adenocarcinoma cell lines and 100% of primary tumors. They were all missense mutations of Gly(12) to Val or Asp."}, {"pubmed": 15489648, "text": "Mutations of BRAF or KRAS oncogenes are early events in the serrated polyp neoplasia pathway. CpG island methylation plays a role in serrated polyp progression to colorectal carcinoma."}, {"pubmed": 15514939, "text": "Detection of K-ras mutations in normal colonic mucosa might serve as a high-specificity approach to colorectal cancer."}, {"pubmed": 15523694, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 15528212, "text": "c-Myc antagonized the induction of p21Cip1 mediated by oncogenic H-, K-, and N-Ras and by constitutively activated Raf and ERK2"}, {"pubmed": 15531466, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 15534934, "text": "Co-mutation of p53 and K-ras gene has neither synergic carcinogenesis-promoting effect, nor prognostic effect on rectal cancer."}, {"pubmed": 15548565, "text": "ANCA selectively activates K-ras during induction of a respiratory burst via pathways involving multiple upstream kinases."}, {"pubmed": 15608367, "text": "Simultaneous measurement of K-ras and p16 mutations provides an additional tool in differential diagnosis of chronic pancreatitis and pancreatic adenocarcinoma."}, {"pubmed": 15608639, "text": "comparison with mouse data show a pattern of gene expression indicative of KRAS2 mutation and oncogenic activity"}, {"pubmed": 15734482, "text": "K-ras mutations occur prominently in type 1 and type 2 gastric cancers."}, {"pubmed": 15741570, "text": "Mutations in either the EGFR TK domain or the KRAS gene can lead to lung cancer pathogenesis. EGFR TK domain mutations are the first molecular change known to occur specifically in never smokers."}, {"pubmed": 15815931, "text": "data suggest that mutations of epidermal growth factor receptor (EGFR) and K-RAS genes might separately, but not cooperatively, contribute to lung adenocarcinoma pathogenesis"}, {"pubmed": 15824172, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 15846069, "text": "Activating KRAS2 mutations were found in 82% of lethal metastatic pancreatic neoplasms."}, {"pubmed": 15923428, "text": "The results obtained from the RASCAL studies suggest that Ki-ras mutations might have an effect on survival rate of colorectal cancer patients, and that the specific codon 12 glycine/valine mutation might play a role in the progression of this neoplasia."}, {"pubmed": 15923430, "text": "Specific TP53 mutations in L3 domain alone (only in DFS) or in combination with specific Ki-ras mutations at codon 13 are associated with a worse prognosis in sporadic colorectal cancer."}, {"pubmed": 15943410, "text": "The sequential accumulation of mutations in K-ras drives the transition from normal epithelium through increasing adenomatous dysplasia to colorectal cancer."}, {"pubmed": 15958551, "text": "Observational study of gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 15991278, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 15994075, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16015387, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16043828, "text": "Clinical trial of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 16077965, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16091732, "text": "Mutant human Kras(D12) suppresses IL-18 production in murine colorectal tumor cells, which may contribute to evasion of the local immune system during tumor development"}, {"pubmed": 16098678, "text": "Clinical evidence that suggests a role for K-Ras in the formation of colorectal metastases. (review)"}, {"pubmed": 16110022, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16112461, "text": "controversial link of KRAS mutations in colorectal cancer with chromosomal instability and patient prognosis (review)"}, {"pubmed": 16139926, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 16142311, "text": "MUC5AC and MUC2, TFF1 and TFF3, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum"}, {"pubmed": 16142319, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 16142319, "text": "Ras mutations do not play a significant role in the pathogenesis of multiple myeloma in the Spanish population"}, {"pubmed": 16144912, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16158056, "text": "hepatocyte growth factor signaling and Ki-ras oncogene activation have roles in colorectal cancer"}, {"pubmed": 16169155, "text": "mechanistic insights are now possible into how K-Ras contributes to pancreatic ductal carcinogenesis (review)"}, {"pubmed": 16219426, "text": "While most aberrant crypt foci do not have adenopolyposis coli mutations, a large proportion has KRAS mutations. (review)"}, {"pubmed": 16257181, "text": "The results suggest that oncogenic K-Ras enhances the malignant phenotype and identify the mitogen-activated protein kinase p38 as a target to inhibit oncogenic K-Ras-induced pancreatic tumor cell migration."}, {"pubmed": 16331576, "text": "Allelic loss on 12p12-13 region would influence the KRAS2 expression by reducing the gene-dosage in colon carcinogenesis."}, {"pubmed": 16354586, "text": "Mutation and elevated expression of KRAS2 is associated with the development of testicular germ cell tumors"}, {"pubmed": 16356174, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16373972, "text": "KRAS has a role in villous growth in colorectal adenomas"}, {"pubmed": 16397024, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 16448675, "text": "Polymorphisms in some insulin-related genes are associated with an increased risk of colon cancer with specific KRAS2 and TP53 mutations, implying a link between these genetic changes and specific mutational pathways in carcinogenesis."}, {"pubmed": 16456810, "text": "Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"}, {"pubmed": 16458330, "text": "Mutations do not confer a growth advantage to somatic heterozygous clusters or maintenance turnover units."}, {"pubmed": 16474404, "text": "Cardio-facio-cutaneous (CFC) syndrome involves dysregulation of the RAS-RAF-ERK pathway."}, {"pubmed": 16474405, "text": "Germline KRAS mutations are a cause of human disease and infer that the constellation of developmental abnormalities seen in Noonan syndrome spectrum is due to hyperactive Ras."}, {"pubmed": 16482519, "text": "Mutations in transfect Ki-ras promote the formation of benign lung tumors and suggest potential targets for the development of novel chemotherapeutic and chemopreventive agents during the early stages of lung tumor progression."}, {"pubmed": 16520020, "text": "These findings suggest that endogenous Nore1B recruits active Ras to the APC-T cell interface and mediates the interaction between Ras and Carma1."}, {"pubmed": 16533526, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 16534842, "text": "Genomic instability may occur on 12p-12-13 of Kras2 gene in the development and progression of colon carcinoma. The high LOH of Kras2 gene may directly influence the transcription and translation of wild type Kras2 gene."}, {"pubmed": 16552337, "text": "K-ras mutations were detected in 70% of neoplastic tissue samples, but no mutated DNA resulted in circulating DNA samples in pancreatic cancers."}, {"pubmed": 16573741, "text": "In 239 Thai adult AML cases, 35 RAS mutations were found in 32 cases (13%) predominantly classified as M1/M2 (53%) followed by M4/M5 (38%). Ten cases were positive for NRAS codon 12, 11 for NRAS codon 61, 13 for NRAS codon 13, and one for KRAS codon 13."}, {"pubmed": 16575407, "text": "Rodent and human tumor cells containing constitutively activated Raf/Raf/MEK/ERK pathways were resistant to mda-5-induced killing."}, {"pubmed": 16618717, "text": "Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 16672071, "text": "The role of K-ras codon 12 and codon 13 mutations in human papillomavirus virus-associated colon tumors."}, {"pubmed": 16687659, "text": "A nuclease hypersensitive polypurine-A polypyrimidine element within the promoter of the KRAS proto-oncogene regulates transcription."}, {"pubmed": 16721785, "text": "BRAF mutations are as uncommon as KRAS mutations in prostate adenocarcinoma"}, {"pubmed": 16756473, "text": "the combination of an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes may play an important role in both the hyperfunction of follicular thyroid carcinoma and the carcinogenetic process"}, {"pubmed": 16760301, "text": "In 50 of the 66 primitive colorectal tumor cases at least one significant alteration was identified in Ki-Ras and/or TP53 and/or p16(INK4A) genes."}, {"pubmed": 16761621, "text": "ras may be involved in early stages of larynx carcinogenesis and may be activated by other mechanisms different from mutations, such as epigenetic events"}, {"pubmed": 16765042, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 16774937, "text": "trichostatin A-induced cell death of Ki-Ras-transformed cells is enhanced by inhibition of NF-kappaB"}, {"pubmed": 16808798, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16818665, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 16879389, "text": "KRAS mutation occurred frequently (26.5%) in adenomas and particularly in adenomas with villous architecture."}, {"pubmed": 16889753, "text": "These data describe a functional association between K-Ras4B and nucleolin"}, {"pubmed": 16896030, "text": "Ki-ras proto-oncogene mutation and p53 gene overexpression is associated with sporadic colorectal adenomas"}, {"pubmed": 16905440, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 16918136, "text": "K-ras mutations are associated with colorectal cancers"}, {"pubmed": 16923573, "text": "analysis of H-RAS, K-RAS and N-RAS expression in acute myeloid leukemia"}, {"pubmed": 16937524, "text": "BRAF, K-ras and BAT26 are expressed in colorectal polyps and stool"}, {"pubmed": 16953233, "text": "Concomitant KRAS and BRAF mutations increased along progression of MSS colorectal cancer, suggesting that activation of both genes is likely to harbour a synergistic effect"}, {"pubmed": 16969076, "text": "Recurrent KRAS codon 146 mutations is associated with human colorectal cancer"}, {"pubmed": 16973828, "text": "6 haplotype blocks were identified across the KRAS locus in endometriosis patients. No germline variants or differences in SNPs or haplotypes were seen between cases and controls."}, {"pubmed": 16973828, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16988471, "text": "KRAS and p53 gene mutations, which are rarely simultaneous and are associated with specific DI aneuploid values, do not represent a synergistic evolutionary pathway but may influence mechanisms of chromosomal instability."}, {"pubmed": 17056636, "text": "Phenotypic variability may be related, at least in part, to specific genotypes and possibly reflects the central role of K-Ras in a number of different signalling pathways."}, {"pubmed": 17060486, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 17071580, "text": "These findings suggest that continuous K-Ras activation accelerates cell growth and evokes a feedback system through IGFBP-4/2 to prevent excessive growth."}, {"pubmed": 17130841, "text": "Presence of an oncogenic KRAS allele results in a dynamic physical interaction between endogenous N-RAS and gelsolin that correlates with survival in colorectal cancer cell lines."}, {"pubmed": 17133351, "text": "K-RAS is uniquely oncogenic in the colonic epithelium, though the molecular aspects of its oncogenic contribution are not necessarily conserved across cell lines."}, {"pubmed": 17149612, "text": "data suggest that mutations of the k-ras oncogene may induce activation of ERK1/2 in colorectal carcinoma"}, {"pubmed": 17170014, "text": "RASSF1A methylation was observed in a high frequency in endometrioid endometrial carcinoma whereas K-ras and B-raf mutations were observed in a low frequency"}, {"pubmed": 17172815, "text": "Rna silencing of K-ras(V12) markedly decreased K-ras(V12) gene expression and inhibited cellular proliferation of lung cancer cells."}, {"pubmed": 17184525, "text": "High-resolution melting analysiswill enable screening of gene mutations, such as KRAS to allow appropriate therapeutic choices for patients and accelerate research aimed at identifying novel mutations in human cancer."}, {"pubmed": 17192038, "text": "Urine might be a better resource for detecting K-ras mutation in circulating DNA in patients with colorectal cancer."}, {"pubmed": 17192902, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 17198183, "text": "association between K-ras mutation and smoking in pancreatic cancer patients"}, {"pubmed": 17210246, "text": "Taken together, the observations indicate that both H-Ras(G12V) and K-Ras4B(G12V) activates non-conventional and perhaps unique effector pathways to induce cytoplasmic vacuolation in glioblastoma cells."}, {"pubmed": 17227126, "text": "This pilot study suggests that low-level fractional allelic loss or K-ras mutation in the negative/atypical cytology samples of bile duct with malignant outcome is a representation of morphologically subtle molecular alterations."}, {"pubmed": 17270239, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17285540, "text": "Observational study of genotype prevalence, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 17320764, "text": "analysis of oxidative posttranslational modifications of cysteine thiols of p21ras associated with redox modulation"}, {"pubmed": 17321325, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17324647, "text": "One female patient exhibiting the distal phalangeal creases had a mutation in the KRAS gene."}, {"pubmed": 17332249, "text": "patients having juvenile myelomonocytic leukemia with NRAS or KRAS2 glycine to serine substitution received no chemotherapy, but hematologic improvement was observed during a 2- to 4-year follow up."}, {"pubmed": 17332339, "text": "K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling."}, {"pubmed": 17352027, "text": "The wild-type Kras2 gene effectively inhibits the growth of the colonic adenocarcinoma cell line Caco-2."}, {"pubmed": 17354229, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17360030, "text": "findings show that RASSF1A hypermethylation and KRAS mutations and BRAF mutations are inversely correlated and play an important role in the development of cervical adenocarcinomas"}, {"pubmed": 17366577, "text": "mutational analysis of KRAS, BRAF, and MAP2K1/2 in 56 patients with CFC syndrome; comparison of the genotype-phenotype correlation of CFC with that of Costello syndrome suggest a significant clinical overlap but not genotype overlap."}, {"pubmed": 17393356, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17393356, "text": "data suggest that BRAF mutations might be present less frequently than KRAS mutations in Greek patients with colorectal carcinomas"}, {"pubmed": 17409930, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 17436386, "text": "Mutations of K-ras and Dpc4 genes can accumulate already in non-malignant, inflammatory pancreatic tissue, suggesting its applicability in monitoring of further destruction of pancreatic tissue and progression into malignancy."}, {"pubmed": 17440063, "text": "KRAS mutations were present in 3 of 16 serrated compared with 14 of 33 non-serrated hyperplastic aberrant crypt foci"}, {"pubmed": 17449174, "text": "Circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer."}, {"pubmed": 17459062, "text": "KRAS KRAS mutations were observed significantly frequently in bronchial-type tumors"}, {"pubmed": 17465446, "text": "Genetically, the non-polypoid growth type of submucosal invasive colorectal carcinoma shows much less frequent K-ras mutation."}, {"pubmed": 17471559, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17487277, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17487504, "text": "c-kit expression is not alternative to BRAF and/or KRAS activation."}, {"pubmed": 17504988, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17534846, "text": "it is suggested that atypical adenomatous hyperplasia (AAH) could develop by either KRAS or EGFR gene mutation, but AAH harbouring a KRAS gene mutation might not progress further to an invasive cancer"}, {"pubmed": 17549340, "text": "Activated K-ras is associated with non-small cell lung cancer"}, {"pubmed": 17551339, "text": "A KRAS mutation in a baby girl with an early clinical diagnosis of cardio-facio-cutaneous syndrome associated with a large ulcerating hemangioma, is reported."}, {"pubmed": 17554370, "text": "KRAS G34A mutation was relatively common to all classes of specimen, whereas TP53 gene C742T and G818C mutations were significantly more frequent in lichen sclerosus than normal genital skin."}, {"pubmed": 17568059, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 17575133, "text": "study of EGFR, HER2, TP53& KRAS mutations of p14arf expression of non-small cell lung cancers in relation to smoking"}, {"pubmed": 17575320, "text": "study reveals there are differences in the frequencies & types of K-ras & p53 mutations found in pancreatic adenocarcinomas of patients in high-pollution & low-pollution regions in Egypt & suggests that environmental factors may explain these differences"}, {"pubmed": 17580276, "text": "among adenocarcinomas, nonmucinous and mucinous bronchioloalveolar carcinoma components were significantly associated with EGFR and K-ras gene mutations, respectively"}, {"pubmed": 17591931, "text": "In bronchioalveolar carcinoma/adenocarcinoma with bronchioalveolar features mucinous differentiation was significantly correlated with the absence of EGFR mutation and presence of KRAS mutation."}, {"pubmed": 17592266, "text": "In 2 cases of ovarian tumors the same mutations of KRAS occurred in both the atypical proliferative serous (borderline) tumor and the high-grade serous carcinoma component of the tumor, indicating a clonal relationship."}, {"pubmed": 17596643, "text": "EGFR and K-ras mutations may have a role in progression of resected non-small-cell lung cancer"}, {"pubmed": 17601930, "text": "De novo germline HRAS (G12A) and KRAS (F156L) mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features."}, {"pubmed": 17607370, "text": "NSCLC cases with wt- or mutant KRAS, downregulation of EGFR expression was a rare event although upregulation in bone metastases was observed more frequently in wt K-RAS cases."}, {"pubmed": 17629419, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17629419, "text": "an important relationship between K-ras codon 12 mutations and overall survival in colorectal cancer patients"}, {"pubmed": 17632319, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 17632319, "text": "tobacco does not play a major part in acquisition of K-ras mutations in the pancreatic epithelium; although both smoking & K-ras mutations have important roles in the etiopathogenesis of exocrine pancreatic cancer, the 2 processes may act independently"}, {"pubmed": 17636402, "text": "Mutations in KRAS is associated with colon tumors"}, {"pubmed": 17638924, "text": "oncogenic K-RAS/ERK in pancreatic adenocarcinoma facilitates TGFbeta-induced transcriptional down-regulation of the tumor suppressor PTEN in a SMAD4-independent manner"}, {"pubmed": 17659731, "text": "Combined with screening of K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 represents a very sensitive approach in screening for pancreatic malignancy."}, {"pubmed": 17663506, "text": "KLF6 and p53 mutations are involved in the development of nonpolypoid colorectal carcinoma, whereas K-ras and B-raf mutations are not"}, {"pubmed": 17671710, "text": "Kras mutant lung cancer patients have a significantly worse prognosis than wild-type patients."}, {"pubmed": 17697521, "text": "The majority of colorectal and gastric cancer cells with KRAS mutations are homogeneous because they have the same KRAS mutation."}, {"pubmed": 17704260, "text": "2 novel mutations (K5E, G12S) were identified in 7 patients withcardio-facio-cutaneous syndrome, Costello syndrome or Noonan syndrome."}, {"pubmed": 17704924, "text": "Report genetic alterations of K-ras in Korean colorectal cancer patients."}, {"pubmed": 17707462, "text": "tumor budding and podia formation were observed to be significantly higher in the 32 (34.7%) of colorectal tumors with K-ras gene mutations (29 mutations in codon 12, 3 in codon 13)"}, {"pubmed": 17710156, "text": "data support the notion that K-ras-dependent inhibition of anoikis plays an important casual role in colorectal carcinoma progression"}, {"pubmed": 17712732, "text": "KRAS is rarely mutated in pilocytic astrocytomas."}, {"pubmed": 17714760, "text": "The K-RAS gene was screened for mutations in Congenital cystic airway malformation/congenital pulmonary airway malformation...no mutations were present"}, {"pubmed": 17729418, "text": "Wild type K-ras2 is related to the negative regulation of cell proliferation, metabolism and transcriptional control in colon carcinoma cells."}, {"pubmed": 17805054, "text": "experiments provide a rationale for targeting Ras and associated signaling pathways in mesothelioma and also suggest cap-dependent translation as one mechanism by which Ras induces proliferation in this disease."}, {"pubmed": 17873613, "text": "The regulation of p21WAF1/CIP1, independent of p53 or bcl-2 expression, appears to be associated with Kras mutations."}, {"pubmed": 17875937, "text": "Data suggest that the intrinsic k-Ras/Ras GTPase activity, the responsiveness of these proteins to GTPase-activating proteins, and guanine nucleotide dissociation all regulate developmental programs in vivo."}, {"pubmed": 17904685, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 17910045, "text": "Frequently mutated in high hyperdiploid childhood acute lymphoblastic leukemia."}, {"pubmed": 17910045, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17943694, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 17943694, "text": "study of point mutations in RAS oncogenes in papillary thyroid carcinoma; 2 mutations found (GAA/CAA at codon 31 of K-RAS & CAA/CAC at codon 61 of N-RAS); data confirm previous studies, showing RAS mutations are more rare in PTC than follicular neoplasms"}, {"pubmed": 17960171, "text": "54% of childhood CBF-AML had RTKs and/or Ras mutations"}, {"pubmed": 17974974, "text": "In conclusion, the data support a model whereby RbAp48 regulates cellular morphology and cytoskeletal organization by increasing K-Ras activity and signaling through MAPK."}, {"pubmed": 17998284, "text": "KRAS WT status is associated to survival benefit in cetuximab treated metastatic colorectal cancer."}, {"pubmed": 18038880, "text": "k-ras codon 12 mutation is associated with non-small cell lung carcinoma"}, {"pubmed": 18049799, "text": "Smoking and diabetes were associated with pancreatic cancer patients positive for K-ras codon 12 mutations"}, {"pubmed": 18075308, "text": "Quantification of mutant KRAS2 in pancreatic juice differentiates pancreatic adenocarcinoma from chronic pancreatitis, and may be a useful early detection tool for pancreatic cancer."}, {"pubmed": 18172263, "text": "KRAS2 c.34G > T somatic prescreening, followed by MUTYH hotspot mutation analysis when positive, can identify patients with (atypical) MUTYH-associated polyposis"}, {"pubmed": 18172263, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 18199160, "text": "A worse clinical outcome was found for CIMP-high, microsatellite stable colorectal cancer with KRAS/BRAF mutation but not for those lacking KRAS/BRAF mutation."}, {"pubmed": 18202412, "text": "Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18202412, "text": "results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic colorectal cancer patients treated with cetuximab"}, {"pubmed": 18208799, "text": "All cases were wild-type for HER2. Mutations of EGFR and K-ras genes represent an early event in lung adenocarcinomagenesis, and AAH convincingly seems to be a precursor lesion in a subset of cases of adenocarcinoma."}, {"pubmed": 18221484, "text": "genetic alterations of KRAS and PIK3CA may play equivalent roles in endometrial carcinogenesis"}, {"pubmed": 18224685, "text": "Mutations in the K-ras is associated with colon cancers"}, {"pubmed": 18224685, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 18265644, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 18265644, "text": "The data support that the frequencies and patterns of somatic mutation of the K-ras gene in colorectal cancer are variable among populations."}, {"pubmed": 18268007, "text": "while activated HrasV12 promotes differentiation and growth arrest in these endodermal progenitors, KrasV12 promotes their proliferation"}, {"pubmed": 18289366, "text": "K-ras mutations have a limited role in development of sinonasal cancer"}, {"pubmed": 18289366, "text": "Observational study of genotype prevalence. (HuGE Navigator)"}, {"pubmed": 18296105, "text": "Some smoking characteristics, i.e. being an ex-smoker, frequency and inhalation, may be associated with risk for colorectal cancer characterized by the wild-type KRAS gene, especially in men."}, {"pubmed": 18299280, "text": "KRAS polymorphisms were indicated to be involved in risk for the development of atypical adenomatous hyperplasia that progresses to lung adenocarcinoma."}, {"pubmed": 18299280, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18303429, "text": "first direct comparison of survival of resected patients with either EGFR or KRAS mutant lung adenocarcinomas compared with those wild type for both genes; EGFR & KRAS mutations define distinct molecular subsets of resected lung adenocarcinoma"}, {"pubmed": 18316791, "text": "KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy"}, {"pubmed": 18334834, "text": "In patients with lung adenocarcinoma, mutation analyses of EGFR and KRAS show whether or not to apply treatments targeting against EGFR and the selection of dosage for such treatments."}, {"pubmed": 18343945, "text": "Our data provide evidence that PIK3CA and BRAF contribute to the tumorigenesis of IPMN/IPMC, but at a lower frequency than KRAS."}, {"pubmed": 18355852, "text": "high frequency of mutations in the PIK3CA, HRAS and KRAS genes leads us to believe that dysregulation of the phosphatidylinositol 3-kinase or Ras pathway is significant for the development and progression of penile carcinoma."}, {"pubmed": 18383861, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18386236, "text": "apart from K-ras codons 12/13 point mutations, overexpression of the ras family genes is important in the development of colorectal cancer but it appears not to be predictive of survival."}, {"pubmed": 18392710, "text": "The incidence of K-ras mutation may be associated with the hypersecretion of mucin in IPMN patients."}, {"pubmed": 18418018, "text": "KRAS mutation may occur at a very low frequency in Chinese NSCLC patients regardless of pathology, smoking status, or gender."}, {"pubmed": 18418018, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18418066, "text": "Kras may uniquely contribute to the initiation of tumors in endodermally-derived tissues by expanding a stem/progenitor cell population"}, {"pubmed": 18418864, "text": "Data show that germ cell single base substitution mutation frequencies are very similar to somatic tissue Kirsten-RAS mutation frequencies."}, {"pubmed": 18431556, "text": "Before panitumumad administration KRAS oncogene must be analysed to determine \"continuous activation\" or wild type gene is involved."}, {"pubmed": 18432074, "text": "K-ras mutation has been detected in the tumor tissue of 25 patients (33%). K-ras mutation hasn't been detected in the blood. tumors with K-ras mutation have a worse prognosis and often lead to disemination"}, {"pubmed": 18435933, "text": "CpG island methylator phenotype in colorectal neoplasms may result from activating mutations in either BRAF or KRAS."}, {"pubmed": 18490377, "text": "The G-rich strand of a nuclease hypersensitive element, located in the human KRAS promoter, can fold into a dynamic intra-molecular G-quadruplex that can assume two distinct conformations."}, {"pubmed": 18500270, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18509354, "text": "may be involved with imatinib resistance in chronic myeloid leukemia"}, {"pubmed": 18544172, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18549880, "text": "Provide a unique view of the tumor-initiating effects of oncogenic KRAS in a zebrafish model of pancreatic cancer."}, {"pubmed": 18559541, "text": "Increased frequency of K-ras mutations are associated with colorectal oncogenesis"}, {"pubmed": 18577988, "text": "KRAS mutations are associated with cetuximab failure in EGFR FISH+ colorectal cancer."}, {"pubmed": 18592002, "text": "RAS signaling network is extensively dysregulated in colorectal carcinomas."}, {"pubmed": 18592405, "text": "Mutational activation of the K-ras gene, HPV infection and tobacco or alcohol abuse, can be considered independently or in combination as high risk factors for esophageal squamous cell carcinoma development."}, {"pubmed": 18592405, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18594528, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18614859, "text": "A variety of molecular assays have been devised to detect mutated KRAS in pancreatic cancer."}, {"pubmed": 18621636, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18626007, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18641128, "text": "analysis of a signaling mechanism for the regulation of the Ras/ERK pathway based on the eNOS-dependent differential activation of N-Ras and K-Ras at specific cell compartments"}, {"pubmed": 18663146, "text": "K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations"}, {"pubmed": 18669174, "text": "This is the first report in colorectal carcinoma of humans of internal tandem duplication longer than 1 codon in th KRAS gene and first insertion detected in exon 2."}, {"pubmed": 18669866, "text": "KRAS mutations and PI3KCA/PTEN deregulation significantly correlate with resistance to cetuximab."}, {"pubmed": 18669866, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18676680, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18676755, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18676835, "text": "both Kras and integrin alpha1beta1 cooperate to drive the growth of non-small cell lung cancer in vivo"}, {"pubmed": 18677542, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18692554, "text": "All of the KRAS-mutant Microsatellite instability (MSI)-H (high) tumors harbored sequence alterations MLH1, which implies that KRAS mutation more frequently and almost exclusively occurs in DNA mismatch repair gene-mutant MSI-H tumors."}, {"pubmed": 18701506, "text": "Mutation in KRAS is associated with childhood acute lymphoblastic leukemia"}, {"pubmed": 18757341, "text": "KRAS and BRAF mutations can impair response to anti-EGFR therapy for colorectal neoplasms"}, {"pubmed": 18776048, "text": "Bayesian network analysis of these and other datasets revealed that PTRF might be a potentially important component of the ERBB signaling network"}, {"pubmed": 18782444, "text": "BRAF, KRAS and PIK3CA mutations occur prior to malignant transformation demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis"}, {"pubmed": 18782444, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18794081, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 18794094, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18794099, "text": "Observational study of gene-disease association, gene-environment interaction, pharmacogenomic / toxicogenomic, and genetic testing. (HuGE Navigator)"}, {"pubmed": 18804418, "text": "Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18832461, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 18833187, "text": "All K-ras positive patients revealed a poor survival prognosis and had a tumor relapse after resection."}, {"pubmed": 18834226, "text": "With at least 3 markers methylated, new CIMP-positive colorectal cancers were closely associated with proximal tumor location, low frequency of KRAS mutation, and high frequency of BRAF mutation."}, {"pubmed": 18836286, "text": "although the PAK4 gene is not activated by mutation in cell lines with gene amplification, an oncogenic form of the KRAS2 gene is present in these cells and oncogenic KRAS2 can activate PAK4"}, {"pubmed": 18843035, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 18922928, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 18922928, "text": "The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers."}, {"pubmed": 18932251, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18945298, "text": "The frequency of KRAS mutations in the melanocytic aggregate (five of 18, 28%) was second to BRAF V600E, while in melanoma, the frequency was also second to BRAF V600E"}, {"pubmed": 18946061, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 18946061, "text": "Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab."}, {"pubmed": 18946221, "text": "Hereditary pancreatitis patients with PRSS1 mutations also had mutations in BRAF and KRAS2."}, {"pubmed": 18957720, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19001320, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19002263, "text": "KRAS mutation is related with a random CpG island methylation pattern which may lead to CpG island methylator phenotype in colorectal cancer ."}, {"pubmed": 19013464, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19013894, "text": "the presence of mutations in the KRAS oncogene can be used to predict which patients are unlikely to benefit from treatment with epidermal growth factor receptor-directed therapy."}, {"pubmed": 19018267, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19018267, "text": "ovarian cancer patients with KRAS or BRAF mutations may benefit from CI-1040 treatment"}, {"pubmed": 19020799, "text": "Mutations in the KRAS are associated with Noonan syndrome."}, {"pubmed": 19020799, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19026650, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 19026650, "text": "The digital melt curve assay detected 16 (59%) of 27 advanced adenoma samples that contained KRAS mutations, compared with 7% with the Hemoccult, 15% with the HemoccultSensa, and 26% with the PreGenPlus assays."}, {"pubmed": 19047118, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19047918, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19056857, "text": "KRAS mutations in either primary or metastatic tumors from patients with colorectal cancer is concordant."}, {"pubmed": 19057271, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19064568, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19064568, "text": "The prevalence of mutant KRAS2 is similar in familial pancreatic adenocarcinoma as in sporadic pancreatic adenocarcinomas."}, {"pubmed": 19087308, "text": "presence of the KRAS G12V mutation in the cells escaping apoptosis and inducing angiogenesis via IL8 may confer a more aggressive phenotype"}, {"pubmed": 19096301, "text": "KRAS, and CMET mutations are associated with advanced non-small cell lung cancer."}, {"pubmed": 19096301, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19096302, "text": "KRAS mutations or TP53 mutations are associated with lung adenocarcinoma."}, {"pubmed": 19096302, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19101897, "text": "to find kRAS mutations in bladder tumor samples"}, {"pubmed": 19103203, "text": "p53 mutation is an initiating mutation in the majority of colitis-associated neoplasia, and K-RAS activation is an alternative gatekeeping mutation."}, {"pubmed": 19107910, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19121089, "text": "oncogenic KRAS could cause the accumulation of phosphatidylinositides and modulate the cell shape and migration."}, {"pubmed": 19124802, "text": "Evidence from several randomized studies has established that advanced colorectal tumors harboring a mutation in the KRAS gene do not respond to epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab."}, {"pubmed": 19133693, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19137007, "text": "miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation."}, {"pubmed": 19141999, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19142971, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19144677, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19146951, "text": "p21(Ras)-mediated survival signaling is regulated by via a PI(3)K-AKT pathway, which is dependent upon both PDK1 and PKCdelta, and PDK1 activates and regulates PKCdelta to determine the fate of cells containing a mutated, activated p21(Ras)."}, {"pubmed": 19147861, "text": "The genes involving MSI-L carcinogenesis are similar to MSS but the timing and frequency of the KRAS mutation is different."}, {"pubmed": 19162366, "text": "mutations are associated with post-operative recurrence of lung adenocarcinomas"}, {"pubmed": 19164213, "text": "KRAS mutations were associated with lower response rate to cetuximab plus irinotecan in colorectal cancer patients(4% v 27% in nonmutated patients; P = .021) and shorter PFS (3.0 v 5.3 months; P = .021)."}, {"pubmed": 19164213, "text": "Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19164452, "text": "MGMT hypermethylation is associated with G:C > A:T mutations in KRAS, but not in APC, suggesting that MGMT hypermethylation may succeed APC mutations but precedes KRAS mutations in colorectal carcinogenesis."}, {"pubmed": 19170196, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19172191, "text": "activation of PIK3CA may be an important molecular event contributing to the maintenance of OSE transformation initiated by oncogenes such as K-ras"}, {"pubmed": 19179548, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19179548, "text": "Report the importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer."}, {"pubmed": 19190079, "text": "Mutation in KRAS is associated with adrenocortical carcinomas."}, {"pubmed": 19190129, "text": "Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans."}, {"pubmed": 19190129, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19190631, "text": "Overexpression and mutations of Kras lead to common altered gene expression patterns in NIH3T3 cell."}, {"pubmed": 19196673, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19206169, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19208745, "text": "KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with pancreatic intraepithelial neoplasia."}, {"pubmed": 19228630, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19234440, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19237633, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 19238210, "text": "mutation in KRAS were associated with increased resistance to gefitinib in lung cancer cell lines"}, {"pubmed": 19238633, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19240718, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19247083, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19270482, "text": "Mutations of KRAS were present in 9.6% (9 of 94) of the samples: eight in codon 12 and one in codon 13. EGFR mutations were never found in tumors with KRAS mutations, suggesting a mutually exclusive relationship."}, {"pubmed": 19270482, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19270646, "text": "We found KRAS2 gene mutations at codon 12 in all eight cases of Adenosquamous carcinoma of the pancreas"}, {"pubmed": 19273710, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19281127, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19281127, "text": "There was no significant predictive value for therapeutic response of K-ras mutations for advanced non-small cell lung cancer."}, {"pubmed": 19282104, "text": "study of KRAS/BRAF mutation status in a large and well-documented cohort of primary and metastatic renal cell carcinoma"}, {"pubmed": 19282454, "text": "hnRNP A1/Up1 completely abrogates the cooperative quadruplex-to-ssDNA transition that characterizes the KRAS quadruplex and facilitates the association between the quadruplex and its complementary polypyrimidine strand."}, {"pubmed": 19284554, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19289583, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19289622, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19295453, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19302287, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19303097, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19307945, "text": "k-ras mutations are associated with advanced pancreatic carcinoma in response to combined gefitinib, paclitaxel, and 3-dimensional conformal radiation treatment."}, {"pubmed": 19309232, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 19326463, "text": "Alcohol consumption is weakly associated with an increased risk of having a K-ras mutated pancreatic ductal adenocarcinoma"}, {"pubmed": 19326463, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19339720, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19339720, "text": "The benefit of cetuximab was limited to patients with KRAS wild-type tumors."}, {"pubmed": 19344998, "text": "quercetin and luteolin significantly decreased ERK phosphorylation"}, {"pubmed": 19349489, "text": "In this review, we summarize the initial discovery of RAS mutations in NSCLC, describe work exploring associations with clinical factors and outcomes, and provide an overview of current approaches to targeting KRAS mutant NSCLC."}, {"pubmed": 19351817, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19358278, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19358724, "text": "KRAS mutations were found in 60 (15%) samples with 58 ovarian samples deriving from malignant tissue and 2 samples deriving from benign tissue."}, {"pubmed": 19358724, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19360305, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19362747, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19366826, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19367287, "text": "Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19369630, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19372139, "text": "miR-18a* may function as a tumor suppressor by targeting on K-Ras. Therefore, the miRNA may also be a potential therapeutic agent or target for cancer therapy."}, {"pubmed": 19376842, "text": "EGFR/KRAS mutation testing of multiple lung adenocarcinomas can assist in differentiating multiple primary lung adenocarcinomas from metastatic lesions."}, {"pubmed": 19378369, "text": "Several key studies have demonstrated that patients with mutant KRAS do not respond to treatment with epidermal growth factor inhibitors. This finding has several implications for clinicians who treat patients with metastatic colorectal cancer."}, {"pubmed": 19380522, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19380522, "text": "cases with the KRAS-LCS6 variant have significantly reduced survival time and suggest that this variant may alter the phenotype or therapeutic response of this disease."}, {"pubmed": 19390304, "text": "EGFR-targeting monoclonal antibodies such as cetuximab or panitumumab are ineffective in patients with activating mutations in KRAS.[review]"}, {"pubmed": 19396835, "text": "study reports on the occurrence of premature closure of cranial sutures in subjects with Noonan syndrome, and their specific association with mutations in the KRAS gene"}, {"pubmed": 19398573, "text": "KRAS mutational analyses could help to identify a subgroup of patients with metastatic colorectal neoplasms who have higher chances of benefiting from EGFR inhibition."}, {"pubmed": 19398573, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19418727, "text": "Codons 12 & 13 of K-ras were mutated in 23.33% of patients. 28.57% were at codon 12, 57.14% were at codon 13, & 14.29% at both. They were more frequent in tumors in the left hemicolon and in well-differentiated adenocarcinomas & mucinous carcinomas."}, {"pubmed": 19418727, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19419940, "text": "KRAS mutation is a relatively common event in endometrial carcinogenesis, but with no prognostic value."}, {"pubmed": 19419940, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19420344, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19430562, "text": "Mutations in KRAS were found in 30% patients in the low-grade carcinoma group, however, they were not found in the high-grade carcinoma group. KRAS and BRAF mutations were mutually exclusive, and both mutations were observed in 40%."}, {"pubmed": 19430562, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19440799, "text": "oncogenic properties of KRAS and BRAF but not NRAS, HRAS, and PIK3CA contribute to the tumorigenesis of periampullary and ampullary tumors"}, {"pubmed": 19453520, "text": "Data show that KRAS mutation was detected in 201 tumours (39.4%)."}, {"pubmed": 19473722, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19474002, "text": "data confirm that KRAS and BRAF mutations do occur in the same cell and that BRAF V600E mutation is associated with CIMP+ status."}, {"pubmed": 19478384, "text": "Observational study of gene-disease association and genetic testing. (HuGE Navigator)"}, {"pubmed": 19487299, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19490893, "text": "These findings point to a previously underappreciated role of Ras in mitotic progression and demonstrate that mitotic stress induced by the Ras oncogene."}, {"pubmed": 19515263, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19521964, "text": "KRAS mutations are associated with colorectal neoplasms."}, {"pubmed": 19527492, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19533561, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19543899, "text": "Alterations in TP53, APC, K-ras, and DCC genes in the non-dysplastic ulcerative colitis and Crohn's disease colon, were analyzed."}, {"pubmed": 19543899, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19545448, "text": "overexpressed wild-type KRAS has a role in downstream signaling and cancer cell growth"}, {"pubmed": 19546608, "text": "Review: KRAS mutation testing in colorectal cancer."}, {"pubmed": 19549707, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19549774, "text": "Detection of KRAS mutational status in CTCs, by gene expression array, has potential for clinical application in selecting metastatic colorectal cancer patients most likely to benefit from cetuximab therapy."}, {"pubmed": 19551857, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19561230, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19571295, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19571709, "text": "Ki-ras mutations (Table 3) showed that rectal tumors were more likely to have mutations in Codons 12 and 13 than either proximal or distal colon tumors"}, {"pubmed": 19574674, "text": "Mutation pattern of K-ras gene is associated with colorectal cancer."}, {"pubmed": 19583261, "text": "Data demonstrate that the hypervariable region of K-Ras4B contributes in a major way to the interaction with calmodulin, while the catalytic domain of K-Ras4B provides a way to control the interaction by nucleotide binding."}, {"pubmed": 19584075, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19584155, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19584155, "text": "Results suggest that the mutations of EGFR, KRAS, BRAF between primary tumors and corresponding lymph node metastases should be considered whenever mutations are used for the selection of patients for EGFR-directed tyrosine kinase inhibitor therapy."}, {"pubmed": 19596959, "text": "KRAS does not seem an \"a priori\" negative factor for TKI-based treatment of NSCLC"}, {"pubmed": 19596959, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19603018, "text": "Assessing KRAS and BRAF mutations might help optimising the selection of the candidate metastatic colorectal cancer patients to receive anti-EGFR moAbs."}, {"pubmed": 19603018, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19603024, "text": "KRAS mutation was associated with lack of response (P=0.002) and shorter progress free survival (P=0.09) in patients with metastatic colorectal cancer."}, {"pubmed": 19603024, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19625176, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19628078, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19629485, "text": "Data show that the presence of a K-ras mutation (13.3%) was not associated with either PFS or OS."}, {"pubmed": 19629485, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19637313, "text": "strong inter-relation between DR4 AND DR5 overexpression and presence of oncogenic KRAS/ BRAF mutations in colon cancer."}, {"pubmed": 19638574, "text": "Sorafenib inhibits NSCLC cell growth by targeting B-RAF in cells with wild-type KRAS and C-RAF in those with mutant KRAS."}, {"pubmed": 19639197, "text": "KRAS mutation may only be involved in carcinogenesis of partial gastric cancers and the different mutation types of KRAS may take part in development of gastric cancer at different stages."}, {"pubmed": 19639197, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19640859, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 19651236, "text": "existing evidence on the relationship between K-ras mutations and tobacco smoking in adenocarcinomas of the pancreas, colorectum and lung [review]"}, {"pubmed": 19661383, "text": "study of colorectal cancer cell lines that differed only in the mutational status of their KRAS or BRAF genes; data suggest that glucose deprivation can drive acquisition of KRAS pathway mutations in tumors"}, {"pubmed": 19667264, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19669908, "text": "Observational study of gene-disease association and DATA ERROR. (HuGE Navigator)"}, {"pubmed": 19671843, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19671843, "text": "No difference in outcome was seen between patients harboring KRAS transition versus transversion mutations in non-small cell lung cancer."}, {"pubmed": 19672255, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19672874, "text": "High-throughput copy number and gene expression data of 36 microsatellite stable sporadic colon cancers resected from patients of a single institution characterized for mutations in APC, KRAS, TP53 and loss of 18q were analyzed."}, {"pubmed": 19672874, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19678923, "text": "KRAS mutations correlate with expression of DCN and TPM1 in colorectal cancer."}, {"pubmed": 19679059, "text": "Mutations in KRAS protein is associated with Colorectal Carcinoma."}, {"pubmed": 19679400, "text": "In colorectal neoplasms a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses."}, {"pubmed": 19679400, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19681119, "text": "Investigated the prevalence of PTPN11, HRAS, KRAS, NRAS, BRAF, MEK1, and MEK2 mutations in a relatively large cohort of primary embryonal Rhabdomyosarcoma (RMS) tumors. HRAS and KRAS were found to be rarely mutated."}, {"pubmed": 19681124, "text": "KRAS mutation is associated with sarcomatoid carcinomas of the lung."}, {"pubmed": 19686742, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19692168, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19702696, "text": "Several studies have demonstrated the absence of objective response in patients treated with irinotecan-cetuximab after failure of irinotecan, when the tumour presents a KRAS mutation."}, {"pubmed": 19704056, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19723643, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19724844, "text": "K-RAS mutations were more frequent in males and were associated with smoking habits in 411 lung adenocarcinomas"}, {"pubmed": 19724844, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19727729, "text": "In all cases of our series of patients with squamous cell anal carcinoma wild-type K-ras was observed."}, {"pubmed": 19727962, "text": "KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases."}, {"pubmed": 19727962, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19734844, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19738126, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19738388, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19740513, "text": "EGFR and KRAS status of primary lung carcinomas may not predict the status in the corresponding metastases."}, {"pubmed": 19740513, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19745602, "text": "LIN28B plays an important role in radiation responses of lung cancer cells through inhibiting let-7g microRNA processing and increasing translation of KRAS."}, {"pubmed": 19762526, "text": "a sizable subgroup of non-small cell lung carcinomas harbor KRAS amplification, some of which also contain point mutations, and suggest that an increased KRAS copy number may drive p21 overexpression."}, {"pubmed": 19765726, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 19787214, "text": "KRAS mutations are associated with non-small cell lung cancers."}, {"pubmed": 19789336, "text": "KRAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects."}, {"pubmed": 19797353, "text": "organochlorine compounds and coffee may have independent roles in the aetiopathogenesis of pancreatic ductal adenocarcinoma through modulation of KRAS activation"}, {"pubmed": 19801192, "text": "Studies provide models for Ras in association with Raf kinase, RalGDS and PI3Kalpha and PI3Kgamma."}, {"pubmed": 19813061, "text": "KRAS mutation and microsatellite instability are associated with colorectal cancer."}, {"pubmed": 19813061, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19815694, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 19824059, "text": "incidence of KRAS mutation; KRAS splice variants: KRAS4A & KRAS4B in colorectal cancer(CRC); results highlight role of KRAS isoforms in CRC, their utility as a prognostic biomarker & importance of KRAS alterations as a potential therapeutic target"}, {"pubmed": 19826477, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19833857, "text": "RAS and CSF3R mutations in severe congenital neutropenia."}, {"pubmed": 19839777, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19843849, "text": "Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer , and this may potentially contribute to the phenotypic differences of KRAS and BRAF mutations in colon tumors."}, {"pubmed": 19847166, "text": "Suppression of TBK1 induced apoptosis specifically in human cancer cell lines that depend on oncogenic KRAS expression"}, {"pubmed": 19853286, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 19854533, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19854534, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19855375, "text": "EGFR and KRAS mutations were found in 33 (10%) and 78 (23%) of lung adenocarcinomas, respectively, whereas 226 (67%) cases were negative for both mutations"}, {"pubmed": 19855375, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19862647, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19865112, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19874312, "text": "assessment of KRAS mutations in juvenile myelomonocytic leukaemia"}, {"pubmed": 19881551, "text": "Data show that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1."}, {"pubmed": 19881948, "text": "BRAF and KRAS oncogenes have different transforming capability in colon cancer"}, {"pubmed": 19884549, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19884549, "text": "KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan."}, {"pubmed": 19884551, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19884556, "text": "BRAF status, EGFR amplification, and cytoplasmic expression of PTEN were associated with outcome measures in KRAS wild-type patients treated with a cetuximab-based regimen."}, {"pubmed": 19884556, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19888477, "text": "analysis of KRAS mutation in tumor samples by PCR and sequence analysis"}, {"pubmed": 19893451, "text": "Study identified the previously reported pathogenic mutation of NTRK3 in a KRAS/BRAF wild-type tumor and 2 somatic mutations in the Src family of kinases (YES1 and LYN) that would be expected to cause structural changes."}, {"pubmed": 19903786, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19908233, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19913317, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19913317, "text": "The high number of KRAS mutations in codons 61 and 146 emphasizes the importance to expand current mutation analyses"}, {"pubmed": 19921572, "text": "Mutation in KRAS reduces the effectiveness of Cetuximab combined with chemotherapy in advanced colorectal cancer patients."}, {"pubmed": 19921572, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19934290, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19935791, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19936766, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19936766, "text": "VEGFR1, VEGFR2, and PDGFRalpha are over-expressed in K-ras mutated colorectal adenocarcinoma."}, {"pubmed": 19936839, "text": "KRAS mutation is associated with resistance to EGFR-I therapy in colon cancer."}, {"pubmed": 19952717, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19956635, "text": "Uncategorized study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 19960433, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19960433, "text": "frequency of KRAS and p53-Ab correlates with tumor stage only in the Type I endometrial carcinoma"}, {"pubmed": 19995707, "text": "In this study the presence of mutations at codon 12 of the KRAS gene in 78 women with ovarian tumor were studied to see if there was a link."}, {"pubmed": 19995707, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20008640, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20010090, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20010090, "text": "The study suggests that activating KRAS mutants is a particularly important independent predictive marker in metastatic colorectal cancer patients treated with cetuximab"}, {"pubmed": 20012784, "text": "Screening for BRAF, RET, KRAS, NRAS, and HRAS mutations, as well as RET-PTC1 and RET-PTC3 rearrangements, was performed on cases of Hashimoto thyroiditis with a dominant nodule"}, {"pubmed": 20018398, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20020061, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20020061, "text": "These results suggest a role for KRAS mutations in the propensity of primary colorectal tumors to metastasize to the lung."}, {"pubmed": 20022659, "text": "Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20023269, "text": "Molecular studies showed 3 (20%) of 15 oncocytic adenocarcinomas of lung with EGFR mutations and 3 additional cases with KRAS mutations."}, {"pubmed": 20035238, "text": "Matrix-assisted laser desorption ionization remains a potent and highly clinically significant predictor of survival after first-line treatment with erlotinib in non-smll-cell lung patients with wild-type EGFR and independent of mutations in KRAS."}, {"pubmed": 20035238, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20038723, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20049644, "text": "KRAS mutations only in metastases is not associated with resistance to anti-EGFR treatment in primary colorectal tumors."}, {"pubmed": 20049644, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20049979, "text": "18/19 (94.7%) metastatic colorectal cancer smears were perfectly adequate for codon 12 and 13 KRAS mutational analysis by direct gene sequencing."}, {"pubmed": 20056178, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20068568, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20086114, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20087229, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20098682, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20098682, "text": "developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF and PIK3CA genes for mutations. The assays were validated on 294 tumor DNA samples from patients with advanced colorectal cancer"}, {"pubmed": 20100685, "text": "KRAS mutation testing, preferably at diagnosis, must now be considered a new standard of care for patients with metastatic colorectal cancer being considered for EGFR-targeting"}, {"pubmed": 20100958, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20100964, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20101149, "text": "Tumors from A/J and cBy mice displayed different Kras mutations that were remarkably similar to the variations in mutation spectrum reported in smokers and never smokers."}, {"pubmed": 20108024, "text": "Features of KRAS mutations in lung cancer contrast with the features of EGFR mutations."}, {"pubmed": 20117855, "text": "KRAS mutations were solely and significantly linked to ERK activation in lung adenocarcinoma."}, {"pubmed": 20118768, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20124452, "text": "phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination"}, {"pubmed": 20137853, "text": "Mutations in TP53, KRAS, or EGFR are not major contributors to the RCC development even in the absence of VHL inactivation."}, {"pubmed": 20145159, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20147298, "text": "whereas H-Ras and N-Ras were unable to localize to the plasma membrane in the presence of USP17, K-Ras4b localization was unaffected"}, {"pubmed": 20150643, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20150826, "text": "Mutations in KRAS is associated with lung adenocarcinoma."}, {"pubmed": 20150826, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20159991, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20162668, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 20162668, "text": "Specific KRAS mutation is an informative prognostic factor in both sporadic and hereditary CRC and applied in an algorithm with BRAF(V600E) and MSI may identify sporadic CRC patients with poor clinical outcome."}, {"pubmed": 20177422, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20183914, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20184776, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20186026, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20233436, "text": "data support the model of BRAF and K-ras mutations arising in distinct colorectal cancer subsets associated with different clinicopathological and dietary factors, acting as mutually exclusive mechanisms of activation of the same signalling pathway"}, {"pubmed": 20234366, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20237506, "text": "KRAS mutations are associated with relapsed childhood high hyperdiploid acute lymphoblastic leukemia."}, {"pubmed": 20302979, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20303012, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20303012, "text": "Our study suggests that mutations of KRAS, not BRAF, may play a role in the pathogenesis of prostate carcinoma in Chinese patients."}, {"pubmed": 20305537, "text": "KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype."}, {"pubmed": 20305537, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20307197, "text": "K-RAS codon 12 GAT mutation is present at measurable levels in normal appearing mucosa. All tumors carried K-RAS mutation, in most cases as a mutant subpopulation."}, {"pubmed": 20309588, "text": "Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20336783, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20350743, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 20361930, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20371679, "text": "KRAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant."}, {"pubmed": 20372787, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20372787, "text": "analysis of KRAS mutations in Slovene patients with colorectal cancer"}, {"pubmed": 20381121, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20381121, "text": "Our results showed significant number of EGFR FISH positive/amplified lung adenocarcinomas harboring KRAS mutation"}, {"pubmed": 20383576, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20385028, "text": "KRAS mutations are very infrequent in triple-negative breast tumors."}, {"pubmed": 20385028, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20395213, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20398393, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20398393, "text": "Suggest that most (but not all) commercial services provide analysis that is accurate and comparable with direct sequencing for KRAS mutations in colorectal neoplasms."}, {"pubmed": 20413299, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20418097, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20421765, "text": "K-ras mutations did not have any significant effect on Sorafenib treated patients with advanced non-small cell lung cancer."}, {"pubmed": 20432164, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20444249, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20453000, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20459770, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20459770, "text": "Only one mutation in the K-RAS gene was identified in tonsil squamous cell carcinoma cohorts."}, {"pubmed": 20473902, "text": "Our study indicates for the first time, that oncogenic ras and loss of Smad signaling cooperate to upregulate EGFR and erbB2, which plays a role in promoting invasion."}, {"pubmed": 20482381, "text": "The formalin-fixed and paraffin-embedded samples from 60 patients with colorectal cancer were tested and 19 mutations were detected in KRAS gene."}, {"pubmed": 20495538, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20501503, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20512148, "text": "In line with a redirection of autocrine toward paracrine HH signaling by a KRAS-DYRK1B network, we find high levels of GLI1 expression restricted to the stromal compartment and not to SHH-expressing tumor cells in pancreatic adenocarcinoma."}, {"pubmed": 20526288, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20530271, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20532039, "text": "activation of K-ras did not depend upon EGFR and resulted in the phosphorylation of Akt and induction of VEGF expression"}, {"pubmed": 20542658, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20550522, "text": "Data show that FcgammaRIIa and FcgammaRIIIa polymorphisms are not useful as molecular markers for outcome in mCRC patients, and KRAS status and skin toxicity are the only reliable biomarkers to identify patients that would benefit from anti-EGFR therapy."}, {"pubmed": 20559149, "text": "KRAS mutations are associated with lung adenocarcinomas."}, {"pubmed": 20559149, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20559151, "text": "KRAS gene mutations are associated with non-small cell lung cancer."}, {"pubmed": 20559151, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20563851, "text": "HER2, but not EGFR gene amplification, is frequently observed in KRAS and BRAF wild type colorectal cancer patients"}, {"pubmed": 20563851, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20565773, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 20565773, "text": "Observed a significant association of SMAD4 gene aberrations with KRAS mutant status suggesting the involvement of at least two molecules in the advanced tumor grade in colorectal cancers in a Kashmiri population."}, {"pubmed": 20570890, "text": "biological, biochemical and prognostic significance of Ras pathway alterations in colorectal and other solid tumor malignancies; mutations in exon 4 of KRAS were found to occur commonly and to predict a more favorable clinical outcome in colorectal cancer"}, {"pubmed": 20571907, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20571907, "text": "PIK3CA mutations may have a role in KRAS and BRAF wild type colorectal cancer"}, {"pubmed": 20575464, "text": "High resolution melting is a reliable screening method to identify mutations in the KRAS gene in colorectal cancer."}, {"pubmed": 20578946, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20578946, "text": "Only a single gene alteration, of uncertain role, was found in the KRAS gene in an Noonan syndrome patient also presenting a PTPN11 gene mutation."}, {"pubmed": 20580219, "text": "Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20580219, "text": "The meta-analysis strongly suggests that KRAS mutations represent adverse predictive and prognostic biomarkers for tumour response and survival in mCRC patients treated with cetuximab."}, {"pubmed": 20583472, "text": "assessment of K-ras gene expression changes in the development of the HPV positive cervical cancers; findings indicate high expression of ras among high risk HPV infection can be a marker of cervical cancer development"}, {"pubmed": 20583607, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20591910, "text": "Mutations in KRAS and BRAF genes are not directly implicated in the development of a MELF (macrocystic, elongated, and fragmented) pattern of invasion in endometrial carcinoma."}, {"pubmed": 20591910, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20592359, "text": "analysis of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors"}, {"pubmed": 20603437, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20603437, "text": "Results are the first to indicate that the KRAS 3'UTR polymorphism may predict for cetuximab responsiveness in KRASwt mCRC patients."}, {"pubmed": 20610624, "text": "Findings identify miR-96 as a potent regulator of KRAS in pancreatic cancer."}, {"pubmed": 20616366, "text": "Using traditional PCR and direct sequencing, we found KRAS mutations in 47 (40%) patients and BRAF(V600E) in 10 (8.5%)"}, {"pubmed": 20617134, "text": "Clinical relevance of KRAS in human cancers."}, {"pubmed": 20619739, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20619739, "text": "if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA exon 20 mutations (in that order) gives additional information about the efficacy of cetuximab plus chemotherapy in metastatic colorectal cancer."}, {"pubmed": 20624322, "text": "EML4-ALK fusion gene was present at a high frequency in Chinese NSCLC patients, particularly in those with adenocarcinomas lacking EGFR/KRAS mutations"}, {"pubmed": 20627194, "text": "PCR is practically applicable to KRAS/BRAF genotyping using small amounts of biopsied colorectal tumor cells."}, {"pubmed": 20628283, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20628283, "text": "Of the 750 cases of rectal cancer with tumor mutation information, 28.9% had a KRAS2 mutation, and 48.3% had a TP53 mutation. The majority of both KRAS2 and TP53 mutations were transitions."}, {"pubmed": 20630828, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20630999, "text": "Results suggest that RAGE, NOX, and H-Ras/Raf-1 are implicated in the up-regulation of HSF1 or PAI-1 in vascular EC under diabetes-associated metabolic stress."}, {"pubmed": 20631636, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20645028, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20645028, "text": "samples of metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene"}, {"pubmed": 20646601, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20647319, "text": "Findings support the hypothesis that the KRAS-variant is a genetic marker for increased risk of developing OC and suggest that the KRAS-variant may be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities."}, {"pubmed": 20647319, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20652941, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20652953, "text": "data provide evidence that c-Kit, p53 codon 72, and K-ras codon 12 are independent prognostic factors in patients with stage II colorectal cancer"}, {"pubmed": 20661086, "text": "KRAS gene mutations are associated with lung adenocarcinomas with features of the mucinous subtype of bronchioloalveolar carcinoma."}, {"pubmed": 20661086, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20673328, "text": "Over expression of pro apoptotic markers: p27KIP1 and KRAS4A isoforms was significantly higher in CRC subset with TRAIL-R1 and TRAIL-R2 expression"}, {"pubmed": 20675343, "text": "frequently downregulated miR-217 can regulate KRAS and function as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC)."}, {"pubmed": 20676756, "text": "KRAS-variant frequencies might be increased among BRCA1 carriers"}, {"pubmed": 20676756, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 20678218, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20681447, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20681447, "text": "The frequency of K-RAS gene mutations with non-small cell lung cancer in our center is very low and is similar to that in Asia patients, and is lower than that in Caucasian population."}, {"pubmed": 20682398, "text": "Investigated the methylation of the SFRP2, P16, DAPK1, HIC1, and MGMT genes, as well as the mutation of amino acid codons 12 and 13 of the KRAS gene in normal and tumor tissue DNA of patients diagnosed with sporadic colorectal cancer."}, {"pubmed": 20682398, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20682656, "text": "Wild-type K-Ras.GTP in association with Gal-3 contributes to thyroid carcinoma malignancy."}, {"pubmed": 20683036, "text": "K-ras mutation in blood appears to indicate K-ras mutation in tumour, while the absence of blood K-ras mutation does not prove lack of mutation in the tumour."}, {"pubmed": 20683036, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20686305, "text": "Somatic mutations in K-ras and epigenetic alterations in SFRP2 genes play a role in development of mucinous type anal adenocarcinoma."}, {"pubmed": 20686428, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20688547, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20688547, "text": "a natural history for hyperdiploid leukemia in which prenatal mitotic catastrophe is followed by a postnatal KRAS mutation to produce the leukemic cell phenotype."}, {"pubmed": 20696815, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20696815, "text": "The amplification-refractory mutation system with formalin-fixed, paraffin-embedded specimen-derived DNA samples of the human KRAS protein exhibited an acceptable feasibility and robustness suitable for routine clinical practice."}, {"pubmed": 20699365, "text": "In KRAS mutant tumors, PIK3CA mutation restores cyclin D1 expression and G(1)-S cell cycle progression so that they are no longer dependent on KRAS and MEK/ERK signaling."}, {"pubmed": 20702788, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20703476, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20712532, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20718705, "text": "KRAS mutation is associated with anti-EGFR therapy response in colorectal cancer."}, {"pubmed": 20725992, "text": "presence of activating KRAS mutations is significantly correlated to an upregulation of 13 genes (adjusted P-value <0.05), among them DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase"}, {"pubmed": 20734064, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20736745, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 20802181, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20810036, "text": "Noonan syndrome and systemic lupus erythematosus is reported in a patient with a novel KRAS mutation."}, {"pubmed": 20813562, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20813562, "text": "study supports that mutations in the KRAS gene make at least a minor contribution to OSCC tumorigenesis"}, {"pubmed": 20819778, "text": "Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"}, {"pubmed": 20824720, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20840818, "text": "Expression level of EGFR protein and mutation frequency of KRAS gene in primary tumors were higher than that in metastases."}, {"pubmed": 20840818, "text": "Meta-analysis of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20842128, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20842128, "text": "data show that EGFR gene copy number and KRAS mutation status are neither predictive nor prognostic factors for pathological tumour response and disease-free survival in locally advanced rectal cancer patients treated with preoperative chemoradiation"}, {"pubmed": 20845292, "text": "K-ras exon 1 gene mutations were found with low frequency in the bladder cancer tumors from Kashmir valley, which suggests that K-ras gene might be involved in a sub-set of bladder tumors."}, {"pubmed": 20845292, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 20846262, "text": "review focused on KRAS gene mutations with special reference to lung cancers, and pointed out important issues remaining to be resolved [review]"}, {"pubmed": 20848649, "text": "Observational study of genetic testing. (HuGE Navigator)"}, {"pubmed": 20855820, "text": "Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20860430, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20871266, "text": "KRAS mutation is associated with lung cancer."}, {"pubmed": 20871271, "text": "Kras gene mutation and copy number is associated with thymic carcinomas and thymomas."}, {"pubmed": 20880116, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20881644, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20884623, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20888703, "text": "Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine was active and well tolerated. KRAS mutation status was not a predictive factor for pathologic response in this study."}, {"pubmed": 20933246, "text": "Report on the clinical utility of reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutatations."}, {"pubmed": 20935157, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20937558, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20939111, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20947270, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20947270, "text": "The presence of KRAS mutations and loss of PTEN expression were not associated with impaired response to cetuximab-based chemoradiotherapy and 3-year disease free survival."}, {"pubmed": 20949557, "text": "Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 20949621, "text": "role of germline KRAS mutations in developmental disorders"}, {"pubmed": 20955384, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 20955384, "text": "Sixty-nine per cent of endocervical-like mucinous borderline tumour of the ovary showed KRAS mutations"}, {"pubmed": 20959479, "text": "KRASG12D is associated with pancreatic cancer."}, {"pubmed": 20959488, "text": "K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia."}, {"pubmed": 20959826, "text": "Observational study of gene-disease association and genetic testing. (HuGE Navigator)"}, {"pubmed": 20959826, "text": "The KRAS mutation is a negative predictive factor for survival in patients rectal and colon cancer."}, {"pubmed": 20972333, "text": "Results reveal an unexpected role for WT1 as a key regulator of the genetic network of oncogenic KRAS and provide important insight into the mechanisms that regulate proliferation or senescence in response to oncogenic signals."}, {"pubmed": 20972872, "text": "Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20978259, "text": "Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"}, {"pubmed": 20979647, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21031422, "text": "Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age."}, {"pubmed": 21036740, "text": "KRAS mutation-positive lung cancer displaying high levels of Myc could be treated by inhibiting Myc transactivation function."}, {"pubmed": 21036746, "text": "REsults show a high concordance in the KRAS status between the primary tumour and metastases."}, {"pubmed": 21048031, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 21051183, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21051183, "text": "findings indicate that somatic mutations in KRAS and PIK3CA but not BRAF oncogenes are closely associated with the development of cholangiocarcinoma in Chinese population"}, {"pubmed": 21055216, "text": "Mutation of oncogene K-ras at codon 12 and codon 13 is a common molecular event in colorectal carcinogenesis, which might be related with age and tumor location."}, {"pubmed": 21055216, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21063026, "text": "We report 2 cases with Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation"}, {"pubmed": 21070916, "text": "KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers."}, {"pubmed": 21072204, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21073737, "text": "Data reveal that HIF-1alpha and HIF-2alpha work together to modulate cancer metabolism and regulate genes signature overlapping with oncogenic KRAS."}, {"pubmed": 21074889, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21074889, "text": "mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients"}, {"pubmed": 21079152, "text": "we demonstrate that somatic mutations in the related KRAS gene can also be associated with a nonmalignant syndrome of autoimmunity and breakdown of leukocyte homeostasis"}, {"pubmed": 21080251, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 21081081, "text": "Multiple cellular proteins control the dynamics of membrane association and intercompartmental movement of K-ras to an important degree even under basal cellular conditions."}, {"pubmed": 21097396, "text": "let-7a over-expression represses the expression of k-Ras protein and significantly inhibits the growth of A549 lung cancer cells."}, {"pubmed": 21099348, "text": "Study suggests that concomitant expression of MMP-7 and IGF type 1 receptor correlates with poor prognosis in WT KRAS patients treated with anti-EGFR."}, {"pubmed": 21102258, "text": "Mutations of EGFR, BRAF, and KRAS in adenocarcinoma were mutually exclusive and inversely correlated with RASSF1A methylation"}, {"pubmed": 21103049, "text": "Data show that among 181 CRC patients, stratified by microsatellite instability status, DNA sequence changes were identified in KRAS (32%), BRAF (16%), PIK3CA (4%), PTEN (14%) and TP53 (51%)."}, {"pubmed": 21109984, "text": "K-ras mutations appear more homogeneously distributed than methylation of p16 and MGMT and LOH at 18q, 17p, and 5q in colorectal cancer"}, {"pubmed": 21122130, "text": "Pyrosequencing provided sufficient analytical sensitivity and specificity to assess the KRAS mutation status in routine formalin-fixed CRC samples."}, {"pubmed": 21127395, "text": "Twenty paired specimens of colorectal cancer and adjacent normal tissues were examined for K-ras mutations and annexin A1 expression."}, {"pubmed": 21129603, "text": "This review focuses on current knowledge regarding the molecular landscape of metastatic colorectal cancer including and beyond KRAS, and will summarize novel rationally-developed combinatorial regimens that are being evaluated in early clinical trials."}, {"pubmed": 21129606, "text": "KRAS gene mutations are widely recognized alterations involved in biology and the clinical management of lung adenocarcinoma.This review reports the molecular bases that have led clinical application of detection for such genetic impairments."}, {"pubmed": 21129611, "text": "KRAS mutations are a predictor of resistance to panitumumab or cetuximab.Studies of patients receiving treatment show that tumors carrying KRAS mutations don't respond to EGFR-targeted monoclonal antibodies or show survival benefit from such treatments."}, {"pubmed": 21131919, "text": "Primary esophageal melanomas of Caucasian patients harbor mutations of c-Kit, KRAS and BRAF in varied frequencies."}, {"pubmed": 21150464, "text": "Kras mutation plus increased copy number is associated with non-small cell lung cancer."}, {"pubmed": 21155011, "text": "Data show that KRAS mutation and PTEN protein expression are significantly correlated with the response rate and survival time of Chinese metastatic colorectal cancer patients treated with cetuximab."}, {"pubmed": 21159816, "text": "KRAS and RREB1 are targets of miR-143/miR-145, revealing a feed-forward mechanism that potentiates Ras signaling"}, {"pubmed": 21161326, "text": "Data suggest that expression status of AR and EPI mRNAs might be evaluated as dynamic predictors of response in KRAS WT patients receiving any cetuximab-based therapy."}, {"pubmed": 21161938, "text": "KRAS mutations arise more frequently than BRAF mutations in Moroccan patients with colorectal carcinomas."}, {"pubmed": 21168197, "text": "Mutations in PIK3CA, KRAS and NRAS were exclusive to tumors of uterine origin and age-adjusted Cox proportional hazards modeling associated advanced age, stage and TP53 mutations with decreased survival in the uterine subset."}, {"pubmed": 21169348, "text": "Mutated KRAS status in tumors of Japanese patients with metastatic colorectal cancer is associated with lack of response to panitumumab therapy"}, {"pubmed": 21169357, "text": "KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways."}, {"pubmed": 21174225, "text": "Combination chemotherapy with biweekly cetuximab and irinotecan was effective for pretreated metastatic colorectal cancer with wild-type KRAS."}, {"pubmed": 21175807, "text": "Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling."}, {"pubmed": 21178719, "text": "KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma"}, {"pubmed": 21187500, "text": "In a group of clinically selected patients, EGFR and KRAS analysis was able to define distinct molecular subsets of lung adenocarcinoma."}, {"pubmed": 21187522, "text": "40 KRAS wild-type, 40 codon 12-mutated and 32 codon-13 mutated samples were analysed by Ampli-set-K-RAS and K-RAS StripAssay kit."}, {"pubmed": 21209378, "text": "study analyzed 90 samples of cutaneous T-cell lymphomas patients and found 2 KRAS (G13D) and 2 NRAS (Q61K) mutations"}, {"pubmed": 21228335, "text": "KRAS mutation is associated with treatment response for metastatic colorectal cancer."}, {"pubmed": 21228365, "text": "Compared with wild-type KRAS colorectal cancers, KRAS-mutated CRCs had a lower frequency of high microsatellite instabilities, a higher chance of having brisk mitosis and apoptosis, and a greater mean of mitotic figures and apoptotic cells"}, {"pubmed": 21239505, "text": "KRAS mutation seems to be associated with metastasis in specific sites, lung and brain, in colorectal cancer patients"}, {"pubmed": 21242956, "text": "study demonstrates that chip-based TGCE is capable of rapidly screening low-abundance K-ras mutations with high sensitivity, reproducibility, simplicity, and significant savings of time and sample"}, {"pubmed": 21252116, "text": "Studies identify a novel proapoptotic gene target, CYFIP2, which is downregulated by IMP-1, and mediates the regulation of cell survival and K-Ras expression in colon cancer cells."}, {"pubmed": 21257709, "text": "Findings suggest strategies to target nucleolin as a general approach to inhibiting ErbB- and Ras-driven cancers."}, {"pubmed": 21257719, "text": "Data show distinct significant correlations between TITF-1 protein expression and DNA copy gain with mutations in the lung adenocarcinoma-prevalent EGFR and KRAS oncogenes."}, {"pubmed": 21262926, "text": "the role of Pim-1 in pancreatic ductal adenocarcinoma (PDAC) growth transformation and validate Pim-1 kinase as a potential molecular marker for mutated K-Ras activity."}, {"pubmed": 21263241, "text": "There was an incremental increase in KRAS mutation frequency with increasing villous compartment of colorectal neoplasms."}, {"pubmed": 21271222, "text": "KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib."}, {"pubmed": 21277645, "text": "mutations confer antineoplastic drug resistance"}, {"pubmed": 21283084, "text": "Alterations of the KRAS gene is associated with myelodysplastic syndromes and acute myeloid leukemia."}, {"pubmed": 21298467, "text": "The diagnostic utility of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer (EPC) has not been properly studied"}, {"pubmed": 21300795, "text": "autophagy is critically involved in malignant transformation by oncogenic K-Ras and show that reactive oxygen species-mediated JNK activation plays a causal role in autophagy induction through up-regulation of ATG5 and ATG7."}, {"pubmed": 21305640, "text": "140/513 (27.3%) colorectal tumors wildtype for KRAS codons 12 and 13 harbored a mutation in another of the RAS pathway genes."}, {"pubmed": 21307665, "text": "analysis of gallbladder carcinomas, gallbladder adenomas, and high-grade dysplastic lesions for the BRAF and the KRAS mutations"}, {"pubmed": 21311557, "text": "Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model."}, {"pubmed": 21332555, "text": "K-ras mutations were involved in colorectal laterally-spreading tumors in different manners according to tumor location."}, {"pubmed": 21335545, "text": "Studies indicate that the function of PKCdelta in tumor cells depends on a specific oncogenic context, as loss of PKCdelta in NSCLC cells suppressed transformed growth only in cells dependent on oncogenic K-ras for proliferation and survival."}, {"pubmed": 21336309, "text": "oncogenic Ras efficiently activates the ERK pathway both by activating Raf and by inhibiting MEK SUMOylation, thereby inducing carcinogenesis"}, {"pubmed": 21364579, "text": "Both primary tumours and liver metastases can be used for KRAS mutation analysis."}, {"pubmed": 21364589, "text": "Kras(G12D) allele promotes metastasis in pancreatic cancer cells partly through the downregulation of E-cadherin."}, {"pubmed": 21375404, "text": "A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of India"}, {"pubmed": 21383284, "text": "KRAS mutational analysis provides useful additional risk stratification to guide use of adjuvant chemotherapy in colorectal cancer."}, {"pubmed": 21385921, "text": "Effective inhibition of the EGFR signaling by the drug combination in KRAS wild-type cells but not in KRAS mutant cells."}, {"pubmed": 21385923, "text": "data exclude the possibility of an association between KRAS rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer"}, {"pubmed": 21386094, "text": "Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors."}, {"pubmed": 21387273, "text": "Non-BAC adenocarcinoma is related to smoking history and has a poor prognosis. BAC/adenocarcinoma with bronchioloalveolar features adenocarcinoma, however, has a more favorable prognosis."}, {"pubmed": 21390154, "text": "K-ras gene mutation is a common event in Chinese colorectal cancer (CRC) patients, but may not be a prognostic factor in CRC , while BRAF is rarely mutated in Chinese CRC patients."}, {"pubmed": 21404058, "text": "TF may participate in both K-ras and p53 mutations involved in colorectal carcinogenesis."}, {"pubmed": 21408138, "text": "Allele-specific qPCR assays for the most frequent activating mutations in EGFR, KRAS, BRAF and PIK3CA in tumor-positive fine needle cytological aspirates were compared against histological material of primary tumors."}, {"pubmed": 21411444, "text": "NF-kappaB activation is a novel target of oncogenic KRAS in endometrial carcinogenesis"}, {"pubmed": 21414214, "text": "these results suggest that a considerable proportion of NSCLC in Chinese population showed discrepancy in KRAS and EGFR mutation status between primary tumors and corresponding metastases."}, {"pubmed": 21424008, "text": "Folding motifs have been uncovered in a nuclease hypersensitive element (NHE) with a complex guanine pattern, located in the human KRAS promoter. A new G-rich motif of 21 nt capable of forming a parallel G-quadruplex was disrupted by bound protein UP1."}, {"pubmed": 21424126, "text": "data indicated that colorectal cancers with KRAS and PIK3CA bi-mutations are more likely to develop into liver metastasis"}, {"pubmed": 21427714, "text": "The frequency of KRAS mutations was significantly higher in lesions with the adenomatous pattern than in lesions with the hyperplastic pattern."}, {"pubmed": 21435948, "text": "The KRAS variant might be a genetic marker for development of triple-negative breast cancer in premenopausal women."}, {"pubmed": 21436632, "text": "evaluation of the status of 90 non-selected colorectal cancer Peruvian patients; only 16.7% (15/90) of tumours exhibited KRAS mutations (codons 12 and 13)"}, {"pubmed": 21441955, "text": "demonstrate that mutant K-Ras enhances ETS2 loading onto the promoter, and ETS requires its transcriptional activity to increase GSK-3beta gene transcription in pancreatic cancer cells"}, {"pubmed": 21443421, "text": "a possible etiological role of the Ki-ras mutation in the development of the low-grade mucinous tumors of the appendix"}, {"pubmed": 21447798, "text": "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells."}, {"pubmed": 21457162, "text": "Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma"}, {"pubmed": 21468700, "text": "Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive colorectal cancer."}, {"pubmed": 21477882, "text": "gene amplification is associated with non-small cell lung carcinoma progression in both Swiss and Amertican cohorts"}, {"pubmed": 21478103, "text": "A review of several studies revealed a high rate of compliance of the KRAS gene mutational status in primary and metastatic tumors."}, {"pubmed": 21483104, "text": "Heterogeneity of KRAS and BRAF mutation status intra-tumorally in colorectal cancer was assessed."}, {"pubmed": 21497370, "text": "KRAS mutation in metastatic tumors is more commonly associated with advanced stages of cancer and correlates with a heavy smoking history."}, {"pubmed": 21502435, "text": "KRAS mutations in 23 adenosquamous carcinomas of lung"}, {"pubmed": 21508389, "text": "Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer."}, {"pubmed": 21510309, "text": "Semiquantitative analysis of K-ras point mutation in endoscopically-collected pancreatic juice appears to be a useful tool for identifying chronic pancreatitis patients at high risk for developing pancreatic cancer."}, {"pubmed": 21514245, "text": "c-Raf plays a unique role in mediating K-Ras signaling in non-small cell lung carcinoma and makes it a suitable target for therapeutic intervention."}, {"pubmed": 21527506, "text": "K-ras gene mutations were detected in four NSCLC cases (3.5%)."}, {"pubmed": 21531130, "text": "Using human CRC samples, authors were able to show that there is crosstalk between the KRAS-mediated pathway and other signalling pathways."}, {"pubmed": 21543894, "text": "the KRAS-variant was enriched in non-acral melanoma (25%), and miR-137 under expression was significantly associated with melanomas with the KRAS-variant."}, {"pubmed": 21544811, "text": "Data show that IL-8 overexpression is induced by activating mutations of KRAS or EGFR in non-small cell lung cancer (NSCLC) cells."}, {"pubmed": 21550229, "text": "KRAS mutation status is a treatment effect modifier for anti-EGFR antibodies in metastatic colorectal cancer"}, {"pubmed": 21555681, "text": "Case Report: KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib."}, {"pubmed": 21573497, "text": "K-rasVal12 and mutant Apc have a synergistic role in intestinal neoplasms"}, {"pubmed": 21573767, "text": "Heterogeneous distribution of K-ras codon 12 and 13 mutations within primary tumor, or between primary tumor and lymph node metastases, was demonstrated for 15 (20%) of 74 colon cancer patients having K-ras mutations."}, {"pubmed": 21586612, "text": "To define functions of STAT3 in vivo, authors test the impact of conditional inactivation of STAT3 in KRAS-driven PDAC."}, {"pubmed": 21592614, "text": "the incidence of EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung were similar to those of Asian patients with adenocarcinoma"}, {"pubmed": 21603900, "text": "These findings add information about the impact of specific amino acid changes in the Kras gene."}, {"pubmed": 21606339, "text": "low- and high-resolution mapping of nucleosome boundaries around p53 REs within the p21 promoter have provided insight into the mechanism of p53 binding to its sites in cells and the consequent changes in nucleosome occupancy at such sites"}, {"pubmed": 21607617, "text": "Combined mutations in codons 12 and 13 of KRAS are relatively infrequent and most commonly occur in prostate carcinomas."}, {"pubmed": 21607772, "text": "In patients with surgically resected lung adenocarcinomas, the KRAS and EGFR gene mutation status of tumors was not associated with disease-free survival."}, {"pubmed": 21615826, "text": "The incidence of KRAS mutations in Chinese patients with Esophageal Squamous Cell Carcinoma was not low. KRAS mutations were mainly located in codon 12."}, {"pubmed": 21624768, "text": "Stromal cells in colorectal carcinoma do not share KRAS mutations that the epithelial component harbors."}, {"pubmed": 21632860, "text": "The application of highly sensitive methods for the detection of KRAS mutations significantly improves the identification of mCRC patients resistant to anti-EGFR MoAbs."}, {"pubmed": 21636548, "text": "KRAS mutations are not associated with response to Bexarotene plus erlotinib therapy in lung carcinogenesis."}, {"pubmed": 21645454, "text": "the relationship between the mutation of K-ras gene and non-small cell lung cancer"}, {"pubmed": 21665177, "text": "Grossly polypoid colorectal adenocarcinomas with a persistent pre-existing adenomatous polyp with villous architecture are strongly associated with KRAS mutations."}, {"pubmed": 21670079, "text": "A pathway in which Max & RXRalpha inhibit miR-193a activates the PLAU & K-Ras oncogenes is important for distinct aspects of cellular transformation. miR-193a controls anchorage-independent growth in soft agar through K-Ras."}, {"pubmed": 21678640, "text": "mutation kit analysis identified a total rate of 44.8% mutations in patients with colorectal cancer; most mutations (82.4%) were identified within codon 12 and the minority on codon 13"}, {"pubmed": 21681971, "text": "An evaluation of cytomorphologic features of advanced lung adenocarcinomas that might be associated with KRAS mutational status."}, {"pubmed": 21688344, "text": "These data demonstrate a role for rs712 polymorphism of the KRAS in susceptibility of oral squamous cell carcinoma."}, {"pubmed": 21698197, "text": "conclude that, in the colon and pancreas, Cten is a downstream target of Kras and may be a mechanism through which Kras regulates of cell motility"}, {"pubmed": 21699410, "text": "Comparison of KRAS mutation tests in colorectal cancer patients."}, {"pubmed": 21699772, "text": "Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool."}, {"pubmed": 21700687, "text": "In total, 29% of the false-negative or doubtful cytology results were accompanied by RASSF1A methylation or KRAS mutation results that were highly suggestive of malignancy."}, {"pubmed": 21705950, "text": "Combining routine cytology with FISH and K-ras mutational analyses improves diagnostic yield of endoscopic ultrasound-guided fine needle aspiration of solid pancreatic masses."}, {"pubmed": 21720997, "text": "KRAS mutation is associated with nonsmall cell lung cancer."}, {"pubmed": 21737635, "text": "KRAS mutation strongly predicts for a lack of clinically meaningful benefit in colorectal cancer patients."}, {"pubmed": 21738012, "text": "mitochondrial functional loss may be mediated by oncogenic K-Ras-induced mitophagy during early tumorigenesis even in the absence of hypoxia"}, {"pubmed": 21742770, "text": "STK33 downregulation or dominant mutant overexpression had no effect on KRAS signaling or survival of cancer cells."}, {"pubmed": 21743433, "text": "The detection of KRAS mutant allele-specific imbalance in lung adenocarcinomas may identify patients with more aggressive disease."}, {"pubmed": 21795973, "text": "compared with KRAS codon 12 mutations, codon 13-mutated metastatic colorectal cancer presents as a more aggressive disease frequently associated with local and distant metastases at first diagnosis"}, {"pubmed": 21797849, "text": "An unusual phenotypic effect of the specific KRAS mutation or a coincidence of two independent disorders may be considered. KRAS mutation-associated phenotypes appear to be subject to considerable clinical heterogeneity"}, {"pubmed": 21807965, "text": "Data suggest that recurring DNA copy alterations are important for tumor progression in the Kras(LA2) model of lung cancer and that the requirement for these alterations may be dependent on the genetic background of the mouse strain."}, {"pubmed": 21811765, "text": "The KRAS mutation occurred more frequently in lung tumor patients whose ;ung tumor diameter was >/= 31 mm than in those whose tumor diameter was <30 mm."}, {"pubmed": 21825899, "text": "Heterogeneous KRAS mutations within the primary colorectal tumor might play an important role for discordant KRAS status between primary and metastatic sites."}, {"pubmed": 21836482, "text": "Neoadjuvant chemoradiotherapy did not alter KRAS codon 12 or 13 or microsatellite instability results in rectal adenocarcinoma."}, {"pubmed": 21839537, "text": "KRAS mutation is an early hit in lung adenocarcinoma development."}, {"pubmed": 21842425, "text": "Our results suggest that response to Panitumumab treatment is not only controlled by the KRAS status but may also be essentially influenced by other regulating factors."}, {"pubmed": 21847063, "text": "KRAS mutations are associated with treatment response in non-small cell lung cancer."}, {"pubmed": 21851273, "text": "KRAS mutation status predicts a patient's likely response to the monoclonal antibody cetuximab."}, {"pubmed": 21855038, "text": "Mutant KRAS is associated with low drug response in metastatic colorectal cancer."}, {"pubmed": 21860425, "text": "the results provide strong evidence that CTNNB1 is the driver in these contexts and that KRAS(G12D) and Pten loss promote the program set in motion by the CTNNB1."}, {"pubmed": 21862683, "text": "Patients with pancreatic cancer with KRAS mutations showed a worse response to chemotherapy than those with wild-type KRAS."}, {"pubmed": 21865138, "text": "APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men."}, {"pubmed": 21871821, "text": "Genetic analysis revealed individual heterozygous mutations in the KRAS (phenotype of CFC/Noonan syndrome) and BRAF genes (phenotype of CFC syndrome)"}, {"pubmed": 21873159, "text": "HKe3 cells stably overexpressing oncogenic KRAS showed increased expression of miR-200c, miR-221 and miR-222 and reduced expression of its target PTEN exclusively in 3D culture. These miRNAs were also overexpressed in colorectal tumor specimens."}, {"pubmed": 21873171, "text": "Under serum-starved conditions, the expression level of RRM2 protein increased in HCT116 cells compared to HKe3 cells (HCT116 cells with a disruption in oncogenic KRAS), and the re-expression of KRAS in HKe3 cells induced the expression of RRM2."}, {"pubmed": 21876558, "text": "The K-RAS protein is associated with mitochondria, and induces a rapid suppression of respiratory chain complex-I and a decrease in mitochondrial transmembrane potential by affecting the cyclosporin-sensitive permeability transition pore."}, {"pubmed": 21876563, "text": "Our method for the detection of KRAS gene mutations may be useful to supplement histo/cytopathologic evaluations for pancreatic cancer, and is superior to serum CA19-9 in EUS-FNAB histo/cytopathology-indeterminate patients"}, {"pubmed": 21884745, "text": "colorectal cancer patients with low levels of tumor-infiltrating lymphocytes , a high CD1a(+)/DC-LAMP(+) tumor-infiltrating DC ratio, and a KRAS mutation in codon 13 are at a high risk of disease recurrences"}, {"pubmed": 21894049, "text": "KRAS mutation is associated with metastatic pancreatic ductal adenocarcinoma."}, {"pubmed": 21897875, "text": "IFN-beta contributes to Ras transformation"}, {"pubmed": 21900245, "text": "Paxillin enables attachment-independent tyrosine phosphorylation of focal adhesion kinase and transformation by RAS"}, {"pubmed": 21901162, "text": "In sporadic colorectal tumourspatients, the most frequently mutated gene was APC (68.9% of tumours), followed by KRAS (31.1%), TP53 (27.2%), BRAF (8.7%) and CTNNB1 (1.9%)."}, {"pubmed": 21910869, "text": "Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy"}, {"pubmed": 21943101, "text": "KRAS mutation G12V enhances the ability of colon adenocarcinoma cells to migrate and invade through filopodia formation and PI3K-dependent Cdc42 activation"}, {"pubmed": 21945923, "text": "Validated liquid-based cytology for EGFR and KRAS gene mutations and set appropriate laser capture microdissection and direct sequencing benchmarks."}, {"pubmed": 21947301, "text": "KRAS mutation detection may be reliably performed with high accuracy, allowing treatment decisions for lung cancer."}, {"pubmed": 21949883, "text": "KRAS mutations are associated with non-small cell lung cancer."}, {"pubmed": 21962894, "text": "KRAS mutation is associated with metastatic colorectal cancer"}, {"pubmed": 21982684, "text": "KRAS gene may be instable during the metastatic process observed in non-small cell lung cancer, whereas the mutant KRAS genotype in the primary tumor could be more likely to change back to the wild-type after metastasis."}, {"pubmed": 21985784, "text": "KRAS knockdown using shRNA suppressed ERK signaling in all of the KRAS mutant colorectal cancer cell lines examined."}, {"pubmed": 21989023, "text": "Data show that high-resolution melting analysis is a sensitive and accurate screening methodology for K-ras codons 12 and 13 mutations in clinical samples."}, {"pubmed": 21994416, "text": "Results indicate that early-stage colorectal cancer (CRC) with the KRAS-lethal-7 (let-7) miRNA complementary site (LCS6) variant have a better outcome."}, {"pubmed": 22000810, "text": "KRAS mutation is associated with metastatic colorectal cancer."}, {"pubmed": 22006538, "text": "DNA methylation of each marker was quantified using combined bisulfite restriction analysis (COBRA) and analyzed along with various genetic factors associated with CRC [the BRAF and KRAS mutations, MLH1 methylation and microsatellite instability"}, {"pubmed": 22011285, "text": "KRAS mutations in primary NSCLC foci may be a more accurate biomarker than in metastases to reflect KRAS mutation status."}, {"pubmed": 22016105, "text": "strong positive correlation between the fraction of mutated KRAS alleles and the fraction of cancer cells in the samples indicate homogeneity of KRAS mutation status in colorectal carcinoma"}, {"pubmed": 22016468, "text": "Cell growth retardation was inhibited upon knockdown of K-Ras and an increase in the level of miR-622 in 16HBE-T cells"}, {"pubmed": 22020370, "text": "role of KRAS mutations in esophageal squamous-cell carcinoma carcinogenesis (Review)"}, {"pubmed": 22043994, "text": "This article reviewes the spectrum of KRAS/BRAF genotype and the impact of KRAS/BRAF mutations on the clinicopathological features and prognosis of patients with colorectal cancer. [review]"}, {"pubmed": 22044911, "text": "Letter: K-ras mutations in plasma correspond to computed tomographic findings in patients with pancreatic cancer and may serve as prognostic biomarker."}, {"pubmed": 22049925, "text": "study presents a novel functional interaction of p16 and K-Ras. Re-expression of the tumor suppressor in pancreatic cancer cells restricted Ras oncoprotein activity, which resulted in loss or reduction of their transforming potential"}, {"pubmed": 22080568, "text": "Human lung adenocarcinoma cases lacking EGFR, KRAS, and ALK mutations had a worse prognosis for relapse and death, compared with cases with EGFR, KRAS, or ALK mutations"}, {"pubmed": 22082529, "text": "KRAS mutant cancer cells showed variable response to AZD6244."}, {"pubmed": 22113502, "text": "loss of heterozygosity at Kras can provide cancer cells functional growth advantages and promote metastasis."}, {"pubmed": 22114137, "text": "African Americans with microsatellite stable tumors had a higher proportion of KRAS mutations than Caucasians that were isolated to proximal colon cancers and primarily driven by mutations in codon 13."}, {"pubmed": 22115708, "text": "Adenoma with intermediate-methylation epigenotype correlated to KRAS-mutation((+))."}, {"pubmed": 22135231, "text": "Data indicate that PIK3CA mutations occur in lung adenocarcinomas, usually concurrently with EGFR, KRAS, and anaplastic lymphoma kinase (ALK)."}, {"pubmed": 22138963, "text": "KRAS mutation is inversely associated with interval cancers and with MSI, suggesting that it is a marker of the chromosomal instability pathway associated with slow tumor growth."}, {"pubmed": 22139083, "text": "Data indicate that RNA interference of KRAS variant caused a significant decrease in cell survival in the KRAS variant carrying epithelial ovarian cancer cell line."}, {"pubmed": 22140652, "text": "This is the first description of an oncogenic gene fusion of KRAS, one of the most studied proto-oncogenes."}, {"pubmed": 22157687, "text": "BRAF and KRAS mutations were observed in six (46.2%) and four (30.3%) filiform serrated adenomaS, respectively."}, {"pubmed": 22157931, "text": "Report validity EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection."}, {"pubmed": 22177492, "text": "A considerable proportion of NSCLC in Chinese patients showed discrepancy in KRAS and EGFR mutation status between primary tumors and corresponding metastases."}, {"pubmed": 22178589, "text": "Report mutations in KRAS, EGFR, and BRAF in cholangiocarcinoma and identify therapeutic targets for tyrosine kinase inhibitors."}, {"pubmed": 22188534, "text": "Mutations in kras proteins are present in benign lichenoid keratosis."}, {"pubmed": 22189714, "text": "This study provides a step forward towards understanding the molecular and pathological significance of the KRAS-variant."}, {"pubmed": 22190283, "text": "Gene mutations of K-ras are not associated with the postoperative prognosis of patients with hepatocellular carcinoma."}, {"pubmed": 22195963, "text": "The small number of tumors with co-expression of mutant K-Ras and MST2 has elevated apoptosis rates"}, {"pubmed": 22198706, "text": "Mutations detected in KRAS in microdissected samples from different areas of the same tumor (colon cancer) differed according to immunophenotype."}, {"pubmed": 22199277, "text": "RET mutations may have a role in medullary thyroid carcinoma, while BRAF, AKT1, and CTNNB1 do not; the role of HRAS, KRAS, and NRAS mutations are not determined"}, {"pubmed": 22200795, "text": "GLUT1 overexpression status was significantly correlated with gene mutation status, including EGFR and Kras"}, {"pubmed": 22210048, "text": "the activity of myeloblastin was significantly altered in the lung adenocarcinoma biopsies harboring a KRAS gene mutation."}, {"pubmed": 22213982, "text": "The significance of tests for KRAS mutation in colorectal cancer is described together with varius test methods for the said mutation.[review]"}, {"pubmed": 22222375, "text": "These results strongly suggested that the oncogenic RAS upregulates EZH2 through MEK-ERK signaling, resulted in downregulation of tumor suppressors including RUNX3 in pancreatic carcinogenesis."}, {"pubmed": 22228631, "text": "Plasma cell-free DNA and plasma mutant KRAS levels (pmKRAS) were strongly correlated."}, {"pubmed": 22228640, "text": "Our findings suggest that EGFR/KRAS mutations do not occur in pure pulmonary squamous cell carcinoma (SQCC)."}, {"pubmed": 22245873, "text": "The mutation status of the KRAS gene is likely involved in mTOR pathway and to be a prognosis marker for colorectal cancer in kidney transplantation."}, {"pubmed": 22247021, "text": "Not all mutant KRas proteins affect patient survival or downstream signaling in a similar way. The heterogeneous behavior of mutant KRas proteins implies that ther interventions may need to take into account the specific mutant KRas expressed by the tumor"}, {"pubmed": 22248908, "text": "Savings of drug costs minus the costs for the determination of KRAS status accounted for EUR 779.42 (SD +/-336.28) per patient per cycle."}, {"pubmed": 22252179, "text": "there is a high frequency of G to A transition of codon 12 mutation of the K-ras gene, with significant correlation with tumour size and tumour location"}, {"pubmed": 22259183, "text": "The KRAS status varied among different areas of the same metastatic focus in metastatic colorectal adenocarcinomas."}, {"pubmed": 22261536, "text": "The rareness of the TP53 mutation shown in this study supports that SCC seems to develop from multipotential stem cells in dysplasia or adenocarcinoma. The mutual wild type status of KRAS among the lesions further supported their identical clonality."}, {"pubmed": 22264792, "text": "Mutated Kras(G12D)-activated AP-1 induces IL-1alpha, which, in turn, activates NF-kappaB and its target genes IL-1alpha and p62, to initiate IL-1alpha/p62 feedforward loops for inducing and sustaining NF-kappaB activity."}, {"pubmed": 22267755, "text": "mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC."}, {"pubmed": 22269385, "text": "K-RAS mutation may regulate the ERK pathway, which in turn increases the expression of GGT2"}, {"pubmed": 22282465, "text": "These data suggest the activation of mitogen-activated protein kinase pathway as a possible novel mechanism of primary resistance to imatinib in GISTs"}, {"pubmed": 22287190, "text": "KRAS mutation is associated with colorectal serrated adenocarcinoma."}, {"pubmed": 22290300, "text": "KRAS mutant allele-specific imbalance is associated with colorectal adenocarcinoma."}, {"pubmed": 22302539, "text": "findings implicate that N116S change in KRAS is a hyperactive mutation which is a causative agent of Noonan syndrome through maldevelopment of the heart"}, {"pubmed": 22305241, "text": "These findings support the hypothesis that endometriosis-associated and independent endometrioid adenocarcinoma may develop via different molecular pathways and that KRAS mutations have an important role only in the former tumors."}, {"pubmed": 22307873, "text": "An inherited polymorphism of a let-7 miRNA binding site in KRAS leads to abnormal endometrial growth and endometriosis."}, {"pubmed": 22314188, "text": "Colon adenocarcinomas with KRAS mutations have higher survival rates and morphologic characteristics distinct from those with BRAF mutations."}, {"pubmed": 22317764, "text": "Data indicate that 266 (76.2%) tumors harbored EGFR mutations, 16 (4.6%) HER2 mutations, 15 (4.3%) EML4-ALK fusions, 7 (2.0%) KRAS mutations, and 2 (0.6%) BRAF mutations."}, {"pubmed": 22317887, "text": "Report of oncogenic BRAF/KRAS mutations in sporadic glomus tumors."}, {"pubmed": 22327383, "text": "The presence of both KRAS mutations and the active form of NF-kappaB in CRC tumors indicates poor patient prognosis."}, {"pubmed": 22331825, "text": "BRAF genotype, but not KRAS, was found to be an independent prognostic biomarker."}, {"pubmed": 22337533, "text": "KRAS mutation is associated with colorectal cancer."}, {"pubmed": 22341439, "text": "data suggest that TAK1 functions as a prosurvival mediator in cancer cells displaying hyperactive KRAS-dependent Wnt signaling."}, {"pubmed": 22342683, "text": "K-Ras knockdown abolished the insulin-like growth factor-1 (IGF-1)-induced ERK pathway in the K-Ras mt pancreatic ductal adenocarcinomas cells"}, {"pubmed": 22348416, "text": "All mucinous growths in congenital pulmonary airway malformations were characterized by KRAS missense mutations."}, {"pubmed": 22349355, "text": "cigarette smoking may be a stronger risk factor for KRAS mutation-negative tumors located in the proximal colon"}, {"pubmed": 22374786, "text": "The presence of activating GNAS mutations, in association with KRAS or BRAF mutations, is a characteristic genetic feature of colorectal villous adenoma."}, {"pubmed": 22383492, "text": "Oncogenic KRAS can downregulate Bmp4 through a transcriptional pathway that depends on ERK. These findings point to a unique link between two pathways that are frequently altered in colon cancer."}, {"pubmed": 22383975, "text": "analysis of FGFR2 point mutations in 466 endometrioid endometrial tumors and their relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations"}, {"pubmed": 22386733, "text": "KRAS mutations were present rarely in stidied cohort of samples with breast cancer"}, {"pubmed": 22394035, "text": "mutation of KRAS gene may serve as useful clinical tool for analyzing point mutations in various clinical samples"}, {"pubmed": 22398042, "text": "KRAS mutations were found only in the presence of neoplasia in patients with longstanding ulcerative colitis in India."}, {"pubmed": 22407852, "text": "KRAS mutations to be more frequent than NRAS mutations in pediatric patients with acute myeloid leukemia."}, {"pubmed": 22417847, "text": "we have analyzed the prevalence of somatic mutations in the FGFR3, PIK3CA, AKT1, KRAS, HRAS, and BRAF genes in bladder cancers"}, {"pubmed": 22421763, "text": "Four of the 27 patients were positive for K-ras mutation"}, {"pubmed": 22422135, "text": "KRAS mutations are less common than previous reports and do not correlate with survival in pancreatobiliary neoplasms."}, {"pubmed": 22426079, "text": "Data indicate that TaqMan(R) Mutation Detection assay is an important technology to consider in the field of mutation detection for KRAS, BRAF and EGFR point mutation screening."}, {"pubmed": 22427190, "text": "Investigation the prevalence of mutations in the KRAS gene and its correlation with demographic characteristics, tumor location and stage in 100 colorectal carcinoma patients from India."}, {"pubmed": 22430133, "text": "KRAS mutations were higher in males compared to females and higher in adenocarcinomas compared to other forms of lung cancers"}, {"pubmed": 22430215, "text": "expression of these oncogenes markedly stimulated ERK1/2 activities and morphologically transformed IECs."}, {"pubmed": 22436609, "text": "Our data do not support the hypothesis that the KRAS variant rs61764370 is implicated in the aetiology of sporadic or of familial breast cancer."}, {"pubmed": 22441881, "text": "the expression of EGFR protein by immunohistochemistry and KRAS gene mutation at codons 12 and 13 by using paraffin-embedded and formalin-fixed primary tumor tissues from 205 patients with squamous cell carcinoma of the head and neck"}, {"pubmed": 22446022, "text": "KRAS may have a role in response of metastatic colorectal cancer to cetuximab"}, {"pubmed": 22459936, "text": "KRAS mutations play a limited role in the development of sinonasal cancer."}, {"pubmed": 22460425, "text": "In the KRAS gene, 10 substitutions at codon 12 were observed in lung adenocarcinomas from a Chiba Prefecture, Japan cohort."}, {"pubmed": 22488932, "text": "Metopic suture involvement has not been described before, expanding the main different cranial sutures which can be affected in Noonan syndrome and KRAS gene mutations"}, {"pubmed": 22489692, "text": "Mutation of KRAS is associated with colorectal cancer."}, {"pubmed": 22498935, "text": "Twelve of 94 cases (13%) analyzed for KRAS mutations were found to have a mutation in this study of patients with endometrial cancer."}, {"pubmed": 22510757, "text": "KRAS mutations occurred in conventional adenomas, which were more commonly located in the proximal colon and associated with higher risk for colorectal cancer."}, {"pubmed": 22517696, "text": "Mutations in the KRAS gene are a negative predictive factor for response to cetuximab with very high specificity and low sensitivity"}, {"pubmed": 22522845, "text": "CpG island methylation phenotype based on seven loci, BRAF V600E mutation and KRAS mutation in signet ring cell carcinoma were compared with mucinous and conventional adenocarcinomas"}, {"pubmed": 22526587, "text": "Tumors with KRAS mutations and NF-kappaB activation may be a unique subtype of colorectal cancer, and be more tolerant of chemotherapy and have a poorer prognosis."}, {"pubmed": 22528563, "text": "The aim of the present study was to determine the frequency of EGFR and KRAS mutations in non-small cell lung cancer in the West European Dutch population."}, {"pubmed": 22535956, "text": "AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-induced autophagy in cancer cells."}, {"pubmed": 22537608, "text": "KRAS mutations are associated with response to therapy in colorectal neoplasms."}, {"pubmed": 22537942, "text": "Expression of RBM5 mRNA and protein was negatively correlated with expression of EGFR and KRAS mRNA and protein in NSCLC tissues."}, {"pubmed": 22541434, "text": "Of 26 non-small cell lung cancer cell lines, 14 were KRAS mutant and 12 were wild type; short-term GATA2 knockdown led to specific decreased cell viability and increased apoptosis in KRAS mutant NSCLC cells, comparable to the effect seen with loss of KRAS itself."}, {"pubmed": 22549179, "text": "data indicate that miRNA-143 expression levels serve as an independent prognostic biomarker for CRC in KRAS wild-type patients"}, {"pubmed": 22563078, "text": "MSP58 activates the DNA damage response and p53/p21 signaling pathways."}, {"pubmed": 22569482, "text": "In this work we describe a simple and efficient method for synthesis of milligram quantities of functionally active, fully processed K-Ras4B, and we observe K-Ras4B dimerization in vitro."}, {"pubmed": 22579930, "text": "KRAS, BRAF, and PIK3CA mutations in colorectal cancer have sustained prevalence rate in the Taiwanese population."}, {"pubmed": 22583358, "text": "K-ras mutations were detected in 17 (19.3%) colon cancer samples."}, {"pubmed": 22586484, "text": "In the present study, we did not find any significant correlations between KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression and various clinicopathological features in Chinese patients with colorectal cancer."}, {"pubmed": 22588152, "text": "Chemotherapy effect seems to increase with tumor size. However, this small study could not identify subgroups of patients who did or did not derive significant benefit from adjuvant chemotherapy based on T-size or KRAS status."}, {"pubmed": 22589270, "text": "study examined the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases"}, {"pubmed": 22609129, "text": "KRAS mutations are associated with advanced colorectal neoplasms."}, {"pubmed": 22613949, "text": "Cancer cells expressing oncogenic KRAS were found to be highly dependent on the transcription factor GATA2 and the DNA replication initiation regulator CDC6."}, {"pubmed": 22617127, "text": "The numbers of primary lesions with wild-type and mutant KRAS codons 12 and 13 were 8 and 13, respectively."}, {"pubmed": 22635024, "text": "Single nucleotide polymorphism in KRAS is associated with synchronous endometrial and ovarian cancer."}, {"pubmed": 22638623, "text": "KRAS mutation status is predictive of cetuximab response in the Japanese metastatic colorectal cancer patients."}, {"pubmed": 22641662, "text": "Oncogenic KRAS regulates 3D-specific miRNAs that are possibly associated with colorectal development in vivo."}, {"pubmed": 22662244, "text": "These findings further validate the importance of the KRAS-variant in breast and ovarian cancer risk, and support the association of this variant as a genetic marker for HBOC families previously considered uninformative."}, {"pubmed": 22666783, "text": "this study is the first to examine the prevalence of EGFR and KRAS mutations in a South American Brazilian population."}, {"pubmed": 22669205, "text": "In 76 patients with colorectal neoplasms, 5 missense mutations were detected in KRAS. 7 patients had multiple mutations, MSH2 and KRAS, APC and KRAS."}, {"pubmed": 22672749, "text": "In patients with KRAS wild-type locally advanced rectal cancer, the addition of cetuximab to the chemoradiation with irinotecan plus capecitabine regimen was not associated with improved clinical outcome compared with chemoradiation without cetuximab"}, {"pubmed": 22674181, "text": "KRAS mutation is not associated with response to therapy in metachronous and synchronous metastatic colorectal adenocarcinoma"}, {"pubmed": 22675430, "text": "KRAS and PIK3CA mutations frequently coexist in patients with colorectal cancer, and are associated with clinical characteristics and outcome."}, {"pubmed": 22683711, "text": "Mosaicism for HRAS c.37G>C and KRAS c.35G>A mutations was found in two individuals with Schimmelpenning syndrome."}, {"pubmed": 22699145, "text": "Data indicate that 14% with pancreatic ductal adenocarcinomas (PDACs) and 7% ampullary adenocarcinomas (A-ACs) had mutations in both KRAS and BRAF."}, {"pubmed": 22701724, "text": "KRAS is a target of miR-30c, and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling."}, {"pubmed": 22706026, "text": "The combined effects of EGFR downregulation, ligand competition, and immune effector function conspire to inhibit tumor growth in xenograft models of cetuximab-resistant BRAF and KRAS mutant cancers."}, {"pubmed": 22708448, "text": "Relationship of activating mutation in K-ras gene with essential clinical characteristics of colorectal tumor disease in different age groups."}, {"pubmed": 22711838, "text": "An acetylation-mimetic mutation in K-RAS4B suppressed guanine nucleotide exchange factor-induced nucleotide exchange and inhibited in vitro transforming activity."}, {"pubmed": 22713664, "text": "Six KRAS mutations were detected by cobas that were not detected by Sanger, and five were confirmed by MPP."}, {"pubmed": 22729813, "text": "Investigated correlation between KRAS mutations and characteristics of non-advanced and advanced colorectal adenomas. KRAS mutations were detected in 31 % of the non-advanced adenomas, in 57.5 % of advanced adenomas and in 62.5 % of early carcinomas."}, {"pubmed": 22729835, "text": "Aim of this study was to characterize further the expression of RUNX3 in lung cancers.Inactivation of RUNX3 was observed in 70% of the adenocarcinoma samples, and this was associated with promoter hypermethylation but not biased to EGFR/KRAS mutations."}, {"pubmed": 22734028, "text": "Cetuximab addition to first line chemotherapy seems to benefit patients with KRAS mutant metastatic colorecttal neoplasms."}, {"pubmed": 22735045, "text": "This study emphasizes the functionality of cancer molecular genetic platforms dedicated to KRAS genotyping, which allow the use of molecular predictive biomarkers by different medical institutions."}, {"pubmed": 22744738, "text": "data showed that there was no significant difference in the mutation frequency of the KRAS gene between primary and distant metastatic colorectal tumors or lymph node metastatic tumors"}, {"pubmed": 22745110, "text": "Digital PCR provides a robust, quantitative measure of the proportion of KRAS mutant alleles in routinely obtained samples"}, {"pubmed": 22753589, "text": "KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer."}, {"pubmed": 22761399, "text": "The most significant discovery of the integrated validation is the down-regulation of FABP5 and PDCD4 in KRAS-activated human tumor bronchial epithelial cells."}, {"pubmed": 22770374, "text": "Authors found that EGFR WT/KRAS mutant advanced non-small cell lung cancer patients are associated with an increased resistance to treatment, specific mutant KRAS may account for differential sensitivity to an EGFR tyrosine kinase inhibitor."}, {"pubmed": 22773810, "text": "Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1."}, {"pubmed": 22791568, "text": "K-RAS mutations and amino acid substitutions are associated with metastatic colorectal cancer."}, {"pubmed": 22798500, "text": "In CRC patients treated with cetuximab, activating mutation signatures for KRAS (75 genes) were developed."}, {"pubmed": 22800643, "text": "A novel interplay between K-ras and H-ras, with possible implications for colorectal carcinogenesis."}, {"pubmed": 22804747, "text": "KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas."}, {"pubmed": 22804917, "text": "Data indicate that in KRAS mutated tumours increased miR-200b and decreased miR-143 expression were associated with a good progression-free survival (PFS) upon treatment."}, {"pubmed": 22805857, "text": "K-ras mutation is strongly associated with perineural invasion phenotypically. K-ras mutation is an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy."}, {"pubmed": 22810479, "text": "Review and meta-analysis found that K-ras gene mutations seem not to correlate with the prognosis of patients with colorectal cancer."}, {"pubmed": 22810899, "text": "KRAS mutations predicted shorter survival for patients with advanced lung adenocarcinoma."}, {"pubmed": 22833420, "text": "Standard cytology provides adequate material for the assessment of EGFR and Kras mutational status in non-small cell lung cancer and colorectal cancer patients."}, {"pubmed": 22833671, "text": "Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner"}, {"pubmed": 22842183, "text": "the frequency and spectrum of K-ras mutations among colorectal cancers Iraqi patients"}, {"pubmed": 22843693, "text": "CD151 links alpha(3)beta(1)/alpha(6)beta(1) integrins to Ras, Rac1, and Cdc42 by promoting the formation of multimolecular complexes in the membrane, which leads to the up-regulation of adhesion-dependent small GTPase activation"}, {"pubmed": 22848379, "text": "Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis."}, {"pubmed": 22864777, "text": "Phospho-ERK may be a useful marker in combination with K-Ras for improving the prognosis of colorectal cancer."}, {"pubmed": 22865324, "text": "KRAS mutations in codons 12 and 13 of exon 2 in one hundred formalin-fixed paraffin-embedded (FFPE) colorectal cancer samples by three different methods"}, {"pubmed": 22865907, "text": "RAS mutations are frequent events in sporadic medullary thyroid carcinoma."}, {"pubmed": 22876814, "text": "Organs initially involved by distant metastasis were different according to the KRAS mutational status inmetastatic or recurrent colorectal cancer (MRCRC) patients."}, {"pubmed": 22876876, "text": "Assessment of the prognostic value of KRAS codon 12 and codon 13 mutations in tumor tissue from patients with advanced colorectal cancer using CAPOX or FUFOX treatment regimens."}, {"pubmed": 22898351, "text": "MSI status, KRAS and BRAF mutation rates varied remarkably among the colonic carcinoma subsites irrespective of right- and left-sided origin."}, {"pubmed": 22922794, "text": "in Japanese colorectal cancer patients the KRASp.G13D mutation had prognostic impact in relation to disease-free survival in stage I-III disease, while the prognosis of stage IV patients without anti-EGFR antibody therapy was unaffected by KRAS status."}, {"pubmed": 22927534, "text": "Codon 13 KRAS mutation is a negative predicitive tumor marker in colorectal carcinoma treated with combined antineoplastic agents."}, {"pubmed": 22929917, "text": "Red blood cell folic acid is significantly deficient in colorectal cancer patients with K-ras mutations."}, {"pubmed": 22930660, "text": "KRAS mutant subpopulations are present in a large number of thyroid tumors."}, {"pubmed": 22931052, "text": "heterogeneity in frequencies of KRAS/PIK3CA somatic mutations is consistent with already-reported discrepancies in distribution of germline mutations for other malignancies within Sardinian population."}, {"pubmed": 22938585, "text": "Data indicate that KRAS, BRAF, PIK3CA, and AKT1 mutations can be rapidly and accurately detected for cancer diagnosis."}, {"pubmed": 22946697, "text": "Data indicate that of the 32 cardio-facio-cutaneous syndrome (CFC) patients, 28 (88%) had a known mutation in a gene that is causative for CFC, including BRAF (n = 21), MEK1 (n = 2), MEK2 (n = 4), and KRAS (n = 1)."}, {"pubmed": 22948721, "text": "Data suggests that KRAS codon 12 mutation may not represent a homogeneous entity in metastatic colorectal cancer when treated with cetuximab-based first-line therapy."}, {"pubmed": 22964644, "text": "Data indicate that epiregulin (EREG) expression significantly correlated with KRAS expression or KRAS copy number in KRAS-mutant non-small-cell lung cancer (NSCLC) cell lines."}, {"pubmed": 22971512, "text": "A high frequency of KRAS gene mutations exists in Chinese patients with colorectal cancer, and are associated with poor survival, tumor differentiation and liver metastasis."}, {"pubmed": 22972628, "text": "metastatic colorectal cancer patients with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations"}, {"pubmed": 22982650, "text": "KRAS mutation is associated with response to therapy in non-small-cell lung cancer."}, {"pubmed": 22983505, "text": "K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients."}, {"pubmed": 22988093, "text": "Data show that Med23 RNAi specifically inhibits the proliferation and tumorigenicity of lung cancer cells with hyperactive Ras activity."}, {"pubmed": 23010532, "text": "no evidence for association between endometriosis risk and rs61764370 or any other SNPs in KRAS"}, {"pubmed": 23010994, "text": "KRAS mutation is suggested to be poor prognostic factors in CRLM."}, {"pubmed": 23013731, "text": "KRAS mutation is associated with early-stage low-grade endometrial cancers."}, {"pubmed": 23014527, "text": "A higher frequency of KRAS mutation G12C in women, their younger age, and lesser smoking history together support a heightened susceptibility to tobacco carcinogens."}, {"pubmed": 23015072, "text": "KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines."}, {"pubmed": 23021375, "text": "EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways have roles in colorectal cancer and treatment [review]"}, {"pubmed": 23022742, "text": "findings show intratumoral heterogeneity of KRAS mutational status is rare in non-small cell lung cancer (NSCLC); finding is in line with hypothesis that oncogenic activation of KRAS is an early event and a bona fide \"driver mutation\" in NSCLC"}, {"pubmed": 23026567, "text": "Baseline sPLA(2)IIa expression predicts response to sPLA(2)IIa inhibition in some K-ras mutant lung cancer cells."}, {"pubmed": 23026641, "text": "KRAS mutations were not detected in lung cancer patients harboring mutations in either EGFR or P53."}, {"pubmed": 23027075, "text": "This study provided further evidence for the prognostic importance of KRAS status in terms of recurrence-free and overall survival in patients with colorectal cancer liver metastases."}, {"pubmed": 23027861, "text": "a previously unknown link between activated K-Ras and menin, an important interplay governing tumor activation and suppression in the development of lung cancer."}, {"pubmed": 23030695, "text": "These data support the utility of the therascreen KRAS kit as a means of selecting patients who may benefit from cetuximab therapy."}, {"pubmed": 23033302, "text": "the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data."}, {"pubmed": 23055340, "text": "KRAS and BRAF mutations are infrequent or absent, respectively in Intestinal-type sinonasal adenocarcinoma"}, {"pubmed": 23059812, "text": "Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes."}, {"pubmed": 23065691, "text": "KRAS G>A mutation is associated with relapse in duodenal adenocarcinoma."}, {"pubmed": 23075074, "text": "A meta-analysis was performed to compare KRAS gene mutations in colorectal cancer tissue samples with primary and metastatic colorectal cancers"}, {"pubmed": 23090042, "text": "Specific morphologic features in colon cancer suggest a higher likelihood of the presence of KRAS mutations. These morphologic features overlap partially with those associated with DNA mismatch repair gene mutations"}, {"pubmed": 23090619, "text": "Metastatic colorectal cancer patients with KRAS codon 13 mutations demonstrate a greater clinical response to anti-EGFR treatment than patients with other KRAS mutations [review]"}, {"pubmed": 23092099, "text": "KRAS G12A is important for IL-2-independent growth of PLT-2 cells and suggests the possibility of involvement of KRAS mutation with disease progression."}, {"pubmed": 23093229, "text": "The low rate of K-ras and EGFR mutations, coupled with the high surface expression of EGFR, suggests similarity in the EGFR signalling pathway between Squamous cell anal carcinoma and squamous cell carcinoma of the head and neck."}, {"pubmed": 23096709, "text": "The results confirm a strong correlation between activating RAS mutations and nevus sebaceus."}, {"pubmed": 23096712, "text": "The findings provide evidence that HRAS and KRAS mutations are sufficient to cause nevus sebaceus without genome instability, LOH, or secondary mutation."}, {"pubmed": 23098991, "text": "Studied differential miRNA expression in metastatic colorectal cancer by microarrays from primary tumors of 33 patients who had wild-type KRAS/BRAF and third- to sixth-line anti-EGFRmAb treatment, with/without irinotecan."}, {"pubmed": 23099803, "text": "Ddata suggest that KRAS alterations are linked to clinical phenotypes in endometrial carcinomas with increase in copy-number and mRNA expression levels from primary to metastatic lesions."}, {"pubmed": 23111797, "text": "By identifying the KRAS mutational status at the metastasized colorectal carcinoma, a statement about the benefit of an anti-EGFR-therapy can be given, which is nowadays the basis of diagnostic and therapy of this cancer."}, {"pubmed": 23112547, "text": "In proximal colon lesions, the incidence of KRAS mutations is significantly higher in the granular-type than in the non-granular-type of colorectal laterally spreading tumor."}, {"pubmed": 23116683, "text": "QoL was evaluable in 627/666 patients (94%) with KRAS wild-type tumours; of these 52% received FOLFIRI, and 48% FOLFIRI plus cetuximab. Pattern mixture analysis revealed no significant differences."}, {"pubmed": 23122493, "text": "indicate that patients with mutant KRAS tumors fail to benefit from adjuvant chemotherapy and do not respond to EGFR inhibitors[review]"}, {"pubmed": 23125007, "text": "One hundred and ten patients (51%) were identified who were potentially nonresponders to anti-EGFR therapy: 90/209 patients (43%) harbored the KRAS mutations."}, {"pubmed": 23134218, "text": "High KRAS expression is associated with the proliferation and invasion of non-small cell lung cancer."}, {"pubmed": 23135349, "text": "Analysis of hypermethylation status of a panel of genes and KRAS mutation detection offer a similar diagnostic yield in the evaluation of pancreatic masses."}, {"pubmed": 23136247, "text": "Molecular characterization of single CTCs demonstrated considerable intra- and interpatient heterogeneity of EGFR expression and genetic alterations in EGFR, KRAS, and PIK3CA"}, {"pubmed": 23155050, "text": "ras-Induced up-regulation of CTP:phosphocholine cytidylyltransferase alpha contributes to malignant transformation of intestinal epithelial cells"}, {"pubmed": 23155138, "text": "KRAS gene mutation predict poor prognosis in colorectal cancer patients, treated with EGFR inhibitors."}, {"pubmed": 23157823, "text": "In Chinese colorectal carcinoma patients, KRAS mutations are associated with gender, age, tumor differentiation and primary tumor sites"}, {"pubmed": 23157824, "text": "Codon 12, 13 in KRAS gene and codon 600 in BRAF gene are the most common mutation points in Chinese colorectal cancer. KRAS and BRAF mutations are mutually exclusive. KRAS and BRAF gene mutation is higher in females than that in males."}, {"pubmed": 23157826, "text": "The detection rate of KRAS mutation is higher in female colorectal carcinoma patients than males. The presence of KRAS mutation does not significantly correlate with patients' age, tumor site, differentiation grades and histological types."}, {"pubmed": 23157828, "text": "KRAS mutation has no significant correlation with colorectal carcinoma patients' age, tumor site, tumor gross appearance, degree of differentiation, depth of invasion, TNM stages, lymphatic invasion, abdominal or distant metastases and prognosis."}, {"pubmed": 23161513, "text": "Intercellular transfer of mutant KRAS is a characteristic feature of invasive colonic cancer cells."}, {"pubmed": 23174662, "text": "KRAS mutations are found in up to 95% of pancreatic cancer cases."}, {"pubmed": 23182985, "text": "Studies indicate that only mutant KRAS codon G12A was associated with a negative predictive effect on overall survival (OS)."}, {"pubmed": 23188063, "text": "KRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II colorectal cancer ."}, {"pubmed": 23188824, "text": "there are conserved components of mutant K-Ras signaling and phenotypes but that many depend on cell context and environmental cues"}, {"pubmed": 23190154, "text": "Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an important event in a subset of peripheral nerve sheath tumours not related to neurofibromatosis"}, {"pubmed": 23199549, "text": "Kras mutation and p53 overexpression rates in pseudomyxoma peritonei are comparable to those of colorectal adenomas and mucinous colorectal cancer."}, {"pubmed": 23207070, "text": "The present study revealed that ESCC of Brazilian patients do not present mutations in hot spots of EGFR, K-RAS and BRAF and only a minor proportion present overexpression of EGFR or HER2."}, {"pubmed": 23208128, "text": "KRAS mutation is associated with lung cancer and is not associated with response to EGFR-tyrosine kinase inhibitors or chemotherapy."}, {"pubmed": 23208952, "text": "Activating GNAS mutations are often associated with KRAS mutations as a characteristic genetic feature of pyloric gland adenomas (PGAs) of the stomach and duodenum."}, {"pubmed": 23224067, "text": "Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas."}, {"pubmed": 23224736, "text": "We find that LDHB expression correlates to both KRAS genomic copy number gain and KRAS mutation in lung cancer cell lines and adenocarcinomas."}, {"pubmed": 23232572, "text": "Low-grade bladder papillary carcinoma is associated with mutation in the FGFR3 or in some cases mutations in RAS genes."}, {"pubmed": 23233484, "text": "Results support a role for the PAK4 and PAK1 in the proliferation of mutant KRAS-driven colorectal carcinoma cells via pathways not involving RAF/MEK/ERK and PI3K/AKT signaling"}, {"pubmed": 23236152, "text": "Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells."}, {"pubmed": 23238036, "text": "presence of KRAS mutations in plasma in advanced non-small cell lung cancer may be a marker of poor prognosis and may also hold predictive value."}, {"pubmed": 23240926, "text": "The prevalence of RAS mutations in the present series of medullary thyroid cancer (MTC) was 10.1%, and 17.6% when considering only RET-negative cases. RAS mutations were found in MTC tumor tissue but not in peripheral blood indicating their somatic origin"}, {"pubmed": 23242173, "text": "Laboratories and clinicians need to be aware of the decrease in correct mutation call rate proportionally with decreasing percentage of tumor cells and that external quality assurance schemes need to address low tumor cell percentage in the test samples."}, {"pubmed": 23242438, "text": "KRAS mutations were frequently identified in mucinous adenocarcinoma subtypes."}, {"pubmed": 23242442, "text": "collegiate smokers (former smokers who smoked between 101 lifetime cigarettes and 5 pack-years)with advanced-stage lung cancers represent a distinct subgroup of patients with a higher frequency of KRAS mutations and lower frequency of EGFR mutations compared with never smokers"}, {"pubmed": 23263441, "text": "This article presents the case of a 64-year-old patient with a glandular papilloma of the right main bronchus including the immunohistochemical and molecular work-up as well as a review of the current literature."}, {"pubmed": 23264394, "text": "Approximately 90% of medullary thyroid cancers had mutually exclusive mutations in RET, HRAS, and KRAS, suggesting that RET and RAS are the predominant driver pathways in medullary thyroid cancer."}, {"pubmed": 23266750, "text": "only one mutation (K-Ras codon 13; Gly to Asp) was detected among the 61 hepatocellular carinoma patients studied; findings indicated that the activation of Ras proto-oncogenes by mutations in codons 12, 13 and 61 does not play a major role in hepatocellular carcinogenesis"}, {"pubmed": 23267865, "text": "KRAS mutations, detected in pancreatic cyst fluid, are associated with mucinous cysts and progression and development of malignancy and should be considered in assessing pancreatic cysts."}, {"pubmed": 23274581, "text": "KRAS mutation is associated with esophageal squamous cell carcinoma."}, {"pubmed": 23280667, "text": "Findings indicate that K-RAS regulates both caveolin-1 expression and other factors affecting caveolin-1 functions in colon cancer-derived cell migration."}, {"pubmed": 23284732, "text": "KRAS mutations are not associated with early stage colorectal cancer."}, {"pubmed": 23288781, "text": "KRAS destruction by RC-U occurred through a ubiquitin-dependent, proteasome-mediated degradation pathway. RC-U inhibited pancreatic cancer cell growth in vitro and in vivo."}, {"pubmed": 23293113, "text": "we have shown that patients harbouring KRAS low frequency mutations benefit less than others from anti-EGFR therapy."}, {"pubmed": 23297805, "text": "Our results confirm the importance of point mutations in KRAS codons 12, 13, and 61 in the molecular pathogenesis of colorectal adenocarcinomas in the Turkish population."}, {"pubmed": 23299277, "text": "Quality control and assurance of KRAS genotyping is critical, and standardization of the methodology is warranted"}, {"pubmed": 23300780, "text": "FGFR2, KRAS and PIK3CA are frequently mutated in primary and metastatic endometrial lesions."}, {"pubmed": 23302304, "text": "EGFR mutation rate is related with gender, smoking history and pathological type in non-small cell lung cancer patients, and is also related with differentiation and smoking history in adenocarcinoma patients."}, {"pubmed": 23302307, "text": "About one third of patients with colorectal adenocarcinoma have KRAS gene mutation, which might be related to patients' gender."}, {"pubmed": 23307237, "text": "The status of EGFR and KRAS mutation in serum was not prognostic in patients with advanced non-small cell lung cancer"}, {"pubmed": 23310942, "text": "This study shows that 21% of Nigerian colorectal patients carry a KRAS mutation; half the rate in Caucasians."}, {"pubmed": 23313110, "text": "The G12C KRAS mutation is a strong negative predictor for EGFR-TKI treatment, whereas other KRAS mutation types have not negatively predicted treatment efficacy compared with that for the wild-type KRAS genotype."}, {"pubmed": 23313659, "text": "mutational status of N-RAS and K-RAS genes in a cohort of 504 Chinese acute myeloid leukemia patients; mutation frequency of N-RAS and K-RAS were 9.7 percent and 2.9 percent respectively; concluded RAS mutations are associated with some biologically specific subtypes of AML but don't impact clinical outcome in Chinese patients"}, {"pubmed": 23318454, "text": "Findings support the development of ISG15 conjugation inhibitors for treating breast and also other cancers expressing oncogenic Ki-Ras."}, {"pubmed": 23319376, "text": "the imbalance in expression of Aurora-A and BRCA2 regulates RAS-induced genomic instability and tumorigenesis"}, {"pubmed": 23322774, "text": "MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA by repressing RAS p21 GTPase activating protein 1 (RASA1)"}, {"pubmed": 23324583, "text": "KRAS mutations is associated with colorectal cancer."}, {"pubmed": 23334325, "text": "we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity"}, {"pubmed": 23335286, "text": "prevalence of KRAS mutations was identified in patients with ICC, BilIN-3, and BilIN-2 compared with BilIN-1. Furthermore, KRAS mutations were detected in LBD lesions and PBG lesions"}, {"pubmed": 23337026, "text": "EGFR and KRAS mutational rates were comparable in primary and unpaired metastatic lung adenocarcinoma in pre-chemotherapy and postchemotherapy groups."}, {"pubmed": 23341890, "text": "The prevalence of EML4-ALK, EGFR status and KRAS mutations in 208 Chinese patients with non-small cell lung cancer, is reported."}, {"pubmed": 23344532, "text": "Report K-ras mutations in pancreatic ductal carcinoma and their relationship to patient survival."}, {"pubmed": 23348904, "text": "KRAS-mutated carcinomas frequently develop in contiguity with a residual polyp and show molecular features distinct from other colorectal carcinomas, in particular from tumors with neither BRAF nor KRAS mutation."}, {"pubmed": 23352033, "text": "Data indicate that the concordance between EGFR and KRAS mutational status in 29 paired scraped smears and needle washing was 100%, with 7 paired samples showing the same EGFR mutation and 8 paired samples showing the same KRAS mutations."}, {"pubmed": 23355875, "text": "sensitive, fast, and cost-effective screening method for KRAS mutations, and successfully detected low-abundance KRAS mutations in clinical samples, which will allow provision of more precise individualized cancer therapy."}, {"pubmed": 23357969, "text": "EGFR and KRAS mutations are frequent in adenocarcinomas and are not prognostic factors for survival."}, {"pubmed": 23370967, "text": "Data indicate that Ras inhibition by Salirasib (FTS) induced autophagy in several cell lines, including mouse embryonic fibroblasts and the human cancer cell lines HeLa, HCT-116 and DLD-1."}, {"pubmed": 23374602, "text": "BRAF and codon 12 KRAS mutations predict for adverse outcome of colorectal cancer patients receiving cetuximab."}, {"pubmed": 23376846, "text": "HB-EGF overexpression and Kras(G12D) together, but neither alone, increase cancer cell proliferation."}, {"pubmed": 23388101, "text": "Report KRAS mutations in ovarian serous carcinoma."}, {"pubmed": 23392229, "text": "KRAS mutations are associated with lung cancer."}, {"pubmed": 23398044, "text": "Mutations in genes pertaining to the canonical RAS pathway are found in a minority of adenoid cystic carcinomas, and that activating KIT mutations are either absent or remarkably rare in these cancers."}, {"pubmed": 23403319, "text": "study demonstrated that RAS mutations frequently occur in Mixed Lineage Leukemia (MLL)-rearranged infant acute lymphoblastic leukemia (ALL) cases and especially in t(4;11)-positive infant ALL patients and their presence represents an independent poor prognostic factor"}, {"pubmed": 23435671, "text": "KRAS is rather a prognostic than a predictive biomarker in pancreatic cancer"}, {"pubmed": 23437064, "text": "KRAS mutations in codon 13 have similar behavior as KRAS WT."}, {"pubmed": 23453624, "text": "cell-autonomous phosphoinositide 3-kinase and 3-phosphoinositide-dependent protein kinase 1 are key effectors of oncogenic Kras in the pancreas, mediating cell plasticity, acinar-to-ductal metaplasia, and pancreatic ductal adenocarcinoma formation"}, {"pubmed": 23455880, "text": "Data suggest that KRAS mutations in SW48 colorectal cancer cells are linked to resistance to sunitinib."}, {"pubmed": 23456389, "text": "Mutations in different KRAS codons may have different effects on rectal cancer resistance to neoadjuvant chemoradiation therapy"}, {"pubmed": 23464485, "text": "Down-regulated expression of K-Ras mRNA."}, {"pubmed": 23473612, "text": "This study confirmed that KRAS testing is definitely part of the management of most of metastatic colorectal cancer patients, despite discrepancies observed in the rate of prescription and the time of results."}, {"pubmed": 23473635, "text": "KRAS mutation is not associated with treatment response in rectal cancer."}, {"pubmed": 23474907, "text": "Data indicate that (4-Chloro-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone and (4-bromo-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone inhibited cell growth through inhibition of both alpha-1 Na(+)/K(+)-ATPase (NAK) and Ras oncogene activity."}, {"pubmed": 23486266, "text": "KRAS mutations are associated with solid predominant lung tumors."}, {"pubmed": 23495083, "text": "KRAS mutations are associated with metastatic lung adenocarcinoma."}, {"pubmed": 23496764, "text": "Wild-type copies of HRas, NRas and KRas play unique roles in the context of mutant KRas-driven tumors."}, {"pubmed": 23498145, "text": "The current study demonstrates that the presence of GNAS in combination with KRAS in pancreatic cystic fluid obtained by EUSFNA improves the sensitivity for diagnosis of intraductal papillary mucinous neoplasms"}, {"pubmed": 23510802, "text": "Data show that KRAS codon 12/13 mutations have negative prognostic value in metastatic colorectal cancer patients treated with FOLFOX/XELOX, but is not predictive of treatment benefit with cediranib, using progression-free survival and overall survival."}, {"pubmed": 23511557, "text": "Kirsten Ras (KRAS)-mutated CRC was associated with statistically significantly poorer survival after diagnosis than KRAS-wild-type CRC."}, {"pubmed": 23511561, "text": "Large multicentre study demonstrated that KRAS mutations and DNA MMR deficiency have a role in a small subgroup of gastric cancer."}, {"pubmed": 23514584, "text": "In patients with colorectal cancer expressing mutant KRAS, high levels of plasma KRAS was associated with early disease progression."}, {"pubmed": 23520442, "text": "KRAS mutation rate decreased from 4.6% (3/66) to 3.0% (2/66) with Neoadj-Chemo."}, {"pubmed": 23524403, "text": "KRAS as a prognostic marker of non-small-cell lung cancer (Review)"}, {"pubmed": 23526092, "text": "There was no association between the mutations and expression pattern of K-ras, APC and p53 in colorectal cancer among Indians."}, {"pubmed": 23528430, "text": "colorectal tumor tissue was analyzed utilizing WAVE mutation analysis to determine if regions of the tumor display heterogeneity in the expression of mutated KRAS and if regions within tissue blocks uniformly display resistant or susceptible phenotypes"}, {"pubmed": 23532108, "text": "Examination of 6 PDACs revealed that 4 of 5 gastric-type IPMNs negative for GNAS mutations contained mutations in codon 12 of KRAS. Mutations in codon 13 of KRAS were not identified in PDACs and IPMNs."}, {"pubmed": 23535601, "text": "the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in pancreatic ductal adenocarcinoma, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway"}, {"pubmed": 23538047, "text": "Mutation status of KRAS is the same in primary colorectal neoplasms and metastasis."}, {"pubmed": 23538866, "text": "KRAS mutational status could have an impact to the decision to give chemotherapy or EGFR-TKIs as second-line treatment to patients with non-small cell lung cancer, mainly in patients harboring WT-EGFR."}, {"pubmed": 23548132, "text": "About one fourth of mCRC cases wild-type for KRAS codons 12 and 13 present other mutations either in KRAS, BRAF, or PIK3CA, many of which may explain the lack of response to anti-EGFR therapy observed in a significant proportion of these patients."}, {"pubmed": 23555182, "text": "TIMP1 is an upregulated gene product and a proliferative inducer of K-Ras(G12D)-mutated pancreatic ductal cells through the ERK2 signaling pathway."}, {"pubmed": 23555992, "text": "Breast tumors with KRAS codon 12 mutations seem to present a worse prognosis."}, {"pubmed": 23558076, "text": "DAB2IP expression was reduced in patients with pancreatic cancer compared with those with no cancer. DAB2IP expression was correlated with the KRAS gene, perineurial invasion and clinical stage of the disease."}, {"pubmed": 23564819, "text": "KRAS mutations are not associated with tyrosine kinase inhibitors treatment efficacy in non-small cell lung cancer."}, {"pubmed": 23565280, "text": "The association of survival in PDAC patients with CDKN2A aberrations in tumors was not statistically significant, the sub-group with concomitant KRAS mutations and CDKN2A alterations were associated with lower survival."}, {"pubmed": 23566315, "text": "Studies indicate that inhibition of targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS."}, {"pubmed": 23580570, "text": "Data show that somatic cell knockin of both KRAS G12V and oncogenic PIK3CA mutations in human breast epithelial cells results in cooperative activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways."}, {"pubmed": 23599154, "text": "Our findings suggest that in a subset of ductal adenocarcinomas, KRAS mutant allele-specific imbalance correlates with the progression to undifferentiated carcinoma of the pancreas."}, {"pubmed": 23608713, "text": "K-RAS mutations are associated with a worse overall survival in patients with non-small cell lung cancer, especially in patients with adenocarcinoma and early stage."}, {"pubmed": 23609009, "text": "presence of a K-ras gene mutation was a poor prognostic factor"}, {"pubmed": 23613396, "text": "K-RAS and B-RAF mutations do not seem to be predictive of treatment outcome as potential biomarkers for bevacizumab therapy in metastatic colorectal cancer."}, {"pubmed": 23619604, "text": "Identification of a novel association of KRAS mutations with solid growth pattern and tumor-infiltrating leukocytes in non-mucinous lung adenocarcinomas."}, {"pubmed": 23625203, "text": "This study demonstrated that either BRAF or RAS mutations were present in two thirds of follicular variants of papillary thyroid carcinomas and these mutations were mutually exclusive."}, {"pubmed": 23625655, "text": "findings demonstrate that the presence of a K-ras mutation correlated with high initial CEA and CA 19-9 levels in patients with metastatic colorectal cancer"}, {"pubmed": 23630215, "text": "KRAS mutation status is not a significant prognostic marker in patients with resected non-small-cell lung cancer."}, {"pubmed": 23640097, "text": "The mutational spectrum of KRAS exon 1 in bladder tumours, colorectal cancer (CRC) and chronic myeloid leukemia (CML), was analysed."}, {"pubmed": 23645765, "text": "KRAS mutations are associated with colorectal cancer."}, {"pubmed": 23657052, "text": "The KRAS mutation rate of Japanese colorectal cancer patients was 37.6%."}, {"pubmed": 23660563, "text": "A meta-analysis indicates that K-ras gene mutation analysis is useful for the differential diagnosis of pancreatic adenocarcinomas."}, {"pubmed": 23660947, "text": "Establishment of molecular subgroups based on KRAS and BRAF mutation status is important and should be considered in future prognostic studies in colorectal carcinoma."}, {"pubmed": 23702733, "text": "Mutational activation of KRAS does not seem to play any significant role in the development and progression of gastrointestinal stromal tumors."}, {"pubmed": 23709419, "text": "Cigarette smoking did not influence the frequency of KRAS mutations in lung adenocarcinomas in Korean patients, but influenced qualitative differences in the KRAS mutations."}, {"pubmed": 23723075, "text": "Results show that HDAC6 and SIRT2 regulate the acetylation state of K-RAS in cancer cells"}, {"pubmed": 23724098, "text": "These results suggested KRAS mutations have an independent prognostic value for chemotherapy in advanced non-small cell lung cancer."}, {"pubmed": 23725851, "text": "Adding panitumumab to irinotecan did not improve the overall survival of patients with wild-type KRAS tumours."}, {"pubmed": 23728071, "text": "We also examined 61 of our cases for the presence of PIK3CA, AKT1, PTEN and K-RAS mutations."}, {"pubmed": 23729268, "text": "There was significant association (p < 0.05) between KRAS mutations, age and the tumor differentiation."}, {"pubmed": 23729275, "text": "The T allele of the let-7 binding site polymorphism rs712 in KRAS 3' UTR was associated with a significantly increased risk of gastric cancer."}, {"pubmed": 23729361, "text": "Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population. This lack of overlap was also observed in ALK-positive cancers with acquired resistance to crizotinib"}, {"pubmed": 23739246, "text": "Suggest that activating mutations of EGFR, HRAS, and KRAS contribute to the pathogenesis of human seborrheic keratosis."}, {"pubmed": 23743931, "text": "Report the role of KRAS mutations in the detection and classification of pancreatic mucinous neoplasms by endoscopic ultrasound fine-needle aspiration."}, {"pubmed": 23752186, "text": "we found that EVI1 upregulated KRAS expression through suppression of miR-96 in pancreatic cancer cells"}, {"pubmed": 23755178, "text": "Both the CRP single nucleotide polymorphism rs7553007 and KRAS/BRAF mutations were independent prognostic factors for colorectal cancer patients with synchronous liver metastasis."}, {"pubmed": 23755925, "text": "KRAS mutations are associated with colonic neoplasms."}, {"pubmed": 23765179, "text": "acquired EGFR and KRAS mutations do not constitute the main mechanism of resistance to anti-EGFR mAb"}, {"pubmed": 23773459, "text": "KRAS mutations are associated with colorectal neoplasms."}, {"pubmed": 23774633, "text": "KRAS mutation is associated with myelodysplastic syndromes and acute myeloid leukemia."}, {"pubmed": 23787801, "text": "KRAS mutation is not associated with response to chemotherapy in non-small-cell lung cancer."}, {"pubmed": 23790176, "text": "Taiwanese patients with metastatic colorectal cancer respond better to a cetuximab plus chemotherapy regime if their tumors have the wild-type KRAS gene"}, {"pubmed": 23791006, "text": "Sinonasal intestinal-type adenocarcinomas share common alterations of the EGFR pathway with colorectal adenocarcinomas, except for a lower frequency of KRAS and BRAF mutations."}, {"pubmed": 23800114, "text": "demonstrated associations of KRAS mutations with well-differentiated and mucinous ovarian carcinomas."}, {"pubmed": 23806795, "text": "Race was not statistically significantly associated with KRAS mutational status in patients with non small cell lung cancer."}, {"pubmed": 23817662, "text": "KRAS mutations are associated with lung cancer."}, {"pubmed": 23820584, "text": "These findings indicate that KRAS/MAPK1 amplification is critical for the growth of a subset of type II ovarian carcinomas."}, {"pubmed": 23821376, "text": "This study investigated the impact of KRAS, NRAS, BRAF, PI3KCA and TP53 status on outcome of elderly metastatic colorectal cancer patients"}, {"pubmed": 23828694, "text": "An antisense oligonucleotide specific to a K-ras point mutation promotes apoptosis in PC-2 cells."}, {"pubmed": 23838952, "text": "Gallbladder cancer has a high frequency of K-ras codon 12 mutation with poorer outcomes in resected stage II and III disease."}, {"pubmed": 23841470, "text": "KRAS mutations,found in smokers, are often activated in lung cancers, with mutations in about 20% of NSCLCs. Most are single amino acid substitutions in codons 12, 13, or 61. It is a negative marker for the efficacy of EGFR TKI in patients with NSCLC"}, {"pubmed": 23849768, "text": "Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non responsive colorectal cancer patients for the anti-EGFR treatment is 28.26%."}, {"pubmed": 23851676, "text": "Higher frequency of k-ras mutations are associated with endometrial carcinomas with significant mucinous differentiation."}, {"pubmed": 23864308, "text": "KRAS mutations are associated with response to chemoradiation in rectal cancer."}, {"pubmed": 23865079, "text": "loss of RASSF1A may be involved in pathogenesis of colorectal cancer (CRC), its expression was found predominantly in K-ras wild-type CRCs."}, {"pubmed": 23874486, "text": "Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy."}, {"pubmed": 23878395, "text": "Data indicate that p38delta mediates oncogene-induced senescence through a p53- and p16(INK4A)-independent mechanism."}, {"pubmed": 23885463, "text": "we did not find a correlation between the presence of a K-ras mutation and the presence of Epiregulin and Amphiregulin in colon cancer tissue."}, {"pubmed": 23887294, "text": "KRAS G12C mutations were associated with primary lung adenocarcinoma, whereas KRAS G12R mutations favored pancreatic adenocarcinoma"}, {"pubmed": 23887305, "text": "our findings suggest that loss of CDKN2A and, to a lesser extent, KRAS and PIK3CA somatic mutations have a role in the progression of a benign to an atypical proliferative Brenner tumor"}, {"pubmed": 23908594, "text": "Findings support the development of CDK and Raf co-targeting strategies in EGFR/HER-2-overexpressing or RAS/RAF mutant breast cancer (BC)."}, {"pubmed": 23919423, "text": "evaluated mutations in four driver genes, epidermal growth factor receptor (EGFR), Kirsten ras oncogene (KRAS), c-MET, and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), in Chinese lung adenocarcinoma patients"}, {"pubmed": 23922984, "text": "There was no difference in overall survival after starting EGFR-TKI in patients with KRAS mutation and EGFR/ KRAS WT."}, {"pubmed": 23928793, "text": "The brain microenvironment negatively regulates miRNA-768-3p to enhance K-ras and promote metastasis."}, {"pubmed": 23930206, "text": "The frequencies of EGFR, KRAS, BRAF, and HER-2 mutations in BM-NSCLC were 2.6, 38.5, 0, and 0% respectively. The incidence of KRAS mutation was significantly higher in female and younger patients."}, {"pubmed": 23932486, "text": "The frequencies of somatic EGFR, KRAS, and ALK gene abnormalities reflect the diverse ethnicity and smoking patterns of non-small-cell lung cancers patients in the United States."}, {"pubmed": 23934321, "text": "In patients with pancreatic ductal adenocarcinoma, solute carrier transporter (SLC) levels were not found to be associated with KRAS mutation status in exon 2"}, {"pubmed": 23936455, "text": "a complex regulatory system involving TP53, KRAS, and let-7a"}, {"pubmed": 23945926, "text": "This case to be the first description of a solitary serrated polyp with KRAS mutation, similar to the lesions occurring as polyposis in longstanding IBD"}, {"pubmed": 23965232, "text": "KRAS mutations with synchronous TP53 mutations occur predominantly in low-grade mucinous carcinomas, suggesting a specific molecular background of this ovarian cancer type."}, {"pubmed": 23975373, "text": "A let-7 KRAS rs712 polymorphism increases colorectal cancer risk."}, {"pubmed": 23975858, "text": "There was a negative correlation between KRAS codon 12 mutations and the level of HLA class I antigens in primary and metastatic tumors."}, {"pubmed": 23978462, "text": "KRAS mutations are associated with colorectal neoplasms."}, {"pubmed": 23983135, "text": "No associations were found with CRC harboring G>T mutations in KRAS/APC."}, {"pubmed": 23988776, "text": "in lung adenocarcinomas, KRAS mutations are prevalent in male smokers; EGFR mutations are associated with female sex, nonsmoking and lepidic and micropapillary growth; TTF1 has a role in survival; BRAF mutations have roles in survival"}, {"pubmed": 23996697, "text": "The KRAS rs712 polymorphism in let-7 miRNA binding site has no association with nasopharyngeal carcinoma risk."}, {"pubmed": 23999427, "text": "Stem cells with Kras(G12D) activation and Smad4 depletion can produce tumors that are multipotent and susceptible to epithelial mesenchymal transformation and metastasis."}, {"pubmed": 23999847, "text": "frequency of K-RAS mutations in the Puerto Rican population studied was 39 percent and mutant K-RAS was associated with advanced colorectal cancer stage, mucinous histotype and ulcerated tumors"}, {"pubmed": 24006859, "text": "mutations in KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA detected in Asian patients were not predictive of clinical benefits from cetuximab treatment."}, {"pubmed": 24011934, "text": "Data indicate that dual targeted inhibitors of PI3K/mTOR in combination with inhibitors of RAS/ERK signalling as a potentially effective approach to treating ovarian cancer."}, {"pubmed": 24013837, "text": "Clinical relevance of KRAS mutations in predicting the efficacy of cetuximab-containing therapy for metastatic colorectal patients in the Japanese population."}, {"pubmed": 24018645, "text": "KRAS/NRAS mutation predicts early lung recurrence and worse survival after curative resection of colorectal liver metastases."}, {"pubmed": 24018808, "text": "abnormal [beta]-catenin expression showed an inverse relationship with the presence of KRAS mutations in ovarian endometrioid adenocarcinoma"}, {"pubmed": 24021343, "text": "Primary and recurrent anal cancer expresses wild type KRAS, unaffected by treatment, supporting trials targeting EGFR in poor risk/recurrent anal cancer."}, {"pubmed": 24024839, "text": "RAS mutations, in addition to KRAS exon 2 mutations, predict a lack of response to anti-EGFR therapy in patients with metastatic colorectal cancer."}, {"pubmed": 24040001, "text": "Data indicate that differentially expressed IL-17, IL-22, and IL-23 levels are associated with K-ras in a stage-specific fashion along colorectal cancer progression and an association was established between mutant K-ras and GM-CSF and IFN-gamma."}, {"pubmed": 24040454, "text": "Report analysis of KRAS mutations in non-small cell lung carcinomas."}, {"pubmed": 24055406, "text": "Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning."}, {"pubmed": 24067137, "text": "KRAS mutations were associated with poorer overall survival of patients with pediatric B cell precursor acute lymphoblastic leukemia."}, {"pubmed": 24073892, "text": "KRAS mutation status does not seem to represent a strong prognostic variable."}, {"pubmed": 24078161, "text": "no significant associations have been detected between KRAS mutations and clinicopathologic variables and MSI in Tunisian patients as previously reported."}, {"pubmed": 24103274, "text": "Review/Meta-analysis:  K-ras mutation analysis alone is not recommended for the diagnosis of pancreatic carcinoma."}, {"pubmed": 24104864, "text": "KRAS status was an independent predictor of overall and recurrence-free survival."}, {"pubmed": 24105326, "text": "7 KRAS mutations were detected in adult Korean patients with acute myeloid leukemia; most common mutation was G-to-A transition in the second base of KRAS codon 13; study could not find any statistical differences of clinical features according to KRAS mutaion status"}, {"pubmed": 24119562, "text": "study demonstrated that mucinous adenocarcinomas with KRAS mutations have clinicopathologic characteristics different from those of mucinous adenocarcinoma without such mutations"}, {"pubmed": 24122611, "text": "KRAS gene mutations were found in 4 (5%) of 28 patients with squamous cell anal cancer"}, {"pubmed": 24136682, "text": "KRAS mutation impairs the therapeutic effect exerted by cetuximab-mediated antibody-dependent cellular cytotoxicity"}, {"pubmed": 24139215, "text": "Of 54 intrahepatic cholangiocarcinoma cases, 7.4% were mutant for KRAS, 7.4% were mutant for BRAF, and these were mutually exclusive. These cases were associated with a higher tumor stage and a greater likelihood of lymph node involvement."}, {"pubmed": 24139521, "text": "When genotypes of BRAF/KRAS mutated s-BOTs and corresponding implants were compared, no patient presented with a fully matching mutation profile of s-BOT and all corresponding implants."}, {"pubmed": 24139827, "text": "KRAS mutations are associated with non-small-cell lung cancer."}, {"pubmed": 24152947, "text": "Studies suggest that understanding the underlying biology of tumor-stroma interactions and tumor heterogeneity are critical to guiding rational approaches to designing treatments tailored to targeting KRAS in the stroma-rich microenvironment."}, {"pubmed": 24154848, "text": "miR-27a suppresses tumorigenesis of esophageal squamous cell carcinoma by targeting KRAS."}, {"pubmed": 24156711, "text": "Despite the overlapping clinical features, Rasopathy syndromes exhibit unique fenotypical features and the precise molecular diagnostics may lead to confirmation of each syndrome."}, {"pubmed": 24166518, "text": "Report role of KRAS oncogenetic risk classification in the prognosis of adult T-cell acute lymphoblastic leukemia."}, {"pubmed": 24172884, "text": "Androgen-induced AR activating signal upregulates let-7a that targets CMYC and KRAS and contributes to ER-, PR-, AR+ breast cancer pathogenesis."}, {"pubmed": 24186144, "text": "The presence of KRAS mutation in both mucinous adenocarcinoma and complex mucinous changes indicates that KRAS mutational activation is implicated in the pathogenesis of a significant subset of endometrial mucinous carcinoma."}, {"pubmed": 24192124, "text": "This review will focus on the current (EGFR and KRAS mutations)and future biomarkers in the advanced NSCLC field and also address potential related targeted therapies for these patients."}, {"pubmed": 24200637, "text": "Data indicate that coexistence of EML4-ALK fusion or ALK copy number increase and EGFR, MET, and KRAS mutations in tumor tissue from two treatment-naive Chinese non-small cell lung cancer (NSCLC) patients."}, {"pubmed": 24205021, "text": "K-ras gene mutation is not associated with response to chemotherapy in colorectal cancer patients."}, {"pubmed": 24205279, "text": "overall genomic and transcriptional landscape of lung adenocarcinoma is affected, but only to a minor extent, by EGFR and KRAS mutation status"}, {"pubmed": 24216479, "text": "RAS is the most frequently mutated oncogene in cancers. Isoprenylcysteine carboxylmethyltransferase (ICMT) methylates RAS and other CaaX-containing proteins."}, {"pubmed": 24219000, "text": "The presence of K-Ras mutations has prognostic value in colon cancer patients, and also predicts the responsiveness to inhibitors of EGFR signaling."}, {"pubmed": 24222113, "text": "KRAS mutations are associated with proliferative thyroid lesions."}, {"pubmed": 24228126, "text": "Case Report: mucinous bronchioloalveolar carcinoma with K-ras mutation arising in type 1 congenital cystic adenomatoid malformation."}, {"pubmed": 24240690, "text": "Ras regulates KIF2C to control cell migration pathways in transformed human bronchial epithelial cells."}, {"pubmed": 24242294, "text": "Here we report a sensitive and inexpensive assay for KRAS mutations based on a PNA-mediated PCR clamping."}, {"pubmed": 24244261, "text": "The combination of lenalidomide and cetuximab appeared to be well tolerated but did not have clinically meaningful activity in KRAS-mutant metastatic colorectal cancer patients."}, {"pubmed": 24247240, "text": "Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination."}, {"pubmed": 24247407, "text": "Prognosis after progression to firstline FIr-B/FOx may be significantly favourable in MCRC pts re-challenged with intensive regimens, and unfavourable in c.35 G>A KRAS mutant patients."}, {"pubmed": 24248599, "text": "Data indicate that sp-Erf2/zDHHC9 palmitoylates Ras proteins in a highly selective manner in the trans-Golgi compartment to facilitate PM targeting via the trans-Golgi network, a role that is most certainly critical for Ras-driven tumorigenesis."}, {"pubmed": 24259266, "text": "the joint presence of CDKN2A methylation and KRAS mutations independently predicted recurrence of cancer and was associated with poor overall and cancer-specific survival."}, {"pubmed": 24263065, "text": "Tumor KRAS has minor clinical impact, whereas plasma KRAS status seems to hold important predictive and prognostic information."}, {"pubmed": 24276238, "text": "We show that loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors"}, {"pubmed": 24281417, "text": "KRAS mutations are at high risk for early pulmonary recurrence in colorectal carcinoma."}, {"pubmed": 24282149, "text": "Results suggest that the cancer-associated rs61764370 variant exerts a biological effect not through transcriptional modulation of KRAS but rather by tuning the expression of the microRNA let-7."}, {"pubmed": 24293274, "text": "Study reveals functional and mechanistic links between miRNA-30b and oncogene KRAS, PIK3CD and BCL2 in the pathogenesis of colorectal carcinoma."}, {"pubmed": 24297898, "text": "Mutant KRAS is a druggable target for pancreatic cancer."}, {"pubmed": 24297914, "text": "identified inositol trisphosphate receptors as unique effectors of K-Ras4B that antagonize the prosurvival signals of other K-Ras effectors."}, {"pubmed": 24312577, "text": "GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct"}, {"pubmed": 24330663, "text": "KRAS mutation did not have prognostic value in patients with metachronous or synchronous metastatic CRC."}, {"pubmed": 24331409, "text": "mutation patterns are quantitatively and qualitatively distinct between non-small-cell lung cancer and colorectal cancer"}, {"pubmed": 24335104, "text": "KRAS mutation did not reduce sensitivity to bortezomib or dexamethasone in myeloma patients."}, {"pubmed": 24338482, "text": "Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis."}, {"pubmed": 24340014, "text": "Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells."}, {"pubmed": 24340949, "text": "The detection of activating somatic mutations in gene KRAS using pyrosequencing technique"}, {"pubmed": 24349411, "text": "This study is the first to compare different SMIs in combination with IR for the treatment of K-RAS mutant rectal cancer, and our findings suggest that Chk1/2 inhibitors should be evaluated in new clinical trials for LARC."}, {"pubmed": 24366883, "text": "A protumorigenic role for CLPTM1L that is critical for Ras-driven lung cancers, with potential implications for therapy and chemosensitization."}, {"pubmed": 24368337, "text": "Findings suggest that miR-200c is a potent inhibitor of tumor progression and therapy resistance, by regulating a multitude of oncogenic pathways including the RAS pathway."}, {"pubmed": 24371145, "text": "Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5).extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1."}, {"pubmed": 24371225, "text": "KRAS requires S181 phosphorylation to manifest its oncogenic properties, implying that its inhibition represents a relevant target to attack KRAS-driven tumors."}, {"pubmed": 24372748, "text": "correlation between KRAS or BRAF mutations and prognosis was not observed"}, {"pubmed": 24374738, "text": "The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism."}, {"pubmed": 24377583, "text": "KRAS gene mutation is not associated with chronic myeloid leukemia."}, {"pubmed": 24386371, "text": "Smad4 represents a barrier in KRAS-mediated malignant transformation of the near normal immortalized human pancreatic duct epithelial (HPDE) cell"}, {"pubmed": 24388967, "text": "Oncogenic KRAS plays a central role in controlling multiple metabolic changes such as stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metabolism, increased autophagy, and macropinocytosis. (Review)"}, {"pubmed": 24389431, "text": "High KRAS mRNA expression is associated with non-small-cell lung cancer growth and progression."}, {"pubmed": 24394008, "text": "results suggest that the frequency of wild-type KRAS in cancer associated with familial adenomatous polyposis was approximately 40%, although it was lower than that in sporadic cancer"}, {"pubmed": 24397598, "text": "the first BRAF V600/601 and KRAS G12-K16 screening study in primary mediastinal B-cell lymphoma that failed to identify hotspot mutations in this specific subtype"}, {"pubmed": 24398677, "text": "Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer."}, {"pubmed": 24399305, "text": "The suppression of K-ras expression by siRNA interfered with this synergism and inhibited both EGFR and Akt activity in A549 cells."}, {"pubmed": 24407191, "text": "As second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer."}, {"pubmed": 24430184, "text": "Sag is a Kras-cooperating oncogene that promotes lung tumorigenesis"}, {"pubmed": 24439221, "text": "results indicate that serrated lesions of the appendix often harbor KRAS mutations rather than BRAF mutations and suggest that the serrated pathway in the appendix is likely different than in the colon and rectum"}, {"pubmed": 24439569, "text": "mutations result in lower disease control rate after the first-line platinum-based chemotherapy"}, {"pubmed": 24440911, "text": "Results identify miR-134 as a novel RTK-regulated tumor-suppressive hub that mediates RTK and RTK-inhibitor effects on GBM malignancy by controlling KRAS and STAT5B."}, {"pubmed": 24440976, "text": "KRAS mutations are more common in African Americans than among Caucasians and are associated with advanced stage in colorectal cancer patients."}, {"pubmed": 24443225, "text": "A KRAS somatic mutation was identified in 25% (7/28) of the TP53 mutated tumors"}, {"pubmed": 24454858, "text": "KRAS gene was wild type in 18 cases, whereas one mucinous carcinoma harboured a point mutation at codon 12"}, {"pubmed": 24461128, "text": "Knockdown of ACK1 abrogated bosutinib-induced inhibition of cell migration and invasion specifically in KRAS mutant cells. This finding was further confirmed in an in vivo zebrafish metastatic model"}, {"pubmed": 24463346, "text": "Studies suggest the potential predictive role of mutant KRAS in the context of chemosensitivity of non-small-cell lung cancer (NSCLC) which may depend on the individual drug types."}, {"pubmed": 24467518, "text": "KRAS (G-->A) mutation does not affect in vivo anti-cancer efficacy of cetuximab in gastric cancer xenograft model."}, {"pubmed": 24480914, "text": "Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia."}, {"pubmed": 24491301, "text": "K-Ras mutation activates CSCs, contributing to colorectal tumorigenesis and metastasis in CRC cells harboring APC mutations. Initial activation of beta-catenin by APC loss and further enhancement through K-Ras mutation induces CD44, CD133, CD166 expression."}, {"pubmed": 24496383, "text": "systemic delivery of MNPsiCDK4 significantly inhibited tumor growth in an A549 NSCLC xenograft murine model, with depressed expression of CDK4 and mutational KRAS status."}, {"pubmed": 24498230, "text": "GNAS mutant colon tumors commonly have synchronous mutations in KRAS."}, {"pubmed": 24503901, "text": "This study investigated the proteome modulated by oncogenic KRAS in immortalized airway epithelial cells."}, {"pubmed": 24505083, "text": "expression of oncogenic KRAS shifts the balance of DNA repair toward the highly error-prone alternative nonhomologous end-joining pathway."}, {"pubmed": 24505265, "text": "Oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients."}, {"pubmed": 24519534, "text": "ADM is a new target of oncogenic KRAS in the setting of hypoxia"}, {"pubmed": 24522420, "text": "42% of colorectal cancer tissue samples had KRAS mutations. Their frequency and distribution are similar to those reported in the literature, except for G12C mutation"}, {"pubmed": 24525237, "text": "Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response."}, {"pubmed": 24534449, "text": "we review the latest published literature specific to KRAS mutation testing techniques--{REVIEW}"}, {"pubmed": 24548858, "text": "RAD21 expression in CRC is associated with aggressive disease especially in KRAS mutant tumours and resistance to chemoradiotherapy."}, {"pubmed": 24549645, "text": "KRAS mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma."}, {"pubmed": 24552817, "text": "rs712, rs9266, and one novel variant may have a functional role in regulation of KRAS by disrupting complementary sites of various miRNAs, including let-7 and miR-181."}, {"pubmed": 24560515, "text": "Although the sensitive pyrosequencing method was used, no EGFR, KRAS or BRAF mutations could be found"}, {"pubmed": 24577055, "text": "Our findings suggest that IL-8 expression is associated with certain clinicopathological features including age and is a potent prognostic marker in lung adenocarcinoma, especially in oncogenic KRAS-driven adenocarcinoma."}, {"pubmed": 24582914, "text": "RAS mutations beyond KRAS exon 2 and 3 were identified in 17% of locally advanced rectal cancer patients."}, {"pubmed": 24594115, "text": "KRAS gene insertions represent a diagnostic and clinical challenge due to the difficult and unusual pyrosequencing findings and the lack of information regarding its clinical impact."}, {"pubmed": 24594201, "text": "Activating KRAS mutations were associated with lung cancer."}, {"pubmed": 24594684, "text": "After activating hK-rasG12D gene expression, hK-rasG12D transgenic goat fetal fibroblast cells were transformed into tumorgenesis cells."}, {"pubmed": 24595526, "text": "In prostate cancer, EGFR mutations occur more commonly than KRAS mutations and EGFR and KRAS mutations may be mutually exclusive"}, {"pubmed": 24595598, "text": "In this cetuximab-treated colorectal cancer population, EGFR gain was associated with better outcome and PTEN protein expression with longer TTP in KRAS WT, KRAS WT/AREG high and KRAS/BRAF WT subpopulations"}, {"pubmed": 24598028, "text": "The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells."}, {"pubmed": 24624786, "text": "Mutations of the KRAS gene (exon 2) were detected in 36.3% of cases of CRC, more often in women (41.1%) than in men (31.2%). 8 different types of KRAS mutations were identified, the most frequent replacement of G12D (33.7%), G12V (32.7%) and G13D (12.5%)"}, {"pubmed": 24629489, "text": "No correlation was found between the frequency of cancer recurrence and KRAS mutations in surgical margins"}, {"pubmed": 24632950, "text": "Findings demonstrated that oncogenic K-Ras activates the signaling cascade p38/PDPK1/PKCdelta/p47(phox)/NOX1 for ROS generation and consequent malignant cellular transformation."}, {"pubmed": 24642661, "text": "KRAS and BRAF genes were wild-type in all squamous cell anal carcinoma cases."}, {"pubmed": 24642668, "text": "study found incidence of KRAS mutations in metastatic colorectal cancer (mCRC) was similar to that of non-mCRC as previously reported; KRAS codon 13 mutations might be associated with younger female patients with mCRC"}, {"pubmed": 24642870, "text": "The KRAS mutation rate is significantly higher in women than in men and tumors on the right colon have a higher frequency of KRAS mutations than those on the left."}, {"pubmed": 24648348, "text": "Blockade of autophagy results in a mutant KRAS-dependent senescence-to-apoptosis switch in cancer cells treated with IR and erlotinib."}, {"pubmed": 24651628, "text": "No patients exhibiting phospho-S6rp-positive staining and an activating KRAS mutation demonstrated a prolonged response of everolimus in endometrial cancer."}, {"pubmed": 24659028, "text": "Increased KRAS mutation is associated with colorectal cancer progression and poor response to therapy."}, {"pubmed": 24666267, "text": "Mutations in KRAS exons 3 and 4 predict resistance to anti-EGFR therapies."}, {"pubmed": 24675495, "text": "K-ras mutations are common among the Saudi colorectal cancer population, especially pG12V and pG12D in codon 12, and are more frequent in sigmoid and rectal adenocarcinomas and stage IVB tumors."}, {"pubmed": 24681874, "text": "Results support the role of KRAS mutational status in pancreatic cancer biology and suggest may serve as prognostic marker."}, {"pubmed": 24687927, "text": "KRAS mutations in either codon 12 or 13 are associated with inferior survival in patients with resected stage III colon cancer"}, {"pubmed": 24688052, "text": "we identify altered regulation of folate metabolism in KRAS-mutant NSCLC cells that may account for higher antifolate activity in this subtype of NSCLC."}, {"pubmed": 24694341, "text": "KRAS mutations are more common in heavy smokers, and lung adenocarcinomas with KRAS mutation are more likely to invade the visceral pleura."}, {"pubmed": 24694877, "text": "Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways."}, {"pubmed": 24696490, "text": "Enhanced KRAS activity increases bovine herpesvirus 1 oncolytic capacity in cancer cells."}, {"pubmed": 24700299, "text": "Mutations in KRAS were associated with rectal cancer."}, {"pubmed": 24709419, "text": "The SMURF2:UBCH5 complex is critical in maintaining KRAS protein stability."}, {"pubmed": 24715238, "text": "Data shows that KRAS genotype, specifically the c.35 G>A KRAS mutation, may indicate poor prognosis in metastatic colorectal cancer patients."}, {"pubmed": 24720724, "text": "In a Brazilian cohort of patients with metastatic colorectal cancer, tumors had overall percentage of wild-type and mutated KRAS was 62.8% and 31.9%, respectively, with a greater percentage in women."}, {"pubmed": 24724096, "text": "Reexpression of Let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma."}, {"pubmed": 24727325, "text": "A let-7 microRNA-complementary site (LCS6) polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression in colon cancer."}, {"pubmed": 24732316, "text": "The KRAS-variant may be a genetic marker of risk for type 2 endometrial cancers."}, {"pubmed": 24737308, "text": "In cytogenetically normal acute myeloid leukemia, activating K-RAS mutations in codons 12, 13, or 61 were detected in 3 of 204 patients. Activating K-RAS mutations may cooperate with mutated NPM1 to induce leukemia."}, {"pubmed": 24742923, "text": "From a practical perspective, small biopsies may not adequately represent a tumor's full mutational profile, particularly for later arising but prognostically important mutations such as those in the KRAS and BRAF genes"}, {"pubmed": 24747441, "text": "Integrin alpha(v)beta expression and the resulting KRAS-RalB-NF-kappaB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance."}, {"pubmed": 24763823, "text": "kras and p53 undergo separate pathways in colorectal tumorogenesis. Interestingly, mutations in the K-ras gene might be considered a valuable prognostic factor correlated to poor outcome"}, {"pubmed": 24766281, "text": "The loss of the wild-type KRAS allele may be a common secondary genetic change in KRAS-related JMML and may affect the differentiation behavior of early JMML progenitors."}, {"pubmed": 24767862, "text": "Two (15%) of 13 patients with MTS were found to harbor a KRAS mutation and loss of MLH1 expression"}, {"pubmed": 24768329, "text": "While KRAS mutation status per se is neither prognostic nor predictive in stage III-IV lung adenocarcinoma, subtype-specific analysis may indeed identify clinically relevant subgroups of patients that may ultimately influence treatment decisions."}, {"pubmed": 24774510, "text": "This study indicated that mutations of KRAS, PIK3CA and NRAS were rare in advanced gastric cancer."}, {"pubmed": 24778079, "text": "study failed to promote (18)F-FDG PET/CT uptake as a surrogate examination for KRAS mutation testing"}, {"pubmed": 24788807, "text": "Implementation of KRAS testing did not influence CRC OS. Our data support the use of KRAS testing to guide administration of EGFR inhibitors for treatment of metastatic CRC without diminished OS."}, {"pubmed": 24798549, "text": "KRAS mutations are associated with colorectal cancer."}, {"pubmed": 24799053, "text": "PS detection of low-frequency mutations may improve the KRAS predictive value for EGFR therapy selection."}, {"pubmed": 24803537, "text": "findings identified Yap as a critical oncogenic KRAS effector and a promising therapeutic target for PDAC and possibly other types of KRAS-mutant cancers"}, {"pubmed": 24806883, "text": "Characteristics and prognosis of colorectal cancer with NRAS mutations are different from those with KRAS or BRAF mutations."}, {"pubmed": 24811330, "text": "The frequency of KRAS mutations in metastatic colorectal cancer reported by the major Australian test sites is very similar to that reported by other large overseas studies."}, {"pubmed": 24821886, "text": "Case Report: KRAS mutated pancreatic adenocarcinoma developing on treatment with combined BRAF and MEK inhibition for metastatic melanoma."}, {"pubmed": 24833563, "text": "RAC1b overexpression constitutes a marker of poor prognosis in KRAS/BRAF WT mCRC patients treated with first-line FOLFOX/XELOX therapy."}, {"pubmed": 24853419, "text": "Rasfonin is a robust inhibitor of pancreatic cancers with the K-ras mutation."}, {"pubmed": 24859378, "text": "Data show that patients with a mutation in KRAS codon 13 experienced worse outcome than those with a mutation in KRAS codon 12 but both mutations are associated with a significantly higher mortality."}, {"pubmed": 24859998, "text": "The high-resolution melting method developed was shown to be a reliable method for KRAS mutation detection"}, {"pubmed": 24861525, "text": "APC, KRAS, and TP53 gene mutations were more common in colorectal cancer than in stomach cancer"}, {"pubmed": 24861917, "text": "Chinese colorectal cancer patients with either KRAS or PIK3CA mutations are more susceptible to distant metastasis."}, {"pubmed": 24866065, "text": "A KRAS or NRAS mutation was found in 31% and 62% of benign hyperplastic thyroid nodules and follicular thyroid carcinomas respectively."}, {"pubmed": 24866168, "text": "EGFR and KRAS mutations were present in adenocarcinoma of the lung but not squamous tumors."}, {"pubmed": 24870739, "text": "There were no clearly pathogenic mutations in the KRAS gene in a cohort with thymic tumors."}, {"pubmed": 24875049, "text": "Using an inducible RAS expression system, we show that overexpression of RAS disrupts the circadian clock and leads to an increase of the circadian period while RAS inhibition causes a shortening of period length."}, {"pubmed": 24883309, "text": "Results demonstrated that the SPACE-HRM system we set up is a high sensitive assay that can be used for EGFR and KRAS allele enrichment and reliable detection"}, {"pubmed": 24885062, "text": "Tumors with KRAS mutations in codons 61 and 146 account for an appreciable proportion of colorectal cancers."}, {"pubmed": 24888607, "text": "Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage."}, {"pubmed": 24889043, "text": "In 14 % of ovarian clear cell carcinomas, a KRAS mutation occurs in codon 2 exon 2."}, {"pubmed": 24889488, "text": "KRAS mutation is associated with high-risk stage II colon cancer."}, {"pubmed": 24890702, "text": "This helps to clarify the confusing body of literature regarding the clinical implications of the KRAS-LCS6 genetic variant on colorectal cancer outcomes, indicating that it should not be used to personalize therapeutic strategies."}, {"pubmed": 24893629, "text": "KRAS-mutation is associated with non-small cell lung cancer."}, {"pubmed": 24902368, "text": "Our results suggest that the presence of a KRAS mutation in colorectal carcinoma is associated with alterations in the nuclear morphometric properties of contrast and ellipticity."}, {"pubmed": 24906690, "text": "KRAS mutations are known to promote the emergence of aggressive subclones in the evolution of colorectal cancer."}, {"pubmed": 24913817, "text": "miR125a loss may have a role in k-ras dependent lung carcinogenesis"}, {"pubmed": 24918610, "text": "The results from this prospective cohort study further support an influence of sex and lifestyle factors on different pathways of colorectal carcinogenesis, defined by KRAS and BRAF mutation status of the tumours."}, {"pubmed": 24931611, "text": "KRAS CRC regulates MEK-dependent, ADAM17-mediated shedding of soluble decoy MET."}, {"pubmed": 24934485, "text": "Report no KRAS mutations in thyroid carcinoma showing thymus-like elements."}, {"pubmed": 24935174, "text": "Amplified PAK1, as well as KRAS amplification/mutation, may represent unique opportunities for developing targeted therapeutics for the treatment of gastric cancer."}, {"pubmed": 24938521, "text": "KRAS mutation is associated with pancreatic mucinous cysts."}, {"pubmed": 24947927, "text": "KRAS mutations are associated with response to chemotherapy in cancer."}, {"pubmed": 24947996, "text": "Data suggest that the K-Ras - JNK1/2 axis could be a potential target in cancer stem cells (CSCs) or proliferating cancer stem-like cells (CSLCs)-directed therapies against pancreatic cancer."}, {"pubmed": 24952473, "text": "Findings indicate that KRAS mutations at codon-12 are associated with different metabolomic profiles that might affect the responses to cancer treatments."}, {"pubmed": 24954536, "text": "Using a colon cancer cell line, study found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation."}, {"pubmed": 24956168, "text": "K-RAS Mutation is associated with non small cell lung cancer."}, {"pubmed": 24956256, "text": "KRAS codons 12 and 13 mutation status was the first validated molecular biomarker for anti-EGFR antibodies"}, {"pubmed": 24958732, "text": "Studies indicate that K-RAS gene mutations cause GTPase RAS to remain locked in constitutively active signals through the downstream cascades leading to proliferation."}, {"pubmed": 24964758, "text": "Variable KRAS mutations may have different effects on colon cancers; further studies are needed to verify these results"}, {"pubmed": 24973952, "text": "The frequency and characteristics of KRAS gene mutation in Turkish non-small cell lung cancer patients"}, {"pubmed": 24987838, "text": "Non-invasive QTA can differentiate the presence of K-ras mutation from pan-wildtype NSCLC and is associated with patient survival."}, {"pubmed": 24993163, "text": "Activating FGFR2-RAS-BRAF mutations play a critical role in the pathogenesis of most cases of ameloblastoma."}, {"pubmed": 24994038, "text": "EGFR or KRAS mutations were detected with xTAG liquidchip technology"}, {"pubmed": 24998203, "text": "In KRAS-dependent pancreatic ductal adenocarcinoma cell lines, HNRNPA2B1 interacts with and regulates the activity of KRAS G12V and G12D."}, {"pubmed": 24998492, "text": "significant KRAS mutation discordance between the adenoma and carcinoma component of the colorectal tumor lesion."}, {"pubmed": 25002494, "text": "up-regulation of KIF2C and KIF2A by ERK1/2 caused aberrant lysosomal positioning and mTORC1 activity in a mutant K-Ras-dependent cancer and cancer model."}, {"pubmed": 25004944, "text": "Report high concordance rate between next generation sequencing and standard testing for KRAS."}, {"pubmed": 25009008, "text": "Clinicopathologic characteristics, survival outcomes, functional impact, and gene expression profiling were similar between patients with KRAS 12/13 and those with NRAS or KRAS 61/146-mutated colorectal cancers"}, {"pubmed": 25013125, "text": "In tDNA, 50 mutations (36 EGFR, 5 ERBB2, 4 KRAS, 3 BRAF, and 2 PIK3CA) were identified, of which 26 were detected in cfDNA. These data demonstrate the feasibility and potential utility of mutation screening in the detection of a range of tumor biomarkers"}, {"pubmed": 25023699, "text": "These data suggest that disabling of the G1 Q checkpoint could represent a novel vulnerability of cancer cells harboring K-Ras and possibly other mutations that disable the Q-dependent checkpoint."}, {"pubmed": 25023700, "text": "results indicate MTH1 is a novel and critical component of oncogenic KRAS-associated malignancy and its inhibition is likely to yield significant tumor-suppressive outcomes in KRAS-driven tumors."}, {"pubmed": 25029118, "text": "We sought to investigate whether mucinous features, such as signet-ring cell feature and extracellular mucin, are associated with EGFR and KRAS mutations in patients with lung adenocarcinoma"}, {"pubmed": 25029561, "text": "oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis"}, {"pubmed": 25032217, "text": "Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients."}, {"pubmed": 25039399, "text": "The adenocarcinoma showed expression of CK20 and p53, but CK7 in patches. The molecular profile of the adenocarcinoma showed a mutation in KRAS and wild-type BRAF, which might be associated with malignant transformation of intracranial mature teratomas."}, {"pubmed": 25041017, "text": "Only one (2.8%) had a K-ras mutation."}, {"pubmed": 25050586, "text": "KRAS mutations were detected in 13.6% of the colorectal cancer precursor lesions, namely in adenomas and in hyperplastic polyps, but in no serrated adenoma. In CRC cases, 46.8% exhibited KRAS mutation."}, {"pubmed": 25050641, "text": "Oncogenic KRAS upregulated mir31 in lung carcinogenesis."}, {"pubmed": 25065594, "text": "study surveyed the ability of 12 different oncogenic KRAS mutations to induce pancreatic tumors in an in vivo tumorigenesis assay; results suggest the spectrum of KRAS mutations observed in human pancreatic cancer reflects selection based on variable tumorigenic capacities, including ability to activate MAPK/ERK signaling"}, {"pubmed": 25070947, "text": "Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC zeta activation, which is perturbed in neurofibromatosis type 1."}, {"pubmed": 25073438, "text": "KRAS, BRAF, and PIK3CA mutations were evaluated in 204 colorectal carcinoma samples; the frequency of KRAS, BRAF, and PIK3CA mutations was 23.5, 9.8, and 5.9 %, respectively."}, {"pubmed": 25076326, "text": "Data indicate that high KRAS gene expression corresponded to low survival rates."}, {"pubmed": 25081901, "text": "The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in recurrent/metastatic head and neck squamous cell carcinoma patients"}, {"pubmed": 25086186, "text": "A mutually exclusive pattern of FGFR2, HER2, and KRAS gene amplification and survival trends in gastric cancer patients."}, {"pubmed": 25090459, "text": "The presented data subclassified colorectal cancers (CRCs) based on their activated signaling pathways and identify a role for c-MET and IGF1R-driven PI3K signaling in CRCs, which is superior to KRAS mutational tests alone."}, {"pubmed": 25103069, "text": "in pancreatic undifferentiated rhabdoid carcinomas the pleomorphic giant cell subtype is characterized by KRAS alterations and the anaplastic monomorphic subtype correlates with the absence of KRAS alterations"}, {"pubmed": 25105841, "text": "NRAS and KRAS mutations have a role in Down syndrome acute lymphoblastic leukemia that lacks JAK2 mutations"}, {"pubmed": 25120214, "text": "DNA mutational analysis in lebanese population shows that mutations of EGFR and KRAS are present in 8.5% and 37.7% respectivement in lung adenocarcinoma."}, {"pubmed": 25122432, "text": "KRAS is an independent prognostic marker in resected stage I lung adenocarcinoma. Differential outcomes are associated with codon and amino acid specific KRAS mutations."}, {"pubmed": 25127693, "text": "The variant G-allele of the KRAS-LCS6 polymorphism was significantly associated with better overall survival in patients with oropharyngeal squamous cell carcinoma"}, {"pubmed": 25132659, "text": "Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics."}, {"pubmed": 25133424, "text": "Inhibition of proliferation by K-RAS depended on antiproliferative RAS effector RASSF1A and blockade of the RAS-activated proproliferative RAF/MAPK pathway by tumor suppressor menin"}, {"pubmed": 25137136, "text": "KRAS showed a direct connection to numerous cancer-related pathways, such as MAPK signaling pathway, suggesting that it may be a central communication hub in breast cancer."}, {"pubmed": 25137394, "text": "KRAS mutations in serial blood samples revealed that individual patient's circulatin tumor cells exhibited different mutational status of KRAS during treatment."}, {"pubmed": 25155157, "text": "The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT."}, {"pubmed": 25155261, "text": "Meta-analysis found that cetuximab objective response rate (ORR) of metastatic colorectal cancer (mCRC) patients with KRAS mutation was 8%, whereas the ORR of mCRC patients with wild-type KRAS was 34%."}, {"pubmed": 25158139, "text": "KRAS oncogene mutations originated from the guanosine nucleotide and over half of all transversions in lung cancer and colorectal cancer were c.34 G>T and c.35 G>T, respectively. c.35 G>A was the most frequent type of transition in both cancers."}, {"pubmed": 25164765, "text": "Targeted sequencing on primary, metastatic, and normal tissue from colorectal cancer patients found a high degree of concordance for KRAS, NRAS, and BRAF mutations that were identical in both the primary and metastatic tumors."}, {"pubmed": 25167228, "text": "KRAS mutational subtype and copy number is associated with in vitro response of pancreatic cancer cell lines to MEK inhibition."}, {"pubmed": 25183481, "text": "LCS6-variant (of the KRAS gene) patients with metastatic colorectal cancer have an excellent response to anti-EGFR mAb monotherapy, without any benefit from the addition of chemotherapy."}, {"pubmed": 25197873, "text": "KRAS (41%) and PIK3CA (8%) mutations in Colorectal cancer in patient-derived xenograft models closely paralleled patient tumors (35 to 51% KRAS, 12 to 21% PIK3CA)."}, {"pubmed": 25201577, "text": "These results supported the role of the KRAS rs712 polymorphism as a potential genetic biomarker for the extension of papillary thyroid cancer."}, {"pubmed": 25210032, "text": "expression of K-Ras and RalB and possibly RalA proteins is critical for maintaining low levels of p53, and down-regulation of these GTPases reactivates p53 by significantly enhancing its stability, contributing to suppression of malignant transformation"}, {"pubmed": 25210493, "text": "A higher number of gene mutations and the DAXX/ATRX and KRAS gene mutations are correlated with a poor prognosis of Chinese patients with pancreatic neuroendocrine tumors."}, {"pubmed": 25216999, "text": "No relation was found between the K-ras oncogene mutation and reduced survival, in contrast to what has been established in the international medical literature"}, {"pubmed": 25222473, "text": "NQO1 expression was significantly more frequent in non-small cell lung carcinoma patients with KRAS mutations, suggesting that oxidative stress may be important in the pathogenesis, worse prognosis, and resistance to treatment reported in these patients."}, {"pubmed": 25224251, "text": "LKB1 CN in combination with KRAS mutation predicted brain metastasis in NSCLC."}, {"pubmed": 25227306, "text": "KRAS mutation is associated with response to chemotherapy in colorectal liver metastases."}, {"pubmed": 25244542, "text": "The frequency of KRAS and BRAF mutations was low; KRAS mutations were detected in 1.6% and BRAF mutations in 4.7% of the biopsies for anal carcinoma."}, {"pubmed": 25245423, "text": "These findings support a model in which targeting MUC1-C inhibits mutant KRAS signaling in Non-small cell lung cancer cells and thereby reverses the epithelial-mesenchymal transition phenotype and decreases self-renewal."}, {"pubmed": 25248381, "text": "This study suggests that patients with mCRC with KRAS-mutated subclones (at least those with a KRAS-mutated subclones fraction lower or equal to 1%) had a benefit from anti-EGFR therapies."}, {"pubmed": 25248721, "text": "Differences in the KRAS mutational status during colorectal cancer disease progression."}, {"pubmed": 25253780, "text": "our study identifies coordinate hyperactivation of Notch1 and Ras/MAPK pathways as novel biomarkers for poor breast cancer outcome."}, {"pubmed": 25257576, "text": "None of the 66 tumors harbored mutations in KRAS exon 2, thus excluding KRAS mutations as a common event in squamous cell carcioma of the anogenital and head and neck region and as a cause of p16(INK4a) expression in these tumors."}, {"pubmed": 25267307, "text": "KRAS and BRAF mutation analysis could be used in the selection of patients for anti-EGFR therapy."}, {"pubmed": 25274248, "text": "KRAS mutations are associated with pseudomyxoma peritonei."}, {"pubmed": 25294886, "text": "KRAS exon 2 mutations are independent predictors of shorter time to recurrence in patients with resected stage III distal colon cancers receiving adjuvant therapy"}, {"pubmed": 25297496, "text": "KRAS mutation in adenocarcinoma of the gastrointestinal type arising from a mature cystic teratoma of the ovary."}, {"pubmed": 25302858, "text": "KRAS mutations are associated with poor prognosis in Non-Small Cell Lung Cancer patients. Good diagnostic performance obtained from Malignant pleural effusion samples for detecting KRAS mutations."}, {"pubmed": 25304374, "text": "AKR1B10 is a unique enzyme involved in pancreatic carcinogenesis via modulation of the Kras-E-cadherin pathway."}, {"pubmed": 25305448, "text": "Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway."}, {"pubmed": 25326806, "text": "These results suggest that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor was effective in CRC harboring with KRAS and PIK3CA mutations."}, {"pubmed": 25337237, "text": "Report KRAS mutation status in colorectal neoplasms and neuroendocrine differentiation in primary/metastatic colorectal neoplasms."}, {"pubmed": 25339352, "text": "Our findings illuminate the mechanistic details of KRAS-mediated drug resistance and provide a preclinical rationale to improve the management of lung tumors harboring KRAS mutations with NRF2 pathway inhibitors."}, {"pubmed": 25341034, "text": "Binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)alpha activation and promotes pancreatic tumor growth under hypoxic conditions."}, {"pubmed": 25359494, "text": "KRas G12V has higher aggressiveness than KRas G13D in a colorectal cancer model"}, {"pubmed": 25361550, "text": "Although, the KRAS LCS6 is neither constitutional nor somatic biomarker for endometriosis, increased expression ratio of KRAS mRNA indicates its role in the implantation of endometrial tissue outside the uterine cavity."}, {"pubmed": 25361845, "text": "Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions."}, {"pubmed": 25367198, "text": "KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type colorectal cancers in Chinese patients."}, {"pubmed": 25373533, "text": "This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy"}, {"pubmed": 25382779, "text": "SMYD3-mediated methylation of MAP3K2 increases mutant K-Ras-induced activation of ERK1/2. (Review)"}, {"pubmed": 25401377, "text": "scFv(CD44v6)-conjugated nanocarriers provide a highly efficient and safe platform for KRAS suppression in pancreatic cancer."}, {"pubmed": 25412182, "text": "KRAS gene mutations were detected 11 of 24 cases in exon 4 mutations."}, {"pubmed": 25415430, "text": "KRAS mutation is associated with metastatic lung adenocarcinomas."}, {"pubmed": 25427200, "text": "c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation."}, {"pubmed": 25427437, "text": "KRAS mutations occur in rare gastrointestinal stromal tumors with wild type KIT and PDGFRA."}, {"pubmed": 25427581, "text": "In this retrospective analysis, triplet chemotherapy with OCX was well tolerated and achieved encouraging efficacy in metastatic colorectal cancer irrespective of RAS/RAF mutation status."}, {"pubmed": 25444464, "text": "KRAS mutation is associated with refractory metastatic colorectal cancer"}, {"pubmed": 25450872, "text": "mutations are associated with decreased cancer-specific survival after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer"}, {"pubmed": 25453050, "text": "Mutated KRAS caused higher (18)F-FDG accumulation possibly by upregulation of GLUT1"}, {"pubmed": 25466250, "text": "Suppression of TET1-dependent DNA demethylation is critical for KRAS-mediated transformation."}, {"pubmed": 25468813, "text": "HER2 gene amplifications, and wild type KRAS genes are common in eyelid sebaceous carcinomas"}, {"pubmed": 25477374, "text": "miR-143 and miR-145 and the predicted target proteins API5, ERK5, K-RAS, and IRS-1 display regional differences in expression in the colon"}, {"pubmed": 25491172, "text": "Study sequenced a large clinical series of patients with metastatic colorectal cancer (mCRC) for RAS and PIK3CA mutations. RAS alterations occurred in 48% of mCRC cases, with mutations within KRAS exon 2 in 43%, KRAS exons 3 and 4 in 3%, and NRAS in 2% of cases. PIK3CA mutations occurred in about 10% of mCRC and were significantly associated with concurrent RAS mutation."}, {"pubmed": 25491325, "text": "KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes in metastatic colorectal cancer."}, {"pubmed": 25499080, "text": "Data suggest that the status of p53 and KRAS may be considered for the targeted therapy against NF-kappaappa B in lung cancer patients."}, {"pubmed": 25500542, "text": "mir206 targets ANXA2 and KRAS genes in pancreatic adenocarcinoma."}, {"pubmed": 25500543, "text": "LRP6 phosphorylation by ERK1/2 may provide a unique point of convergence between KRAS/MAPK and Wnt/beta-catenin signalings during oncogenesis"}, {"pubmed": 25513781, "text": "Report low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients."}, {"pubmed": 25515650, "text": "Missense mutations were identified in the BRAF and KRAS genes in cutaneous melanoma cell line."}, {"pubmed": 25527633, "text": "IRS2 copy number gain, IGF-1R, IR-A, and IGFBP6 RNA expression levels, and KRAS and BRAF mutational status were identified as candidate predictive biomarkers for response to BMS-754807."}, {"pubmed": 25532942, "text": "activation of the RAS-mitogen-activated protein kinase pathway by BRAF and RAS mutations contributes significantly to the tumorigenesis of sporadic SCAP"}, {"pubmed": 25535726, "text": "Lung metastasis was more likely to develop during the disease course in patients whose tumour had a KRAS mutation than in those whose tumour did not have a KRAS mutation."}, {"pubmed": 25537670, "text": "K-Ras 4A expression was 2.7-fold higher in endometriosis than non-endometriosis eutopic samples; this overexpression mainly occurs through the proliferative phase of menstrual cycle"}, {"pubmed": 25541062, "text": "an MEK1/2 inhibitor potentiated the anti-tumor effects of cisplatin in KRAS-dependent lung cancer cells and an animal model through inhibition of BIM degradation."}, {"pubmed": 25551625, "text": "in different macroscopic subtypes of colorectal adenoma, KRAS mutation was noted more frequently in lateral spreading tumors than polypoid neoplasms; mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner"}, {"pubmed": 25561800, "text": "Report mutations in SNP loci of K-RAS in neoplastic intestinal polyps and colorectal cancer."}, {"pubmed": 25577224, "text": "In unselected advanced non-small-cell lung cancer patients, KRAS mutations could be used as a potential negative predictor of clinical benefit from epidermal growth factor receptor tyrosine kinase inhibitors.[meta-analysis]"}, {"pubmed": 25599653, "text": "Each mutation generates a distinct signature, with the most variability seen between G13D and the codon 12 KRAS mutants"}, {"pubmed": 25605154, "text": "KRAS codon 12 and 13 mutations are associated with pancreatic adenocarcinoma."}, {"pubmed": 25605225, "text": "high-resolution melt and allele-specific PCR could detect as low as 1.25% KRAS- or BRAF-mutant alleles."}, {"pubmed": 25609577, "text": "KRAS mutant allele-specific imbalance is a significant event in colorectal cancer, specifically associated with G13D mutation, and featuring a heterogeneous spatial distribution, that may have a role to predict the response to EGFR inhibitors."}, {"pubmed": 25613309, "text": "Results suggest that WT1 and c-MYC expression is important for survival in KRAS mutant tumors as opposed to KRAS wild-type non-small cell lung tumors."}, {"pubmed": 25616942, "text": "The KRAS(G12D) mutation identifies a subset of ampullary adenocarcinoma patients with poor prognoses and may be used to identify patients at risk of early recurrence and poorer survival who may benefit from adjuvant therapy."}, {"pubmed": 25628445, "text": "KRAS mutations are associated with response to chemotherapy in colorectal cancer."}, {"pubmed": 25632066, "text": "Addition of cetuximab to GEMOX chemotherapy improved progress-free survival in biliary tract neoplasms but this did not correlate with KRAS mutation status."}, {"pubmed": 25632202, "text": "KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, in Japanese patients with curatively resected colorectal carcinoma."}, {"pubmed": 25633745, "text": "KRAS is a critical regulator for the metastatic behavior associated with mesenchymal features of breast cancer cells, implicating a novel therapeutic target for basal-type breast cancer."}, {"pubmed": 25634006, "text": "Latin American populations had a low frequency of KRAS mutations compared with European/North American populations."}, {"pubmed": 25636086, "text": "The frequencies of KRAS and IDHs mutations, which are associated with poor disease-free survival, were significantly higher in hepatitis-negative LCBs"}, {"pubmed": 25637496, "text": "KRAS gene mutation is associated with non small cell lung carcinoma."}, {"pubmed": 25647260, "text": "HPV presence was not associated with age, stage or grade of tumours, MSI or mutations in KRAS, TP53 or BRAF genes."}, {"pubmed": 25663768, "text": "miR-21 promotes malignant behaviors of colon cancer cells by regulating RASA1 expression via RAS pathways."}, {"pubmed": 25663779, "text": "Report high rates of KRAS mutations in Chinese colorectal carcinoma patients."}, {"pubmed": 25666295, "text": "KRAS mutations are associated with Metastatic Colorectal Cancer."}, {"pubmed": 25687873, "text": "It was concluded that a serum sample might alternatively be used when it is difficult to obtain tumor tissues for analyzing the status of KRAS mutation in patients with advanced colorectal cancer."}, {"pubmed": 25688918, "text": "Mutated KRAS and mutated BRAF seem to be prognostic factors in patients with Colorectal cancer who undergo lung metastasectomy."}, {"pubmed": 25689095, "text": "KRAS mutations portend a worse outcome with increased risk of recurrence in early-stage Non-small cell lung cancer and poorer survival in metastatic stage. It is associated with Adenocarcinoma subtype and smoking, and is common in Caucasian patients."}, {"pubmed": 25691052, "text": "KRAS amplification confers resistance to ROS1 targeting drugs in lung cancer."}, {"pubmed": 25695224, "text": "KRAS mutations were associated with stage IV lung adenocarcinoma adrenal metastases."}, {"pubmed": 25695684, "text": "RAS mutations cause vascular tumors including pyogenic granuloma"}, {"pubmed": 25699356, "text": "results suggest that KRAS mutation may be a useful prognostic marker for patients with metastatic colorectal cancer receiving mFOLFOX6 +/- bevacizumab therapy, especially for patients treated with mFOLFOX6 + bevacizumab"}, {"pubmed": 25702091, "text": "this is the first study focused on the effect of statins in selected patients with advanced-stage NSCLC harbouring KRAS mutation treated with EGFR-TKIs. A randomized prospective clinical trial should be conducted to confirm our results in the future."}, {"pubmed": 25702261, "text": "patients with KRAS mutations except for patients with KRAS codon 13 mutations that seem to be resistant to neoadjuvant CRT and less likely to achieve a pCR."}, {"pubmed": 25703330, "text": "MEKi induced the expression of negative regulators of mTORC1, including TSC1, TSC2 and Deptor, which occurred more significantly in BRaf-mutant cells than in KRas-mutant cells."}, {"pubmed": 25713627, "text": "The prognostic significance of KRAS gene mutations, evaluated by using two methods in patients with colorectal cancer, is reported."}, {"pubmed": 25713893, "text": "KRAS mutation is a poor prognostic factor in patients with metastatic colorectal cancer. In KRAS mutation metastatic colorectal cancer, mutation at codon 12 or at codon 13 had no relationship with prognosis."}, {"pubmed": 25722381, "text": "MEK1/2 inhibitor trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive non-small cell lung carcinoma."}, {"pubmed": 25742472, "text": "Neither all RAS gene mutation status nor PIK3CA mutation status was prognostic for PFS or OS."}, {"pubmed": 25742883, "text": "High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients"}, {"pubmed": 25757545, "text": "Based on our findings, we conclude that the hybcell-based compact sequencing technology represents a valuable alternative to the existing methods used for the detection of clinically relevant point mutations in the KRAS gene"}, {"pubmed": 25768080, "text": "KRAS mutation is associated with endometrial carcinomas and concomitant hyperplasia."}, {"pubmed": 25778307, "text": "Report KRAS mutation discordance between primary colorectal nsoplasms and their metastases."}, {"pubmed": 25778332, "text": "Review/Meta-analysis: suggest that rs712 polymorphism in Kras gene 3'-luntranslated region may increase susceptibility to cancer risk in Chinese population."}, {"pubmed": 25781862, "text": "In multivariable analyses, in both patients with EGFR-mutant and KRAS-mutant lung adenocarcinomas, advanced stage at the time of diagnosis was found to be independently associated with shorter survival."}, {"pubmed": 25788415, "text": "activated K-Ras regulation of brain neural stem cells proliferation requires Raf binding and suppression of retinoblastoma (Rb) function"}, {"pubmed": 25798815, "text": "KRAS(G12V)-transformed cells in transgenic zebrafish showed activation of the ERK-MAP kinase pathway and expressed the zebrafish homologue for human CXCL8, a cytokine produced by mammalian Ras-transformed cells in tumor-associated inflammatory lesions."}, {"pubmed": 25809746, "text": "Tumor mutant KRAS status is associated with an increased risk of venous thromboembolism in patients with metastatic colorectal cancer."}, {"pubmed": 25811077, "text": "miR-134 may function as a tumor suppressor in cell proliferation by targeting KRAS in renal cell carcinoma cells."}, {"pubmed": 25813150, "text": "gLCR has the capacity to detect one mutated allele in an excess of at least one million wild type alleles (0.0001 %) and is therefore an ideal technique for confirming doubtful KRAS mutation screening results obtained by other techniques"}, {"pubmed": 25813151, "text": "KRAS and EGFR co-mutation was detected in one case. PPMA patients with ALK rearrangements or KRAS mutation represent a unique subtype in Non-Small-Cell Lung Carcinoma"}, {"pubmed": 25815786, "text": "The frequency of mutations in either KRAS or PIK3CA were significantly higher in patients without lymph node metastasis than those with."}, {"pubmed": 25823645, "text": "the Eprobe system had a higher sensitivity for detecting KRAS mutations in colorectal cancer patient samples; these mutations could not be identified by Sanger sequencing"}, {"pubmed": 25828472, "text": "An inflammatory cue from oncogenic hepatocytes upon induction of kras(V12) expression causes a rapid recruitment of neutrophils to oncogenic liver and the neutrophils play a promoting role in early hepatocarcinogenesis."}, {"pubmed": 25840541, "text": "KRAS mutations were more prevalent in tubular-type than colloid-type intraductal papillary mucinous neoplasms-associated invasive carcinoma."}, {"pubmed": 25851630, "text": "KRAS mutations are usually present in the majority of metastatic colorectal cancer cells."}, {"pubmed": 25864038, "text": "FOLFOX adjuvant chemotherapy benefits patients with stage II or III colorectal cancer with KRAS mutant tumors and is worth further investigation"}, {"pubmed": 25867268, "text": "Study demonstrated the presence of recurrent GNAS and KRAS mutations in gastric foveolar metaplasia and gastric heterotopia lesions in the duodenum."}, {"pubmed": 25884297, "text": "The presence of a KRAS mutation in colon cancer patients increases the likelihood of disseminated disease."}, {"pubmed": 25886136, "text": "Among 264 patients, mutations in KRAS exon 2, KRAS exons 3 or 4, NRAS, BRAF and PIK3CA were detected in 34.1%, 3.8%, 4.2%, 5.4% and 6.4%, respectively. Thus, a total of 12.1% of patients without KRAS exon 2 mutations had other RAS mutations"}, {"pubmed": 25894374, "text": "Deacetylation of K-Ras by Sirt1 increased the transformation of Ras-GTP to Ras-GDP, promoting the activation of downstream of ERK1/2. In reverse, Ras/ERK pathway could also regulate Sirt1 transcription."}, {"pubmed": 25896895, "text": "Overexpression of mutant KRAS in Caco-2 cells led to an increase in CIP2A expression and cell proliferation."}, {"pubmed": 25902334, "text": "The data suggest a role for redox-dependent activation of wild-type KRAS through cysteine 118 in oncogenic HRAS-driven tumorigenesis."}, {"pubmed": 25902737, "text": "The KRAS gene mutations (especially in codon 12) are the most frequent genetic abnormalities both in primary and in central nervous system metastatic lesions of non-small cell lung cancer."}, {"pubmed": 25905463, "text": "Results show that KRAS expression is downregulated by miR-193b that targets its 3'-UTR in pancreatic ductal adenocarcinoma and dysregulation of the miR-193b-KRAS axis appears to be involved in pancreatic carcinogenesis."}, {"pubmed": 25911860, "text": "Review\\Meta-analysis: KRAS gene mutation is associated with poorer prognosis in colorectal cancer patients."}, {"pubmed": 25911864, "text": "Report EGFR expression/KRAS mutations and the effect of EGFR expression on stage, prognosis and response to conventional chemotherapy agents."}, {"pubmed": 25917266, "text": "KRAS mutations are associated with recurrence in hyperdiploid acute lymphoblastic leukemia."}, {"pubmed": 25921169, "text": "A high rate of homozygous and heterozygous mutations of codon 12, but not codon 13 and 61, may influence the invasive ductal carcinoma of breast risk in the South Indian population."}, {"pubmed": 25926041, "text": "Case Report: coexisting KRAS/NRAS mutations in caecal adenocarcinoma and contiguous tubulovillous adenoma."}, {"pubmed": 25926253, "text": "KRAS mutational status can be determined in biopsies representing bronchial pulmonary carcinomas because when a mutation is present it is generally present in all the histological patterns"}, {"pubmed": 25929517, "text": "The aim of this study was to evaluate the prognostic role of MMR status, BRAF mutations and specific KRAS point mutation in 762 patients in Chinese population, and several clinicopathologic features to better stratify colorectal cancer patients"}, {"pubmed": 25931041, "text": "RAS mutations constitute a frequent molecular event in RET-negative sporadic medullary thyroid carcinoma in Polish patients."}, {"pubmed": 25934695, "text": "CREB plays a key role in the K-RAS(V12)-mediated neoplastic phenotype and represents a suitable therapeutic target for murine and human K-RAS(V12)-induced tumors"}, {"pubmed": 25936883, "text": "EGFR and KRAS mutation were associated with non-small cell lung carcinoma."}, {"pubmed": 25941399, "text": "The effector-binding region of activated K-RAS4B is occluded by interaction with the membrane in one of the NMR-observable, and thus highly populated, conformational states."}, {"pubmed": 25946211, "text": "KRAS mutations and SEPT9 promoter methylation were present in 34% (29/85) and in 82% (70/85) of primary tumor tissue samples."}, {"pubmed": 25947035, "text": "RAS mutation status may assist in identifying a particular sub-set of multiple myeloma patients, who especially benefit from ASCT in the era of novel agents."}, {"pubmed": 25950441, "text": "Findings suggest that a high frequency of K-ras mutations occurs in Chinese metastatic colorectal cancer patients and that K-ras mutation is required to select patients for eligibility for cetuximab therapy."}, {"pubmed": 25956913, "text": "Studied the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC)."}, {"pubmed": 25961464, "text": "Estrogen withdrawal and a low estrogen state increase breast cancer risk in women with the KRAS-variant."}, {"pubmed": 25970685, "text": "Our results suggest that smoking is not a major cause of adenocarcinomas in situ. Rather, smoking may play a role in progression of adenocarcinomas in situ to invasive adenocarcinoma with AIS features"}, {"pubmed": 25971870, "text": "Determination of mutated KRAS seems to be of limited value in predicting long-term outcome in adenoma in the major duodenal papilla."}, {"pubmed": 25972319, "text": "The results suggest a possible association between KRAS mutations and mucinous differentiation in endometrial carcinogenesis"}, {"pubmed": 25987236, "text": "CYP1B1, KRAS and MTHFR variants are associated with shorter telomere length in postmenopausal women"}, {"pubmed": 25997687, "text": "KRAS activating mutation is relatively low in Korean colorectal cancer patients."}, {"pubmed": 25997988, "text": "KRAS mutation analysis may offer additional discriminatory power in separating benign microglandular hyperplasia from endometrial adenocarcinoma with microglandular pattern."}, {"pubmed": 25999467, "text": "ABL phosphorylates tyrosine 137 of H-, K-, and NRAS."}, {"pubmed": 26009992, "text": "The incidence of missense mutations in KRAS was much higher in patients with early treatment failure than in other groups"}, {"pubmed": 26015399, "text": "K-Ras stabilization by estrogen via PKCdelta has a role in endometrial tumorigenesis"}, {"pubmed": 26019684, "text": "PIK3CA amplification may be an early and important event in colorectal carcinogenesis and may drive the development of left-side tubular adenomas independently with KRAS mutation."}, {"pubmed": 26020803, "text": "miR-155 plays an important role in oncogenic K-Ras transformation mediated by cellular redox regulation"}, {"pubmed": 26026309, "text": "The K-ras mutational status of the primary colorectal cancer differed from that of the liver metastasis, and codon 13 mutations may explain such discrepancies."}, {"pubmed": 26028026, "text": "mTORC1/SREBP pathway is a major mechanism through which common oncogenic signaling events induce de novo lipid synthesis to promote aberrant growth and proliferation of cancer cells"}, {"pubmed": 26028111, "text": "Our results indicate that KRAS mutations are associated with inferior survival benefits for Non-Small Cell Lung Cancer but not for those treated with chemotherapies integrating cetuximab."}, {"pubmed": 26028667, "text": "Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway."}, {"pubmed": 26028668, "text": "High mesothelin expression was strongly associated with mutant KRAS/wild-type EGFR and poor prognosis in advanced lung cancer."}, {"pubmed": 26031776, "text": "There is 20.3% KRAS discordance between primary and recurrent colorectal tumors, which is higher rate than is generally known."}, {"pubmed": 26033401, "text": "KRAS and PIK3CA genotype may be considered as negative predictive markers and should carry out the analysis expeditiously."}, {"pubmed": 26037647, "text": "The structural data and measurements, obtained herein, indicate that measurable biochemical properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF."}, {"pubmed": 26038887, "text": "KRAS codon 12 mutations specifically G12V and G12S mutations were associated with worse prognosis after resection of colorectal liver metastasis especially among patients with recurrence after surgery."}, {"pubmed": 26042813, "text": "This study revealed that specific epidemiologic and clinicopathologic characteristics are associated with mismatch repair status stratified by KRAS mutation."}, {"pubmed": 26047463, "text": "In transgenic mice programmed to express both mutant oncogenes in the lung epithelium, the resulting tumors express either the KRAS, or the EGFR oncogene."}, {"pubmed": 26049686, "text": "Meta-analysis: robust estimates of overall RAS mutation prevalence and individual variation patterns in metastatic colorectal cancer patients."}, {"pubmed": 26051715, "text": "K-Ras self-association can regulate effector binding and activity."}, {"pubmed": 26055143, "text": "cyclin D1 expression cooperates with KRAS and PTEN alterations in pathogenesis of NSCLC, and they could serve as potential multiple molecular markers for specific subgroups of NSCLC patients as well as prognostic markers for this type of cancer."}, {"pubmed": 26055897, "text": "EGFR and KRAS mutation status are both predictive factors for the treatment efficacy."}, {"pubmed": 26056087, "text": "Data suggest that detection of the c.34G>T KRAS transversion could imply biallelic germline mutY DNA glycosylase MUTYH mutation and lead to genetic counseling."}, {"pubmed": 26077004, "text": "Based on the findings, it is concluded that the occurrence of the KRAS-LCS6 TG genotype was statistically significantly different in association with status of the HER2 gene in breast cancer."}, {"pubmed": 26077912, "text": "KRAS Mutation is associated with recurrence in Colorectal Liver Metastases."}, {"pubmed": 26085527, "text": "Elevated calcium levels clinically observed in adenocarcinomas may explain calmodulin's involvement in recruiting and stimulating PI3Kalpha through interaction with its n/cSH2 domains as well as K-Ras4B; importantly, it also explains why K-Ras4B specifically is a key player in ductal carcinomas, such as pancreatic, colorectal, and lung cancers. [Review]"}, {"pubmed": 26086204, "text": "LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux"}, {"pubmed": 26090869, "text": "BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias may have a role MEK-ERK pathway activation"}, {"pubmed": 26108998, "text": "Our data show that combined targeting of MEK and PI3K-AKT with mTOR is a better option than single agents alone for KRAS mutant NSCLC, thus opening the possibility of a beneficial treatment strategy in the future."}, {"pubmed": 26110767, "text": "Secondly, we show the molecular consequences of allele imbalance by deletion of either, a wild-type or a mutant allele in KRASG13D/WT CRC cells"}, {"pubmed": 26121087, "text": "Data show that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease."}, {"pubmed": 26121270, "text": "Tissue micro array availability, BRAF mutation and KRAS mutation were all independent prognostic factors for colorectal cancer survival."}, {"pubmed": 26122820, "text": "Report KRAS mutations/copy number variations and chromosome aberrations in colorectal adenocarcinomas."}, {"pubmed": 26124380, "text": "In patients with mutant KRAS codon 13, the mOS was not significantly different."}, {"pubmed": 26125448, "text": "In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in overall survival"}, {"pubmed": 26132860, "text": "miR-10b was selectively increased in exosomes of cells with wild-type KRAS, while miR-100 was increased in exosomes of cells with mutant KRAS."}, {"pubmed": 26135109, "text": "(18)F-FDG PET/CT scans may be useful for predicting the KRAS status of metastatic CRC and help in determining the therapeutic strategies against metastatic CRC."}, {"pubmed": 26160192, "text": "Report a mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix."}, {"pubmed": 26160882, "text": "Colon cancers from Asians have a lower rate of KRAS mutations than blacks or whites."}, {"pubmed": 26161927, "text": "KRAS mutation status seems to identify two different subtypes of pancreatic ductal adenocarcinoma with similar outcome but distinct molecular features and probably different therapeutic targets."}, {"pubmed": 26161928, "text": "In SW48 cells, exon 2 mutations of the KRAS gene may influence antitumor effects of regorafenib."}, {"pubmed": 26163758, "text": "RAS mutations are associated with colorectal carcinoma."}, {"pubmed": 26177347, "text": "The results suggested that KRAS mutation could be associated with a reduced efficacy of chemoradiotherapy and a shortened survival time."}, {"pubmed": 26209642, "text": "KRAS mutations are associated with nonsmall-cell lung cancer."}, {"pubmed": 26210240, "text": "Patients with CRC and KRAS wt may derive greater survival benefit from (90)Y radioembolization therapy than patients with KRAS mutant."}, {"pubmed": 26220150, "text": "Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic Colorectal cancer."}, {"pubmed": 26222068, "text": "The prevalence of oncogenic RAS mutations was higher among Arab Asian children than in other countries. RAS mutations in AML were found to coexist with other genetic aberrations, particularly MLL rearrangement"}, {"pubmed": 26245271, "text": "In salivary gland neoplasms, no KRAS mutations at codon 12 and 13 could be observed in the data at hand."}, {"pubmed": 26245900, "text": "BCL-XL up-regulation by STAT3 contributes to mutant KRAS-mediated apoptosis resistance. Such resistance can be overcome by potent BIM induction and concurrent BCL-XL antagonism"}, {"pubmed": 26252055, "text": "KRAS mutation neither on primary tumor nor in circulating tumor cells was associated with clinical-pathological parameters in metastatic colorectal cancer."}, {"pubmed": 26252300, "text": "The KRAS mutation status does not influence the tumor response to the radiotherapy and survival in locally advanced rectal cancer patients who received preoperative chemoradiotherapy and curative surgery."}, {"pubmed": 26252302, "text": "These findings indicate that miR-143/145 rs4705343 and KRAS rs712 may contribute to the etiology of Cervical Squamous Cell Carcinoma in Chinese women."}, {"pubmed": 26253102, "text": "RAS-positive thyroid nodules, especially in older individuals, frequently demonstrate a benign phenotype.Cytologically benign nodules, even if RAS-positive, may be candidates for a non-operative observational strategy"}, {"pubmed": 26257060, "text": "activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis"}, {"pubmed": 26260959, "text": "Data indicate that a RAS mutation was found in 24 thyroid aspirates with 8 NRAS and 16 KRAS."}, {"pubmed": 26262587, "text": "Data show that epidermal growth factor receptor (EGFR)-mediated signaling in mutant KRAS protein (K-ras) pancreatic cancer cells does not follow canonical mitogen-activated protein kinase (MAPK) signaling."}, {"pubmed": 26267534, "text": "Data show that small molecule protein kinase inhibitor DEL-22379 blocks proliferation of tumor cells harboring RAS-ERK pathway oncogenes."}, {"pubmed": 26268359, "text": "data suggest one-step screening platform for KIF5B-RET as well as EGFR, K-RAS, ALK oncogenic mutations be necessary for lung adenocarcinoma patients"}, {"pubmed": 26275461, "text": "Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1"}, {"pubmed": 26279302, "text": "a potent tumor-suppressive function for Lfng"}, {"pubmed": 26281864, "text": "Demonstrate a correlation between occurrence of DPYD gene variant c.496A>G and KRAS wild type status of colorectal cancer tissue."}, {"pubmed": 26289340, "text": "detection of somatic KRAS A146T and Q61H mutations in 2 out of 4 (50%) sarcomatoid Salivary duct carcinoma variants, is reported."}, {"pubmed": 26299074, "text": "Suggest common mutations of the KRAS gene can be used as an early determining marker for early diagnosis of prostate adenocarcinoma."}, {"pubmed": 26299805, "text": "KRAS and BRAF oncogenes have roles in colorectal cancer development and therapy resistance [review]"}, {"pubmed": 26316738, "text": "KRAS 3'-UTR rs712 polymorphism interfered with has-let-7g/mRNA interaction, and showed that the minor allele was associated with an elevated risk for development of lung cancer in COPD."}, {"pubmed": 26318427, "text": "Studies indicate that KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance to anti-EGFR monoclonal antibodies."}, {"pubmed": 26318594, "text": "KRAS mutations are frequent in our series of microsatellite instable cancers cases and are often found in a subpopulation of the tumour and not in the whole tumour"}, {"pubmed": 26325669, "text": "Data suggest that Src kinases inhibitors may act with different mechanisms in non-small cell lung cancer (NSCLC) depending on EGF receptor (EGFR)/Ras protein (Ras) mutational profile."}, {"pubmed": 26333174, "text": "K-Ras is the Direct Target of miR-622. MiR-622 inhibited colorectal cancer cells proliferation and migration and tumor metastasis by suppressing K-Ras."}, {"pubmed": 26336887, "text": "KRAS/NRAS mutations are common in mesonephric carcinoma and are often accompanied by gain of 1q and mutations in chromatin remodeling genes"}, {"pubmed": 26339434, "text": "Case Report: undifferentiated pleomorphic sarcoma with two missense mutations - KRAS mutation (35G > A, G12D) and PIK3CA mutation (1636C > A, Q546K."}, {"pubmed": 26347132, "text": "anti-EGFR therapy is restricted to KRAS wild-type patients as it has been shown that KRAS exon 2-mutated patients do not respond to this therapy--{REVIEW}"}, {"pubmed": 26351322, "text": "combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers"}, {"pubmed": 26352110, "text": "The significant association between mutated KRAS and tumor grade suggests that KRAS mutations may be involved in the formation of poorly differentiated clusters (PDC) of neoplastic cells in colorectal cancer"}, {"pubmed": 26353932, "text": "Results suggest a different pattern of sensitivity/resistance to cisplatin depending on the Kirsten Ras protein (KRAS) mutational status."}, {"pubmed": 26359368, "text": "NF2/merlin inactivation augments mutant RAS signaling by promoting YAP/TEAD-driven transcription of oncogenic and wild-type RAS, resulting in greater MAPK output and increased sensitivity to MEK inhibitors."}, {"pubmed": 26362194, "text": "In three cases of papillary carcinoma arising in struma ovarii (PSCS), novel BRAF and KRAS mutations were identified in two of three tumors suggesting that mutations in PCSO may differ from those commonly identified in papillary carcinoma of the eutopic thyroid."}, {"pubmed": 26369631, "text": "The concept that cotargeting MEK and CDK4/6 would prove efficacious in KRAS-mutant (KRAS(mt)) colorectal cancers."}, {"pubmed": 26372703, "text": "Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001-0.08), P<0.0001)."}, {"pubmed": 26374070, "text": "KRAS mutations are indicators of malignant transition in the progression to lung adenocarcinoma."}, {"pubmed": 26376292, "text": "BRAF and KRAS mutations show together a high prevalence in stage II and III MSI colon cancer and, when combined, are associated with poor survival compared to dWT cancers, which status confers an excellent cancer-specific survival."}, {"pubmed": 26384309, "text": "K-Ras mutation is associated with response to chemotherapy in metastatic colorectal cancer."}, {"pubmed": 26393682, "text": "let-7 is a tumor suppressor that negatively regulates RAS, also in Ewing Sarcoma, and HIF-1alpha may contribute to the aggressive metastatic behavior of Ewing Sarcoma"}, {"pubmed": 26400062, "text": "our studies suggest that Ras activation is a key determinant for dissemination and poor prognosis of ERalpha(+)/luminal breast cancer in humans"}, {"pubmed": 26400304, "text": "The KRAS gene may contribute to the formation of borderline mucinous cystadenoma."}, {"pubmed": 26416458, "text": "the presence of KRAS mutations has a mild negative impact on overall survival in advanced NSCLC patient treated with a first-line platinum-containing regimen"}, {"pubmed": 26418750, "text": "Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy."}, {"pubmed": 26428229, "text": "Negative correlation between KRAS mutation and oncological outcome after resection of colorectal liver metastasis."}, {"pubmed": 26429158, "text": "KRAS gene mutations may have a prognostic role in colorectal cancer"}, {"pubmed": 26432508, "text": "KRAS Mutations are associated with Non-Small-Cell Lung Cancer."}, {"pubmed": 26433205, "text": "Data suggest that over-expression of lincRNA-p21 promotes up-regulation of p21 at both mRNA and protein levels in hepatic stellate cells; expression of lincRNA-p21 and p21 is down-regulated in cirrhotic liver patients as compared to normal subjects."}, {"pubmed": 26446234, "text": "RAS and BRAF wild-type status could help select an elderly and unfit population that could benefit from anti-epidermal growth factor receptor single agent therapy."}, {"pubmed": 26452035, "text": "Findings suggest that COX-2 deletion contributes to the repression of K-ras-induced lung tumorigenesis by reducing tumor cell proliferation, decreasing the production of PGE2, and increasing the production of 13,14-dihydro-15-keto-PGE2, possibly via the MAPK pathway."}, {"pubmed": 26453300, "text": "GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B"}, {"pubmed": 26457648, "text": "Data show that RAS protein activation was the initiating oncogenic event, with polycomb repressive complex 2 (PRC2) subunits impairment being a secondary event."}, {"pubmed": 26463840, "text": "KRAS mutations in lung adenocarcinoma were not associated with asbestos exposure."}, {"pubmed": 26468985, "text": "KRAS mutant lung adenocarcinomas appear to have a more intricate RAS linked signaling network than WT tumors."}, {"pubmed": 26471290, "text": "KRAS mutations are not associated with inferior progression-free and overall survival in advanced NSCLC patients treated with standard first-line platinum-based chemotherapy."}, {"pubmed": 26474433, "text": "Data show that KRAS protein codon 12 mutations were detected in 100% pancreatic ductal adenocarcinomas."}, {"pubmed": 26477488, "text": "Transfection of constitutively activated K-rasG12V in pancreatic cancer cells led to the transcriptional upregulation of MUC4 at the transcriptional level by AP-1, MAPK, JNK and NF-kappaB pathways and at the posttranscriptional level by RalB GTPase."}, {"pubmed": 26479291, "text": "The RAS/MAPK and PI3K/mTOR pathways are activated in the majority of cases of UPS. The RAS/MAPK pathway distinguishes a subgroup of patients with localized UPS with a worse outcome."}, {"pubmed": 26483334, "text": "EGFR and KRAS mutations were low in lung squamous cell carcinomas, and had no significant correlation with clinical features."}, {"pubmed": 26498594, "text": "KRAS mutant circulating free DNA was detected in patients with exocrine pancreatic cancer and associated with overall survival."}, {"pubmed": 26508156, "text": "Data indicate that KRAS protein mutation detection in archival tumour tissue showed no correlation to survival, whereas plasma KRAS status remained a strong predictive and prognostic factor."}, {"pubmed": 26515332, "text": "rs61764370 and rs712 polymorphisms of the KRAS are functional and it may play an important role in the development of colorectal cancer (CRC) and oxaliplatin-based chemotherapy efficiency and prognosis of CRC."}, {"pubmed": 26520186, "text": "This confirms the heterogeneity of KRAS mutations and could suggest to expand KRAS testing in SCC to assess impact of RAS in SCC, which remains poorly investigated."}, {"pubmed": 26520779, "text": "Prognosis impact of KRAS mutations in non-small cell lung cancer.[review]"}, {"pubmed": 26523369, "text": "KRAS mutation may occur with MSI in colorectal cancers with wild-type BRAF. If a mutation in KRAS co-exists with MSI, then strong methylation of the MLH1 gene is unlikely"}, {"pubmed": 26525741, "text": "SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type who have received oxaliplatin based adjuvant chemotherapy."}, {"pubmed": 26530529, "text": "Data indicate that tumors with proto-oncogene proteins BRAF or KRAS mutations were in correlation with elevated serum level of carbohydrate antigen (CA19-9) and carcinoma embryonic antigen (CEA)."}, {"pubmed": 26535719, "text": "Here we aimed to investigate the relationship between KRAS rs712 polymorphisms and hepatocellular carcinoma susceptibility"}, {"pubmed": 26541605, "text": "Vitamin C is selectively toxic to cells with mutant KRAS or BRAF alleles."}, {"pubmed": 26544625, "text": "Data show that Ras protein regulates inhibitor of growth protein 4 (ING4)-thymine-DNA glycosylase (TDG)-Fas protein axis to promote apoptosis resistance in pancreatic cancer."}, {"pubmed": 26547258, "text": "study concluded that 26% of patients had detectable FLT3-ITD or RAS mutation at transformation from myelodysplastic syndrome to acute myeloid leukemia, and these mutations were associated with very poor outcome"}, {"pubmed": 26549032, "text": "Cytokines IL-2/7/9 stimulation activates PI3K/Akt pathways downstream of Ras in RasGRP1 T-cell acute lymphoblastic leukemia (T-ALL)."}, {"pubmed": 26560143, "text": "analysis of HRAS, KRAS and NRAS expression in colorectal tumor cells"}, {"pubmed": 26562302, "text": "Data show that tet methylcytosine dioxygenase 2 TET2, isocitrate dehydrogenases 1/2 IDH1/IDH2, serine/arginine-rich splicing factor 2 SRSF2, splicing factor 3b subunit 1 SF3B1, and ras proteins (KRAS/NRAS) are not conserved in dog mast Cell tumors."}, {"pubmed": 26563370, "text": "The recurring expression of NF-kB, SHH, K-RAS, and PTX3 in vimentin- and CD44-positive breast cancer cells allows to speculate that breast cells acquire the ability to express these molecules in concomitance to EMT phenomenon."}, {"pubmed": 26565026, "text": "Ras.GDP weakly binds to the catalytic but not to the allosteric site of Sos."}, {"pubmed": 26573509, "text": "The TG/GG of KRAS-LCS (rs61764370) had a benefit from docetaxel treatment compared with the TT allele in terms of PFS."}, {"pubmed": 26575954, "text": "Overexpression of mTORC1 is associated with pancreatic cancer cells expressing mutant Ras."}, {"pubmed": 26581482, "text": "Data show that 11/105 patients failed all molecular analysis: no mutations in oncogenes EGFR, KRAS and NRAS were detected, and no ALK gene rearrangements or MET gene amplifications were identified."}, {"pubmed": 26582224, "text": "In lung adenocarcinomas, EGFR mutation was higher in female and non-smoking patients, KRAS mutation only in patients with wild-type EGFR gene was higher."}, {"pubmed": 26590425, "text": "Study reports that oncogenic K-Ras, but not H-Ras, suppresses non-canonical Wnt/Ca(2+) signaling, an effect that contributes strongly to its tumorigenic properties."}, {"pubmed": 26592447, "text": "pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53"}, {"pubmed": 26596833, "text": "upregulated miRNA-622 inhibited cell proliferation, migration, and invasion via repressing K-Ras in the progression of glioblastoma, and miR-622-K-Ras pathway can be recommended as a potential target for treatment of glioblastoma"}, {"pubmed": 26597160, "text": "Using the extensive guanine-rich region of the kRAS core promoter, and particularly the G4mid structure, future drug discovery programs will have potential to develop a potent, specifically targeted small molecule to be used in the treatment of cancers"}, {"pubmed": 26600545, "text": "PIK3CA mutations were observed in 32% (8) of the 25 breast cancer tissues examined, Sequencing of exon 2 of KRAS suggested that 20% (5) of the 25 samples harbored a mutation and 16% (4) of BRAF harbored a mutation."}, {"pubmed": 26610798, "text": "No difference was found in overall survival between KRAS codon 12 versus codon 13 mutations in metastatic colorectal cancer"}, {"pubmed": 26616508, "text": "use of sorafenib has been ineffective in the management of advanced Colorectal cancer (CRC) patients with KRAS mutation, combination of selective BRAF inhibitors plus EGFR inhibitors may represent a good therapeutic strategy in BRAF-mutant CRC."}, {"pubmed": 26616848, "text": "mEGFR are associated with higher response rate (RR) to brain metastasis radiotherapy than wild-type EGFR/RAS or mKRAS."}, {"pubmed": 26616862, "text": "KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes."}, {"pubmed": 26631045, "text": "miR-613 is frequently downregulated in ovarian cancer and is a potential tumor-suppressing miRNA that may decrease ovarian cancer development and/or progression. KRAS regulation by miR-613 might play a role in its regulation of the malignant behavior of ovarian cancer."}, {"pubmed": 26636714, "text": "KRAS mutation is associated with lung cancer."}, {"pubmed": 26646269, "text": "KRAS mutation was found in 38 (81%) cases, of which 12 (32%) showed intratumor heterogeneity (ITH) and 9 (23%) were found to have KRAS mutant allele amplification."}, {"pubmed": 26648033, "text": "Kras single nucleotide polymorphisms rs12228277 and rs61761074 of intron 2 result in differential binding patterns of lung nuclear proteins.Rs61761074 demonstrated a significant correlation with allele frequency in non-small-cell lung cancer."}, {"pubmed": 26649302, "text": "our study suggested that black rice anthocyanins extract suppress metastasis in breast cancer cells by targeting the RAS/RAF/MAPK pathway"}, {"pubmed": 26650777, "text": "As depicted in Figure 3, APC (25%) followed by KRAS (20%), TP53 (14%), and PIK3CA (11%) were the most frequently mutated genes."}, {"pubmed": 26655175, "text": "As an example of the application of this platform we performed the analysis of six common mutations in the codon 12 of KRAS gene (G12A, G12C, G12D, G12R, G12S, and G12V)."}, {"pubmed": 26656490, "text": "KRAS promoter oligonucleotide with decoy activity dimerizes into a unique topology consisting of two G-quadruplex units.Nucleotides of the MAZ binding G-rich motif are dynamic and could be available for sequence or structure based recognition"}, {"pubmed": 26657862, "text": "miR-31 directly targets and reduces expression of negative regulators of RAS/MAPK signaling"}, {"pubmed": 26662311, "text": "comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses."}, {"pubmed": 26677873, "text": "this study was unable to confirm that KRAS-driven tumor lines require macroautophagy for growth."}, {"pubmed": 26681038, "text": "We observed no statistically significant association between BC risk and the let-7a KRAS rs712 polymorphism"}, {"pubmed": 26684803, "text": "KRAS mutation is associated with response to therapy in pancreatic cancer."}, {"pubmed": 26684859, "text": "Data indicate that ninety-three percent of the patients had KRAS protein mutations in tumor DNA."}, {"pubmed": 26691448, "text": "These results revealed differences in the genetic profiles of KRAS, NRAS, PIK3CA and BRAF at mutation hotspots between Chinese CRC patients and those of Western countries."}, {"pubmed": 26710843, "text": "The KRAS variant impact on breast cancer development risk."}, {"pubmed": 26712103, "text": "this study shows that combining the analysis of KRAS mutational status and computed tomographic features could better predict survival in patients lung adenocarcinoma"}, {"pubmed": 26715198, "text": "KRAS mutation is a negative prognostic factor in mCRC patients undergoing LM."}, {"pubmed": 26716649, "text": "High KRAS expression is associated with Pancreatic cancer."}, {"pubmed": 26722374, "text": "These results indicate that CREG1 is a down-stream effector of KRAS in a sub-type of non-small cell lung cancer cells and a novel candidate biomarker or therapeutic target for KRAS mutant non-small cell lung cancer."}, {"pubmed": 26723875, "text": "The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib."}, {"pubmed": 26725968, "text": "Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer."}, {"pubmed": 26728377, "text": "Data show that microRNA miR-365 could inhibit the proliferation and promote the apoptosis in SOSP-9607 osteosarcoma cells probably by mediating the expression of KRAS protein."}, {"pubmed": 26732596, "text": "The expression level of KTRAS was positively correlated to the activity of ERK pathway in glioma cell proliferation."}, {"pubmed": 26740498, "text": "treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC retrospectively in a cohort of patients with non-small cell lung cancer, were evaluated."}, {"pubmed": 26744320, "text": "The data support an in vivo plasticity model of human colon cancer initiation that merges the intrinsic stem cell properties of aberrant colon stem cells with the embryonic stem cell-like program induced by KRASmut to optimize malignant transformation."}, {"pubmed": 26747707, "text": "Results show that oncogenic KRAS can activate Rho through miR-31-mediated regulation of RASA1 indicating miR-31 acts as a KRAS effector to modulate invasion and migration in pancreatic cancer."}, {"pubmed": 26749281, "text": "None of the clinicopathological parameters were associated with the expressions of FIH-1 and SOCS3 at mRNA level."}, {"pubmed": 26754455, "text": "In operated pancreatic adenocarcinoma, incidence of mutations was: Kirsten rat sarcoma viral oncogene homolong (KRAS) = 87%."}, {"pubmed": 26766588, "text": "Modulation of Polycomb repressive complexes by either Ezh2 overexpression or Eed deletion enhances KRAS-driven adenomagenesis and inflammation"}, {"pubmed": 26771140, "text": "KRAS mutation is associated with pancreatic cancer."}, {"pubmed": 26775593, "text": "Results showed that the presence of KRAS activating mutations in patients with metastatic or recurrent non-small cell lung cancer are correlated with worse prognosis."}, {"pubmed": 26775732, "text": "KRAS mutations are associated with response to therapy in metastatic colorectal cancer."}, {"pubmed": 26786089, "text": "KRAS Mutation is associated with Recurrence in rectal cancer."}, {"pubmed": 26789109, "text": "KRAS mutations are associated with non-small-cell lung cancer."}, {"pubmed": 26795563, "text": "Ras overexpression outcome depends on the clonogenic potential of the recipient keratinocyte and that only the stem cell compartment is competent to initiate tumorigenesis."}, {"pubmed": 26799184, "text": "KRAS mutation is associated with liver cancer."}, {"pubmed": 26799289, "text": "KRAS mutation is associated with colon cancer."}, {"pubmed": 26802155, "text": "This study failed to show improvement in ORR or PFS with combination therapy of selumetinib and erlotinib over monotherapy in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer"}, {"pubmed": 26804118, "text": "Activating HRAS, KRAS and EGFR mutations play a major role in the pathogenesis of sporadic SGH. These results support the concept that SGH is a true benign neoplasm rather than a reactive hyperplasia."}, {"pubmed": 26808395, "text": "Alternative pathways through mutations in KRAS gene are associated with the progression of Colorectal polyps to cancer and may provide insights into the genetic characteristics of skirts."}, {"pubmed": 26810856, "text": "As a consequence, Slug transcription is down-regulated relieving A549 cells from Slug-mediated repression of E-cadherin transcription, thereby diminishing the metastatic potential of these oncogenic Ras-expressing NSCLC cells"}, {"pubmed": 26812186, "text": "Meta-analysis: no significant difference between KRAS G13D and other KRAS mutant colorectal tumours in terms of treatment benefit from anti-EGFR mAbs."}, {"pubmed": 26820797, "text": "KRAS and PIK3CA mutations can influence the response of DLD1 colorectal cancer cell lines to MEK and PI3K inhibitors, but that the effect is dependent on the experimental model used to assess drug sensitivity."}, {"pubmed": 26823891, "text": "Case Report: KRAS mutation-positive bronchial surface epithelium type lung adenocarcinoma with strong expression of TTF-1."}, {"pubmed": 26829311, "text": "Authors identified 9 neoplasms, all invasive mucinous adenocarcinomas or mixed mucinous/nonmucinous adenocarcinomas, with mutations of KRAS."}, {"pubmed": 26829579, "text": "we employed a double-stranded toehold-exchange probe, which is labeled with fluorescent molecules (FAM) and quenchers (Dabcyl), to detect KRAS mutations in cancer tissues."}, {"pubmed": 26833129, "text": "MUC1 expression significantly correlated with that of MYC and its target genes in human KRAS mutant NSCLC tumors."}, {"pubmed": 26837759, "text": "findings demonstrate that KRAS affects the homeostasis of MA4-expressing HSPCs, suggesting that KRAS activation in MA4(+) B-ALL is important for tumor maintenance rather than initiation"}, {"pubmed": 26840022, "text": "KRAS mutations are associated with non-small-cell lung cancer."}, {"pubmed": 26842186, "text": "The results suggest a prevalence of KRAS mutation at 42.8% in Indian population."}, {"pubmed": 26842935, "text": "Aurora kinases are important KRAS targets in lung cancer."}, {"pubmed": 26848526, "text": "Data show that expressions of histone deacetylase 6 protein (HDAC6) and c-myc protein are increased in fibroblasts transformed with activated K-ras protein."}, {"pubmed": 26851024, "text": "Confirm contribution of PTPRZ1, and especially PTPRQ, in CRC carcinogenesis and demonstrated that PTPRQ expression is correlated with KRAS mutation."}, {"pubmed": 26852690, "text": "miR-1 was suppressed by LMP1 and its tumour-suppressive effects were mediated chiefly by repressing K-ras expression in nasopharyngeal carcinoma."}, {"pubmed": 26854029, "text": "Kras insertion mutations cause reduced intrinsic GTP hydrolysis rates, protein accumulation in the GTP-bound conformation and resistance to GAP-mediated GTP hydrolysis. Kras with switch 2 insertions are impaired for PI3 kinase binding and Akt activation."}, {"pubmed": 26854235, "text": "KRAS engages AGO2 to enhance cellular neoplastic transformation."}, {"pubmed": 26867649, "text": "Data suggest bisphenol S binds to K-Ras4B binding pocket previously identified as binding site for various low molecular weight compounds including bisphenol A (another plasticizer/endocrine disruptor)."}, {"pubmed": 26868125, "text": "A high molecular and genetic concordance between primary tumor (PR) and PDX was confirmed by the evaluation of biliary epithelial markers, tissue architecture, genetic aberrations (including K-RAS G12D mutation), and transcriptomic and microRNA profiles"}, {"pubmed": 26880715, "text": "Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells"}, {"pubmed": 26881434, "text": "CDK1 is a synthetic lethal target for KRAS mutant tumors."}, {"pubmed": 26882436, "text": "KRAS mutation is associated with lung adenocarcinomas."}, {"pubmed": 26883054, "text": "both mRNA and protein KRAS expression were significantly decreased in SCC-15 cells in which miR-126 was overexpressed."}, {"pubmed": 26887348, "text": "Studied the role of KRAS mutation status as a prognostic factor in surgically resected colorectal cancer patients with liver and lung metastases."}, {"pubmed": 26891420, "text": "The combination of tivantinib and CETIRI was well tolerated but did not significantly improve PFS in previously treated KRAS WT metastatic colorectal cancer"}, {"pubmed": 26892442, "text": "KRAS and, infrequently, BRAF mutations are observed in a subset of small intestinal adenocarcinomas, and are associated with higher pT classification and more frequent pancreatic invasion"}, {"pubmed": 26902163, "text": "Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection."}, {"pubmed": 26902995, "text": "Molecular dynamics simulations help provide a mechanistic explanation of key mutational events in one of the most oncogenic proteins in cancer, KRAS-4B."}, {"pubmed": 26910894, "text": "KRAS mutations may, in part, drive the histologic progression of colorectal adenomas toward a villous histology and higher grades of dysplasia"}, {"pubmed": 26921316, "text": "This study identifies the molecular basis for the S-phase arrest caused by Q deprivation in KRas-driven cancer cells that arrest in S-phase in response to Q deprivation."}, {"pubmed": 26925650, "text": "KRAS mutations are Associated with Metastatic Colorectal Cancer."}, {"pubmed": 26927447, "text": "KRAS mutations appear to be unrelated to clinical outcome in pancreatic cancer. [review]"}, {"pubmed": 26930719, "text": "findings indicate that multiple cis-regulatory motifs in the 3' UTR of KRAS finely modulate its expression, and sequence alterations within a binding motif may disrupt the precise functions of trans-regulatory factors, potentially leading to aberrant KRAS expression"}, {"pubmed": 26933204, "text": "the RAS mutation in lymphoid cells is tightly linked with various autoimmune symptoms. The presence of the RAS mutation in lymphocytes should be reconsidered as a pathogenesis in cases of autoimmunity."}, {"pubmed": 26945839, "text": "High KRAS expression is associated with Metastasis in Colorectal Cancer."}, {"pubmed": 26951514, "text": "our findings demonstrate that coexpression of Bmi1 and KRASG12D could lead to transformation of human pancreatic duct-derived cells cells in vitro"}, {"pubmed": 26958889, "text": "oncogenic mutant K-Ras interacts with a negatively charged lipid bilayer membrane in multiple orientations."}, {"pubmed": 26959608, "text": "Thus ERK5 signaling is unlikely to play a role in tumor cell proliferation downstream of KRAS or BRAF or in tumor cells with ERK5 amplification. These results have important implications for the role of ERK5 as an anti-cancer drug target"}, {"pubmed": 26967456, "text": "Intratumoral heterogeneity of the KRAS mutational status is rare in pancreatic ductal adenocarcinoma. In addition, no KRAS heterogeneity between primary tumors and metastatic lymph nodes was detected in this study."}, {"pubmed": 26968810, "text": "Data show that KRAS, MTA1 and HMGA2 are direct targets of miR-543."}, {"pubmed": 26970110, "text": "Mutations within codon 146 of KRAS are associated with oculoectodermal syndrome and encephalocraniocutaneous lipomatosis."}, {"pubmed": 26970738, "text": "Results of APC and DCC LOH, KRAS and microsatellite instability indicate our colorectal cancer cases were typical of sporadic cancers following the 'chromosomal instability' pathway."}, {"pubmed": 26973241, "text": "we established that the most potent compound, ophiobolin A, exerts its K-ras4B-specific activity through inactivation of calmodulin. Our data suggest that specific interference with the K-ras4B/calmodulin interaction selectively inhibits CSC."}, {"pubmed": 26977001, "text": "Results show that the presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in non-small cell lung cancer patients treated with second- or third-line pemetrexed or docetaxel."}, {"pubmed": 26977885, "text": "The therapeutic potential of PKCiota-ELF3-NOTCH3 signal inhibition to more effectively treat KRAS LADC."}, {"pubmed": 26979257, "text": "KRASG12V may be a marker of adenomatoid odontogenic tumors"}, {"pubmed": 26989027, "text": "Our data suggest that KRAS, NRAS, and BRAF mutations predict response to cetuximab treatment in metastatic colorectal cancer patients."}, {"pubmed": 26991344, "text": "Our findings indicate that BRAF and KRAS mutations as well as mutation heterogeneity predict poor outcome in CRC patients subsequent to liver resections and might help guide treatment decisions."}, {"pubmed": 26992209, "text": "KRAS point mutations are associated lung cancer."}, {"pubmed": 26997442, "text": "Low incidence of KRAS mutations in adenocarcinomas of the ampulla of Vater suggest no major role in tumorigenesis."}, {"pubmed": 27004837, "text": "RAS mutation in mCRC metastasectomy patients was associated with shorter overall survival"}, {"pubmed": 27008036, "text": "KRAS mutations are more common in females and smokers, but are not associated with chronic obstructive pulmonary disease status in non-small cell lung cancer patients."}, {"pubmed": 27012422, "text": "mutant KRAS can be bypassed by L-ascorbic acid in an SVCT-2-dependent manner. Furthermore, SVCT-2 in mutant KRAS colon cancer may act as a potent marker for potentiating L-ascorbic acid co-treatment with cetuximab."}, {"pubmed": 27016292, "text": "KRAS mutation is associated with Colorectal Liver Metastases."}, {"pubmed": 27020206, "text": "Serrated lesions of the appendix are frequently found in serrated polyposis patients and are most commonly of SSA-type morphology, frequently associated with KRAS mutation."}, {"pubmed": 27020587, "text": "KRAS mutation is associated with lymph node metastasis in Rectal Cancer."}, {"pubmed": 27036313, "text": "Increased staining for phosphorylated ERK1/2 does not correlate to BRAF or KRAS mutations in colorectal neoplasms."}, {"pubmed": 27037031, "text": "Development of Brain metastases (BM) from colorectal cancer (CRC) is associated with young age, lung metastases, rectal primary and KRAS mutation."}, {"pubmed": 27039744, "text": "KRAS Mutation is associated with Metastatic Colorectal Cancers."}, {"pubmed": 27041569, "text": "These findings identify a key mechanism of tolerance to Ras-Raf pathway inhibitors and suggest that blocking either AMPK or autophagy in combination with these targeted inhibitors could increase tumor regression and decrease the likelihood of eventual recurrence."}, {"pubmed": 27041576, "text": "Ras-induced senescent cells are hindered in their ability to recruit BRCA1 and 53BP1 to DNA damage sites. Whereas BRCA1 is downregulated at transcripts levels, 53BP1 loss is caused by activation of cathepsin L-mediated degradation of 53BP1 protein. we discovered a marked downregulation of vitamin D receptor (VDR) during OIS, and a role for the vitamin D/VDR axis regulating the levels of these DNA repair"}, {"pubmed": 27057007, "text": "Ras isoforms' dimer conformations are not uniform; instead, the isoform-specific dimers reflect the favoured interactions of the HVRs (hypervariable regions) with cell membrane microdomains, biasing the effector-binding site orientations, thus isoform binding selectivity."}, {"pubmed": 27062566, "text": "Analysis of KRAS mutation combined with immunohistochemical expression of CD44 and CD166 identified subgroups of patients with colon adenocarcinoma at higher risk of lymph node involvement by the tumor and development of liver and lung metastasis."}, {"pubmed": 27064574, "text": "KRAS Mutation is associated with response to therapy in Rectal Cancer."}, {"pubmed": 27070580, "text": "Forty-nine paired tissues with both primary adenocarcinoma of lung and matched brain metastasis were collected. Thirteen patients (26.5%) were discordant for the status of EGFR between primary and metastatic sites. K-ras gene could be checked in paired specimens from 33 patients, thirteen patients (39.6%) were discordant for the status of K-ras."}, {"pubmed": 27072218, "text": "Similarly, there was no association between KRAS mutation status and survival parameters.  As a result, the effect of KRAS mutation status on clinicopathological features, survival time and prognosis is unclear."}, {"pubmed": 27072236, "text": "There were not statistical significant differences between carriers of KRAS mutated alleles between SD and PD groups. No significant difference was found between response rates and toxicity and DPD or UGT1A1 genotypes. Our results suggested that determination of DPD or UGT1A1 genotypes could not be useful for predicting severe toxicity of irinotecan in our population."}, {"pubmed": 27082577, "text": "The KRAS mutated Colorectal Cancers have less aggressive phenotype in comparison to the BRAF-mutated Colorectal Cancers."}, {"pubmed": 27096769, "text": "The results of our study are compatible with other studies and indicate the correlation between K-ras gene mutation and colorectal cancer incidence. Identification of K-ras gene mutation may complement other diagnostic methods at early stage of colorectal cancer."}, {"pubmed": 27100819, "text": "recent years, there has been significant advancement in the understanding of the biology of KRAS and its downstream effectors. This has translated into a multitude of important preclinical studies and clinical trials that are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer recent years, there has been significant advancement in the understanding of the biology of KRAS and its downstream"}, {"pubmed": 27116958, "text": "Braf and Kras genes mutation were reveled in gastritis and adenocarcinoma patients."}, {"pubmed": 27117408, "text": "overactivity of KRAS due to mutation inhibits localization of Ago2 to multivesicular endosomes (MVEs) and decreases Ago2 secretion in exosomes."}, {"pubmed": 27119512, "text": "Data indicate acquired KRAS, NRAS or HRAS mutations in more than one third of patients after cetuximab exposure."}, {"pubmed": 27121230, "text": "Inhibition of EGFR and KRAS downstream with a P13K/Akt inhibitor could be useful for treating NSCLC."}, {"pubmed": 27133754, "text": "In multivariate analysis, KRAS mutation was associated with poor prognosis."}, {"pubmed": 27146067, "text": "RAS proteins are essential for intracellular signal transmission."}, {"pubmed": 27154241, "text": "Results suggest that SECs are of neoplastic origin and that KRAS mutations play an important role in the tumorigenesis of ECs and SECs."}, {"pubmed": 27156442, "text": "analysis provides further information on the mutational profiles of pulmonary sarcomatoid carcinoma and demonstrates for the first time a role of KRAS mutations in driving the aggressiveness of this type of cancer"}, {"pubmed": 27175909, "text": "the central autophagy regulator TFEB is expressed and active in PDAC, but autophagy is sustained after TFEB knockdown, suggesting alternative bypass signaling. TFEB is dispensable for gemcitabine-induced cell death, but inversely correlated with KRAS expression."}, {"pubmed": 27179269, "text": "conclude that from the point of view of practical KRAS mutation testing for predictive purposes in patients with colorectal cancer"}, {"pubmed": 27182622, "text": "This study demonstrated that KRAS and TP53 mutations are frequently detected in LIFE bronchoscopy samples from former lung cancer patients with early stage lung cancer. These mutations were found not only in abnormal lesions but also in histologically normal tissues in samples from active smokers, from ex-smokers and never smokers."}, {"pubmed": 27183870, "text": "K-ras mutation is associated with pancreatic cancer."}, {"pubmed": 27184911, "text": "Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression."}, {"pubmed": 27215184, "text": "Study shows that during the development and progression of pancreatic cancer, oncogenic KRas causes metabolic changes that lead to increased generation of mitochondrial reactive oxygen species."}, {"pubmed": 27221845, "text": "KRAS Mutations are associated with response to therapy in Metastatic Colorectal Cancer."}, {"pubmed": 27221928, "text": "The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk."}, {"pubmed": 27225938, "text": "this meta-analysis suggests that K-Ras mutations are associated with a worse overall survival in pancreatic cancer patients"}, {"pubmed": 27226433, "text": "the study identifies mutations in KRAS and POT1 as novel determinants of outcome after chemoimmunotherapy using chlorambucil and anti-CD20 treatment."}, {"pubmed": 27234382, "text": "This is the first report of somatic KRAS mutations in oncocytic sinonasal papillomas and metachronous sinonasal squamous cell carcinoma"}, {"pubmed": 27234640, "text": "To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab"}, {"pubmed": 27237100, "text": "the analysis of K-ras mutations in pancreatic juice has a considerable diagnostic value in pancreatic cancer (Meta-Analysis)"}, {"pubmed": 27244540, "text": "KRAS mutation is associated with recurrent and colorectal liver metastases."}, {"pubmed": 27256640, "text": "The aim of the current study was to clarify the frequency of relevant alterations of the 3'UTR regions of the KRAS gene and the effect of KRAS 3'UTR polymorphisms on the prognosis of patients with codon 12, 13 and 61 mutations in a Turkish population with pancreatobiliary tumors"}, {"pubmed": 27264476, "text": "KRAS mutation status was an independent predictor of overall survival among patients undergoing liver resection of colorectal liver metastases."}, {"pubmed": 27270901, "text": "A concordance rate of 81.0 % was detected in KRAS mutation between primary tumor and metastatic lesion in Chinese patients with colorectal cancer"}, {"pubmed": 27312358, "text": "Overexpression of mutated K-RAS in gastrointestinal cancer cell lines led to more aggressive phenotypes, with increased proliferation, decreased apoptosis, and increased motility and invasion. IGF-1R blockade suppressed cell growth, colony formation, migration, and invasion, and up-regulated chemotherapy-induced apoptosis of gastrointestinal cancer cells, even when mutated K-RAS was over-expressed."}, {"pubmed": 27314237, "text": "Our study provides a rationale to strengthen NK cell immunotherapy through a combination with cetuximab for RAS and BRAF mutant mCRC patients."}, {"pubmed": 27329725, "text": "Our data suggest that Kras mutations increase telomerase activity and telomere length by activating the RAS/MEK pathway, which contributes to an aggressive phenotype of NSCLC."}, {"pubmed": 27336603, "text": "Epidermal growth factor receptor mutation and KRAS amino acid substitutions seem to predict site-specific recurrence and metastasis after NSCLC surgery"}, {"pubmed": 27343315, "text": "Oncogenic mutations in Her-2/neu or k-ras had no association with the severity of endometrial cancer."}, {"pubmed": 27345584, "text": "Here we review the current knowledge about the classification of this tumor subtype and its association with five key features: mutation status of the BRAF or KRAS genes, the CpG island methylation phenotype, microsatellite instability, immune cell infiltration, and overexpression of GTPase RAC1b"}, {"pubmed": 27346571, "text": "A significantly higher proportion (54%) of early onset colorectal cancer cases harbored KRAS mutations, a finding that was independent of tumor stage."}, {"pubmed": 27356691, "text": "KRAS gene mutations are associated with Urinary Bladder Cancer."}, {"pubmed": 27358379, "text": "Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival"}, {"pubmed": 27373829, "text": "Activating EGFR mutations were found in 14.1% of all tumors, whereas KRAS mutations were found in 30.5% of all tumors."}, {"pubmed": 27381829, "text": "activated Ras, protumorigenic COX-2 and Notch1 have roles in in papillary mucinous neoplasm onset"}, {"pubmed": 27382031, "text": "The results demonstrated the lack of activity of anti-EGFRs in RAS(KRAS and NRAS) and BRAF wild-type, right-sided tumors, thus suggesting a potential role for primary tumor location in driving treatment choices"}, {"pubmed": 27384483, "text": "RAS-driven tumors induce PI3K/AKT-dependent beta-catenin activation"}, {"pubmed": 27391150, "text": "Mutational activation of Kit-, Ras/Raf/Erk- and Akt- pathways indicate the biological importance of these pathways and their components as potential targets for therapy."}, {"pubmed": 27412232, "text": "Data suggest that the co-existence of KRAS mutations and high MYC expression predicts anti-mitotic drug sensitivity."}, {"pubmed": 27415425, "text": "It has been concluded that VMP1-mediated autophagy cooperated with Kras to promote pancreatic ductal adenocarcinoma initiation."}, {"pubmed": 27430246, "text": "Data suggest that the rs61764370 single nucleotide polymorphism may be associated with an increased risk of metastatic disease in osteosarcoma (OS) by disrupting the interaction between microRNA let-7a and KRAS mRNA."}, {"pubmed": 27435400, "text": "These results suggest that cetuximab treatment in combination with IL-21 adjuvant therapy in patients with EGFR-positive pancreatic cancer results in significant NK cell activation, irrespective of KRAS mutation status, and may be a potential therapeutic strategy"}, {"pubmed": 27438990, "text": "Results indicate that MLH1-hypermethylated BRAF wild-type colorectal carcinomas can harbor KRAS mutations and arise from precursor polyps resembling conventional tubular/tubulovillous adenomas."}, {"pubmed": 27439864, "text": "Reduced insulin receptor substrate-1 (IRS-1) staining in lung adenocarcinoma tissue microarray displayed a significant survival disadvantage, especially within the Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant subgroup."}, {"pubmed": 27440441, "text": "There is a relationship between KRAS mutation status and local recurrence after image-guided ablation of lung adenocarcinoma. Specifically, KRAS mutation status of the ablated lesion is a significant predictor of time to local recurrence, independent of size and margin."}, {"pubmed": 27444698, "text": "KRAS mutation is associated with colorectal cancer."}, {"pubmed": 27447549, "text": "our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression."}, {"pubmed": 27449290, "text": "Data show that Williams-Beuren syndrome transcription factor (WSTF) release was mediated by neuregulin-3 (NRG3) following KRASG12V expression in intestinal epithelial cells."}, {"pubmed": 27451147, "text": "SLC25A22 promotes proliferation and migration of colorectal cancer (CRC) cells with KRAS mutations, and formation and metastasis of CRC xenograft tumors in mice. Patients with colorectal tumors expressing increased levels of SLC25A22 have shorter survival times. SLC25A22 induces intracellular synthesis of aspartate."}, {"pubmed": 27458004, "text": "Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (72%), as well as TP53 (26%), CRBN (12%), and CRBN pathway genes (10%) was observed."}, {"pubmed": 27461636, "text": "These results indicated that genotype. GT/GG of rs61764370 was not a genetic susceptible risk factor for cancer, and rs61764370 could not be used as a biomarker for estimating cancer risk in Caucasian population."}, {"pubmed": 27466537, "text": "No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer."}, {"pubmed": 27468967, "text": "The KRAS mutation was associated with Depression severity and higher rates of probable Depression in older Metastatic Colorectal Cancer patients.("}, {"pubmed": 27477280, "text": "ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer"}, {"pubmed": 27488117, "text": "High KRAS expression is associated with hepatocellular carcinoma."}, {"pubmed": 27494869, "text": "miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression"}, {"pubmed": 27502722, "text": "RAS and GNAS mutations were associated with worse progression-free survival (PFS) at univariate analysis (P = 0.006 and 0.011, respectively). At multivariate analysis, only KRAS mutations were independently associated with PFS (P = 0.012); GNAS mutations were not-being significantly associated with other poor prognostic features such as incomplete cytoreduction or KRAS mutations"}, {"pubmed": 27509933, "text": "study evaluated the KRAS oncogene and its relationship with clinicopathologic features in 33 Kurdish colorectal cancer patients; 12 samples had a nucleotide change, 11 in codon 12 and 1 in codon 13; there was no significant relationship between the mutation and clinical and pathological aspects of the disease"}, {"pubmed": 27514845, "text": "GNAS mutation is a highly specific test for IPMN. When GNAS testing is added to CEA and KRAS, a significantly greater overall accuracy (86.2%) is achieved."}, {"pubmed": 27515134, "text": "These data suggest that SIRT1 is involved in hydroquinone -induced malignant transformation associated with suppressing p53 signaling and activation of KRAS."}, {"pubmed": 27517148, "text": "KRAS mutation is associated with poor relapse-free-survival, but not with overall survival in patients with ampullary adenocarcinoma.[meta-analysis]"}, {"pubmed": 27517152, "text": "recombinantly tailored beta-defensin can intensively enter into the K-Ras mutant pancreatic cancer cells through macropinocytosis-mediated process"}, {"pubmed": 27518729, "text": "Mutation in KRAS gene is associated with Advanced Lung Adenocarcinoma."}, {"pubmed": 27530493, "text": "KRAS mutations were observed in 255 patients (32%) and were correlated with negative histopathological factors in resected non-small-cell lung cancer."}, {"pubmed": 27550813, "text": "repression of endogenous mir-200 expression is one of the important cellular responses to KRAS activation during tumor initiation and progression."}, {"pubmed": 27566041, "text": "KRAS mutation is associated with colorectal liver metastasis."}, {"pubmed": 27569299, "text": "Case Report: KRAS-mutant mucinous adenocarcinoma arose in a longstanding residual neurenteric cyst after partial resection."}, {"pubmed": 27573561, "text": "These analyses revealed similar efficacy and safety among patient subgroups with differing KRAS mutation status, longer or shorter first-line TTP, and age. Ramucirumab is a beneficial addition to second-line FOLFIRI treatment for a wide range of patients with metastatic colorectal carcinoma"}, {"pubmed": 27573925, "text": "The present study evaluated the mutation percentage of two well-known drivers of colorectal cancer (KRAS) and melanoma (BRAF) to further elucidate other risk factors in anal cancer development. In conclusion, a low percentage of mutation was identified in squamous cell carcinoma, adenocarcinomas and highgrade squamous intraepithelial lesion."}, {"pubmed": 27588400, "text": "RAS mutation is associated with infant acute lymphoblastic leukemia."}, {"pubmed": 27592215, "text": "KRAS protein mutation in colorectal liver metastasis, hepatectomy associated with high mortality rate."}, {"pubmed": 27602501, "text": "Results indicate that specific inhibition of PI3K p110alpha could provide an alternative therapeutic approach for colorectal cancer (CRC) patients, particularly those harboring KRAS mutations."}, {"pubmed": 27607580, "text": "Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated non-small cell lung cancer to pro-apoptotic agents."}, {"pubmed": 27620744, "text": "KRAS rs61764370 polymorphism is significantly associated with risk and prognosis of gallbladder malignancy in this endemic belt in North India."}, {"pubmed": 27627705, "text": "a novel EWSR1/ETS chimeric gene, was identified in a patient diagnosed with refractory AML, suggesting a potential role of leukemogenesis in rare cases of AML. This fusion gene is very likely to exhibit oncogenic potential by interfering with the p53/p21-dependent pathway."}, {"pubmed": 27630331, "text": "KRAS mutations were associated with N stage, a polypoid pattern, axial tumor length, and the ratio of the axial to the longitudinal dimensions of the tumor."}, {"pubmed": 27634910, "text": "Mutation analysis Iindicate NRAS as the most commonly mutated gene in myeloma patients followed by KRAS ( and BRAF."}, {"pubmed": 27649783, "text": "these results describe a novel mechanism governing PRKD1 gene expression in pancreatic ductal adenocarcinoma and provide a functional link between oncogenic KRas, NF-kappaB and expression of PRKD1."}, {"pubmed": 27669434, "text": "Rescue experiments with mutated KRas 3'UTR showed very significantly that the anti-tumour effect of miR-193a-3p is via specific direct targeting of KRas and not due to other targets."}, {"pubmed": 27681944, "text": "A potential role for anti-IGF-1R agents in KRAS exon 2 mutant CRC."}, {"pubmed": 27698189, "text": "tyrosine kinase FAK and the laminin subunit LAMB3 as functional targets of miR-1298. Silencing of FAK or LAMB3 recapitulated the synthetic lethal effects of miR-1298 expression in KRAS-driven cancer cells."}, {"pubmed": 27698462, "text": "Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis."}, {"pubmed": 27705932, "text": "Report screening of KRAS mutations in plasma samples from pancreatic cancer patients."}, {"pubmed": 27733477, "text": "The gene signatures identified a different patient population for MEK inhibitor treatment compared with KRAS mutation testing. The predictive power of the MEK signature should be studied further in clinical trials"}, {"pubmed": 27736842, "text": "Three hundred seventy seven patients with wild-type KRAS exon 2 mCRC were randomised."}, {"pubmed": 27737491, "text": "By using this model of curative-intent, margin-negative resection in patients at high risk of recurrence, the authors were able to establish a link between mutation location within the K/NRAS gene and the biology of metastatic colorectal cancer."}, {"pubmed": 27737711, "text": "No significant impact on prognosis was observed for mutated KRAS, NRAS, and PIK3CA genes or combined RAS mutations"}, {"pubmed": 27740967, "text": "In patients with resected stage I lung adenocarcinomas, KRAS mutation was an independent prognostic factor for survival and recurrence, especially in solid predominant tumors."}, {"pubmed": 27753016, "text": "COLD-PCR HRM is a cost-effective way for screening KRAS mutation to predict the worst prognosis in colorectal cancer."}, {"pubmed": 27760825, "text": "Gli1 and Gli2 exhibited different functions in the regulation of p63 expression or proliferation of p63(+) cells in Kras-AR driven tumors."}, {"pubmed": 27764698, "text": "we demonstrated that KRAS-mutant CRC cells could become adaptive to glutamine depletion through asparagine biosynthesis by ASNS"}, {"pubmed": 27769041, "text": "this study shows that miR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42"}, {"pubmed": 27780929, "text": "The in vitro and in vivo inhibitory effect of zoledronic acid was based on the blockade of cell cycle in wild type KRAS-expressing human non-small cell lung cancer cells."}, {"pubmed": 27793187, "text": "KRAS mutation is associated with lung cancer."}, {"pubmed": 27793696, "text": "KRAS-mutant colorectal carcinoma shows intrinsic radioresistance along with rapid upregulation of hnRNP K in response to ionizing radiation that can effectively be targeted by MEK inhibition."}, {"pubmed": 27798894, "text": "The biomarkers KRAS/p16/beta-catenin could be used as a combined biomarker for prediction of local recurrence and stratification of the risk for further surgery"}, {"pubmed": 27805251, "text": "Two genes, namely ZNF518B and EPDR1, exhibit a pattern of isoform abundance dependent on KRAS G13D and G12D mutations."}, {"pubmed": 27815357, "text": "KRAS mutations were rarely found together and those in codons 12 and 13 conferred poor prognosis. For BRAF, more c.1781A>G (p.D594G) colorectal cancers (CRC)carried RAS mutations [14% (3/21)] compared with c.1799T>A (p.V600E) CRCs.For NRAS, 5% (3/60) of codon 61 mutant colorectal cancers had KRAS mutations compared with 44% (10/23) of codons 12 and 13 mutant colorectal cancers"}, {"pubmed": 27834959, "text": "ConclusionThe significantly higher frequency of codon 61 mutation of the ras oncogene in primary and bilateral pterygium specimens compared with normal conjunctiva supports the tumoral origin of pterygium"}, {"pubmed": 27835580, "text": "KY1022, a small molecule that destabilizes both beta-catenin and Ras by targeting the Wnt/beta-catenin pathway, inhibitits cellular events, including epithelial mesenchymal transformation, an initial process of metastasis, and apoptosis in colorectal cancer cells."}, {"pubmed": 27845397, "text": "study is the first to identify driver-follower relationships in correlated motions of K-Ras residue pairs, revealing the direction of information flow during allosteric modulation of its nucleotide-dependent intrinsic activity: active K-Ras Switch-II region motions drive Switch-I region motions, while alpha-helix-3L7 motions control both."}, {"pubmed": 27856453, "text": "Endoplasmic reticulum stress triggers a localized signaling module on the ER surface involving Nox4-dependent calcium mobilization, which directs local Ras activation through ER-associated, calcium-responsive RasGRF."}, {"pubmed": 27857191, "text": "in vitro results showed that the repression of KRAS by miR-16 suppressed the proliferation and invasion and induced the apoptosis of colorectal cancer (CRC) cells, and the in vivo results revealed that miR-16 exerted a tumor-suppressive effect by negatively regulating KRAS in xenograft mice. Taken together, our findings provide evidence supporting the role of miR-16 as a tumor suppressor in CRC by targeting KRAS"}, {"pubmed": 27859136, "text": "In 2,437 NSCLC patients, a \"KRAS signature\" consisting of the mean expression of the top 5 genes showing altered expression in KRAS-mutated patients had a higher prognostic power than KRAS mutation status alone, indicating that secondary effects of a mutation can have a higher prognostic relevance than the primary genetic alteration itself."}, {"pubmed": 27863403, "text": "Report targeted analysis of KRAS, BRAF and PIK3CA mutations in circulating tumor cells captured by a label-free platform and compare to expression in primary tumor tissue and metastases."}, {"pubmed": 27863474, "text": "Data show that Prima-1 kills hypoxic wt p53 KRAS-mutant cells resistant to 3-bromopyruvate (3-BrPA), partly by decreasing GLUT-1 expression."}, {"pubmed": 27863786, "text": "KRAS protein mutation, may guide the extent of thyroidectomy in patients with thyroid neoplasms."}, {"pubmed": 27880931, "text": "Data suggest a role of XIST- correlated small RNA XPi2 in modulating the G-quadruplex formation which may play some essential roles in the KRAS- associated carcinogenesis."}, {"pubmed": 27888800, "text": "Kras mutation appears to be one of the imperative events in the ovarian mucinous adenoma-borderline tumor-carcinoma sequence, as increased numbers of Kras mutations have been shown to be the strongest predictor of unequivocal malignancy in ovarian mucinous neoplasms."}, {"pubmed": 27888823, "text": "No relation between oropharyngeal squamous cell carcinomas and KRAS gene mutations"}, {"pubmed": 27892494, "text": "Kras regulates circular RNA in colon cancer cells."}, {"pubmed": 27906963, "text": "Our data proved that RMRP acted as an oncogene LncRNA to promote the expression of KRAS, FMNL2 and SOX9 by inhibiting miR-206 expression in lung cancer. These data suggested that RMRP might serve as a therapeutic target in lung adenocarcinoma"}, {"pubmed": 27909058, "text": "farnesylation of K-Ras was required for its packaging within extracellular nanovesicles, yet expressing a K-Ras farnesylation mutant did not decrease the number of nanovesicles or the amount of Alix protein released per cell."}, {"pubmed": 27910065, "text": "Studies indicate that frequently altered genes in type I carcinomas are TP53, K-Ras, PTEN, and ss-catenin."}, {"pubmed": 27911734, "text": "Studies indicate that the control of spatiotemporal RAS protein signalling show that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes."}, {"pubmed": 27911859, "text": "KRAS exon 2 codon 13 mutations, compared to codon 12 mutations, seem to be associated with better outcomes following lung metastasectomy in colorectal cancer"}, {"pubmed": 27912827, "text": "This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations."}, {"pubmed": 27913706, "text": "Our data demonstrate an important connection between mRNA translation and KRAS tumorigenesis under the control of STAT1, which can determine the susceptibility of KRAS tumors to pharmacologic inhibition of mRNA translation initiation."}, {"pubmed": 27916952, "text": "multiregion analysis was performed in 60 spatially separated tumor areas according to the pathological tumor node metastasis (pTNM) staging and KRAS, NRAS and BRAF mutations were tested using pyrosequencing.these results suggest the need for multiple RAS testing in different parts of the same tumor and/or more sensitive techniques."}, {"pubmed": 27929127, "text": "In this study we report a new delivery strategy for a G4-decoy oligonucleotide that sequesters MAZ, a transcription factor essential for KRAS transcription. It is based on the use of palmitoyl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with lipid-modified G4-decoy oligonucleotides and a lipid-modified cell penetrating TAT peptide"}, {"pubmed": 27936046, "text": "Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins."}, {"pubmed": 27941888, "text": "we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca(2+)-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling."}, {"pubmed": 27943267, "text": "Alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- tumors originating via specific molecular pathways including the traditional adenoma-carcinoma pathway but not with BRAF+ tumors originating via the serrated pathway"}, {"pubmed": 27974679, "text": "KRAS mutation analysis with PNAClamptrade mark technique using washing fluid from EUS-FNA along with cytological examination may not only improve the diagnostic accuracy of PDACs, but also establish the platform using genetic analysis which would be helpful as diagnostic modality for PDACs."}, {"pubmed": 27984728, "text": "Study demonstrates that stress granules are markedly elevated in mutant KRAS cells following exposure to stress-inducing stimuli. The upregulation of stress granules by mutant KRAS is dependent on the production of the signaling lipid molecule 15-deoxy-delta 12,14 prostaglandin J2 (15-d-PGJ2) and confers cytoprotection against stress stimuli and chemotherapeutic agents."}, {"pubmed": 27993791, "text": "Multiplex detection of KRASG12/G13 mutations in a small amount of unamplified plasma cfDNA using ddPCR has good sensitivity and specificity and good concordance with conventional clinical mutation testing of archival specimens. A higher percentage of mutant KRASG12/G13 in cfDNA corresponded with shorter survival"}, {"pubmed": 27998182, "text": "longitudinal monitoring of urine specimens showed an increase in the quantity of mutant KRAS transrenal DNA, which were highly associated with disease progression and outcome."}, {"pubmed": 27999210, "text": "A panRAF inhibitor, LY3009120, potently inhibited proliferation and tumor growth in BRAF/KRAS mutated colorectal tumors."}, {"pubmed": 27999344, "text": "EGFR and KRAS mutations have a predictive role on brain metastases incidence, recurrence and outcome in Caucasian Non-Small Cell Lung Cancer patients."}, {"pubmed": 28000854, "text": "Our data suggest a possibility that miR-487b may suppress metastasis of colorectal cancer progression through inhibition of KRAS"}, {"pubmed": 28000889, "text": "High KRAS mutation rate is associated between primary colorectal cancer and corresponding metastases."}, {"pubmed": 28006055, "text": "Mutations in BRAFV600E were significantly associated with worse survival after recurrence (SAR) in patients with recurrent stage III colon cancer, and worse SAR for BRAFV600E or KRAS mutant tumors was more strongly associated with distal cancers."}, {"pubmed": 28006059, "text": "Patients with the KRAS-variant with head and neck squamous cell carcinoma significantly benefit from the addition of cetuximab to radiotherapy"}, {"pubmed": 28007627, "text": "ALK/EGFR mutational co-alterations are associated with response to chemotherapy in Non-Small Cell Lung Cancer."}, {"pubmed": 28012797, "text": "The study results improve our understanding of the ATMIN-KRas axis leading to HNSCC migration or invasion and metastasis and facilitates the identification of possible therapy targets of downstream genes for designing effective therapeutic strategies in personalized medicine"}, {"pubmed": 28025078, "text": "Report KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer may depend on tumor histology."}, {"pubmed": 28030835, "text": "Co-targeting translation and proteasome using the combination of Episilvestrol and Bortezomib promoted strong endoplasmic reticulum stress and rapid killing of colon cancer cells with KRAS/BRAF mutations."}, {"pubmed": 28032595, "text": "Generated multiple mutant KRAS-driven cancer cell lines with acquired resistance to the purine-scaffold HSP90 inhibitor PU-H71. Report a Y142N missense mutation in the ATP-binding domain of HSP90alpha that co-occurred with amplification of the HSP90AA1 locus in resistant cells."}, {"pubmed": 28035073, "text": "microRNA expression profiles had clinicopathological implications that were related to EGFR and KRAS mutations, as well as ALK-rearrangement in lung adenocarcinoma."}, {"pubmed": 28039262, "text": "This work provides evidence that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy"}, {"pubmed": 28040692, "text": "BRAF or KRAS mutations are independently associated with shorter time to recurrence, shorter survival after relapse, and overall survival in patients with microsatellite-stable (MSS) subgroups, but not microsatellite-unstable tumors."}, {"pubmed": 28041850, "text": "Study found that the K-Ras anchor binds selected plasma membrane anionic lipids with defined head groups and lipid side chains. The precise amino acid sequence and prenyl group define a combinatorial code for lipid binding that extends beyond simple electrostatics; within this code lysine and arginine residues are non-equivalent and prenyl chain length modifies nascent polybasic domain lipid preferences."}, {"pubmed": 28043144, "text": "EGFR and KRAS mutation status was associated with the expression of AKT, p-AKT, DR5, and DcR1 in non-small cell lung cancer"}, {"pubmed": 28044264, "text": "Combination of PCR HRM with either RFLP or direct DNA sequencing was useful to detect K-RAS exon 2 and extended RAS mutations, respectively. Frequency of all RAS mutations in stage IV Indonesian (41%) was similar among Asians (41-49%), which tend to be lower than western (55%) CRC."}, {"pubmed": 28057438, "text": "oncogenic KRas-induced increase in fluid-phase endocytosis has a key role during cellular transdifferentiation in pancreatic acinar cells. This result supports emerging evidence for endocytosis playing a crucial role in regulating the signaling output of the cells"}, {"pubmed": 28068936, "text": "KRAS mutation is associated with response to chemotherapy in metastatic colorectal cancer."}, {"pubmed": 28074351, "text": "review focuses on the genes, which are frequently mutated in various cancers and are known to be important in the advance and progression of colorectal cancer and melanoma, namely KRAS, NRAS and BRAF"}, {"pubmed": 28077799, "text": "KRAS mutation is associated with inflammatory bowel disease-associated colorectal cancer."}, {"pubmed": 28091917, "text": "Rare mutations in KRAS, NRAS, and BRAF oncogenes have been found in patients with melanoma and colorectal neoplasms."}, {"pubmed": 28096270, "text": "A quantitative, mutation-enrichment next-generation sequencing test for detecting KRAS(G12/G13) mutations in urine cfDNA had good concordance with testing of archival tumor tissue. Changes in mutated urine cfDNA were associated with time to treatment failure."}, {"pubmed": 28099251, "text": "Mutations in each of the KRAS, CDKN2A, TP53, and SMAD4 genes were not associated with overall survival."}, {"pubmed": 28099923, "text": "these evidences demonstrate that let-7-KRAS rs712 G > T polymorphism might be associated with digestive system cancer risk in the Chinese population."}, {"pubmed": 28104621, "text": "A higher percentage of patients with localized pancreatic ductal adenocarcinoma exhibited detectable KRAS mutations in exosome-derived DNA than previously reported for cell-free DNA"}, {"pubmed": 28108627, "text": "The current study uncovers the contribution of oncogenic KRAS to serum marker CA125 production through a mechanism that involves the ERK/c-Myc axis."}, {"pubmed": 28110998, "text": "nuclear Ect2 GEF activity is required for Kras-Trp53 lung tumorigenesis in vivo and that Ect2-mediated transformation requires Ect2-dependent rDNA transcription."}, {"pubmed": 28116986, "text": "Our data suggest that testing for any RAS mutation is unlikely to change the clinical management of thyroid nodules that have indeterminate cytology"}, {"pubmed": 28121262, "text": "Circulating exosomal DNA in 5 out of 9 CP patients enabled the detection of KRAS(G)(12)(D) mutation. In 114 healthy subject-derived circulating exosomal DNA, 2.6% presented with KRAS(G)(12)(D) mutation and none with TP53(R)(273)(H) mutation."}, {"pubmed": 28122482, "text": "Our results demonstrated increased expression of both K-Ras mRNA splicing variants in leiomyoma tissue. However, the ultimate result of KRAS expression on leiomyoma development depends on the overall KRAS isoform balance and, consequently, on activated signaling pathways."}, {"pubmed": 28125730, "text": "KRAS mutational status did not differentiate in the association between aspirin use and survival."}, {"pubmed": 28139399, "text": "Serum and plasma were found to be good materials for detecting cancer-specific DNA in the peripheral blood and the presence of KRAS mutations in blood-derived DNA may be used as a prognostic biomarker for patients with pancreatic cancer."}, {"pubmed": 28150169, "text": "KRAS Polymorphism is associated with recurrence in non-small cell lung cancer."}, {"pubmed": 28152508, "text": "The data provided new insights into the functional interaction between the KRAS and MYC pathways across various cancer types"}, {"pubmed": 28153726, "text": "To our knowledge, this is the first report of a K-Ras(G12D)-selective inhibitor, contributing to the development and study of K-Ras(G12D)-targeting drugs."}, {"pubmed": 28154176, "text": "KRAS K104Q mutant exhibited defects in both guanine nucleotide exchange factors -mediated exchange and GTPase-activating proteins -mediated GTP hydrolysis, consistent with NMR-detected structural perturbations in localized regions of KRAS important for recognition of these regulatory proteins."}, {"pubmed": 28154181, "text": "KRAS mutation is associated with colon and lung cancer."}, {"pubmed": 28161825, "text": "KRAS mutation patients had more frequent lung metastasis and had higher (18)F-FDG uptake compared to WT KRAS in stage IV CRC."}, {"pubmed": 28167505, "text": "Our studies offer a way forward for Hsp90 inhibitors through the rational design of Hsp90 inhibitor combinations that may prevent and/or overcome resistance to Hsp90 inhibitors, providing an effective therapeutic strategy for KRAS-mutant non-small cell lung cancer ."}, {"pubmed": 28169239, "text": "Codon 12 of exon 2 of K--ras gene detected by modified mismatch PCR-RFLP assay is significantly associated with liver metastasis in CRC patients during the first 5 years after surgery."}, {"pubmed": 28179313, "text": "Data suggest that genotyping for KRAS and BRAF mutation status is a gold standard for categorizing colorectal cancer (CRC) for clinical decisions."}, {"pubmed": 28188683, "text": "KRAS mutations and AKT activation are present in Wilms tumors (WT) and may represent novel therapeutic targets for this tumor."}, {"pubmed": 28188750, "text": "KRAS mutations are associated with high-grade tumor in colorectal adenocarcinomas. KRAS and PIK3CA genetic variants are associated with aggressive clinicopathological features in colorectal adenocarcinoma."}, {"pubmed": 28196015, "text": "KRAS mutations were present in all high-grade (HG) lesions, suggesting that this gene has an important role in the pathogenesis of pancreatic adenocarcinomas arising from mucinous cystic neoplasm (MCN)."}, {"pubmed": 28202526, "text": "The mitosis-like condensed chromatin positive phenotype defined a subset of KRAS-mutated lung cancers that were enriched for co-occurring genomic alterations in TP53 and CDKN2A. Results illuminate the basis for the radiation resistance of KRAS-mutated lung cancers."}, {"pubmed": 28202657, "text": "Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types."}, {"pubmed": 28208157, "text": "Specific mutations in KRAS codon 12 are associated with recurrent colorectal cancer."}, {"pubmed": 28214200, "text": "Concurrent MET silver in situ hybridization positivity and KRAS mutation may predict a high risk of recurrence in pancreatobiliary subtype of ampullary adenocarcinomas"}, {"pubmed": 28215705, "text": "Sequencing of over 11,000 advanced human cancers revealed mutant allele imbalance in 55% of 1,168 KRAS mutant tumors of all histologic types, many of which lost WT KRAS through diverse genetic mechanisms. Clonal evolution at the KRAS locus resulting in increased oncogene expression and loss of the normal allele may identify a subset of cancers with increased dependence on MAPK signaling in some tissue contexts."}, {"pubmed": 28216246, "text": "KRAS and BRAF mutations are negatively associated with overall and relapse-free survival in patients who undergo complete liver resection for colorectal cancer liver metastases"}, {"pubmed": 28218784, "text": "Study shows the prevalence of mutations in codons 12 and 13 of K-ras exon 2 comparable between the Middle Eastern population and previous reports from the region. These mutations were associated with adverse features during presentation of the disease, including higher serum CEA, and also associated with poor outcomes in patients presenting with both early and advanced stages of the disease."}, {"pubmed": 28220486, "text": "Our population-based study of 1,081 patients with refractory, KRAS exon 2 wild-type mCRC suggests a possible OS benefit with the combination of Cmab + I compared to Pmab alone without an associated increase in toxicity.With a much larger sample size (n = 1081), our study was better powered to detect an OS difference between combination and EGFR monotherapy."}, {"pubmed": 28220783, "text": "High FOS-like antigen 1 (FOSL1) expression with mutant KRAS protein lung and pancreatic cancer patients showed the worst survival outcome."}, {"pubmed": 28232723, "text": "Study reveals the novel function of NOX4 in reprogramming aerobic glycolysis initiated by activated Kras and inactivated p16 in pancreatic ductal adenocarcinoma."}, {"pubmed": 28233357, "text": "studies provide a deeper understanding of the critical role for WASF3 in facilitating increased invasion potential in cancer cells expressing mutant RAS and supports the idea that targeting WASF3 in metastatic cells overexpressing RAS may be used to suppress invasion and metastasis"}, {"pubmed": 28246207, "text": "The addition of simtuzumab to FOLFIRI did not improve clinical outcomes in patients with metastatic KRAS mutant colorectal carcinoma"}, {"pubmed": 28249840, "text": "Mutations in KRAS, NRAS, and BRAF together occur in more than half of all colorectal cancer cases and are often associated with negative responses to the EGFR inhibitors cetuximab and panitumumab.guideline is clear that we should not be giving EGFR inhibitors to patients with RAS mutations and that patients with BRAF V600E mutations have a much worse prognosis"}, {"pubmed": 28259994, "text": "Overexpression of K-p21Ras was found in all colorectal cancer tissues tested, overexpression of N-p21Ras was found in 85.7% of the colorectal cancertissues, while H-p21Ras expression was not found in any colorectal cancer tissue."}, {"pubmed": 28277374, "text": "Sex differences may affect the presentation of KRAS mutations in patients with colorectal cancer (CRC), which were more frequently detected in women and men with in right-sided CRC; KRAS codon 13 mutations were significantly associated with high-plasma cholesterol"}, {"pubmed": 28280091, "text": "It is unclear if we may have seen greater clinical activity if we were able to fully inhibit Src in this study, but given the requirement that enrolling patients have documented disease progression on cetuximab, acquired resistant KRAS-mutant clones may have been present, limiting future strategies to reverse EGFR resistance"}, {"pubmed": 28285720, "text": "Our finding of frequent KRAS mutation in urachal adenocarcinoma suggests its potential role in the oncogenesis of this neoplasm"}, {"pubmed": 28286004, "text": "Results from all-atom molecular dynamics simulations show how KRas4A interacts with anionic lipid membranes and find that the protein surface charge as well as geometry, in contact with certain lipids can strongly modulate the orientation preference."}, {"pubmed": 28289161, "text": "AFR3 cells harbored the secondary EGFR mutation T790M. Our findings constitute the first report showing acquired wild-type KRAS overexpression and attenuation of afatinib resistance following a drug holiday. The heterogeneous mechanisms of afatinib resistance should facilitate the development of more effective therapeutic strategies for non-small cell lung cancer patients"}, {"pubmed": 28289710, "text": "identified focally upregulated FAK and collagen-associated collective invasion in KRAS and LKB1 comutated human lung adenocarcinoma patients. Our results suggest that patients with LKB1 mutant tumors should be stratified for early treatment with FAK inhibitors"}, {"pubmed": 28295004, "text": "The patients with traditional serrated adenoma showed KRAS and BRAF mutations in 58.4 and 8.3% of cases, respectively. Mutations of these genes were absent.  The study revealed that the subtypes of serrated adenomas substantially differ by sex, age, localization, and molecular genetic characteristics."}, {"pubmed": 28314302, "text": "KRAS mutant status is associated with distant recurrence of rectal cancer"}, {"pubmed": 28322512, "text": "The present study demonstrated that pathological stage I adenocarcinoma harboring EGFR and K-ras gene mutations have distinct clinicopathological features. The presence of these mutations alone were not prognostic factors in patients with resected pathological stage I adenocarcinoma."}, {"pubmed": 28328955, "text": "The possibility of cfDNA-based genotyping of KRAS to early detect the emergence of resistance during chemotherapy."}, {"pubmed": 28328959, "text": "These five SNPs in the KRAS gene and the VEGF gene were not associated with CRC susceptibility."}, {"pubmed": 28330874, "text": "analysis of the G-quadruplex involved in transcriptional regulation of the KRAS proto-oncogene promoter"}, {"pubmed": 28353383, "text": "SP174 immunohistochemistry allows sensitive detection of NRAS and KRAS Q61R mutants."}, {"pubmed": 28368335, "text": "Studies indicate potential mechanisms of resistance to anti-EGFR therapies act through acquired mutations of KRAS and the EGFR ectodomain."}, {"pubmed": 28380455, "text": "Findings indicate neurofibromin 1 (NF1) as the most frequently occurring driver mutation in mucosal melanoma, and RAS alterations, consisting of NRAS and KRAS mutations, were the second most frequent mutation type."}, {"pubmed": 28400509, "text": "KRAS is associated with activation of ERK2, induction of FASN, and promotion of lipogenesis."}, {"pubmed": 28407465, "text": "G12C mutation associated with reduced progression-free survival in non-small cell lung cancer treated with pemetrexed"}, {"pubmed": 28412347, "text": "Additionally, we report that PIP2 forms key contacts with Helix-4 on the catalytic domain of KRas4b that orient the protein in a manner expected to facilitate association with upstream and downstream signaling partners."}, {"pubmed": 28419195, "text": "describes practical clinico-pathological specifications to optimize RAS ctDNA determination. Moreover, OncoBEAMtrade mark is useful to monitor RAS in patients undergoing systemic therapy to detect resistance and evaluate the efficacy of particular treatments"}, {"pubmed": 28422979, "text": "No relationship was noted between KRAS mutation status and standardized uptake value of fluorodeoxyglucose F18."}, {"pubmed": 28423587, "text": "Studies indicate that positive PD-L1 expression was significantly correlated with KRAS mutation and EGFR mutation."}, {"pubmed": 28426398, "text": "analysis of K-RAS and N-RAS mutations in testicular germ cell tumors"}, {"pubmed": 28430611, "text": "KRAS mutations in ctDNA indicated a worse PFS and OS in patients treated by chemotherapy."}, {"pubmed": 28435452, "text": "Mechanistically, increased KRAS expression induced ROS production, which elevated HIF-1alpha and YAP1 expression. Increased HIF-1alpha persistently promoted DDX3 expression via a KRAS/ROS/HIF-1alpha feedback loop."}, {"pubmed": 28448716, "text": "mechanistic insights into the role that phosphorylation at Ser181 plays in regulating K-Ras4B's cellular distribution and activity."}, {"pubmed": 28450086, "text": "that conventional cytology from Endoscopic ultrasound-guided fine-needle aspiration samples is highly specific for the diagnosis of KRAS mutation in pancreatic cancer"}, {"pubmed": 28451792, "text": "KRAS mutation could induce PD-L1 expression through p-ERK signaling in lung adenocarcinoma"}, {"pubmed": 28453172, "text": "K-ras mutations in codon 12 were significantly associated with the I phenotype of gastric signet ring cell carcinoma, and exhibited an inverse relationship with MUC5AC and MUC6 expression."}, {"pubmed": 28453411, "text": "TP53 comutation with KRAS or EGFR is not a significant prognostic marker in patients with resected Non-Small-Cell Lung Cancer. Dual TP53/KRAS mutation seems to be predictive of shortened survival in patients who are treated with platinum-based ACT."}, {"pubmed": 28462395, "text": "Our up-to-date review discusses CaM's role in PI3K signaling at the membrane in KRAS-driven cancers. This is significant since it may help development of K-Ras-specific pharmacology."}, {"pubmed": 28463756, "text": "The results show that KRAS mutations are associated with a worse prognosis than expected in patients treated with FOLFIRI protocol plus bevacizumab compared with the KRAS wild-type population."}, {"pubmed": 28468669, "text": "Using the system, we detected Circulating tumor cells (CTCs) heterozygosity and heterogeneity in KRAS status among CTCs within a patient and between CTCs and tumor tissues"}, {"pubmed": 28468801, "text": "we demonstrate that oncogenic p110alphaH1047R, K-RasG12V, H-RasG12V, and Her2 use a common Akt1-FOXO3a pathway in suppression of DeltaNp63alpha expression and, consequently, promote cell migration/invasion and tumor metastasis. Thus, DeltaNp63alpha may function as a critical integrator of oncogenic signals in cell motility and cancer metastasis."}, {"pubmed": 28475173, "text": "The critical roles of miR-30a and ME1 in the development of KRAS-mutant colorectal cancer indicate therapy potentials for this subtype of cancer."}, {"pubmed": 28488545, "text": "ytoplasmic immunoexpression of BRAF V600E (VE1) protein was found in three specimens: serous superficial papilloma, serous papillary cystadenoma of borderline malignancy, and partially proliferative serous cystadenoma"}, {"pubmed": 28489996, "text": "KRAS mutations were found in 3 patients with endometriosis but found that lesions in deep infiltrating endometriosis, which are associated with virtually no risk of malignant transformation, harbor somatic cancer driver mutations."}, {"pubmed": 28498246, "text": "MEK inhibition in KRas mutant cells results in activation of ER signaling and prevents the abrogation of signaling through ERK1/2 and p90RSK that is achieved in KRas wild-type EC cells."}, {"pubmed": 28498561, "text": "we found that H-Ras proteins and particularly the G12V and G13D variants are significantly more flexible than their K-Ras counterparts.while most of the simulated proteins sampled the effector-interacting state 2 conformational state, G12V and G13D H-Ras adopted an open switch state 1 conformation that is defective in effector interaction"}, {"pubmed": 28508873, "text": "Study results indicate that pleural homed cancer cells harboring activating KRAS mutations are competent of malignant pleural effusion induction. This genotype-phenotype link is primarily mediated via mutant KRAS-dependent CCL2 signaling that results in the recruitment of CD11b+Gr1+ myeloid cells to the pleural space."}, {"pubmed": 28531253, "text": "the genomic pattern according to MATH demonstrated that mutation rates of TP53, IRF5 and KRAS were independently associated with MATH, and the latter two were only significant in male patients. As MATH increased, the fraction of somatic copy number alteration (SCNA) elevated. Moreover, more SCNA events was independently associated with MATH in male than in female"}, {"pubmed": 28538732, "text": "CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells"}, {"pubmed": 28543997, "text": "Our findings showed BRAF and/or KRAS mutations in three of seven cases of low-grade serous neoplasms of the testis"}, {"pubmed": 28544747, "text": "These findings suggest that future trials of everolimus in biliary tract cancer would benefit from preselecting patients based on their K-Ras and PI3K/mTOR pathway activation status."}, {"pubmed": 28551389, "text": "The lack of KRAS, NRAS, BRAF, and PIK3CA mutation in our study may suggest that a subset of eyelid sebaceous carcinomas is unlike that of eyelid sebaceous carcinomas of western countries."}, {"pubmed": 28570009, "text": "KRAS mutations appear to be major driver genetic alterations in both liver and pancreatic mucinous cystic neoplasms (MCNs)."}, {"pubmed": 28570035, "text": "Studies on the metabolic properties of mutant KRAS protein lung tumors have uncovered unique metabolic features that can potentially be exploited therapeutically [Review]."}, {"pubmed": 28576749, "text": "YAP inhibition significantly enhances the antitumor efficacy of a pan-RAF inhibitor, LY3009120, in KRAS-mutant pancreatic cancer."}, {"pubmed": 28583095, "text": "BRAF mutation, rather than KRAS, was a significant prognostic factor in Korean colorectal cancer patients at both early and advanced stages."}, {"pubmed": 28593995, "text": "primary resistance to cetuximab is dependent upon both KRAS mutational status and protein expression level, and acquired resistance is often associated with KRAS(Q61) mutations that function even when protein expression is low."}, {"pubmed": 28600477, "text": "Altogether, these data show that humanized anti-progastrin antibodies might represent a potential new treatment for K-RAS-mutated colorectal patients, for which there is a crucial unmet medical need"}, {"pubmed": 28601386, "text": "ALK and KRAS mutations are associated with acquired resistance to crizotinib in ALK-positive non-small cell lung cancer"}, {"pubmed": 28611106, "text": "we have found that a subgroup of colorectal cancers, defined by having either KRAS or BRAF (KRAS/BRAF) mutations and BCL2L1 (encoding BCL-XL) amplification, can be effectively targeted by simultaneous inhibition of BCL-XL (with ABT-263) and MCL1 (with YM-155)."}, {"pubmed": 28619714, "text": "Suggest that GPR31 acts as a secretory pathway chaperone for KRAS4B in tumor cells."}, {"pubmed": 28623230, "text": "The structure model of the CaM-K-Ras4B HVR association provides plausible clues to CaM's regulatory action in PI3Kalpha activation involving the ternary complex in cell proliferation signaling by oncogenic K-Ras4B."}, {"pubmed": 28630043, "text": "Data suggest that isoform-specific sequences in the allosteric lobes of HRAS, KRAS, and NRAS have an impact on biocatalysis (kinetics of GTP hydrolysis) and interaction with c-Raf kinase, which must be due to allosteric effects on dynamics and conformational states, given the identical active sites of these isoenzymes."}, {"pubmed": 28636636, "text": "KRAS exon 2 mutation is associated with colorectal cancer."}, {"pubmed": 28645942, "text": "We have investigated if the initial source of intratumoral heterogeneity is consequent to multiple independent lineages derived from different crypts harboring distinct truncal APC and driver KRAS mutations, thus challenging the prevailing monoclonal monocryptal model."}, {"pubmed": 28647837, "text": "The defined role of oncogenic KRAS in the regulation of altered metabolic signaling pathways in KRAS-driven cancers.[review]"}, {"pubmed": 28650561, "text": "we describe patients with craniosynostosis and Noonan syndrome due to de novo mutations in PTPN11 and patients with craniosynostosis and CFC syndrome due to de novo mutations in BRAF or KRAS. All of these patients had cranial deformities in addition to the typical phenotypes of CFC syndrome and Noonan syndrome."}, {"pubmed": 28652417, "text": "The model we propose is a variation of the currently existing model and hypothesizes that, in a subgroup of colorectal carcinomas, K-ras mutation may precede APC inactivation, representing the earliest driving force and, probably, an early biomarker of colorectal carcinogenesis."}, {"pubmed": 28653505, "text": "Study underscores genomic alterations that represent early events in the development of Kras mutant LUAD following Gprc5a loss and tobacco carcinogen exposure."}, {"pubmed": 28656305, "text": "Exposure to cetuximab and various concentration of AG490, an inhibitor of JAK2, STAT3 and HSP27 protein levels, except in the KRAS G12V mutant line, SW620...cetuximab may promote SN38 sensitivity via suppression of HSP27, through blocking the JAK/STAT signaling pathway, and shows synergistic effects when combined with SN38 in wild-type RAS CRC cells."}, {"pubmed": 28664935, "text": "we detected mutually exclusive KRAS and MAP2K1 mutations in one-third of cases of Rosai-Dorfman disease"}, {"pubmed": 28665451, "text": "Due to the discordant results (GGT->GTT exon 2 KRAS mutation in the primary tumor, and KRAS-WT in the liver metastases), mutational analysis on liver metastasis was repeated using next-generation sequencing and enriching the sample in tumor cells by manual microdissection; the same type of mutation of the primary tumor (GGT->GTT exon 2 KRAS gene) was confirmed"}, {"pubmed": 28677778, "text": "In the colorectal biopsies from 50 patients with suspected colorectal cancer, 18 cases (36%) contained mutant KRAS, and the amount of mutant DNA accounted for 18.664.2% of the total DNA."}, {"pubmed": 28685592, "text": "Knowing the mutation status of KRAS, BRAF or PIK3CA in stage II colorectal cancer can significantly improve the accuracy of prognoses."}, {"pubmed": 28692044, "text": "Taken together these data support a model where PDHK4 regulates KRAS signalling and its tumorigenic properties and suggest that inhibition of PDHK4 could represent a novel therapeutic strategy to target KRAS mutant colorectal and lung cancers"}, {"pubmed": 28697193, "text": "We observed that in patients with colorectal cancers, we cannot predict KRAS gene mutations using PET/CT parameters (SUVmax, MTV, TLG), hematological parameters (NLR, PLR) or tumor marker CA 19-9. We detected a significant but not very strong association only between CEA and KRAS mutations."}, {"pubmed": 28699162, "text": "Differences between KRAS and EGFR alterations were not significant. The great majority of the analyzed tumor sections (16/19) exhibited two or more morphological growth patterns. Mutant allele frequencies were significantly higher in segments with a predominant solid pattern compared to all other histologies (p < 0.01)."}, {"pubmed": 28701723, "text": "MALAT1 acts as a tumour promoter at least in part by binding miR-217 and sequestering the molecule in the nucleus, thereby promoting oncogenic KRAS expression in PDAC."}, {"pubmed": 28703285, "text": "we used hot-spot mutation sequencing to examine whether KRAS/NRAS mutations, a characteristic feature of mesonephric carcinoma,1 are also present in mesonephric hyperplasia.  None of the mesonephric hyperplasia cases harboured a KRAS or NRAS mutation."}, {"pubmed": 28708207, "text": "Collection of transrenal DNA, being noninvasive, is an attractive assay and easily allows serial monitoring of the disease. Results from preoperative detection showed a close correlation to tumor tissue profiling and demonstrated close associations to the disease. We also observed significant decreases in mutant KRAS DNA concentration after surgery, which confirmed transrenal DNA's sensitivity to treatment response."}, {"pubmed": 28710768, "text": "TAZ was positively correlated with EGFR signaling, and coexpression of TAZ/EGFR conferred a poorer prognosis in lung cancer patients. Our findings identify that targeting TAZ-mediated compensatory mechanism is a novel therapeutic approach to overcome gefitinib resistance in KRAS-mutant/EGFR-wild-type non-small-cell lung cancer ."}, {"pubmed": 28742845, "text": "The mutual exclusivity analysis showed that events in K-ras and p53 were likely to co-occur in pancreatic adenocarcinoma.  The graphical summary of the mutations showed that there were hotspots for protein activation. In the network analysis, no solid association between K-ras and p53 was observed in pancreatic adenocarcinoma. In the survival analysis, neither K-ras nor p53 were associated with both survival events."}, {"pubmed": 28743497, "text": "A novel molecular mechanism describing K-Ras and H-REV107 binding is suggested and insights into new K-Ras effector target drugs are provided."}, {"pubmed": 28745321, "text": "Transgenic mouse line expressing the human Ki-Ras bearing an activating mutation (Ki-Ras((G12V))) selectively in the mammary epithelium develop estrogen receptor alpha (ERalpha)-positive ductal adenocarcinomas with 100% incidence within 3-9 months after Ki-Ras((G12V)) induction."}, {"pubmed": 28749408, "text": "These results indicated that ASCT2 (SLC1A5) could be a novel therapeutic target against KRAS-mutant colorectal cancer."}, {"pubmed": 28754906, "text": "KRAS, SIRT1 and BCL6 are coordinately over-expressed in eutopic endometrium of women with endometriosis"}, {"pubmed": 28755461, "text": "Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas."}, {"pubmed": 28756651, "text": "The rate of EGFR mutation was significantly higher in female and non-smoker patients. In TTF-1 positive cases EGFR mutation was more frequent. Age of the patients over 62-year old was correlated with KRAS mutations. The concordance between ALK IHC and FISH was 58.3%. The MET protein in the cases with MET amplification was 100% positive."}, {"pubmed": 28765579, "text": "This study unravels an anti-metastatic role of AKT1 in the NSCLC cells with KRAS or EGFR mutations, and establishes an AKT1-MARCKS-LAMC2 feedback loop in this regulation."}, {"pubmed": 28796802, "text": "KRAS mutation in cfDNA was associated with a poorer survival in cancer patients for overall survival. [meta-analysis]"}, {"pubmed": 28797274, "text": "KRAS mutation patterns in Sri Lankan metastatic colorectal cancer: p.Gly13Asp (40.0%), p.Gly12Val (24.0%),p.Gly12Cys (12.0%), p.Gly12Ser (12.0%), p.Gly12Asp (8.0%), and p.Gly12Arg (4.0%). The codon 13 mutation was a G>A transition (40.0%), while G>T transversions (32.0%), G>A transitions (24.0%), and G>C transversions (4.0%) were found in the codon 12 mutations."}, {"pubmed": 28846180, "text": "we showed that combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some non-small cell lung cancer cell lines regardless of KRAS mutations."}, {"pubmed": 28849118, "text": "these results suggest that aspirin inhibited human uterine leiomyoma cell growth by regulating KRasp110alpha interaction. Aspirin which targeting on interaction between K-Ras and p110alpha may serve as a new therapeutic drug for uterine leiomyoma treatment."}, {"pubmed": 28850092, "text": "while telomere length did not correlate with the presence of a mutation in BRAF (V-raf murine sarcoma viral oncogene homolog B), PIK3CA (phosphatidylinositol 3-kinase catalytic subunit), or MSI status, it was significantly associated with the occurrence of a mutation in KRAS"}, {"pubmed": 28853218, "text": "Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia."}, {"pubmed": 28858102, "text": "The current meta-analysis suggests that Codon 13 mutation of KRAS gene seems to correlate with the OS of patients with colorectal cancer, but has similar overall survival to those with KRAS wild-type in patients receiving anti-EGFR therapy"}, {"pubmed": 28859058, "text": "KRAS mutation is associated with response to therapy in rectal cancer."}, {"pubmed": 28863262, "text": "results thus provide the first detailed insight into the multiplicity, structure, and membrane organization of K-Ras homomers"}, {"pubmed": 28867179, "text": "These data indicate that RAGE plays a central role in maintaining inflammatory signaling in PDAC that benefits tumor growth."}, {"pubmed": 28867190, "text": "In conclusion, mutant KRAS promotes endosomal degradation in PDAC cell lines, which is impaired by KRAS silencing. Moreover, KRAS silencing activates RAB5A upregulation and drives PDAC subtype-dependent modulation of endosome trafficking."}, {"pubmed": 28873491, "text": "Despite the presence of histological findings indicating long-standing gastroesophageal reflux in 25%, as well as symptomatic gastroesophageal reflux in more than 40%, there was no detectable tissue expression of KRAS or BRAF mutations in adult patients treated for esophageal atresia in childhood."}, {"pubmed": 28879441, "text": "The presence of KRAS mutations did not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma."}, {"pubmed": 28885658, "text": "Circulating tumor DNA may serve as a viable alternative to tissue analysis for the detection of KRAS mutations in colorectal cancer"}, {"pubmed": 28890216, "text": "The presence of a mutation in KRAS is helpful in identifying a mucin-producing Pancreatic cyst and is found in more than 90% of Intraductal Papillary Mucinous Pancreas Neoplasms ."}, {"pubmed": 28899783, "text": "We show that the increased gefitinib sensitivity in cancer cells induced by DHHC20 inhibition is mediated directly through loss of palmitoylation on a previously identified cysteine residue in the C-terminal tail of EGFR."}, {"pubmed": 28901317, "text": "k-RAS gene mutation status was associated with the response of Gefitinib treatment in patients with nonsmall-cell lung cancer"}, {"pubmed": 28931048, "text": "High expression of KRAS is associated with cutaneous squamous cell carcinoma."}, {"pubmed": 28933585, "text": "this study identified a novel mechanism by which oncogenic RAS promotes survival of malignant intestinal epithelial cells. This mechanism is driven by RAS-dependent loss of ATG12 in these cells."}, {"pubmed": 28934759, "text": "KRAS mutation is associated with lung adenocarcinoma."}, {"pubmed": 28935015, "text": "The mutation rate of EGFR in stag I-IIIa NSCLC patients was lower than that in advanced NSCLC patients. And the percentage of the NSCLC patients with EGFR-KRAS double mutations is 0.9%."}, {"pubmed": 28936721, "text": "the resveratrol derivative did not affect the growth of HKe3 cell spheroids derived from HCT116 cells by disruption of the activating mutant KRAS gene. These results suggest that the resveratrol derivative inhibits the growth of HCT116 cell spheroids via inhibition of an oncogenic KRAS-mediated signaling pathway."}, {"pubmed": 28939768, "text": "Plasma membrane polyphosphoinositides depletion caused rapid translocation of K-Ras4B but not H-Ras from the plasma membrane to the Golgi."}, {"pubmed": 28951129, "text": "Ras inhibitor Kobe0065 prevents lung metastasis through inhibition of the Ras-PI3K-Akt-HIF-1alpha-LOX signaling."}, {"pubmed": 28953659, "text": "KRAS mutations were associated with Primary Pulmonary Enteric Adenocarcinomas. KRAS mutations occurred more frequently in Primary Pulmonary Enteric Adenocarcinomas , which are cytokeratin 7-negative (P=.032)."}, {"pubmed": 28953955, "text": "somatic KRAS mutations in polyps represent a potential molecular marker for the risk of developing advanced neoplasia"}, {"pubmed": 28956302, "text": "observed that the trend is highly correlative of the rate of change in KRAS mutant DNA concentrations and the period of monitoring"}, {"pubmed": 28967920, "text": "provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition"}, {"pubmed": 28984674, "text": "Report recurrent KRAS mutations in mesonephric-like adenocarcinomas of the ovaries/uterus best regarded as of Mullerian origin and representing adenocarcinomas which differentiate along mesonephric lines."}, {"pubmed": 29018205, "text": "the effects of NRP1 knockdown in cancer cells are dependent on the genetic status of KRAS."}, {"pubmed": 29024530, "text": "KRAS codon 12 mutations were detected in 23 of 30 fine-needle aspiration (FNA) specimens (77%) compared with 17 of 30 matched formalin-fixed, paraffin-embedded (FFPE) specimens (57%), for a concordance rate of 74%."}, {"pubmed": 29027536, "text": "Mutations in the KRAS gene are associated with invasiveness of implants and a poorer prognosis in patients with serous borderline tumor or atypical proliferative serous tumor."}, {"pubmed": 29059159, "text": "Wild-type KRAS expression promotes acquired resistance to BRAF inhibition in melanoma."}, {"pubmed": 29059173, "text": "High KRAS expression promotes invasion and metastasis of pancreatic ductal adenocarcinoma."}, {"pubmed": 29061646, "text": "KRAS mutation is associated with suppressed Th1/cytotoxic immunity in colorectal cancer, the extent of the effect being modulated by CMS subtype. These results add a novel immunobiological dimension to the biological heterogeneity of colorectal cancer."}, {"pubmed": 29066722, "text": "BCL-XL has a role in modulating RAS signalling to favor breast cancer cell stemness"}, {"pubmed": 29068469, "text": "The HSF1-BAG3-Mcl-1 signal axis is critical for protection of mutant KRAS colon cancer cells from AUY922-induced apoptosis."}, {"pubmed": 29093617, "text": "Digital droplet PCR reliably detects KRAS G12D mutations in stool-derived DNA from colorectal cancer patients, especially at early stages."}, {"pubmed": 29103024, "text": "Data indicate that absence of KRAS, TP53 and SMAD4 genetic alterations may identify a subset of pancreatic carcinomas with better outcome."}, {"pubmed": 29103773, "text": "KRAS mutation was significantly associated with tumor size"}, {"pubmed": 29104111, "text": "This study confirms the tumor suppressor roles of miR-193a-3p, its downstream target affinity to KRAS and clinical significance in patients with colorectal adenocarcinoma."}, {"pubmed": 29104470, "text": "Expression of Ki-67, p53 and K-ras in the intestinal mucosa was detected by immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR), respectively. 1.03% patients (n = 7) underwent polypectomy was confirmed to be the early stage of Colorectal cancer (CRC). Histological analysis for expression of p53 and K-ras can guarantee to screen the early stage of CRC."}, {"pubmed": 29110857, "text": "Programmed cell death 1 ligand 1 protein (PD-L1) expression significantly correlates with overall mutational load and KRAS protein mutational status in pulmonary sarcomatoid carcinomas."}, {"pubmed": 29112457, "text": "FOSL1 is a determinant of lung cancer in vivo and regulates tumor cell proliferation and survival, largely in the context of KRAS mutations through amphiregulin and cell survival gene regulation."}, {"pubmed": 29116623, "text": "KRAS mutations with Microsatellite Instability is associated with Gastric Cancer."}, {"pubmed": 29175303, "text": "Tumor cell content was not associated with mutational rate for EGFR, BRAF and HER2 mutations. DNA quantity was not associated with mutational rate for EGFR, KRAS, BRAF and HER2"}, {"pubmed": 29185262, "text": "KRAS mutations were predominant in non-Squamous cell carcinomas of the cervix and were associated with HPV 18 infection. A combination of KRAS mutation detection and HPV genotyping would be useful in identifying patient with poor prognosis for further interventions."}, {"pubmed": 29185849, "text": "RAS ubiquitylation modulates effector interactions."}, {"pubmed": 29187496, "text": "Mucinous cyst neoplasms (MCNs) more frequently have KRAS mutations and higher risk of malignant progression."}, {"pubmed": 29194647, "text": "Authors analyzed 421 samples from CLM patients for their all-RAS mutation status to compare the overall survival rate (OS), recurrence-free survival rate (RFS), and the pattern of recurrence between the patients with and without RAS mutations."}, {"pubmed": 29199977, "text": "The G12A mutation reduces intrinsic K-Ras GTP hydrolysis by an unexplained mechanism.Study reports crystal structures of G12A K-Ras in complex with GDP, GTP, GTPgammaS and GppNHp, and of Q61A K-Ras in complex with GDP, G12A K-Ras-GTP complex, the switch I region undergoes a significant reorganization such that the Tyr32 side chain points towards the GTP-binding pocket and forms a hydrogen bond to the GTP gamma-phosphate."}, {"pubmed": 29200129, "text": "Of 106 KRAS protein (KRAS) mutations detected in 171 pancreatic juice samples, 58 were detected in the 5-minute samples, 70 mutations were detected in the 10-minute samples, and 65 were detected in the 15-minute samples."}, {"pubmed": 29203670, "text": "These data reveal previously unknown genomic diversity among KrasG12D-initiated GEMM tumors, places them in context of human patients, and demonstrates how to exploit this inherent tumor heterogeneity to discover therapeutic vulnerabilities."}, {"pubmed": 29207158, "text": "Results reveal that KRAS 3'UTR is a target for miR-19a which overexpression suppresses KRAS expression thus inhibiting angiogenesis in colorectal cancer."}, {"pubmed": 29223986, "text": "KRAS mutations were only associated with risk of death."}, {"pubmed": 29229669, "text": "RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in human cancer. With a near 100% KRAS mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. [review]"}, {"pubmed": 29235861, "text": "observations add to a body of evidence suggesting that HRAS and KRAS show meaningful differences in functionality stemming from differential protein dynamics independent of the hypervariable region"}, {"pubmed": 29239694, "text": "A novel prenyl-polybasic domain code determines lipid-binding specificity of the K-Ras membrane anchor."}, {"pubmed": 29239724, "text": "The authors report that one of the K-Ras splice variants, K-Ras4a, is subject to lysine fatty acylation, a previously under-studied protein post-translational modification. Sirtuin 2 (SIRT2), one of the mammalian nicotinamide adenine dinucleotide (NAD)-dependent lysine deacylases, catalyzes the removal of fatty acylation from K-Ras4a."}, {"pubmed": 29240583, "text": "Cecal adenocarcinomas are characterized by a high frequency of KRAS mutations compared with noncecal right colon tumors, frequently display high tumor budding, and this may be a prognostically relevant variable, particularly in patients with stage III or IV disease."}, {"pubmed": 29241739, "text": "G12D and G12C mutations in the KRAS gene are associated with cases of tubular apocrine adenoma (TAA)."}, {"pubmed": 29246442, "text": "RAS signaling can upregulate tumor cell PD-L1 expression through a mechanism involving increases in PD-L1 mRNA stability via modulation of the AU-rich element-binding protein tristetraprolin."}, {"pubmed": 29246726, "text": "the findings demonstrated that mutated K-ras promotes cathepsin L expression and plays a pivotal role in EMT of human lung cancer. The regulatory effect of IR-induced cathepsin L on lung cancer invasion and migration was partially attributed to the Cathepsin L /CUX1-mediated EMT signaling pathway"}, {"pubmed": 29263151, "text": "The role of KRAS oncogenic signaling in cancer cells.[review]"}, {"pubmed": 29273082, "text": "a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary"}, {"pubmed": 29278425, "text": "Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes (IDH, KRAS, TP53) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols."}, {"pubmed": 29282362, "text": "This study provides evidence that germline polymorphisms in VEGFR1, KRAS and ITGAV genes are associated with prognosis in stages II-III colon cancer patients. As stage and tumor location are correlated with prognosis, future genetic studies should stratify colon cancer patients according to these parameters."}, {"pubmed": 29286585, "text": "Our data provide evidence that blocking TfR could significantly inhibit lung adenocarcinoma (LAC) proliferation by targeting the oncogene KRAS; therefore, TfR may be a therapeutic target for LAC. In addition, our results suggest a new method for blocking the signal from the oncogene KRAS by targeting TfR in LAC."}, {"pubmed": 29298116, "text": "We identified activating KRAS mutations in the majority of tissue samples of arteriovenous malformations of the brain that we analyzed. We propose that these malformations develop as a result of KRAS-induced activation of the MAPK-ERK signaling pathway in brain endothelial cells."}, {"pubmed": 29303908, "text": "Data show no patient positive for KRAS mutation and/or p53 mutation was found to have malignant transformation, suggesting detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas."}, {"pubmed": 29309301, "text": "MDM2 amplification in large-duct intrahepatic cholangiocarcinomas is more common than presently considered, and it may represent a unique biliary carcinogenetic process in which KRAS and TP53 mutations are less frequent."}, {"pubmed": 29315556, "text": "our studies demonstrate how KRAS inhibits the tumor suppressor RKIP, thus offering novel justification for targeting RKIP as a strategy to overcome KRAS-induced tumor metastasis and chemoresistance in PDAC."}, {"pubmed": 29321082, "text": "High KRAS expression is associated with Bladder Cancer."}, {"pubmed": 29321164, "text": "Kras protein expression is controlled by a self-regulating feedforward mechanism mediated by eIF5A-PEAK1.Kras protein level is increased during pancreatic ductal adenocarcinoma progression with the highest levels of expression observed in metastatic cell populations."}, {"pubmed": 29329159, "text": "Increased long noncoding RNA HomeoboxA transcript at the distal tip (HOTTIP) expression was associated with poor prognosis independent of KRAS mutation."}, {"pubmed": 29335867, "text": "Identification of KRAS/NRAS/BRAF mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer."}, {"pubmed": 29336889, "text": "studies provide mechanistic and biological insights into the role of KRAS dimerization and highlight a role for disruption of dimerization as a therapeutic strategy for KRAS mutant cancers."}, {"pubmed": 29343688, "text": "Inhibition of Wee1 by its specific inhibitor MK1775 in combination with sorafenib restored the KRAS mutated cells' response to the multi-target tyrosine kinase inhibitor."}, {"pubmed": 29357287, "text": "Fluorescence cross-correlation data indicate no direct interaction between C6-ceramide and KRas4B, suggesting that KRas4B essentially recruits other lipids. A FRET-based binding assay reveals that the stability of KRas4B proteins inserted into the membrane containing C6-ceramide is reduced."}, {"pubmed": 29358307, "text": "the present study demonstrates that miR-422a may serve as a tumor suppressor in osteosarcoma via inhibiting BCL2L2 and KRAS translation both in vitro and in vivo Therefore, miR-422a could be developed as a novel therapeutic target in osteosarcoma."}, {"pubmed": 29360815, "text": "Post-operative mutations in the KRAS gene identified in cell-free DNA from pancreatic ductal adenocarcinoma patients are associated with significantly earlier recurrence and shorter disease-free survival."}, {"pubmed": 29364867, "text": "Human and mouse studies reveal that different gene dosages of an activating KRAS mutation are critical determinants of pancreatic cancer biology, including early progression, metastasis, histopathology, cellular plasticity and clinical aggressiveness."}, {"pubmed": 29371474, "text": "Plasma KRAS mutations were detected in 5/17 (29.4%) patients. KRAS ctDNA detection was associated with shorter survival (8 vs. 37.5 months)."}, {"pubmed": 29413054, "text": "Results highlight the differential expression of K-RAS4A and K-RAS4B in advanced adenocarcinoma NSCLC patients and underline the need to further clarify the enigma behind their biological significance in various cancer types, including NSCLC."}, {"pubmed": 29444439, "text": "two major subtypes of KRAS mutant cancers of the lung, pancreas, and large intestine, which reflect different KRAS effector engagement were identified."}, {"pubmed": 29445180, "text": "show that mutant KRAS facilitates IKKalpha-mediated responsiveness of tumor cells to host IL-1beta, thereby establishing a host-to-tumor signaling circuit that culminates in inflammatory MPE development and drug resistance"}, {"pubmed": 29453361, "text": "Mutations that confer resistance in cancer are even less likely to occur downstream of KRAS than to occur within KRAS."}, {"pubmed": 29454587, "text": "The results indicate that lung cancer patients carrying KRAS mutations are prone to multiple metastases in both lungs."}, {"pubmed": 29489023, "text": "Copy number gains were seen in EGFR (two of 23, 13.0%) and in one (4.3%) of each PIK3CA, KRAS, MET and STK11"}, {"pubmed": 29495114, "text": "High KRAS expression is associated with melanoma."}, {"pubmed": 29504894, "text": "A report of the possible use of abundance measures for K-Ras4A for predicting the survival of lung adenocarcinoma patients with KRAS mutations."}, {"pubmed": 29514096, "text": "Sirt5 inhibitors in combination with chemotherapeutic agents and/or cetuximab may represent a therapeutic strategy for colorectal cancer patients harboring wild-type Kras."}, {"pubmed": 29518181, "text": "Study in Norwegian cohort of primary colorectal cancer patients revealed that BRAFV600E mutations are enriched and associated with metastatic disease in consensus molecular subtype-1 (CMS1) microsatellite stable (MSS) tumors, leading to poor prognosis in this subtype. KRAS mutations are associated with adverse outcome in epithelial (CMS2/CMS3) MSS tumors."}, {"pubmed": 29526175, "text": "CFTR exhibited an inhibitory role in the malignancy of lung adenocarcinoma A549 cells"}, {"pubmed": 29547736, "text": "In addition, 6 other cancer-associated genes (BRAF, NRAS, HRAS, ERK1, ERK2 and PTEN) were also analyzed. In total, four somatic mutations were identified in three out of 101 ovarian endometriotic lesions (4%, 4/101), including a KRAS p.G12V, a PPP2R1A p.S256F and two ARID1A nonsense mutations (p.Q403* and p.G1926*); while no mutations were identified in the remaining 7 genes (BRAF, NRAS, HRAS, ERK1, ERK2, PTEN and PIK3CA)"}, {"pubmed": 29553850, "text": "MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance"}, {"pubmed": 29556349, "text": "Six mutations located at the BRAF, KRAS, and PIK3CA genes have been detected in colorectal cancer patients using a novel multiplex surface enhanced Raman spectroscopy-multiplex PCR method."}, {"pubmed": 29559746, "text": "Mutant KRAS is associated with liver metastasis of colorectal cancer."}, {"pubmed": 29567812, "text": "We find that most JAK2 mutations, some TP53 mutations, and rare KRAS mutations detected in cfDNA are derived from clonal hematopoiesis, CH not tumor. Clinicians ordering plasma genotyping must be prepared for the possibility that mutations detected in plasma, particularly in genes mutated in CH, may not represent true tumor genotype."}, {"pubmed": 29588349, "text": "An actionable requirement for IKKalpha in KRAS-mutant lung adenocarcinoma."}, {"pubmed": 29604100, "text": "The results suggest that somatic mutation of hotspot KRAS in codons 12 and 13 is rare in endometriosis, including cases of deep infiltrating endometriosis (DIE) in Korean patients."}, {"pubmed": 29610327, "text": "Proteoforms with or without the Gly13Asp mutation (G13D) in the KRAS4b isoform were studied in isogenic KRAS colorectal cancer (CRC) cell lines and patient CRC tumors with matching KRAS genotypes. In 2 cellular models, a direct link between knockout of the mutant G13D allele and complete nitrosylation of cysteine 118 of the remaining WT KRAS4b was observed. Major differences in C-terminal carboxymethylation were seen."}, {"pubmed": 29642912, "text": "High metabolic tumor volume is associated with KRAS mutation and poor postoperative outcomes in patients with intrahepatic cholangiocarcinoma."}, {"pubmed": 29644616, "text": "Pesticide exposure may play a great role in malignant transformation of urinary bladder cells through mutation in the K-ras gene."}, {"pubmed": 29658609, "text": "These findings collectively suggest that the triple combination of survivin knockdown with ABT-263 and trametinib treatment, may be a potential strategy for the treatment of KRAS-mutant lung adenocarcinoma. Furthermore, our findings indicate that the welldifferentiated type of KRAS-mutant lung tumors depends, at least in part, on TTF1 for growth."}, {"pubmed": 29662194, "text": "Targeting EGFR ligands may benefit patients who carry EGFR-mutant lung tumors but will not benefit patients with KRAS-mutant lung tumors."}, {"pubmed": 29666387, "text": "This study found \"rare mutations\" in RAS genes in nearly 14% of colorectal cancer (CRC) -i.e., in almost a quarter (24.0%) of KRAS exon 2 wild type CRCs, including 2.3% in KRAS exon 3, 8.2% in KRAS exon 4 and 3.4% in NRAS. Stage I-III patients with PIK3CA or NRAS mutations developed more distant metastases (3-year risk in PIK3CA mutated and wild type patients: 23.3% vs 11.5%, P = 0.03."}, {"pubmed": 29704996, "text": "Mutations in both the p53 tumor suppressor gene and K-ras oncogene are highly frequent in lung tumors from nonsmoking women in China. The predominance of G-->T transversions in both genes and the occurrence of p53 mutations within a specific GC rich region or at specific hotspot codons on the non-transcribed strand are consistent with exposure to smoky coal emissions."}, {"pubmed": 29706533, "text": "Results show that K-Ras has a more substantial population of state 1 in solution than H-Ras, which predominantly favors state 2. The oncogenic mutant K-RasG12D favors state 2, changing the balance of conformational states in favor of interactions with effector proteins."}, {"pubmed": 29715099, "text": "The high incidence of KRAS mutations in papillary mucinous metaplasia suggests that papillary mucinous metaplasia may be a precancerous lesion of a certain subset of mucinous carcinomas of the endometrium"}, {"pubmed": 29715113, "text": "The present case series suggests that the incidence of concomitant KRAS/BRAF mutations in patients with surgically treated colorectal liver metastasis may be higher than previously hypothesized, and associated with more variable survival outcomes than expected."}, {"pubmed": 29739790, "text": "Patients with KRAS exon 2 wild-type (WT) mCRC following failure of fluoropyrimidine-based therapy received i.v. irinotecan and panitumumab every 2 weeks, and everolimus orally throughout a 14-day cycle. The primary endpoint of the phase II study was response rate (RR). Secondary survival outcomes were calculated using the Kaplan-Meier method, and results were analyzed as intention to treat."}, {"pubmed": 29743592, "text": "Proscillaridin A as a selective inhibitor of cells harboring the oncogenic KRas(G12V) allele."}, {"pubmed": 29745066, "text": "Tumor location has been proposed as an additional prognostic indicator and -more recently- as a factor with significant influence on the prognostic value of particular molecular markers and/or combination of markers (KRAS, MSI, APC/MSI), allowing the discrimination of specific disease subsets with considerably disparate outcome and the identification of high risk cases"}, {"pubmed": 29748135, "text": "deletion of the oncogenic KRAS allele resulted in enhanced STIM1 expression and greater Ca(2+) influx."}, {"pubmed": 29755130, "text": "Inhibition of aurora kinases preferentially kills mutant KRAS CRC cells and overcomes KRAS-mediated resistance to anti-EGFR antibodies in vitro and in vivo by restoring PUMA induction."}, {"pubmed": 29756386, "text": "KRAS mutation G12D induces protumerogenic phenotype in macrophages and neoplastic structural and phenotypic changes in pancreatic organoids"}, {"pubmed": 29764594, "text": "KRAS is one of the most common mutations in Non-small cell lung cancer. [review]"}, {"pubmed": 29786130, "text": "KRAS Mutation is associated with Recurrence in Colorectal Cancer Liver Metastases."}, {"pubmed": 29796909, "text": "In a cohort of patients with pancreatic cysts, KRAS and GNAS mutations had no significant diagnostic benefit in comparison with conventional testing."}, {"pubmed": 29808006, "text": "SHP2 inhibition is an unexpected vulnerability of KRAS-mutant non-small-cell lung cancer cells."}, {"pubmed": 29851957, "text": "KRAS mutation is associated with pancreatic cancer."}, {"pubmed": 29858030, "text": "KRAS mutational status can affect the immune microenvironment and survival of lung adenocarcinoma patients"}, {"pubmed": 29896883, "text": "This study investigated a bypass mechanism of resistance to MEK inhibition in KRAS colorectal cancer (CRC). KRAS mutant colorectal cancer cells with refametinib, MEK inhibitor, induced MIF secretion and resulted in activation of STAT3 and MAPK."}, {"pubmed": 29898991, "text": "Although patients with baseline ctDNA RAS mutations had worse outcomes than patients who were WT RAS before initiating treatment, emergent ctDNA RAS mutations were not associated with less favorable patient outcomes in panitumumab-treated patients."}, {"pubmed": 29907857, "text": "Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations."}, {"pubmed": 29908105, "text": "Mutation frequencies in KRAS exon 3 or 4, NRAS, BRAF, and PIK3CA were 5.5%, 2.7%, 8.3%, and 5.5%, respectively."}, {"pubmed": 29912950, "text": "These data highlight that MAPK7 represents a promising target for combination treatment with MEK inhibition in KRAS mutant Non Small Cell Lung Carcinoma."}, {"pubmed": 29921458, "text": "KRAS and NRAS gene mutations are associated with sporadic colorectal cancer."}, {"pubmed": 29937183, "text": "KRAS mutations are associated with colorectal liver metastases."}, {"pubmed": 29945997, "text": "Our preclinical study supports further clinical evaluation of combined MEK inhibition and chemotherapy for lung cancer patients harboring KRAS (G12C) and wild-type p53 status."}, {"pubmed": 29948303, "text": "Colorectal tumors with multiple pit patterns exhibited more advanced pit patterns and higher frequencies of KRAS and/or TP53 mutations than tumors with a single pit pattern"}, {"pubmed": 29956571, "text": "Inhibition of either autophagy or asparagine synthetase reduced KRAS(G12V)-driven tumor cell proliferation, migration, and invasion."}, {"pubmed": 29974407, "text": "The frequency of KRAS mutations was significantly higher in Serrated Lesions subgroups with low and intermediate methylated epigenotype tumors and microsatellite stability."}, {"pubmed": 30013058, "text": "GATAD2B interacts with C-MYC to enhance KRAS driven tumor growth."}, {"pubmed": 30018674, "text": "in Stage I colorectal cancer presence of KRAS mutations, that of simultaneous mutations in PIK3CA gene, or that of multiple KRAS mutations was significantly associated with shorter cancer specific survival; PIK3CA or multiple KRAS mutations were associated with nodal micrometastases and poorly differentiated clusters G3 as well"}, {"pubmed": 30037374, "text": "characteristics of the expression of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) in non-small cell lung cancer"}, {"pubmed": 30047791, "text": "PPARgamma activator, pioglitazone, can activate p21, which is associated with decreased proliferation in 2 aerodigestive preneoplastic cell lines. In addition, the p21 gene may be a potential hypothesis-driven biomarker in translational studies of pioglitazone as a chemoprevention agent for aerodigestive cancer."}, {"pubmed": 30048458, "text": "Mutations of KRAS and DDR2 were found in large cell carcinoma (LCC) and squamous cell carcinoma (SCC) subtypes, respectively, whereas mutations of TP53 were seen in SCC and lung adenocarcinoma subtypes with higher frequencies and LCC subtype with lower frequency in Iranian patients."}, {"pubmed": 30068711, "text": "The LKB1 mutation in KRAS-mutant NSCLC conferred enhanced radiosensitization in combination with trametinib. The WT LKB1 could activate autophagy through AMPK pathway to induce resistance to the combination of trametinib and radiation."}, {"pubmed": 30072474, "text": "Using patient-derived cell line and xenografts, we characterize the mechanism of crizotinib resistance mediated by KRAS amplification in METex14-mutant NSCLC and demonstrate the superior efficacy of the dual MET/PI3K inhibition as a therapeutic strategy addressing this resistance mechanism."}, {"pubmed": 30089886, "text": "That CRISPR-Cas9-mediated genome editing can potentially be used for the treatment of cancer patients, specifically those with oncogenic KRAS mutations."}, {"pubmed": 30104206, "text": "The present study shows that the regulation of KRAS expression by IMP1 is complex and may involve both the IMP1 protein and its mRNA transcript."}, {"pubmed": 30104724, "text": "SHP2 has a critical function in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS."}, {"pubmed": 30110635, "text": "KRAS is frequently mutated in endometriotic epithelium, with a higher mutant allele frequency accompanied by arm-level allelic imbalances."}, {"pubmed": 30121958, "text": "Data suggest that Kirsten Ras protein (KRAS) has prognostic value beyond mutation status in microsatellite stable (MSS) colorectal cancer (CRC)."}, {"pubmed": 30130254, "text": "results demonstrated that O-GlcNAcylation was sufficient and required to accelerate KrasG12D lung tumorigenesis in vivo, which was reinforced by epithelial plasticity programs."}, {"pubmed": 30158525, "text": "Activation of Src might prove effective in treating EGFR/wild-type KRAS colon cancer."}, {"pubmed": 30171261, "text": "These results pinpoint mTOR as a mechanism of resistance to chemotherapy in KRAS-mutant lung cancer and validate a rational and readily translatable strategy that combines mTOR inhibitors with standard chemotherapy to treat KRAS-mutant adenocarcinoma, the most common and deadliest lung cancer subset."}, {"pubmed": 30192821, "text": "We conclude that if transfer of functional K-Ras from extracellular vesicles into the cytoplasm of recipient cells occurs, it must do so at an extremely low efficiency and therefore is unlikely to initiate Ras-ERK MAP kinase pathway signaling. These results suggest that studies claiming functional transfer of protein cargoes from exosomes should be interpreted with caution."}, {"pubmed": 30194290, "text": "PIP5K1A loss reduces oncogenic KRAS signaling."}, {"pubmed": 30194935, "text": "RAS mutations in acute myeloid leukaemia patients"}, {"pubmed": 30199395, "text": "finding of 5 mutations in RAS-expanded genes allowed us to understand the resistance to cetuximab in 33% of KRAS WT exon 2 nonresponder patients. HER2 does not seem to be a potential biomarker for cetuximab-targeted therapy."}, {"pubmed": 30199525, "text": "molecular dynamics simulation of mutation probabilities of KRAS G12 missense mutants"}, {"pubmed": 30220122, "text": "The high frequency of KRAS mutation in endometrial atypical hyperplasia with mucinous differentiation, endometrioid carcinoma with mucinous differentiation and mucinous carcinoma indicates that KRAS mutational activation is implicated in the pathogenesis of endometrial mucinous carcinoma."}, {"pubmed": 30223391, "text": "A non to light smoking habit might contribute to an improvement in prognosis that is equivalent to that of wild-type KRAS, and p53 mutation did not affect survival in smokers harboring KRAS codon 12."}, {"pubmed": 30227250, "text": "Results show mutation in Kras was associated with worse survival results in patients with pancreatic neoplasm. [review]"}, {"pubmed": 30228186, "text": "studies strongly suggest that posttranslational modification(s), including sumoylation mediated by Lys-42, plays a crucial role in K-Ras activities in vivo."}, {"pubmed": 30228208, "text": "Our study demonstrates that [(89)Zr]Zr-Tf is a valuable tool to noninvasively assess oncogene status and target engagement of small-molecule inhibitors downstream of oncogenic KRAS, allowing a quantitative assessment of drug delivery."}, {"pubmed": 30252186, "text": "Despite affecting an identical amino acid in both KARS isoforms, results show that the disease-causing variant p.(Pro228Leu) inhibits specifically mitochondrial, but not cytosolic, translation."}, {"pubmed": 30275015, "text": "KRAS rare codons inhibit both translation efficiency and transcription.  Common codons increase transcriptional rates.  Codon usage can affect KRAS protein conformation."}, {"pubmed": 30276588, "text": "The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases."}, {"pubmed": 30281903, "text": "HIC-5 regulates mitochondrial ROS production in tumor cells while requiring activated KRAS to mediate its effect on NOX4 in oncogene-induced senescence and tumor invasiveness."}, {"pubmed": 30282804, "text": "RRSP is a critical virulence factor that robustly inactivates Ras and Rap1 and augments the pathogenicity of invading bacteria via the combined effects of its N and C lobes."}, {"pubmed": 30294831, "text": "KRAS mutation at codon 12 and the presence of MAPK/ERK pathway proteins were detected suggesting their association with tumorigenesis of adenomatoid odontogenic tumors."}, {"pubmed": 30303876, "text": "Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin."}, {"pubmed": 30306823, "text": "We observed that the designed ss-miR-216b mimics engaged AGO2 to promote the silencing of KRAS. We also tested a new delivery strategy based on the use of palmityl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with ss-miR-216b conjugated with two palmityl chains and a lipid-modified cell penetrating peptide . These versatile nanoparticles suppressed oncogenic KRAS in pancreatic ductal adenocarcinoma cells"}, {"pubmed": 30322949, "text": "Results provide evidence that KRAS and EGFR gene amplifications mediate resistance to the third-generation EGFR TKIs rociletinib and osimertinibin acquired Afatinib-resistant non-small cell lung cancer harboring exon 19 deletion/T790M in EGFR."}, {"pubmed": 30347501, "text": "Targeted degradation of the KRAS oncoprotein through the ODC/AZ pathway at the post-translational level may reflect a more effective future therapeutic strategy for pancreatic cancer patients"}, {"pubmed": 30352902, "text": "KRAS mutation is a recurrent mechanism of primary and secondary resistance to MET tyrosine kinase inhibitors in METex14 lung cancers."}, {"pubmed": 30353028, "text": "the expression of KRAS G12V expression did not change Yap/Taz activity in myoblasts and there was a limited overlap in gene expression between KRAS G12V and YAP1 S127A-driven tumours."}, {"pubmed": 30361395, "text": "Letter: PIK3CA mutation, in particular, mutation of exon 9, has a significant positive association with KRAS mutation in colorectal cancer."}, {"pubmed": 30368666, "text": "There was a high accordance between KRAS mutation status in EBC-DNA and cancer tissue in NSCLC patients what suggests usefulness of monitoring KRAS mutation in EBC-DNA as a biomarker of NSCLC"}, {"pubmed": 30377342, "text": "Nivolumab is an effective and safe treatment option for patients with previously treated, advanced non-squamous non-small-cell lung cancer regardless of KRAS mutations."}, {"pubmed": 30385747, "text": "Gain-of-function mutations in KRAS, FGFR1, and TRPV4 are present in 72% of giant cell lesions of the jaw (GCLJ). TRPV4 mutations induce sustained activation of ERK1/2, indicating that their effects converge with that of KRAS and FGFR1 mutations on the activation of the MAPK pathway in GCLJ."}, {"pubmed": 30389925, "text": "These data underscore a critical sex-specific role for epithelial Stat3 signaling in K-ras mutant Lung adenocarcinomas."}, {"pubmed": 30394984, "text": "No young-age colorectal cancer patients contained a BRAF mutation compared with 46 (10.6%) of 434 in older-age cancer patients (p < 0.001). KRAS mutations were less common in young cancers compared with older cancers (13/57 (22.8%) vs 126/410 (30.7%); p < 0.01). Eleven (19.3%) of 57 young cancers were proximal compared with 228 (51.8%) of 440 (p < 0.001) older cancers."}, {"pubmed": 30401716, "text": "Full-length EGFR and truncated EGFRvIII work through KRAS to upregulate the chemokine CCL2 and drive macrophage infiltration in glioblastoma"}, {"pubmed": 30409919, "text": "Authors demonstrated that enforced PCDH7 expression significantly accelerates Kras(G12D) -driven lung tumorigenesis and potentiates MAPK pathway activation."}, {"pubmed": 30413483, "text": "The coregulation of beta-catenin and RAS stabilities by the modulation of their interaction provides a mechanism for Wnt/beta-catenin and RAS-ERK pathway cross-talk and the synergistic transformation of colorectal cancer by both APC and KRAS mutations."}, {"pubmed": 30414169, "text": "The authors found KRAS exon 2 and BRAF(V600E) mutation rates were 37.7 and 2.8% in colorectal cancer patients. Tumors with KRAS exon 2 mutations were more likely to be present in female and patients aged older than 75 years, right colon and have well-differentiated histology. Tumors with BRAF(V600E) mutations were more likely to be present in the female, right colon and have poorly differentiated histology."}, {"pubmed": 30415007, "text": "A potential avenue for therapeutic treatment of KRAS-mutant cancers which are otherwise difficult targeted by small molecules."}, {"pubmed": 30443000, "text": "Postzygotic KRAS mutation is associated with Schimmelpenning syndrome presenting with lipomatosis, renovascular hypertension, and diabetes mellitus."}, {"pubmed": 30466782, "text": "prolonged MAPK pathway inhibition could result in acquired resistance which is associated with increased malignant phenotype in KRAS mutant gastric cancer."}, {"pubmed": 30467381, "text": "Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis"}, {"pubmed": 30470748, "text": "KRAS promotes these effects by activating a MAPK-dependent signaling pathway leading to MYC upregulation and transcription of the non-oxidative pentose phosphate pathway (PPP) gene RPIA, which results in nucleotide biosynthesis."}, {"pubmed": 30475204, "text": "A dual specificity phosphatase, DUSP6, that negatively regulates phosphorylation of (P)-ERK is up-regulated in EGFR- or KRAS-mutant lung adenocarcinoma (LUAD), potentially protecting cells with mutations in the RAS signaling pathway, a proposal supported by experiments with DUSP6-specific siRNA and an inhibitory drug"}, {"pubmed": 30514331, "text": "Authors demonstrate that co-occurring KRAS mutation/LKB1 loss in NSCLC cells allowed efficient exploitation of glycolysis and oxidative phosphorylation, when compared to cells with each single oncologic genotype."}, {"pubmed": 30535502, "text": "the data indicated that the miR1433p/kRas/Raf/MEK/ERK axis serves a key regulator in the development and progression of laryngeal squamous cell carcinoma (LSCC), suggesting that miR1433p may be a potential prognostic biomarker and therapeutic target in the treatment of LSCC"}, {"pubmed": 30544177, "text": "findings support a causative role of somatic tumour-related mutations of KRAS/BRAF in the overwhelming majority of brain and spinal arteriovenous malformations."}, {"pubmed": 30549028, "text": "The findings strongly suggest that pathogenic hotspot KRAS, FGFR1 and NF1 mutations underlie the vast majority of non-ossifying fibroma of the bone."}, {"pubmed": 30553812, "text": "we found that BLT2, a cell surface GPCR for leukotriene B4 and 12hydroxyeicosatetraenoic acid, is highly upregulated in KRAS mutant LOVO and SW480 colorectal cancer cells and plays critical roles in mediating proliferation through activation of phosphatidylinositol 3kinase (PI3K)/protein kinase B (Akt) and subsequent upregulation of cyclin D1."}, {"pubmed": 30559287, "text": "KRAS-membrane interaction is tuned by multiple factors"}, {"pubmed": 30562355, "text": "introducing a rapid and sensitive microarray-based assay for the multiplex detection of minority mutations of oncogenes (KRAS, NRAS and BRAF) with relevant diagnostics implications in tissue biopsies and plasma samples in metastatic colorectal cancer patients"}, {"pubmed": 30563891, "text": "Findings highlight the prognostic significance of the transcriptional regulator Id1 in KRAS-mutant lung adenocarcinoma and provide mechanistic insight into how it controls tumor growth and metastasis."}, {"pubmed": 30591192, "text": "Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India."}, {"pubmed": 30599853, "text": "Associations have been identified between radiological features and clinical features with Epidermal Growth Factor Receptor (EGFR)/ Kirsten RAt Sarcoma (KRAS) alterations in an independent group of patients with Non-Small Cell Lung Cancer (NSCLC)."}, {"pubmed": 30605727, "text": "KRAS-mutated NSCLC represents a genetically heterogeneous subgroup with a high frequency of co-occurring mutations in cancer-associated pathways, partly associated with distinct KRAS mutation subtypes."}, {"pubmed": 30611220, "text": "Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and possibly reflecting precancerous lesions in other regions of the pancreas. The inclusion of TP53 mutation detection and additional markers must therefore be considered for fully exploiting the clinical potential of pancreatic juice samples in early cancer detection"}, {"pubmed": 30635874, "text": "Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability."}, {"pubmed": 30637861, "text": "Diffusion kurtosis imaging-derived histogram metrics for prediction of KRAS mutation in rectal adenocarcinoma: Preliminary findings."}, {"pubmed": 30638176, "text": "Results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival."}, {"pubmed": 30643167, "text": "a high proportion of adenomatoid odontogenic tumors (27/38, 71%) have KRAS codon 12 mutations"}, {"pubmed": 30644389, "text": "SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle."}, {"pubmed": 30656741, "text": "Targeting the KRAS, p38alpha, and NF-kappaB in lung adenocarcinoma cancer cells has been reported."}, {"pubmed": 30664964, "text": "Kras(G12D) mutation plays a critical role in Treg conversion and contributes to an immunosuppressive tumour microenvironment in pancreatic cancer."}, {"pubmed": 30674639, "text": "Results indicate that oncogene addiction can be targeted for therapy in colon cancer cells harboring the KRAS-mutant."}, {"pubmed": 30676672, "text": "KRAS hotspot mutations remain a rare event in diffuse gliomas. Targeted screening of oligodendrogliomas for KRAS mutations does not provide additional diagnostic benefit in clinical practice."}, {"pubmed": 30678452, "text": "No significant differences were found in the frequency of TP53 and K-ras mutations among patients in the 5 countries."}, {"pubmed": 30680933, "text": "HIC-5 regulates mitochondrial ROS production in tumor cells while requiring activated KRAS to mediate its effect on NOX4 in oncogene-induced senescence and tumor invasiveness."}, {"pubmed": 30683863, "text": "Memory T cells targeting oncogenic mutations in KRAS, SMAD5, and MUC4 detected in peripheral blood of colon cancer patients have been isolated."}, {"pubmed": 30689692, "text": "Response rate (RR), progression-free survival (PFS) and overall survival (OS) were increasingly improved in patients with RAS wild-type, RAS/BRAF wild-type or quadruple (KRAS/NRAS/BRAF/PIK3CA) wild-type tumours treated with anti-EGFR, assessed by standard-of-care."}, {"pubmed": 30709910, "text": "MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival."}, {"pubmed": 30711927, "text": "review of the role of KRAS in predicting transition from hyperplastic endometrium to early-stage well-differentiated endometrial cancer, as well as further invasive proliferation of the tumor to advanced-stage disease [review]"}, {"pubmed": 30720004, "text": "Combining clinical factors and COX-2/C-MET/KRAS expression status, our models provided accurate prognostic information in CRC. They can be used to aid treatment decisions in clinical practice."}, {"pubmed": 30739887, "text": "The aim of this study was to clarify the impact of KRAS mutations on prognosis in patients with stage I-III colorectal cancer"}, {"pubmed": 30760703, "text": "Ras overactivation switches the pattern of PDIA1-dependent Rac1/Nox1 regulation, so that Ras-induced PDIA1 bypass can directly activate Rac1. PDIA1 may be a crucial regulator of redox-dependent adaptive processes related to cancer progression."}, {"pubmed": 30791232, "text": "we confirmed that miR-487b is a CRC suppressor that prevents the EMT process and targets MYC, SUZ12, and KRAS to inhibit the proliferation, migration and invasion of CRC cells. Meanwhile, miR-487b is negatively regulated by DNA methylation"}, {"pubmed": 30809081, "text": "KRAS gene mutations do not affect downstream protein expression in colorectal cancer. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence."}, {"pubmed": 30824880, "text": "Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations."}, {"pubmed": 30833665, "text": "MEK nuclear localization promotes YAP stability via sequestering beta-TrCP in KRAS mutant cancer cells."}, {"pubmed": 30838710, "text": "aimed to elucidate the carcinogenic effects of insulin and the synergistic effect with the KRAS mutation in the early stage of pancreatic cancer through PI3K/AKT and ERK1/2 activation, with MMP-2 gelatinolytic activity playing a vital role in this process"}, {"pubmed": 30840064, "text": "Highly sensitive digital PCR detects low abundance KRAS mutations in colorectal cancer specimens for prediction of treatment outcome in phase 2 clinical trial of panitumumab plus FOLFIRI."}, {"pubmed": 30860980, "text": "These findings indicate that the rs12587 G>T polymorphism in KRAS is associated with increased Wilms tumor susceptibility; polymorphisms of NRAS did not influence the risk."}, {"pubmed": 30867319, "text": "MAPK signaling dependency in epithelial lung cancer cells is due to the scaffold protein interleukin-17 receptor D (IL17RD), which is directly repressed by ZEB1."}, {"pubmed": 30884019, "text": "The presence of KRAS mutations in parental tumours is associated with an acceleration of the growth rate of cultured tumoroids."}, {"pubmed": 30902772, "text": "KRAS mutations in codon35 were detected in about two thirds of specimens with brain arteriovenous malformations"}, {"pubmed": 30916792, "text": "Sinonasal inverted papilloma and sinonasal oncocytic papilloma are two clinical entities with different genetic mutational patterns of EGFR and KRAS. Mixed types with elements of both may harbour both EGFR and KRAS mutations."}, {"pubmed": 30917791, "text": "This study demonstrated that no significant difference of KRAS status between colon cancer and rectal cancer. KRAS mutation was much more frequent in right-sided colon cancer (RCC) compared with left-sided colon cancer (LCC) and LCC patients with KRAS mutation has a poor prognosis compared with KRAS wild type, but RCC patients did not show the similar effect."}, {"pubmed": 30927008, "text": "we used this to investigate mechanisms of cEt-ASO trafficking across a panel of cancer cells. We found that the extent of ASO-mediated KRAS mRNA knockdown varied significantly between cells and that this did not correlate with bulk levels of intracellular accumulation"}, {"pubmed": 30930112, "text": "hese findings indicated that this synthetic miR-143#12 induced a marked growth inhibition by impairing K-RAS-signaling networks in vitro and in vivo."}, {"pubmed": 30932013, "text": "The KRAS-variant and its impact on normal breast epithelial cell biology."}, {"pubmed": 30944457, "text": "beta-Catenin is a potent biomarker candidate for alleviating MEK inhibitor resistance in KRAS mutant colon cancer cells with PIK3CA mutations."}, {"pubmed": 30959742, "text": "These findings suggested that syn-miR-143 acted as a tumor suppressor through the impairment of KRAS networks including the DDX6."}, {"pubmed": 30971271, "text": "KRAS up-regulation is a promising strategy for lung cancer therapy."}, {"pubmed": 30979646, "text": "Patients with wtKRAS tumors appear to have the highest likelihood of experiencing a major response after preoperative chemotherapy.  Codon 13 mutations were independently associated with minor pathologic response."}, {"pubmed": 30987652, "text": "Our findings suggest that mutant K-Ras plays an oncogenic role through downregulating miR-199b in NSCLC and that overexpression of miR-199b is a novel strategy for the treatment of K-Ras-mutated NSCLC."}, {"pubmed": 30988000, "text": "we report a role for MEK-driven lactate production in mTORC1 activation in KRAS-activated cells. KRAS/MEK-induced upregulation of the chicken ovalbumin upstream promoter transcriptional factor II (COUP-TFII) increases the expression of lactate dehydrogenase A (LDHA), resulting in lactate production and mTORC1 activation."}, {"pubmed": 31021322, "text": "Even if the found, KRAS G12D mutation is predicted to be tolerated and has no deleterious effect on the entire Ras protein; the consequence of this missense mutation depends mainly on the position in the protein and the chemical properties of the amino acid involved in the substitution and which shows a strong affinity with the GTP molecule."}, {"pubmed": 31026472, "text": "KRAS mutations occur in almost one-third of brain arteriovenous malformations"}, {"pubmed": 31030485, "text": "KRAS mutation is associated with ovarian mucinous carcinoma."}, {"pubmed": 31036704, "text": "Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence."}, {"pubmed": 31037906, "text": "In colorectal cancer with K-ras gene mutation, the expression of TAK1 protein was positively correlated with the expression of MAP4K2 protein"}, {"pubmed": 31046123, "text": "Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression."}, {"pubmed": 31048689, "text": "Study in tumor cell lines shows that MEK1/2 inhibitors (MEKi) resistance driven by KRAS(G13D) amplification is not reversible; these cells do not exhibit growth defects upon MEKi withdrawal but undergo an ERK1/2-dependent epithelial-to-mesenchymal transition and exhibit resistance to commonly used chemotherapeutics."}, {"pubmed": 31054911, "text": "RAS/TP53 co-mutation was the only factor independently associated with increased risk of recurrence for all groups with resection of colorectal liver metastasis."}, {"pubmed": 31062740, "text": "Two patients harbored KRAS with codon 12 mutations; one harbored the gly12val mutation with a variation of leu597val in the BRAF exon 15 codon, the other harbored mutation in the BRAF exon 15 codon. One patient harbored a codon 117 mutation with a BRAF V600E mutation. The last patient harbored a NRAS exon 2 mutation with the GGT/GAT, V600G mutation in the BRAF exon 15 codon"}, {"pubmed": 31066120, "text": "Knockdown of MSI2 induced downregulation of KRAS, and overexpression of MSI2 upregulated KRAS without causing an increase in the level of KRAS mRNA in bladder cancer. These results indicated that MSI2 post-transcriptionally regulated KRAS expression. Furthermore, MSI2 positively regulated KRAS expression through directly binding to the target sequence UAGUA in the 3'UTR region of KRAS mRNA."}, {"pubmed": 31078621, "text": "In response to hypoxia, pancreatic ductal adenocarcinoma cells that express activated KRAS increase expression of carbonic anhydrase 9, via stabilization of HIF1A and HIF2A, to regulate pH and glycolysis."}, {"pubmed": 31104677, "text": "The study shows a high concordance of KRAS, NRAS, BRAF and PIK3CA gene mutations in plasma against mutation status in tumor tissue."}, {"pubmed": 31109321, "text": "Study demonstrated that Kras harboring G12D mutation in the pancreas is sufficient to induce pancreatic ductal adenocarcinoma in cooperation with TGIF1 deficiency."}, {"pubmed": 31111275, "text": "This study identified a relationship between KRAS mutation and mucinous phenotype in gastric cancer; a high level of intratumour morphological heterogeneity could reflect KRASmut heterogeneity"}, {"pubmed": 31116475, "text": "Our data suggest that dysfunction of cytoplasmic KARS resulted in a decreased level of translation of the nuclear-encoded lysine-rich proteins belonging to the respiratory chain complex, thus impairing mitochondria functions."}, {"pubmed": 31117243, "text": "This study provides significant guidance for narrowing down the number of KRAS mutations to be screened as potential diagnostic biomarkers and to better understand the structural and functional mechanisms of the KRAS protein"}, {"pubmed": 31127626, "text": "Overexpression of HAO2 by plasmid promoted lipid catabolic process, eliminated lipid accumulation, inhibited KRAS expression, controlled the proliferation, migration, and invasion activity of clear cell renal cell carcinoma (ccRCC) tumor cells."}, {"pubmed": 31136360, "text": "Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk."}, {"pubmed": 31138768, "text": "analysis of genetic interactions with a KRAS(G12C) inhibitor in cellular models of KRAS(G12C) mutant lung and pancreatic cancer using CRISPR interference"}, {"pubmed": 31152438, "text": "Rs712 polymorphism T>G in the 3'-untranslated region of KRAS interrupts the interactions between let-7g and KRAS mRNA, leading to a higher cell proliferation index and reduced doubling time of thyroid nodules."}, {"pubmed": 31160609, "text": "Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS."}, {"pubmed": 31162857, "text": "BRAF mutation and dMMR. KRAS and BRAF mutations were independent risk factors for shorter overall survival (OS) in Stage IV tumors but not in Stage I-III tumors. NRAS mutation was an independent risk factor for shorter OS in Stage I-II tumors"}, {"pubmed": 31185482, "text": "A germ-line single-nucleotide polymorphism in the let-7 microRNA-binding site of the KRAS gene was not associated with sporadic endometriosis in an infertile Caucasian population"}, {"pubmed": 31199507, "text": "Results from tumor biopsies and blood-derived ctDNA biopsies were used to investigate the level of concordance for altered KRAS among 433 patients with diverse cancer types in order to determine temporal and spatial effects on concordance across the spectrum of malignancies suggest that presence of KRAS alterations in both tests is an independent prognostic factor for poor survival."}, {"pubmed": 31206466, "text": "Studies suggest that carcinoembryonic antigen and cytology are more accurate than KRAS proto-oncogene [Review and Meta-Analysis]."}, {"pubmed": 31209806, "text": "KRAS exon 3 and PTEN exon 7 mutations had no significant impact on overall survival of small-cell lung cancer patients."}, {"pubmed": 31217166, "text": "Results provide evidence that KRAS activation in gastric adenocarcinoma cells stimulates EMT and transition to cancer stem-like cells, thus promoting metastasis"}, {"pubmed": 31221662, "text": "Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases."}, {"pubmed": 31230347, "text": "Mu-KRAS attenuates Hippo signaling pathway through PKCiota to sustain the growth of pancreatic cancer."}, {"pubmed": 31263025, "text": "Results present evidence that KRAS-mutant pancreatic ductal adenocarcinoma cells can channel their glucose metabolism away from the mitochondria by a previously unappreciated means: programmed mitophagy via the mediator BNIP3L/NIX. Oncogenic KRAS induces NIX expression and suppression of mitochondrial content in a MAPK pathway-dependent fashion."}, {"pubmed": 31266814, "text": "APEH knockdown abrogated RAS-RAF-MAPK signaling in cells expressing the constitutively active (oncogenic) mutant of KRAS (KRASG12V), and selectively inhibited the proliferation of KRAS-transformed pancreatic cancer cells. Taken together, these results identify APEH as a novel drug target for a potential anti-KRAS therapeutic."}, {"pubmed": 31266962, "text": "Oncogenic KRAS, together with beta-Catenin, favours expansion of crypt cells with high ERK activity."}, {"pubmed": 31268978, "text": "Data suggest the mitogenic role of gastrin in activation of K-Ras protein (KRAS) during pancreatic carcinogenesis."}, {"pubmed": 31289919, "text": "KRAS is the most frequently mutated gene in human cancers. Direct inhibition of KRAS via pharmacological inhibitors has been challenging"}, {"pubmed": 31295281, "text": "K-RAS mutation-positive follicular neoplasm/suspicious for follicular neoplasm nodules have a 50% risk of malignancy and surgery should be recommended. Combined use of ACR TIRADS and K-RAS mutation may facilitate risk-stratification of patients with CITNs."}, {"pubmed": 31296870, "text": "Study shows that LIF expression is induced specifically by oncogenic KRAS in pancreatic ductal adenocarcinomas (PDAC) and that LIF depletion by genetic means or by neutralizing antibodies prevents engraftment in pancreatic xenograft models. The related cytokine IL-6 cannot substitute for LIF, suggesting that LIF mediates KRAS-driven malignancies through a non-STAT-signaling pathway."}, {"pubmed": 31309326, "text": "KRAS codon 12G-to-V or G-to-C mutations are independent prognostic factors in patients with stage I-III colorectal cancer."}, {"pubmed": 31324887, "text": "Structures of N-terminally processed KRAS provide insight into the role of N-acetylation."}, {"pubmed": 31325400, "text": "Dual-luciferase reporter assay in pancreatic ductal adenocarcinoma (PDAC) cells validated that TP53TG1 and 3'UTR of KRAS oncogene mRNA competitively bind with miR-96. Data further indicate that TP53TG1 could effectively function as a sponge for miR-96 to modulate the derepression of KRAS, thus promoting PDAC development."}, {"pubmed": 31330153, "text": "These results reveal novel insights into to how KRAS4B may organize on membranes."}, {"pubmed": 31331963, "text": "inhibition of the Golgi-localized PI4-kinases (PI4Ks) translocates K-Ras, and PtdSer to mitochondria and endomembranes, respectively."}, {"pubmed": 31339036, "text": "The dynamics of the KRAS4b G-domain at the bilayer surface are altered in the presence of phosphatidylinositol 4,5-bisphosphate (PIP2), due to the formation of long-lived salt bridges with basic residues on the G-domain."}, {"pubmed": 31341022, "text": "Results highlight a mechanistic connection between KRAS(A146T) and KRAS(V14I) that may have implications for the regulation of these variants."}, {"pubmed": 31343420, "text": "KRAS and BRAF gene mutations correlate with various histologic features of ovarian serous borderline tumor and subsequent development of serous carcinoma."}, {"pubmed": 31347028, "text": "The IntelliPlextrade mark KRAS G12/13 Mutation Kit demonstrates suitable specificity and sensitivity for use in clinical laboratories to determine the mutational status of KRAS codons 12 and 13."}, {"pubmed": 31350822, "text": "Acquired resistance, in patients with initial treatment benefit, is mainly explained by polyclonal emergence of RAS, BRAF, and EGFR mutations in circulating tumor DNA."}, {"pubmed": 31359406, "text": "Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo."}, {"pubmed": 31375828, "text": "In vitro cell models differ in the basal transcriptional profile of the KRAS signalling pathway."}, {"pubmed": 31389831, "text": "The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis."}, {"pubmed": 31390566, "text": "A Spontaneous Aggressive ERalpha+ Mammary Tumor Model Is Driven by Kras Activation."}, {"pubmed": 31396884, "text": "Genetic Changes of P(53) and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand."}, {"pubmed": 31399087, "text": "Cigarette smoking-induced airway epithelium remodeling is mediated by abnormal activation of KRAS-dependent signaling mechanisms."}, {"pubmed": 31399543, "text": "identified a fragment binder to KRas(G12D) and used (1)H (15)N transverse relaxation optimized spectroscopy (TROSY) heteronuclear single-quantum coherence (HSQC) NMR to characterize its binding site as a pocket adjacent to the switch 2 region."}, {"pubmed": 31399545, "text": "Cooperation between KRAS and TP53 oncogenic mutations in pancreatic ductal carcinoma activates the ARF6-AMAP1 pathway to promote tumor malignancies and evade the immune system. KRAS primarily acts to promote eIF4A/4E-dependent mRNA translation to up-regulate ARF6 and AMAP1 protein expression, whereas, TP53 facilitates ARF6 activation by platelet-derived growth factor receptor(PDGFR)."}, {"pubmed": 31406261, "text": "Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer."}, {"pubmed": 31407334, "text": "JAK1/2 inhibition as promising therapy for K-RAS-driven lung AC."}, {"pubmed": 31426677, "text": "KRAS mutation status can help predict recurrence-free survival. Primary tumor location was not a prognostic factor after resection. KRAS mutation status can help design a multidisciplinary approach after curative resection of CLM."}, {"pubmed": 31439256, "text": "The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status has been identified as an important factor in the treatment of colorectal cancer."}, {"pubmed": 31450901, "text": "High Frequency of KRAS Codon 146 is associated with colon Cancer."}, {"pubmed": 31451509, "text": "have shown that targeting ORP5, ORP8, or PI4KIIIalpha depletes the PM of PtdSer resulting in mislocalization of KRAS and reduced nanoclustering of KRAS that remains PM bound in all cell lines tested. In turn, these perturbations of KRAS PM interactions lead to reduced proliferative and tumorigenic capacity of KRAS-mutant cancer cells."}, {"pubmed": 31456520, "text": "Summary of the types of KRAS mutations and their relationship with pancreatic cancer and included the downstream signaling pathway Raf-MEK-ERK, PI3K-AKT, RalGDS-Ral of KRAS (review)"}, {"pubmed": 31472013, "text": "Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer."}, {"pubmed": 31486960, "text": "intramuscular hemangioma capillary type (IHCT) lesions are phenotypically similar to arteriovenous malformation (AVM) and contain the same somatic MAP2K1 or KRAS mutations, suggesting that IHCT is on the AVM spectrum. We propose calling this lesion \"intramuscular fast-flow vascular anomaly."}, {"pubmed": 31492820, "text": "Decitabine is a promising drug for cancer cells dependent on RAS signaling."}, {"pubmed": 31500429, "text": "patients undergoing surgical resection of colorectal cancer and synchronous liver metastases, m-KRAS was associated with right-sided lesions and African-American ethnicity. Compared to wt-KRAS, m-KRAS was associated with a reduced DSS. Additionally, right-sided lesions were an independent negative prognostic factor for DSS."}, {"pubmed": 31506332, "text": "This process occurred when Kras/Erk/ADAM17 signaling was switched on."}, {"pubmed": 31506334, "text": "GSK-J4 as a potential treatment option for cancer patients with KRAS mutations."}, {"pubmed": 31521891, "text": "MiR-143-3p may suppress tumorigenesis in Pancreatic ductal adenocarcinoma by targeting KRAS."}, {"pubmed": 31534204, "text": "Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity."}, {"pubmed": 31543246, "text": "Assessing pathogenic mutations in dental follicles as an attempt to identify early events in odontogenic tumours tumourigenesis."}, {"pubmed": 31551296, "text": "A systems mechanism for KRAS mutant allele-specific responses to targeted therapy."}, {"pubmed": 31562613, "text": "Long Non-coding RNA LINC01420 Contributes to Pancreatic Cancer Progression Through Targeting KRAS Proto-oncogene."}, {"pubmed": 31576556, "text": "A subset of endosalpingiotic lesions are clonal and harbour the same oncogenic driver mutations in KRAS shared with low-grade ovarianserous tumours."}, {"pubmed": 31597434, "text": "KRAS is a useful biomarker in metastatic colorectal cancer (Review)"}, {"pubmed": 31638218, "text": "Our results revealed that increased accumulation of miR143 is likely to modulate levels of KRAS protein expression at the posttranscriptional level by interacting specifically with the complementary site, and consequently inhibiting proliferation of the transfected cells."}, {"pubmed": 31646797, "text": "Our study confirmed that after bevacizumab-based treatment, KRAS status might not be a prognostic factor. We have also shown that left Colorectal cancer (CRC) have more favorable outcomes than right CRC in bevacizumab therapy"}, {"pubmed": 31646798, "text": "Addition of anti-EGFR in left sided K-RAS wild-type metastatic colorectal cancer (mCRC) regarding PFS was beneficial, however there was no difference in terms of OS."}, {"pubmed": 31649109, "text": "Atypical KRAS(G12R) Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer."}, {"pubmed": 31653608, "text": "Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours."}, {"pubmed": 31658042, "text": "Our analyses also revealed that this is irrespective of the presence of mutations as the correlation coefficients in the wildtype study group was similar to the patient group that had KRAS or BRAFmutations"}, {"pubmed": 31659106, "text": "EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment"}, {"pubmed": 31659111, "text": "data suggest that KRAS mutation is predictive of a superior response to immunotherapy. Furthermore, the lack of response of STK11 and KRAS co-mutated NSCLC patients to ICIs, is indeed negated by an additional TP53 mutation."}, {"pubmed": 31673240, "text": "Our results underlined that miR-425-5p might act as an oncogene to participate in the pathogenesis of KRAS-mutated CRC and contribute to increase the aggressiveness of this subcategory of CRC, controlling a complex molecular network"}, {"pubmed": 31674905, "text": "Results show how membrane organization dictates membrane diffusion and trafficking of Ras and offer insight into the spatial regulation of Ras signaling."}, {"pubmed": 31692030, "text": "KRAS mutation and abnormal expression of Cripto-1 as two potential candidate biomarkers for detection of colorectal cancer development."}, {"pubmed": 31695760, "text": "Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8."}, {"pubmed": 31709742, "text": "The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients."}, {"pubmed": 31711449, "text": "KRAS mutations were the most common genetic alterations involving 22.1% of the cases and being mutually exclusive with the EGFR mutations, which were found in 12.6% of them."}, {"pubmed": 31712554, "text": "SNORD50A/B RNAs shape the composition of proteins proximal to KRAS, notably by inhibiting KRAS proximity to the SNARE vesicular transport proteins."}, {"pubmed": 31719050, "text": "Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer."}, {"pubmed": 31720935, "text": "KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases."}, {"pubmed": 31727020, "text": "The MRI findings of rectal cancer, especially texture features, showed an encouraging value for identifying KRAS status."}, {"pubmed": 31729889, "text": "KRAS SNPs are related to colorectal cancer susceptibility and survival in Chinese people."}, {"pubmed": 31736361, "text": "KRas-ERK signalling promotes the onset and maintenance of uveal melanoma through regulating JMJD6-mediated H2A.X phosphorylation"}, {"pubmed": 31758745, "text": "KRAS mutations and activation of the MAPK-ERK signaling pathway occur in implant-associated peripheral giant cell granuloma."}, {"pubmed": 31773354, "text": "The presence of KRAS mutations in the colorectal cancer specimens, especially G12D or G13D mutations, seems to promote pulmonary metastases formation."}, {"pubmed": 31787238, "text": "Novel activating KRAS mutation candidates in lung adenocarcinoma."}, {"pubmed": 31799655, "text": "Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway."}, {"pubmed": 31804006, "text": "RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD."}, {"pubmed": 31822998, "text": "Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations."}, {"pubmed": 31827279, "text": "a direct GTP-dependent interaction between KRAS4A and hexokinase 1 (HK1) is reported, that alters the activity of the kinase, and thereby establishes that HK1 is an effector of KRAS4A"}, {"pubmed": 31834556, "text": "In patients with mutant KRAS, those in the high p53 group exhibited significantly longer OS than those in the low p53 group"}, {"pubmed": 31838964, "text": "Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis."}, {"pubmed": 31839435, "text": "Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study."}, {"pubmed": 31856410, "text": "Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis."}, {"pubmed": 31857578, "text": "Study found recurring KRAS mutations in 26/70 (37.1%) of adenomyosis cases. Multi-regional sequencing reveals oligoclonality in adenomyosis, with some mutations also detected in normal endometrium and/or co-occurring endometriosis. KRAS mutations are more frequent in cases of adenomyosis with co-occurring endometriosis, low progesterone receptor expression, or progestin pretreatment."}, {"pubmed": 31861832, "text": "Loss of heterozygosity (LOH) was analyzed in a cohort of EGFR-mutated non-small-cell lung cancer (NSCLC) patients who were positive or negative for EGFR mutations in their cfDNA. Patients carrying KRAS mutations were also analyzed. No association between KRAS status in cfDNA and number of LOH events was found."}, {"pubmed": 31874105, "text": "The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas."}, {"pubmed": 31874110, "text": "Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma."}, {"pubmed": 31881025, "text": "Results found KRAS exon 2 mutations accounting for 83.69% of metastatic colorectal cancer patients in Jordan. KRAS G12D was the most common one, followed by KRAS G12A and G12T. Also, 10.87% mutations in KRAS are found in exon 3 and 4."}, {"pubmed": 31898667, "text": "HMGA2 and KRAS could be translationally downregulated by the hsa-let-7d-3p, and the loss of hsa-let-7d-3p expression led to the progression of EOC related to the tumorigenesis, invasion, and metastasis."}, {"pubmed": 31900123, "text": "As FOLFIRI+Bevacizumab has recently also been associated with sustained complete remission in a APC/TP53/KRAS triple-mutated patient, these driver genes should be tested and monitored in a more in-depth manner in future patients."}, {"pubmed": 31910789, "text": "The small numbers of KRAS mutations and ALK rearrangements are the limitation of this study for evaluation of diagnostic imaging. The frequency of these genetic alterations was as reported in the literature. We believe that our work will contribute to future meta-analysis."}, {"pubmed": 31911550, "text": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers."}, {"pubmed": 31920150, "text": "Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein."}, {"pubmed": 31926049, "text": "Cardiofaciocutaneous syndrome with KRAS gene mutation presenting as chylopericardium."}, {"pubmed": 31942672, "text": "Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer."}, {"pubmed": 31952366, "text": "KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study."}, {"pubmed": 31953522, "text": "Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma."}, {"pubmed": 31958057, "text": "Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior."}, {"pubmed": 31960612, "text": "Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck."}, {"pubmed": 31983154, "text": "BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model."}, {"pubmed": 31992579, "text": "Detecting mosaic variants in patients with somatic overgrowth syndromes using cell-free circulating DNA and deep sequencing."}, {"pubmed": 31997427, "text": "Frequent KRAS mutations in oncocytic papillary renal neoplasm with inverted nuclei."}, {"pubmed": 32001619, "text": "The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells."}, {"pubmed": 32005111, "text": "Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations."}, {"pubmed": 32017404, "text": "Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients."}, {"pubmed": 32020213, "text": "An albuminbinding domain and targeting peptidebased recombinant protein and its enediyneintegrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with Kras mutation."}, {"pubmed": 32029896, "text": "BCAT2-mediated branched-chain amino acids catabolism is critical for the development of pancreatic ductal adenocarcinoma-harboring KRAS mutations."}, {"pubmed": 32046380, "text": "Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis."}, {"pubmed": 32046984, "text": "Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment."}, {"pubmed": 32066856, "text": "Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population."}, {"pubmed": 32075360, "text": "was no significant difference of K-ras gene mutation between primary malignancies patients with colorectal cancer (CRC) and patients with single CRC"}, {"pubmed": 32088737, "text": "KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients."}, {"pubmed": 32089414, "text": "RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer."}, {"pubmed": 32108374, "text": "Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study."}, {"pubmed": 32109834, "text": "Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study."}, {"pubmed": 32111352, "text": "Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells."}, {"pubmed": 32119223, "text": "It was established that there is no reliable dependence of rate of KRAS gene mutation in patients with colorectal cancer in the region of their residence in Kazakhstan"}, {"pubmed": 32127496, "text": "Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis."}, {"pubmed": 32128676, "text": "The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database."}, {"pubmed": 32130260, "text": "the presence of concomitant EGFR mutation can affect the tyrosine kinase inhibitors response of KRAS-mutated cells."}, {"pubmed": 32139876, "text": "The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer."}, {"pubmed": 32141886, "text": "A subset of papillary fibroelastomas harbor pathogenic KRAS mutations."}, {"pubmed": 32165494, "text": "The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity."}, {"pubmed": 32171651, "text": "Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?"}, {"pubmed": 32193808, "text": "Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer."}, {"pubmed": 32234958, "text": "Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety."}, {"pubmed": 32249202, "text": "Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA."}, {"pubmed": 32271426, "text": "KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis."}, {"pubmed": 32277691, "text": "HPV mediated carcinogenesis: the role of k-ras mutations."}, {"pubmed": 32279996, "text": "Loss of heterozygosity for Kras(G12D) promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma."}, {"pubmed": 32291414, "text": "Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability."}, {"pubmed": 32300895, "text": "Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines."}, {"pubmed": 32308771, "text": "Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation."}, {"pubmed": 32314446, "text": "The combination of KRAS and SMAD4 mutations in DNA obtained from formalin-fixed paraffin-embedded tissues is an independent poor prognostic factor in pancreatic ductal adenocarcinoma"}, {"pubmed": 32315324, "text": "KRAS mutations were identified in codon 12 and 13, and include KRAS_12V, KRAS_G12S, KRAS_G12D, KRAS_G13C and KRAS_G13D were seen in Papillary thyroid carcinoma."}, {"pubmed": 32335126, "text": "PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer."}, {"pubmed": 32373977, "text": "Association between C-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma."}, {"pubmed": 32376889, "text": "Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer."}, {"pubmed": 32384877, "text": "Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component."}, {"pubmed": 32393580, "text": "RAS internal tandem duplication disrupts GTPase-activating protein (GAP) binding to activate oncogenic signaling."}, {"pubmed": 32393751, "text": "KRAS mutations in uterine endometrium are associated with gravidity and parity."}, {"pubmed": 32394229, "text": "Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer."}, {"pubmed": 32414921, "text": "Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane."}, {"pubmed": 32430479, "text": "The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer."}, {"pubmed": 32487083, "text": "Noninvasive KRAS mutation estimation in colorectal cancer using a deep learning method based on CT imaging."}, {"pubmed": 32492752, "text": "KRAS mutations in brown tumor of the jaws in hyperparathyroidism."}, {"pubmed": 32495109, "text": "Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran."}, {"pubmed": 32514015, "text": "PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin beta3-KRAS-dependent pancreatic cancer stem cells."}, {"pubmed": 32552404, "text": "Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling."}, {"pubmed": 32559497, "text": "Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer."}, {"pubmed": 32561852, "text": "Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal."}, {"pubmed": 32568455, "text": "SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC."}, {"pubmed": 32571252, "text": "Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas."}, {"pubmed": 32573499, "text": "TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations."}, {"pubmed": 32573775, "text": "Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma."}, {"pubmed": 32576853, "text": "Genome-wide DNA methylation analysis of KRAS mutant cell lines."}, {"pubmed": 32580297, "text": "Active Compound of Pharbitis Semen (Pharbitis nil Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression."}, {"pubmed": 32591603, "text": "A somatic activating KRAS variant identified in an affected lesion of a patient with Gorham-Stout disease."}, {"pubmed": 32592097, "text": "Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival."}, {"pubmed": 32597321, "text": "Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis."}, {"pubmed": 32605718, "text": "KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population."}, {"pubmed": 32605999, "text": "KRAS(Q61H) Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer."}, {"pubmed": 32612138, "text": "Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe."}, {"pubmed": 32616873, "text": "Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor."}, {"pubmed": 32619782, "text": "Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer."}, {"pubmed": 32628708, "text": "KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study."}, {"pubmed": 32641995, "text": "KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling."}, {"pubmed": 32681943, "text": "Early KRAS oncogenic driver mutations in nonmucinous tissue of congenital pulmonary airway malformations as an indicator of potential malignant behavior."}, {"pubmed": 32692445, "text": "Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer."}, {"pubmed": 32703218, "text": "AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer."}, {"pubmed": 32708716, "text": "Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers."}, {"pubmed": 32709715, "text": "The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer."}, {"pubmed": 32709883, "text": "Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer."}, {"pubmed": 32723394, "text": "Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review."}, {"pubmed": 32727790, "text": "Mutant KRAS Promotes NKG2D(+) T Cell Infiltration and CD155 Dependent Immune Evasion."}, {"pubmed": 32727793, "text": "MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS."}, {"pubmed": 32739163, "text": "The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features."}, {"pubmed": 32743640, "text": "Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations."}, {"pubmed": 32747568, "text": "Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma."}, {"pubmed": 32750661, "text": "KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis."}, {"pubmed": 32763752, "text": "Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis."}, {"pubmed": 32767829, "text": "DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells."}, {"pubmed": 32769881, "text": "Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma."}, {"pubmed": 32779023, "text": "Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning."}, {"pubmed": 32791343, "text": "Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma."}, {"pubmed": 32799314, "text": "Arteriovenous malformation phenotype resembling congenital hemangioma contains KRAS mutations."}, {"pubmed": 32807653, "text": "Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma."}, {"pubmed": 32823550, "text": "IKKbeta Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells."}, {"pubmed": 32839411, "text": "Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation."}, {"pubmed": 32872305, "text": "Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative Stress."}, {"pubmed": 32876508, "text": "Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue."}, {"pubmed": 32892548, "text": "Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer"}, {"pubmed": 32898003, "text": "Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer."}, {"pubmed": 32900796, "text": "Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer."}, {"pubmed": 32913056, "text": "Uncovering a membrane-distal conformation of KRAS available to recruit RAF to the plasma membrane."}, {"pubmed": 32929330, "text": "Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression."}, {"pubmed": 32956987, "text": "KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma."}, {"pubmed": 32972751, "text": "Metabolic regulation of EGFR effector and feedback signaling in pancreatic cancer cells requires K-Ras."}, {"pubmed": 32986951, "text": "Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles."}, {"pubmed": 32991469, "text": "Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer."}, {"pubmed": 33002027, "text": "KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer."}, {"pubmed": 33024263, "text": "The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence."}, {"pubmed": 33053566, "text": "Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits."}, {"pubmed": 33060649, "text": "KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility."}, {"pubmed": 33067762, "text": "KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer."}, {"pubmed": 33068045, "text": "ZEB1 and oncogenic Ras constitute a regulatory switch for stimulus-dependent E-cadherin downregulation."}, {"pubmed": 33073539, "text": "Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway."}, {"pubmed": 33077911, "text": "PLCgamma1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia."}, {"pubmed": 33082413, "text": "Neuron type-specific expression of a mutant KRAS impairs hippocampal-dependent learning and memory."}, {"pubmed": 33099482, "text": "Atypical Mesonephric Hyperplasia of the Uterus Harbors Pathogenic Mutation of Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRAS) and Gain of Chromosome 1q."}, {"pubmed": 33104438, "text": "Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations."}, {"pubmed": 33107184, "text": "SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis."}, {"pubmed": 33112492, "text": "Cell-permeable CaaX-peptides affect K-Ras downstream signaling and promote cell death in cancer cells."}, {"pubmed": 33115932, "text": "Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies KRAS mutation as a biomarker of poor prognosis."}, {"pubmed": 33122623, "text": "RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer."}, {"pubmed": 33137095, "text": "Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis."}, {"pubmed": 33153459, "text": "Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors."}, {"pubmed": 33155198, "text": "MiR-16 inhibits proliferation of cervical cancer cells by regulating KRAS."}, {"pubmed": 33174084, "text": "The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study."}, {"pubmed": 33230296, "text": "KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth."}, {"pubmed": 33237900, "text": "Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing."}, {"pubmed": 33254149, "text": "KRAS mutations are negatively correlated with immunity in colon cancer."}, {"pubmed": 33257571, "text": "Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association."}, {"pubmed": 33257855, "text": "The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer."}, {"pubmed": 33268505, "text": "Loss of Jag1 cooperates with oncogenic Kras to induce pancreatic cystic neoplasms."}, {"pubmed": 33273596, "text": "Clinical features and KRAS mutation in colorectal cancer with bone metastasis."}, {"pubmed": 33288571, "text": "Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation."}, {"pubmed": 33294856, "text": "Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer."}, {"pubmed": 33299528, "text": "Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote Kras/Lkb1/Keap1 Mutant Lung Adenocarcinoma Cell Migration and Invasion."}, {"pubmed": 33302159, "text": "Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model."}, {"pubmed": 33309959, "text": "Discoveries in the redox regulation of KRAS."}, {"pubmed": 33325140, "text": "KRAS G12V mutation upregulates PD-L1 expression via TGF-beta/EMT signaling pathway in human non-small-cell lung cancer."}, {"pubmed": 33325154, "text": "Genomic and prognostic heterogeneity among RAS/BRAF(V600E) /TP53 co-mutated resectable colorectal liver metastases."}, {"pubmed": 33331426, "text": "IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER."}, {"pubmed": 33338532, "text": "Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer."}, {"pubmed": 33347393, "text": "Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis."}, {"pubmed": 33368279, "text": "The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status."}, {"pubmed": 33393503, "text": "BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors."}, {"pubmed": 33402978, "text": "Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population."}, {"pubmed": 33408000, "text": "Diffusion-based determination of protein homodimerization on reconstituted membrane surfaces."}, {"pubmed": 33420374, "text": "PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer."}, {"pubmed": 33432066, "text": "Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer."}, {"pubmed": 33461973, "text": "Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin."}, {"pubmed": 33466280, "text": "KRAS Promoter G-Quadruplexes from Sequences of Different Length: A Physicochemical Study."}, {"pubmed": 33468383, "text": "Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen."}, {"pubmed": 33482197, "text": "Identification of Radil as a Ras binding partner and putative activator."}, {"pubmed": 33502820, "text": "Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy."}, {"pubmed": 33513349, "text": "RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression."}, {"pubmed": 33521700, "text": "The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)."}, {"pubmed": 33544116, "text": "Promotion of cancer cell stemness by Ras."}, {"pubmed": 33549031, "text": "Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings."}, {"pubmed": 33574444, "text": "Targeting the DNA replication stress phenotype of KRAS mutant cancer cells."}, {"pubmed": 33593884, "text": "KRAS (G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma."}, {"pubmed": 33602788, "text": "Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells."}, {"pubmed": 33608534, "text": "KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation."}, {"pubmed": 33620658, "text": "Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder."}, {"pubmed": 33632153, "text": "Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer."}, {"pubmed": 33647504, "text": "Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project."}, {"pubmed": 33669856, "text": "Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients."}, {"pubmed": 33672357, "text": "KRAS(G12C) Can Either Promote or Impair Cap-Dependent Translation in Two Different Lung Adenocarcinoma Cell Lines."}, {"pubmed": 33674596, "text": "KRAS drives immune evasion in a genetic model of pancreatic cancer."}, {"pubmed": 33675098, "text": "Biological significance of KRAS mutant allele expression in ovarian endometriosis."}, {"pubmed": 33676749, "text": "KRAS mutation in pancreatic cancer."}, {"pubmed": 33683689, "text": "A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections."}, {"pubmed": 33709341, "text": "Malfeasance of KRAS mutations in carcinogenesis."}, {"pubmed": 33744389, "text": "True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature."}, {"pubmed": 33753749, "text": "The origins and genetic interactions of KRAS mutations are allele- and tissue-specific."}, {"pubmed": 33773991, "text": "Comparison of Biocartis IDYLLA cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes."}, {"pubmed": 33784337, "text": "Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report."}, {"pubmed": 33788188, "text": "Pulmonary Inflammation and KRAS Mutation in Lung Cancer."}, {"pubmed": 33793658, "text": "Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction."}, {"pubmed": 33795683, "text": "A KRAS-responsive long non-coding RNA controls microRNA processing."}, {"pubmed": 33795873, "text": "Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling."}, {"pubmed": 33801246, "text": "Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation."}, {"pubmed": 33802849, "text": "Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology."}, {"pubmed": 33811729, "text": "Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells."}, {"pubmed": 33825830, "text": "Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival."}, {"pubmed": 33830081, "text": "Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress."}, {"pubmed": 33833221, "text": "Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer."}, {"pubmed": 33833413, "text": "Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells."}, {"pubmed": 33838467, "text": "Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy."}, {"pubmed": 33856403, "text": "Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer."}, {"pubmed": 33858364, "text": "Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases."}, {"pubmed": 33859342, "text": "Searching for treatments for non-G12C-KRAS mutant cancers."}, {"pubmed": 33888645, "text": "LINC00514 promotes gastric cancer cell growth and EMT progression via miR-204-3p/KRAS."}, {"pubmed": 33899342, "text": "Sequence-Selective Covalent CaaX-Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K Signaling."}, {"pubmed": 33910843, "text": "Impact of K-Ras Over-expression in Laryngeal Squamous Cell Carcinoma."}, {"pubmed": 33931487, "text": "Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer."}, {"pubmed": 33931739, "text": "Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis."}, {"pubmed": 33953347, "text": "Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study."}, {"pubmed": 33954928, "text": "Identification of mutant K-RAS in pituitary macroadenoma."}, {"pubmed": 33956502, "text": "Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer."}, {"pubmed": 33961700, "text": "Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer."}, {"pubmed": 33978412, "text": "Normal Mode Analysis of KRas4B Reveals Partner Specific Dynamics."}, {"pubmed": 33982450, "text": "The function and mechanism of the miR-210-3p/KRAS axis in bone marrow-derived mesenchymal stem cell from patients with osteoporosis."}, {"pubmed": 34016959, "text": "Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer."}, {"pubmed": 34021083, "text": "Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer."}, {"pubmed": 34023857, "text": "Pancreatic tumor initiation: the potential role of IL-33."}, {"pubmed": 34044655, "text": "Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients."}, {"pubmed": 34052328, "text": "Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer."}, {"pubmed": 34056834, "text": "Novel findings and expansion of phenotype in a mosaic RASopathy caused by somatic KRAS variants."}, {"pubmed": 34061178, "text": "Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer."}, {"pubmed": 34063999, "text": "Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS."}, {"pubmed": 34065402, "text": "KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer."}, {"pubmed": 34073318, "text": "Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer."}, {"pubmed": 34102999, "text": "Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract."}, {"pubmed": 34111513, "text": "KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin."}, {"pubmed": 34114335, "text": "Mosaic RASopathy due to KRAS variant G12D with segmental overgrowth and associated peripheral vascular malformations."}, {"pubmed": 34115442, "text": "Reevaluating the prognostic value of RAS mutation status in patients with resected liver metastases from colorectal cancer: A systematic review and meta-analysis."}, {"pubmed": 34117033, "text": "Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer."}, {"pubmed": 34120460, "text": "Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer."}, {"pubmed": 34126192, "text": "Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients."}, {"pubmed": 34134622, "text": "High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis."}, {"pubmed": 34161704, "text": "Acquired Resistance to KRAS(G12C) Inhibition in Cancer."}, {"pubmed": 34163115, "text": "Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth."}, {"pubmed": 34176062, "text": "Antipsychotic phenothiazine drugs bind to KRAS in vitro."}, {"pubmed": 34190333, "text": "KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib."}, {"pubmed": 34216687, "text": "PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition."}, {"pubmed": 34217313, "text": "Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer."}, {"pubmed": 34227245, "text": "Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells."}, {"pubmed": 34232546, "text": "The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study."}, {"pubmed": 34233735, "text": "Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis."}, {"pubmed": 34235620, "text": "Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma."}, {"pubmed": 34250383, "text": "Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer."}, {"pubmed": 34250391, "text": "Comprehensive Clinical and Molecular Characterization of KRAS (G12C)-Mutant Colorectal Cancer."}, {"pubmed": 34250412, "text": "Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA."}, {"pubmed": 34254724, "text": "Somatic KRAS mutation affecting codon 146 in linear sebaceous nevus syndrome."}, {"pubmed": 34257283, "text": "Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells."}, {"pubmed": 34257550, "text": "EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma."}, {"pubmed": 34272369, "text": "Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting."}, {"pubmed": 34279918, "text": "Virtual Fluorescence Color Channels by Selective Photobleaching in Digital PCR Applied to the Quantification of KRAS Point Mutations."}, {"pubmed": 34311032, "text": "ANGPTL4 accelerates KRAS(G12D)-Induced acinar to ductal metaplasia and pancreatic carcinogenesis."}, {"pubmed": 34319912, "text": "ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer."}, {"pubmed": 34330898, "text": "The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer."}, {"pubmed": 34333552, "text": "KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer."}, {"pubmed": 34359836, "text": "YTHDF1 Promotes Cyclin B1 Translation through m(6)A Modulation and Contributes to the Poor Prognosis of Lung Adenocarcinoma with KRAS/TP53 Co-Mutation."}, {"pubmed": 34365406, "text": "KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms."}, {"pubmed": 34369256, "text": "Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients."}, {"pubmed": 34380736, "text": "RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity."}, {"pubmed": 34400416, "text": "Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer."}, {"pubmed": 34404770, "text": "ZNF768 links oncogenic RAS to cellular senescence."}, {"pubmed": 34413420, "text": "PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study."}, {"pubmed": 34448791, "text": "Association between autophagy and KRAS mutation with clinicopathological variables in colorectal cancer patients."}, {"pubmed": 34462871, "text": "A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer."}, {"pubmed": 34463887, "text": "Expression profiles of miR-196, miR-132, miR-146a, and miR-134 in human colorectal cancer tissues in accordance with their clinical significance : Comparison regarding KRAS mutation."}, {"pubmed": 34490728, "text": "High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer."}, {"pubmed": 34504076, "text": "Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity."}, {"pubmed": 34511398, "text": "Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer."}, {"pubmed": 34518623, "text": "Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases."}, {"pubmed": 34526658, "text": "EndoBind detects endogenous protein-protein interactions in real time."}, {"pubmed": 34542636, "text": "KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis."}, {"pubmed": 34543685, "text": "Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer."}, {"pubmed": 34549835, "text": "Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors."}, {"pubmed": 34551282, "text": "KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT in insulin signaling and glucose homeostasis."}, {"pubmed": 34557315, "text": "Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma."}, {"pubmed": 34580018, "text": "KRAS mutation analysis by droplet digital PCR of duodenal juice from patients with MODY8 and other pancreatic diseases."}, {"pubmed": 34606602, "text": "Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair."}, {"pubmed": 34610265, "text": "Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis."}, {"pubmed": 34614304, "text": "Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter?"}, {"pubmed": 34618566, "text": "The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS."}, {"pubmed": 34625747, "text": "A structural model of a Ras-Raf signalosome."}, {"pubmed": 34632919, "text": "Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer."}, {"pubmed": 34635780, "text": "Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated inflammation."}, {"pubmed": 34638560, "text": "Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma."}, {"pubmed": 34648846, "text": "FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer."}, {"pubmed": 34654798, "text": "p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer."}, {"pubmed": 34657456, "text": "After decades, RAS mutation has finally become a therapeutic target."}, {"pubmed": 34660806, "text": "Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer."}, {"pubmed": 34663879, "text": "Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1."}, {"pubmed": 34669528, "text": "Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis."}, {"pubmed": 34684076, "text": "Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients."}, {"pubmed": 34686998, "text": "NMR (1)H, (13)C, (15)N backbone resonance assignments of the T35S and oncogenic T35S/Q61L mutants of human KRAS4b in the active, GppNHp-bound conformation."}, {"pubmed": 34688654, "text": "The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer."}, {"pubmed": 34696797, "text": "CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502-5p/KRAS and IGF2BP2/Myc axes."}, {"pubmed": 34725361, "text": "The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors."}, {"pubmed": 34730772, "text": "Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma."}, {"pubmed": 34740862, "text": "Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status."}, {"pubmed": 34758634, "text": "Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer."}, {"pubmed": 34776511, "text": "KRAS mutation: from undruggable to druggable in cancer."}, {"pubmed": 34787842, "text": "(1) H, (15) N and (13) C resonance assignments of the Q61H mutant of human KRAS bound to GDP."}, {"pubmed": 34787849, "text": "Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population."}, {"pubmed": 34792696, "text": "Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome."}, {"pubmed": 34797780, "text": "The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors."}, {"pubmed": 34811396, "text": "Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer."}, {"pubmed": 34820593, "text": "KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases."}, {"pubmed": 34822010, "text": "Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines."}, {"pubmed": 34828284, "text": "Associations of Polymorphisms Localized in the 3'UTR Regions of the KRAS, NRAS, MAPK1 Genes with Laryngeal Squamous Cell Carcinoma."}, {"pubmed": 34830024, "text": "Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers."}, {"pubmed": 34851437, "text": "Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases."}, {"pubmed": 34865865, "text": "The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer."}, {"pubmed": 34879709, "text": "Endothelial k-RasV12 Expression Induces Capillary Deficiency Attributable to Marked Tube Network Expansion Coupled to Reduced Pericytes and Basement Membranes."}, {"pubmed": 34887523, "text": "Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients."}, {"pubmed": 34896362, "text": "D154Q Mutation does not Alter KRAS Dimerization."}, {"pubmed": 34898002, "text": "KRAS signaling in malignant pleural mesothelioma."}, {"pubmed": 34947990, "text": "Past and Future Strategies to Inhibit Membrane Localization of the KRAS Oncogene."}, {"pubmed": 34948093, "text": "Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members."}, {"pubmed": 34948154, "text": "MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer."}, {"pubmed": 34975345, "text": "The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application."}, {"pubmed": 34983849, "text": "Machine learning-driven multiscale modeling reveals lipid-dependent dynamics of RAS signaling proteins."}, {"pubmed": 34990404, "text": "Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition."}, {"pubmed": 35008514, "text": "Targeting the ERbeta/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy."}, {"pubmed": 35011738, "text": "Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer."}, {"pubmed": 35013227, "text": "Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity."}, {"pubmed": 35018527, "text": "Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway."}, {"pubmed": 35039569, "text": "Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma."}, {"pubmed": 35057499, "text": "Dietary Fat Intake and KRAS Mutations in Colorectal Cancer in a Moroccan Population."}, {"pubmed": 35078508, "text": "Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation."}, {"pubmed": 35078985, "text": "Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding."}, {"pubmed": 35082165, "text": "HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression."}, {"pubmed": 35083578, "text": "T7 Endonuclease I-mediated voltammetric detection of KRAS mutation coupled with horseradish peroxidase for signal amplification."}, {"pubmed": 35088684, "text": "Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma."}, {"pubmed": 35098800, "text": "KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block."}, {"pubmed": 35101228, "text": "Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer."}, {"pubmed": 35134344, "text": "Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity."}, {"pubmed": 35152262, "text": "Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity."}, {"pubmed": 35177674, "text": "Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition."}, {"pubmed": 35178045, "text": "Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates."}, {"pubmed": 35188590, "text": "Activating KRAS and GNAS mutations in heterotopic submucosal glands of the stomach."}, {"pubmed": 35194118, "text": "KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence."}, {"pubmed": 35216221, "text": "Targeting KRAS Regulation with PolyPurine Reverse Hoogsteen Oligonucleotides."}, {"pubmed": 35235413, "text": "Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer."}, {"pubmed": 35236983, "text": "Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers."}, {"pubmed": 35257782, "text": "Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant."}, {"pubmed": 35280113, "text": "Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study."}, {"pubmed": 35286386, "text": "The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells."}, {"pubmed": 35290266, "text": "Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases."}, {"pubmed": 35301609, "text": "Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases."}, {"pubmed": 35317947, "text": "Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma."}, {"pubmed": 35319967, "text": "Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers."}, {"pubmed": 35333412, "text": "KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer."}, {"pubmed": 35349855, "text": "Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study."}, {"pubmed": 35353428, "text": "BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type."}, {"pubmed": 35373275, "text": "Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer."}, {"pubmed": 35373279, "text": "Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention."}, {"pubmed": 35378709, "text": "KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis."}, {"pubmed": 35378710, "text": "KRAS(G12R)-Independent Macropinocytosis in Pancreatic Cancer."}, {"pubmed": 35409398, "text": "Identification of Codon 146 KRAS Variants in Isolated Epidermal Nevus and Multiple Lesions in Oculoectodermal Syndrome: Confirmation of the Phenotypic Continuum of Mosaic RASopathies."}, {"pubmed": 35422065, "text": "Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects."}, {"pubmed": 35435290, "text": "Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer."}, {"pubmed": 35456940, "text": "KRAS: A Druggable Target in Colon Cancer Patients."}, {"pubmed": 35484252, "text": "The prognostic value of KRAS mutation in locally advanced rectal cancer."}, {"pubmed": 35546148, "text": "AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis."}, {"pubmed": 35562390, "text": "Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells."}, {"pubmed": 35567350, "text": "KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer."}, {"pubmed": 35579947, "text": "KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer."}, {"pubmed": 35595182, "text": "KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations."}, {"pubmed": 35633344, "text": "PATTERN OF KRAS GENE EXPRESSION IN IRAQI WOMEN OVARIAN CARCINOMA."}, {"pubmed": 35671334, "text": "ctDNA: Moving toward Clinical Utility."}, {"pubmed": 35680020, "text": "Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study."}, {"pubmed": 35686834, "text": "Engineered KRAS G12D-Reactive T Cells Show Promise in Pancreatic Cancer."}, {"pubmed": 35688062, "text": "Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis."}, {"pubmed": 35732135, "text": "KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy."}, {"pubmed": 35732240, "text": "A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer."}, {"pubmed": 35767444, "text": "The Potency of a KRAS Silent Variant."}, {"pubmed": 35789981, "text": "Colorectal cancer-derived exosomes and modulation KRAS signaling."}, {"pubmed": 35806488, "text": "Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer."}, {"pubmed": 35811500, "text": "KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer."}, {"pubmed": 35833881, "text": "KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression."}, {"pubmed": 35838046, "text": "KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer."}, {"pubmed": 35858545, "text": "Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes."}, {"pubmed": 35864332, "text": "Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)."}, {"pubmed": 35866409, "text": "KRAS Mutation: Characterization and Its Impact on Survival Outcome of Patients with Metastatic Colorectal Cancer."}, {"pubmed": 35872166, "text": "Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer."}, {"pubmed": 35891756, "text": "Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer."}, {"pubmed": 35900578, "text": "Both Kras gene mutation and Her2 gene mutation tend to exist in an inverse manner but not mutually exclusive in mucinous ovarian carcinoma: An analysis of 21 taiwanese women."}, {"pubmed": 35936004, "text": "Characterization of KRAS Mutational Regression in Oligometastatic Patients."}, {"pubmed": 35944066, "text": "Functional and biological heterogeneity of KRAS(Q61) mutations."}, {"pubmed": 35965146, "text": "Impact of anatomical liver resection on patient survival in KRAS-wild-type colorectal liver metastasis: A multicenter retrospective study."}, {"pubmed": 35976561, "text": "KRAS mutation status between left- and right-sided colorectal cancer: are there any differences in computed tomography?"}, {"pubmed": 35983994, "text": "EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS (G12D) tumor development and propagation."}, {"pubmed": 35989410, "text": "Correlation of miR-31 and miR-373 expression with KRAS mutations and its impact on prognosis in colorectal cancer."}, {"pubmed": 35991047, "text": "Joint effects of polycyclic aromatic hydrocarbons, smoking, and XPC polymorphisms on damage in exon 2 of KRAS gene among young coke oven workers."}, {"pubmed": 35994329, "text": "Markov State Models and Molecular Dynamics Simulations Reveal the Conformational Transition of the Intrinsically Disordered Hypervariable Region of K-Ras4B to the Ordered Conformation."}, {"pubmed": 36011352, "text": "Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure."}, {"pubmed": 36104708, "text": "Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo."}, {"pubmed": 36116035, "text": "Chronic rhinosinusitis with nasal polyps does not harbor KRAS, BRAF, and EGFR mutations."}, {"pubmed": 36151074, "text": "Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma."}, {"pubmed": 36177801, "text": "Energy balance-related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status."}, {"pubmed": 36194647, "text": "The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET."}, {"pubmed": 36228769, "text": "The dynamicity of mutant KRAS beta2 strand modulates its downstream activation and predicts anticancer KRAS inhibition."}, {"pubmed": 36288643, "text": "Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis."}, {"pubmed": 36308376, "text": "Correlations among KRAS Mutation, Microsatellite Instability, and 18F-FDG Uptake in Colon Cancer."}, {"pubmed": 36317675, "text": "Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma."}, {"pubmed": 36348317, "text": "Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes."}, {"pubmed": 36413402, "text": "Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47."}, {"pubmed": 36418055, "text": "KRAS mutation-induced EndMT of brain arteriovenous malformation is mediated through the TGF-beta/BMP-SMAD4 pathway."}, {"pubmed": 36436020, "text": "Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells."}, {"pubmed": 36443441, "text": "Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation."}, {"pubmed": 36482151, "text": "Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy."}, {"pubmed": 36504219, "text": "Analysis of KRAS, BRAF, and EGFR mutational status in respiratory epithelial adenomatoid hamartoma (REAH)."}, {"pubmed": 36510281, "text": "High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia."}, {"pubmed": 36510353, "text": "Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population."}, {"pubmed": 36514219, "text": "KRAS G12D mutation eliminates reactive oxygen species through the Nrf2/CSE/H 2S axis and contributes to pancreatic cancer growth."}, {"pubmed": 36517805, "text": "The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis."}, {"pubmed": 36522653, "text": "Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer."}, {"pubmed": 36529989, "text": "Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact."}, {"pubmed": 36538983, "text": "Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10."}, {"pubmed": 36581205, "text": "Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin."}, {"pubmed": 36591710, "text": "RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update."}, {"pubmed": 36599679, "text": "Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer."}, {"pubmed": 36639711, "text": "CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b."}, {"pubmed": 36723380, "text": "Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India."}, {"pubmed": 36752878, "text": "KRAS codon 12 mutations characterize a subset of de novo proliferating \"metaplastic\" Warthin tumors."}, {"pubmed": 36853786, "text": "Analysis of KRAS Mutations in Gastrointestinal Tract Adenocarcinomas Reveals Site-Specific Mutational Signatures."}, {"pubmed": 36883374, "text": "The Self-Association of the KRAS4b Protein is Altered by Lipid-Bilayer Composition and Electrostatics."}, {"pubmed": 36906109, "text": "MYC determines lineage commitment in KRAS-driven primary liver cancer development."}, {"pubmed": 36918771, "text": "Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma."}, {"pubmed": 36946612, "text": "KRAS Hijacks the miRNA Regulatory Pathway in Cancer."}, {"pubmed": 36973520, "text": "Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes."}, {"pubmed": 36976740, "text": "[Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer]."}, {"pubmed": 36977195, "text": "KRAS mutations and endometriosis burden of disease."}, {"pubmed": 36990254, "text": "Epidemiological and molecular evaluation of BRAF, KRAS, NRAS genes and MSI in the development of colorectal cancer."}, {"pubmed": 37013448, "text": "RAS gene mutations and histomorphometric measurements in oral squamous cell carcinoma."}, {"pubmed": 37020037, "text": "RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status."}, {"pubmed": 37067057, "text": "FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung."}, {"pubmed": 37070675, "text": "K-Ras4A Plays a More Significant Role than K-Ras4B in Ductal Carcinoma of Breast."}, {"pubmed": 37086630, "text": "Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations."}, {"pubmed": 37088911, "text": "Evaluating whether KRAS/BRAF mutation status, anaemia and obstruction are associated with recurrence and mortality in non-metastatic colorectal cancer."}, {"pubmed": 37140194, "text": "Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients."}, {"pubmed": 37141400, "text": "The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer."}, {"pubmed": 37142051, "text": "Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features."}, {"pubmed": 37154160, "text": "Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition."}, {"pubmed": 37158894, "text": "KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion."}, {"pubmed": 37191843, "text": "The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers."}, {"pubmed": 37194932, "text": "KRAS Mutation Reduces Thymoquinone Anticancer Effects on Viability of Cells and Apoptosis."}, {"pubmed": 37196632, "text": "Air pollution, EGFR mutation, and cancer initiation."}, {"pubmed": 37219599, "text": "KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence."}, {"pubmed": 37226642, "text": "KRAS[G12C] mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer."}, {"pubmed": 37253296, "text": "KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma."}, {"pubmed": 37268708, "text": "Reduced dynamic complexity allows structure elucidation of an excited state of KRAS[G13D]."}, {"pubmed": 37277698, "text": "Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series."}, {"pubmed": 37296038, "text": "KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry."}, {"pubmed": 37298264, "text": "KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy."}, {"pubmed": 37352389, "text": "Smoking and risk of colorectal cancer according to KRAS and BRAF mutation status in a Japanese prospective Study."}, {"pubmed": 37356222, "text": "The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells."}, {"pubmed": 37363990, "text": "Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma."}, {"pubmed": 37468622, "text": "KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming."}, {"pubmed": 37526097, "text": "Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study."}, {"pubmed": 37566020, "text": "Association of the rs8720 and rs12587 KRAS Gene Variants with Colorectal Cancer in a Mexican Population and Their Analysis In Silico."}, {"pubmed": 37572321, "text": "Aberrant accumulation of Kras-dependent pervasive transcripts during tumor progression renders cancer cells dependent on PAF1 expression."}, {"pubmed": 37589222, "text": "Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis."}, {"pubmed": 37609465, "text": "Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer."}, {"pubmed": 37625101, "text": "Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non-Small-Cell Lung Cancer."}, {"pubmed": 37628868, "text": "Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania."}, {"pubmed": 37633182, "text": "Revealing KRas4b topology on the membrane surface."}, {"pubmed": 37682707, "text": "Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer."}, {"pubmed": 37695315, "text": "Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis."}, {"pubmed": 37699930, "text": "The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes."}, {"pubmed": 37701134, "text": "Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value."}, {"pubmed": 37716979, "text": "CRNDE mediated hnRNPA2B1 stability facilitates nuclear export and translation of KRAS in colorectal cancer."}, {"pubmed": 37721193, "text": "Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance."}, {"pubmed": 37758931, "text": "Ceramide synthase CERS4 gene downregulation is associated with KRAS mutation in colorectal cancer."}, {"pubmed": 37768068, "text": "Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression."}, {"pubmed": 37771286, "text": "KRAS mutations in pancreatic cancer: could we talk about a risk factor for the development of thromboembolic phenomena?"}, {"pubmed": 37794133, "text": "S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer."}, {"pubmed": 37805663, "text": "The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer."}, {"pubmed": 37817078, "text": "A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma."}, {"pubmed": 37817679, "text": "Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort."}, {"pubmed": 37831779, "text": "Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer."}, {"pubmed": 37852325, "text": "NRF2 interacts with distal enhancer and inhibits nitric oxide synthase 2 expression in KRAS-driven pancreatic cancer cells."}, {"pubmed": 37857983, "text": "Conditional Overall Survival After Diagnosis of Non-Metastatic Colon Cancer: Impact of Laterality, MSI, and KRAS Status."}, {"pubmed": 37870968, "text": "Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C."}, {"pubmed": 37882674, "text": "Activation of KrasG12D in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma."}, {"pubmed": 37897365, "text": "Mutual promotion of co-condensation of KRAS G-quadruplex and a well-folded protein HMGB1."}, {"pubmed": 37897621, "text": "An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health."}, {"pubmed": 37937641, "text": "SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis."}, {"pubmed": 37943166, "text": "Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum."}, {"pubmed": 37968341, "text": "STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines."}, {"pubmed": 37979334, "text": "Presentation and outcomes of KRAS[G12C] mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence."}, {"pubmed": 38016110, "text": "One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling."}, {"pubmed": 38029547, "text": "Driver gene KRAS aggravates cancer-associated stroke outcomes."}, {"pubmed": 38032636, "text": "KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer."}, {"pubmed": 38037073, "text": "TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma."}, {"pubmed": 38040818, "text": "Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy."}, {"pubmed": 38043062, "text": "Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating beta-catenin."}, {"pubmed": 38055257, "text": "Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer."}, {"pubmed": 38069251, "text": "The Role of KRAS Mutation in Colorectal Cancer-Associated Thrombosis."}, {"pubmed": 38070788, "text": "Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?"}, {"pubmed": 38109937, "text": "The energetic and allosteric landscape for KRAS inhibition."}, {"pubmed": 38139338, "text": "KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort."}, {"pubmed": 38171240, "text": "Unveiling the role of KRAS in tumor immune microenvironment."}, {"pubmed": 38191609, "text": "Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?"}, {"pubmed": 38191673, "text": "Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer."}, {"pubmed": 38206735, "text": "KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma."}, {"pubmed": 38216551, "text": "Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death."}, {"pubmed": 38286198, "text": "Transcriptome sequencing analysis reveals miR-30c-5p promotes ferroptosis in cervical cancer and inhibits growth and metastasis of cervical cancer xenografts by targeting the METTL3/KRAS axis."}, {"pubmed": 38290660, "text": "Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system."}, {"pubmed": 38334958, "text": "RAS G-domains allosterically contribute to the recognition of lipid headgroups and acyl chains."}, {"pubmed": 38351812, "text": "Immunohistochemical phenotype of colorectal carcinoma in patients with KRAS mutation and mismatch repair status."}, {"pubmed": 38374309, "text": "Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma."}, {"pubmed": 38409850, "text": "Genomic analysis of primary epithelial neoplasms of the seminal vesicle identifies a subset of mucinous cystic tumours driven by KRAS mutations."}, {"pubmed": 38430640, "text": "KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia."}, {"pubmed": 38453365, "text": "Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex."}, {"pubmed": 38473778, "text": "Membrane-Driven Dimerization of the Peripheral Membrane Protein KRAS: Implications for Downstream Signaling."}, {"pubmed": 38503004, "text": "Circular RNAs in the KRAS pathway: Emerging players in cancer progression."}, {"pubmed": 38572984, "text": "Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model."}, {"pubmed": 38573819, "text": "STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer."}, {"pubmed": 38579072, "text": "Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer."}, {"pubmed": 38594840, "text": "Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes."}, {"pubmed": 38651826, "text": "Mutant RAS-driven Secretome Causes Skeletal Muscle Defects in Breast Cancer."}, {"pubmed": 38755258, "text": "Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis."}, {"pubmed": 38759471, "text": "Deep neural network for the prediction of KRAS, NRAS, and BRAF genotypes in left-sided colorectal cancer based on histopathologic images."}, {"pubmed": 38774924, "text": "KRAS depletion suppresses ferroptosis and affects Hippo pathway in cataract."}, {"pubmed": 38792177, "text": "Molecular Mechanism of Phosphorylation-Mediated Impacts on the Conformation Dynamics of GTP-Bound KRAS Probed by GaMD Trajectory-Based Deep Learning."}, {"pubmed": 38796063, "text": "Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells."}, {"pubmed": 38875469, "text": "KRAS, NRAS and BRAF Mutational Profile of Colorectal Cancer in a Series of Moroccan Patients."}, {"pubmed": 38896052, "text": "KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis."}, {"pubmed": 38926874, "text": "The correlation between KRAS and TP53 gene mutations and early growth of pulmonary nodules."}, {"pubmed": 39023583, "text": "KRAS and BRAF genetic alterations in lung cancer: A case - control study."}, {"pubmed": 39056802, "text": "KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways."}], "genomic_pos": {"chr": "12", "end": 25250936, "ensemblgene": "ENSG00000133703", "start": 25205246, "strand": -1}, "genomic_pos_hg19": {"chr": "12", "end": 25403870, "start": 25357723, "strand": -1}, "go": {"BP": [{"evidence": "TAS", "gocategory": "BP", "id": "GO:0000165", "qualifier": "involved_in", "term": "MAPK cascade"}, {"evidence": "IMP", "gocategory": "BP", "id": "GO:0001934", "pubmed": 22065586, "qualifier": "involved_in", "term": "positive regulation of protein phosphorylation"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0007265", "qualifier": "involved_in", "term": "Ras protein signal transduction"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0008542", "qualifier": "involved_in", "term": "visual learning"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0010467", "qualifier": "involved_in", "term": "gene expression"}, {"evidence": "IMP", "gocategory": "BP", "id": "GO:0010628", "pubmed": 22065586, "qualifier": "involved_in", "term": "positive regulation of gene expression"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0014009", "qualifier": "involved_in", "term": "glial cell proliferation"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0016601", "qualifier": "involved_in", "term": "Rac protein signal transduction"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0021897", "qualifier": "involved_in", "term": "forebrain astrocyte development"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0030036", "qualifier": "involved_in", "term": "actin cytoskeleton organization"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0030857", "qualifier": "involved_in", "term": "negative regulation of epithelial cell differentiation"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0032228", "qualifier": "involved_in", "term": "regulation of synaptic transmission, GABAergic"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0035022", "qualifier": "involved_in", "term": "positive regulation of Rac protein signal transduction"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0035914", "qualifier": "involved_in", "term": "skeletal muscle cell differentiation"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0043524", "qualifier": "involved_in", "term": "negative regulation of neuron apoptotic process"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0048169", "qualifier": "involved_in", "term": "regulation of long-term neuronal synaptic plasticity"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0048873", "qualifier": "involved_in", "term": "homeostasis of number of cells within a tissue"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0051146", "qualifier": "involved_in", "term": "striated muscle cell differentiation"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0051402", "qualifier": "involved_in", "term": "neuron apoptotic process"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0060252", "qualifier": "involved_in", "term": "positive regulation of glial cell proliferation"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0060441", "qualifier": "involved_in", "term": "epithelial tube branching involved in lung morphogenesis"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0060509", "qualifier": "involved_in", "term": "type I pneumocyte differentiation"}], "CC": [{"evidence": "TAS", "gocategory": "CC", "id": "GO:0000139", "qualifier": "located_in", "term": "Golgi membrane"}, {"evidence": "IDA", "gocategory": "CC", "id": "GO:0005737", "pubmed": 23698361, "qualifier": "located_in", "term": "cytoplasm"}, {"evidence": "TAS", "gocategory": "CC", "id": "GO:0005741", "qualifier": "located_in", "term": "mitochondrial outer membrane"}, {"evidence": "TAS", "gocategory": "CC", "id": "GO:0005789", "qualifier": "located_in", "term": "endoplasmic reticulum membrane"}, {"evidence": "TAS", "gocategory": "CC", "id": "GO:0005829", "qualifier": "located_in", "term": "cytosol"}, {"evidence": "IBA", "gocategory": "CC", "id": "GO:0005886", "qualifier": "is_active_in", "term": "plasma membrane"}, {"evidence": "TAS", "gocategory": "CC", "id": "GO:0005886", "qualifier": "located_in", "term": "plasma membrane"}, {"evidence": "HDA", "gocategory": "CC", "id": "GO:0005925", "pubmed": 21423176, "qualifier": "located_in", "term": "focal adhesion"}, {"evidence": "IDA", "gocategory": "CC", "id": "GO:0009898", "pubmed": 23698361, "qualifier": "located_in", "term": "cytoplasmic side of plasma membrane"}, {"evidence": "HDA", "gocategory": "CC", "id": "GO:0016020", "pubmed": 19946888, "qualifier": "located_in", "term": "membrane"}], "MF": [{"category": "MF", "evidence": "IBA", "id": "GO:0003924", "qualifier": "enables", "term": "GTPase activity"}, {"category": "MF", "evidence": "IMP", "id": "GO:0003924", "pubmed": 26037647, "qualifier": "enables", "term": "GTPase activity"}, {"category": "MF", "evidence": "TAS", "id": "GO:0003924", "qualifier": "enables", "term": "GTPase activity"}, {"category": "MF", "evidence": "IEA", "id": "GO:0003925", "qualifier": "enables", "term": "G protein activity"}, {"category": "MF", "evidence": "IPI", "id": "GO:0005515", "pubmed": [12732644, 24415755, 25416956, 25852190, 30194290, 31980649], "qualifier": "enables", "term": "protein binding"}, {"category": "MF", "evidence": "IBA", "id": "GO:0005525", "qualifier": "enables", "term": "GTP binding"}, {"category": "MF", "evidence": "IBA", "id": "GO:0019003", "qualifier": "enables", "term": "GDP binding"}, {"category": "MF", "evidence": "IEA", "id": "GO:0043495", "qualifier": "enables", "term": "protein-membrane adaptor activity"}, {"category": "MF", "evidence": "IDA", "id": "GO:0044877", "pubmed": 23209302, "qualifier": "enables", "term": "protein-containing complex binding"}]}, "homologene": {"genes": [[6239, 178104], [7165, 1269341], [7227, 41140], [7955, 445289], [8364, 100485959], [9031, 418207], [9598, 473387], [9606, 3845], [9615, 403871], [9913, 541140], [10090, 16653], [10116, 24525]], "id": 37990}, "interpro": [{"desc": "Small GTPase", "id": "IPR001806", "short_desc": "Small_GTPase"}, {"desc": "Small GTPase, Ras-type", "id": "IPR020849", "short_desc": "Small_GTPase_Ras-type"}, {"desc": "P-loop containing nucleoside triphosphate hydrolase", "id": "IPR027417", "short_desc": "P-loop_NTPase"}, {"desc": "Small GTP-binding protein domain", "id": "IPR005225", "short_desc": "Small_GTP-bd_dom"}], "ipi": ["IPI00423568", "IPI00423570"], "map_location": "12p12.1", "name": "KRAS proto-oncogene, GTPase", "other_names": ["GTPase KRas", "K-ras p21 protein", "KRAS-ENOPH fusion", "Kirsten rat sarcoma viral oncogene homolog", "Kirsten rat sarcoma viral proto-oncogene", "Kras-Enoph1 fusion protein", "PR310 c-K-ras oncogene", "c-Kirsten-ras protein", "cellular c-Ki-ras2 proto-oncogene", "cellular transforming proto-oncogene", "oncogene KRAS2", "proto-oncogene GTPase", "transforming protein p21", "v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog"], "pantherdb": {"HGNC": "6407", "_license": "http://pantherdb.org/tou.jsp", "ortholog": [{"MGI": "96680", "ortholog_type": "LDO", "panther_family": "PTHR24070", "taxid": 10090, "uniprot_kb": "P32883"}, {"RGD": "2981", "ortholog_type": "LDO", "panther_family": "PTHR24070", "taxid": 10116, "uniprot_kb": "P08644"}, {"Ensembl": "ENSGALG00000030943", "ortholog_type": "LDO", "panther_family": "PTHR24070", "taxid": 9031, "uniprot_kb": "A0A1D5PT95"}, {"ZFIN": "ZDB-GENE-040808-67", "ortholog_type": "LDO", "panther_family": "PTHR24070", "taxid": 7955, "uniprot_kb": "A0A2R8Q8S1"}, {"ZFIN": "ZDB-GENE-050417-95", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 7955, "uniprot_kb": "F1QNG4"}, {"WormBase": "WBGene00002335", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 6239, "uniprot_kb": "P22981"}, {"FlyBase": "FBgn0003205", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 7227, "uniprot_kb": "P08646"}, {"dictyBase": "DDB_G0292998", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "P32252"}, {"dictyBase": "DDB_G0280437", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q54VD5"}, {"dictyBase": "DDB_G0281385", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "P32253"}, {"dictyBase": "DDB_G0292996", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "P03967"}, {"dictyBase": "DDB_G0270736", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q55CB9"}, {"dictyBase": "DDB_G0270138", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q55CB0"}, {"dictyBase": "DDB_G0270126", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q55CB7"}, {"dictyBase": "DDB_G0270122", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q55CC0"}, {"dictyBase": "DDB_G0270140", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q55CA9"}, {"dictyBase": "DDB_G0270124", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q55CB8"}, {"dictyBase": "DDB_G0283537", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "P32254"}, {"dictyBase": "DDB_G0281253", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "Q54U62"}, {"dictyBase": "DDB_G0293434", "ortholog_type": "O", "panther_family": "PTHR24070", "taxid": 352472, "uniprot_kb": "P15064"}], "uniprot_kb": "P01116"}, "pathway": {"biocarta": {"id": "telpathway", "name": "telomeres telomerase cellular aging and immortality"}, "humancyc": {"id": "PWY66-14", "name": "MAP kinase cascade"}, "kegg": [{"id": "hsa04010", "name": "MAPK signaling pathway - Homo sapiens (human)"}, {"id": "hsa04012", "name": "ErbB signaling pathway - Homo sapiens (human)"}, {"id": "hsa04014", "name": "Ras signaling pathway - Homo sapiens (human)"}, {"id": "hsa04015", "name": "Rap1 signaling pathway - Homo sapiens (human)"}, {"id": "hsa04062", "name": "Chemokine signaling pathway - Homo sapiens (human)"}, {"id": "hsa04068", "name": "FoxO signaling pathway - Homo sapiens (human)"}, {"id": "hsa04071", "name": "Sphingolipid signaling pathway - Homo sapiens (human)"}, {"id": "hsa04072", "name": "Phospholipase D signaling pathway - Homo sapiens (human)"}, {"id": "hsa04137", "name": "Mitophagy - animal - Homo sapiens (human)"}, {"id": "hsa04140", "name": "Autophagy - animal - Homo sapiens (human)"}, {"id": "hsa04150", "name": "mTOR signaling pathway - Homo sapiens (human)"}, {"id": "hsa04151", "name": "PI3K-Akt signaling pathway - Homo sapiens (human)"}, {"id": "hsa04210", "name": "Apoptosis - Homo sapiens (human)"}, {"id": "hsa04211", "name": "Longevity regulating pathway - Homo sapiens (human)"}, {"id": "hsa04213", "name": "Longevity regulating pathway - multiple species - Homo sapiens (human)"}, {"id": "hsa04218", "name": "Cellular senescence - Homo sapiens (human)"}, {"id": "hsa04360", "name": "Axon guidance - Homo sapiens (human)"}, {"id": "hsa04370", "name": "VEGF signaling pathway - Homo sapiens (human)"}, {"id": "hsa04371", "name": "Apelin signaling pathway - Homo sapiens (human)"}, {"id": "hsa04540", "name": "Gap junction - Homo sapiens (human)"}, {"id": "hsa04550", "name": "Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)"}, {"id": "hsa04625", "name": "C-type lectin receptor signaling pathway - Homo sapiens (human)"}, {"id": "hsa04650", "name": "Natural killer cell mediated cytotoxicity - Homo sapiens (human)"}, {"id": "hsa04660", "name": "T cell receptor signaling pathway - Homo sapiens (human)"}, {"id": "hsa04662", "name": "B cell receptor signaling pathway - Homo sapiens (human)"}, {"id": "hsa04664", "name": "Fc epsilon RI signaling pathway - Homo sapiens (human)"}, {"id": "hsa04714", "name": "Thermogenesis - Homo sapiens (human)"}, {"id": "hsa04720", "name": "Long-term potentiation - Homo sapiens (human)"}, {"id": "hsa04722", "name": "Neurotrophin signaling pathway - Homo sapiens (human)"}, {"id": "hsa04725", "name": "Cholinergic synapse - Homo sapiens (human)"}, {"id": "hsa04726", "name": "Serotonergic synapse - Homo sapiens (human)"}, {"id": "hsa04730", "name": "Long-term depression - Homo sapiens (human)"}, {"id": "hsa04810", "name": "Regulation of actin cytoskeleton - Homo sapiens (human)"}, {"id": "hsa04910", "name": "Insulin signaling pathway - Homo sapiens (human)"}, {"id": "hsa04912", "name": "GnRH signaling pathway - Homo sapiens (human)"}, {"id": "hsa04914", "name": "Progesterone-mediated oocyte maturation - Homo sapiens (human)"}, {"id": "hsa04915", "name": "Estrogen signaling pathway - Homo sapiens (human)"}, {"id": "hsa04916", "name": "Melanogenesis - Homo sapiens (human)"}, {"id": "hsa04917", "name": "Prolactin signaling pathway - Homo sapiens (human)"}, {"id": "hsa04919", "name": "Thyroid hormone signaling pathway - Homo sapiens (human)"}, {"id": "hsa04921", "name": "Oxytocin signaling pathway - Homo sapiens (human)"}, {"id": "hsa04926", "name": "Relaxin signaling pathway - Homo sapiens (human)"}, {"id": "hsa04929", "name": "GnRH secretion - Homo sapiens (human)"}, {"id": "hsa04933", "name": "AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human)"}, {"id": "hsa04935", "name": "Growth hormone synthesis, secretion and action - Homo sapiens (human)"}, {"id": "hsa04960", "name": "Aldosterone-regulated sodium reabsorption - Homo sapiens (human)"}, {"id": "hsa05010", "name": "Alzheimer disease - Homo sapiens (human)"}, {"id": "hsa05022", "name": "Pathways of neurodegeneration - multiple diseases - Homo sapiens (human)"}, {"id": "hsa05034", "name": "Alcoholism - Homo sapiens (human)"}, {"id": "hsa05160", "name": "Hepatitis C - Homo sapiens (human)"}, {"id": "hsa05161", "name": "Hepatitis B - Homo sapiens (human)"}, {"id": "hsa05163", "name": "Human cytomegalovirus infection - Homo sapiens (human)"}, {"id": "hsa05165", "name": "Human papillomavirus infection - Homo sapiens (human)"}, {"id": "hsa05166", "name": "Human T-cell leukemia virus 1 infection - Homo sapiens (human)"}, {"id": "hsa05167", "name": "Kaposi sarcoma-associated herpesvirus infection - Homo sapiens (human)"}, {"id": "hsa05170", "name": "Human immunodeficiency virus 1 infection - Homo sapiens (human)"}, {"id": "hsa05200", "name": "Pathways in cancer - Homo sapiens (human)"}, {"id": "hsa05203", "name": "Viral carcinogenesis - Homo sapiens (human)"}, {"id": "hsa05205", "name": "Proteoglycans in cancer - Homo sapiens (human)"}, {"id": "hsa05206", "name": "MicroRNAs in cancer - Homo sapiens (human)"}, {"id": "hsa05210", "name": "Colorectal cancer - Homo sapiens (human)"}, {"id": "hsa05211", "name": "Renal cell carcinoma - Homo sapiens (human)"}, {"id": "hsa05212", "name": "Pancreatic cancer - Homo sapiens (human)"}, {"id": "hsa05213", "name": "Endometrial cancer - Homo sapiens (human)"}, {"id": "hsa05214", "name": "Glioma - Homo sapiens (human)"}, {"id": "hsa05215", "name": "Prostate cancer - Homo sapiens (human)"}, {"id": "hsa05216", "name": "Thyroid cancer - Homo sapiens (human)"}, {"id": "hsa05218", "name": "Melanoma - Homo sapiens (human)"}, {"id": "hsa05219", "name": "Bladder cancer - Homo sapiens (human)"}, {"id": "hsa05220", "name": "Chronic myeloid leukemia - Homo sapiens (human)"}, {"id": "hsa05221", "name": "Acute myeloid leukemia - Homo sapiens (human)"}, {"id": "hsa05223", "name": "Non-small cell lung cancer - Homo sapiens (human)"}, {"id": "hsa05224", "name": "Breast cancer - Homo sapiens (human)"}, {"id": "hsa05225", "name": "Hepatocellular carcinoma - Homo sapiens (human)"}, {"id": "hsa05226", "name": "Gastric cancer - Homo sapiens (human)"}, {"id": "hsa05230", "name": "Central carbon metabolism in cancer - Homo sapiens (human)"}, {"id": "hsa05231", "name": "Choline metabolism in cancer - Homo sapiens (human)"}, {"id": "hsa05235", "name": "PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)"}, {"id": "hsa05417", "name": "Lipid and atherosclerosis - Homo sapiens (human)"}], "netpath": {"id": "Pathway_EGFR1", "name": "EGFR1"}, "pid": [{"id": "cd8tcrdownstreampathway", "name": "Downstream signaling in na&#xef;ve CD8+ T cells"}, {"id": "cd8tcrpathway", "name": "TCR signaling in na&#xef;ve CD8+ T cells"}, {"id": "cmyb_pathway", "name": "C-MYB transcription factor network"}, {"id": "cxcr3pathway", "name": "CXCR3-mediated signaling events"}, {"id": "ephbfwdpathway", "name": "EPHB forward signaling"}, {"id": "er_nongenomic_pathway", "name": "Plasma membrane estrogen receptor signaling"}, {"id": "erbb1_downstream_pathway", "name": "ErbB1 downstream signaling"}, {"id": "erbb1_internalization_pathway", "name": "Internalization of ErbB1"}, {"id": "erbb2erbb3pathway", "name": "ErbB2/ErbB3 signaling events"}, {"id": "gmcsf_pathway", "name": "GMCSF-mediated signaling events"}, {"id": "il2_1pathway", "name": "IL2-mediated signaling events"}, {"id": "mapktrkpathway", "name": "Trk receptor signaling mediated by the MAPK pathway"}, {"id": "mtor_4pathway", "name": "mTOR signaling pathway"}, {"id": "pdgfrbpathway", "name": "PDGFR-beta signaling pathway"}, {"id": "pi3kcipathway", "name": "Class I PI3K signaling events"}, {"id": "pi3kplctrkpathway", "name": "Trk receptor signaling mediated by PI3K and PLC-gamma"}, {"id": "ras_pathway", "name": "Regulation of Ras family activation"}, {"id": "shp2_pathway", "name": "SHP2 signaling"}, {"id": "tcr_pathway", "name": "TCR signaling in na&#xef;ve CD4+ T cells"}, {"id": "tcrraspathway", "name": "Ras signaling in the CD4+ TCR pathway"}, {"id": "trkrpathway", "name": "Neurotrophic factor-mediated Trk receptor signaling"}], "reactome": [{"id": "R-HSA-109582", "name": "Hemostasis"}, {"id": "R-HSA-112314", "name": "Neurotransmitter receptors and postsynaptic signal transmission"}, {"id": "R-HSA-112315", "name": "Transmission across Chemical Synapses"}, {"id": "R-HSA-112316", "name": "Neuronal System"}, {"id": "R-HSA-112399", "name": "IRS-mediated signalling"}, {"id": "R-HSA-112412", "name": "SOS-mediated signalling"}, {"id": "R-HSA-1168372", "name": "Downstream signaling events of B Cell Receptor (BCR)"}, {"id": "R-HSA-1169092", "name": "Activation of RAS in B cells"}, {"id": "R-HSA-1226099", "name": "Signaling by FGFR in disease"}, {"id": "R-HSA-1227986", "name": "Signaling by ERBB2"}, {"id": "R-HSA-1227986", "name": "Signaling by ERBB2"}, {"id": "R-HSA-1227990", "name": "Signaling by ERBB2 in Cancer"}, {"id": "R-HSA-1236382", "name": "Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants"}, {"id": "R-HSA-1236394", "name": "Signaling by ERBB4"}, {"id": "R-HSA-1250196", "name": "SHC1 events in ERBB2 signaling"}, {"id": "R-HSA-1250347", "name": "SHC1 events in ERBB4 signaling"}, {"id": "R-HSA-1266738", "name": "Developmental Biology"}, {"id": "R-HSA-1280215", "name": "Cytokine Signaling in Immune system"}, {"id": "R-HSA-1280215", "name": "Cytokine Signaling in Immune system"}, {"id": "R-HSA-1280218", "name": "Adaptive Immune System"}, {"id": "R-HSA-1433557", "name": "Signaling by SCF-KIT"}, {"id": "R-HSA-162582", "name": "Signal Transduction"}, {"id": "R-HSA-162582", "name": "Signal Transduction"}, {"id": "R-HSA-1643685", "name": "Disease"}, {"id": "R-HSA-1643713", "name": "Signaling by EGFR in Cancer"}, {"id": "R-HSA-166520", "name": "Signaling by NTRKs"}, {"id": "R-HSA-166520", "name": "Signaling by NTRKs"}, {"id": "R-HSA-167044", "name": "Signalling to RAS"}, {"id": "R-HSA-167044", "name": "Signalling to RAS"}, {"id": "R-HSA-168249", "name": "Innate Immune System"}, {"id": "R-HSA-168256", "name": "Immune System"}, {"id": "R-HSA-168256", "name": "Immune System"}, {"id": "R-HSA-171007", "name": "p38MAPK events"}, {"id": "R-HSA-171007", "name": "p38MAPK events"}, {"id": "R-HSA-177929", "name": "Signaling by EGFR"}, {"id": "R-HSA-179812", "name": "GRB2 events in EGFR signaling"}, {"id": "R-HSA-180336", "name": "SHC1 events in EGFR signaling"}, {"id": "R-HSA-186763", "name": "Downstream signal transduction"}, {"id": "R-HSA-186797", "name": "Signaling by PDGF"}, {"id": "R-HSA-187037", "name": "Signaling by NTRK1 (TRKA)"}, {"id": "R-HSA-187037", "name": "Signaling by NTRK1 (TRKA)"}, {"id": "R-HSA-187687", "name": "Signalling to ERKs"}, {"id": "R-HSA-187687", "name": "Signalling to ERKs"}, {"id": "R-HSA-190236", "name": "Signaling by FGFR"}, {"id": "R-HSA-194138", "name": "Signaling by VEGF"}, {"id": "R-HSA-195721", "name": "Signaling by WNT"}, {"id": "R-HSA-1963640", "name": "GRB2 events in ERBB2 signaling"}, {"id": "R-HSA-1963640", "name": "GRB2 events in ERBB2 signaling"}, {"id": "R-HSA-202733", "name": "Cell surface interactions at the vascular wall"}, {"id": "R-HSA-210993", "name": "Tie2 Signaling"}, {"id": "R-HSA-212436", "name": "Generic Transcription Pathway"}, {"id": "R-HSA-2172127", "name": "DAP12 interactions"}, {"id": "R-HSA-2179392", "name": "EGFR Transactivation by Gastrin"}, {"id": "R-HSA-2404192", "name": "Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"}, {"id": "R-HSA-2424491", "name": "DAP12 signaling"}, {"id": "R-HSA-2428924", "name": "IGF1R signaling cascade"}, {"id": "R-HSA-2428928", "name": "IRS-related events triggered by IGF1R"}, {"id": "R-HSA-2428933", "name": "SHC-related events triggered by IGF1R"}, {"id": "R-HSA-2454202", "name": "Fc epsilon receptor (FCERI) signaling"}, {"id": "R-HSA-2871796", "name": "FCERI mediated MAPK activation"}, {"id": "R-HSA-372790", "name": "Signaling by GPCR"}, {"id": "R-HSA-375165", "name": "NCAM signaling for neurite out-growth"}, {"id": "R-HSA-3858494", "name": "Beta-catenin independent WNT signaling"}, {"id": "R-HSA-388396", "name": "GPCR downstream signalling"}, {"id": "R-HSA-4086398", "name": "Ca2+ pathway"}, {"id": "R-HSA-416476", "name": "G alpha (q) signalling events"}, {"id": "R-HSA-422475", "name": "Axon guidance"}, {"id": "R-HSA-438064", "name": "Post NMDA receptor activation events"}, {"id": "R-HSA-4420097", "name": "VEGFA-VEGFR2 Pathway"}, {"id": "R-HSA-442742", "name": "CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling"}, {"id": "R-HSA-442755", "name": "Activation of NMDA receptors and postsynaptic events"}, {"id": "R-HSA-442982", "name": "Ras activation upon Ca2+ influx through NMDA receptor"}, {"id": "R-HSA-5218921", "name": "VEGFR2 mediated cell proliferation"}, {"id": "R-HSA-5621481", "name": "C-type lectin receptors (CLRs)"}, {"id": "R-HSA-5621575", "name": "CD209 (DC-SIGN) signaling"}, {"id": "R-HSA-5637810", "name": "Constitutive Signaling by EGFRvIII"}, {"id": "R-HSA-5637812", "name": "Signaling by EGFRvIII in Cancer"}, {"id": "R-HSA-5637815", "name": "Signaling by Ligand-Responsive EGFR Variants in Cancer"}, {"id": "R-HSA-5654687", "name": "Downstream signaling of activated FGFR1"}, {"id": "R-HSA-5654688", "name": "SHC-mediated cascade:FGFR1"}, {"id": "R-HSA-5654693", "name": "FRS-mediated FGFR1 signaling"}, {"id": "R-HSA-5654696", "name": "Downstream signaling of activated FGFR2"}, {"id": "R-HSA-5654699", "name": "SHC-mediated cascade:FGFR2"}, {"id": "R-HSA-5654700", "name": "FRS-mediated FGFR2 signaling"}, {"id": "R-HSA-5654704", "name": "SHC-mediated cascade:FGFR3"}, {"id": "R-HSA-5654706", "name": "FRS-mediated FGFR3 signaling"}, {"id": "R-HSA-5654708", "name": "Downstream signaling of activated FGFR3"}, {"id": "R-HSA-5654712", "name": "FRS-mediated FGFR4 signaling"}, {"id": "R-HSA-5654716", "name": "Downstream signaling of activated FGFR4"}, {"id": "R-HSA-5654719", "name": "SHC-mediated cascade:FGFR4"}, {"id": "R-HSA-5654736", "name": "Signaling by FGFR1"}, {"id": "R-HSA-5654738", "name": "Signaling by FGFR2"}, {"id": "R-HSA-5654741", "name": "Signaling by FGFR3"}, {"id": "R-HSA-5654743", "name": "Signaling by FGFR4"}, {"id": "R-HSA-5655253", "name": "Signaling by FGFR2 in disease"}, {"id": "R-HSA-5655291", "name": "Signaling by FGFR4 in disease"}, {"id": "R-HSA-5655302", "name": "Signaling by FGFR1 in disease"}, {"id": "R-HSA-5655332", "name": "Signaling by FGFR3 in disease"}, {"id": "R-HSA-5658442", "name": "Regulation of RAS by GAPs"}, {"id": "R-HSA-5663202", "name": "Diseases of signal transduction by growth factor receptors and second messengers"}, {"id": "R-HSA-5673000", "name": "RAF activation"}, {"id": "R-HSA-5673001", "name": "RAF/MAP kinase cascade"}, {"id": "R-HSA-5674135", "name": "MAP2K and MAPK activation"}, {"id": "R-HSA-5675221", "name": "Negative regulation of MAPK pathway"}, {"id": "R-HSA-5683057", "name": "MAPK family signaling cascades"}, {"id": "R-HSA-5684996", "name": "MAPK1/MAPK3 signaling"}, {"id": "R-HSA-6802946", "name": "Signaling by moderate kinase activity BRAF mutants"}, {"id": "R-HSA-6802948", "name": "Signaling by high-kinase activity BRAF mutants"}, {"id": "R-HSA-6802949", "name": "Signaling by RAS mutants"}, {"id": "R-HSA-6802952", "name": "Signaling by BRAF and RAF1 fusions"}, {"id": "R-HSA-6802953", "name": "RAS signaling downstream of NF1 loss-of-function variants"}, {"id": "R-HSA-6802955", "name": "Paradoxical activation of RAF signaling by kinase inactive BRAF"}, {"id": "R-HSA-6802957", "name": "Oncogenic MAPK signaling"}, {"id": "R-HSA-6806834", "name": "Signaling by MET"}, {"id": "R-HSA-73857", "name": "RNA Polymerase II Transcription"}, {"id": "R-HSA-74160", "name": "Gene expression (Transcription)"}, {"id": "R-HSA-74751", "name": "Insulin receptor signalling cascade"}, {"id": "R-HSA-74752", "name": "Signaling by Insulin receptor"}, {"id": "R-HSA-881907", "name": "Gastrin-CREB signalling pathway via PKC and MAPK"}, {"id": "R-HSA-8848021", "name": "Signaling by PTK6"}, {"id": "R-HSA-8849471", "name": "PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases"}, {"id": "R-HSA-8851805", "name": "MET activates RAS signaling"}, {"id": "R-HSA-8878159", "name": "Transcriptional regulation by RUNX3"}, {"id": "R-HSA-8939211", "name": "ESR-mediated signaling"}, {"id": "R-HSA-8951936", "name": "RUNX3 regulates p14-ARF"}, {"id": "R-HSA-9006115", "name": "Signaling by NTRK2 (TRKB)"}, {"id": "R-HSA-9006335", "name": "Signaling by Erythropoietin"}, {"id": "R-HSA-9006927", "name": "Signaling by Non-Receptor Tyrosine Kinases"}, {"id": "R-HSA-9006931", "name": "Signaling by Nuclear Receptors"}, {"id": "R-HSA-9006934", "name": "Signaling by Receptor Tyrosine Kinases"}, {"id": "R-HSA-9006934", "name": "Signaling by Receptor Tyrosine Kinases"}, {"id": "R-HSA-9009391", "name": "Extra-nuclear estrogen signaling"}, {"id": "R-HSA-9026519", "name": "Activated NTRK2 signals through RAS"}, {"id": "R-HSA-9027284", "name": "Erythropoietin activates RAS"}, {"id": "R-HSA-9028731", "name": "Activated NTRK2 signals through FRS2 and FRS3"}, {"id": "R-HSA-9034015", "name": "Signaling by NTRK3 (TRKC)"}, {"id": "R-HSA-9034864", "name": "Activated NTRK3 signals through RAS"}, {"id": "R-HSA-9607240", "name": "FLT3 Signaling"}, {"id": "R-HSA-9634285", "name": "Constitutive Signaling by Overexpressed ERBB2"}, {"id": "R-HSA-9634635", "name": "Estrogen-stimulated signaling through PRKCZ"}, {"id": "R-HSA-9648002", "name": "RAS processing"}, {"id": "R-HSA-9649913", "name": "RAS GTPase cycle mutants"}, {"id": "R-HSA-9649948", "name": "Signaling downstream of RAS mutants"}, {"id": "R-HSA-9656223", "name": "Signaling by RAF1 mutants"}, {"id": "R-HSA-9664565", "name": "Signaling by ERBB2 KD Mutants"}, {"id": "R-HSA-9665348", "name": "Signaling by ERBB2 ECD mutants"}, {"id": "R-HSA-9665686", "name": "Signaling by ERBB2 TMD/JMD mutants"}, {"id": "R-HSA-9669938", "name": "Signaling by KIT in disease"}, {"id": "R-HSA-9670439", "name": "Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants"}, {"id": "R-HSA-9671555", "name": "Signaling by PDGFR in disease"}, {"id": "R-HSA-9673767", "name": "Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants"}, {"id": "R-HSA-9673770", "name": "Signaling by PDGFRA extracellular domain mutants"}, {"id": "R-HSA-9674555", "name": "Signaling by CSF3 (G-CSF)"}, {"id": "R-HSA-9675108", "name": "Nervous system development"}, {"id": "R-HSA-9680350", "name": "Signaling by CSF1 (M-CSF) in myeloid cells"}, {"id": "R-HSA-9682385", "name": "FLT3 signaling in disease"}, {"id": "R-HSA-9703465", "name": "Signaling by FLT3 fusion proteins"}, {"id": "R-HSA-9703648", "name": "Signaling by FLT3 ITD and TKD mutants"}, {"id": "R-HSA-9753510", "name": "Signaling by RAS GAP mutants"}, {"id": "R-HSA-9753512", "name": "Signaling by RAS GTPase mutants"}, {"id": "R-HSA-983705", "name": "Signaling by the B Cell Receptor (BCR)"}], "smpdb": {"id": "SMP00358", "name": "Fc Epsilon Receptor I Signaling in Mast Cells"}, "wikipathways": [{"id": "WP127", "name": "IL-5 signaling pathway"}, {"id": "WP1984", "name": "Integrated breast cancer pathway"}, {"id": "WP2261", "name": "Glioblastoma signaling pathways"}, {"id": "WP2290", "name": "RalA downstream regulated genes"}, {"id": "WP231", "name": "TNF-alpha signaling pathway"}, {"id": "WP2374", "name": "Oncostatin M Signaling Pathway"}, {"id": "WP2586", "name": "Aryl Hydrocarbon Receptor Netpath"}, {"id": "WP2828", "name": "Bladder cancer"}, {"id": "WP2870", "name": "Extracellular vesicle-mediated signaling in recipient cells"}, {"id": "WP3303", "name": "RAC1-PAK1-p38-MMP2 Pathway"}, {"id": "WP35", "name": "G Protein Signaling Pathways"}, {"id": "WP3676", "name": "BDNF-TrkB Signaling"}, {"id": "WP382", "name": "MAPK Signaling Pathway"}, {"id": "WP3844", "name": "PI3K-AKT-mTOR signaling pathway and therapeutic opportunities"}, {"id": "WP3929", "name": "Chemokine signaling pathway"}, {"id": "WP3932", "name": "Focal Adhesion-PI3K-Akt-mTOR-signaling pathway"}, {"id": "WP4155", "name": "Endometrial cancer"}, {"id": "WP4172", "name": "PI3K-Akt signaling pathway"}, {"id": "WP4216", "name": "Chromosomal and microsatellite instability in colorectal cancer"}, {"id": "WP422", "name": "MAPK Cascade"}, {"id": "WP4223", "name": "Ras signaling"}, {"id": "WP4239", "name": "Epithelial to mesenchymal transition in colorectal cancer"}, {"id": "WP4255", "name": "Non-small cell lung cancer"}, {"id": "WP4262", "name": "Breast cancer pathway"}, {"id": "WP4263", "name": "Pancreatic adenocarcinoma pathway"}, {"id": "WP4301", "name": "Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells"}, {"id": "WP4321", "name": "Thermogenesis"}, {"id": "WP4341", "name": "Non-genomic actions of 1,25 dihydroxyvitamin D3"}, {"id": "WP437", "name": "EGF-EGFR signaling pathway"}, {"id": "WP4483", "name": "Relationship between inflammation, COX-2 and EGFR"}, {"id": "WP4535", "name": "Envelope proteins and their potential roles in EDMD physiopathology"}, {"id": "WP4539", "name": "Synaptic signaling pathways associated with autism spectrum disorder"}, {"id": "WP4541", "name": "Hippo-Merlin Signaling Dysregulation"}, {"id": "WP4549", "name": "Fragile X Syndrome"}, {"id": "WP4659", "name": "Gastrin signaling pathway"}, {"id": "WP4666", "name": "Hepatitis B infection"}, {"id": "WP4674", "name": "Head and Neck Squamous Cell Carcinoma"}, {"id": "WP4685", "name": "Melanoma"}, {"id": "WP4806", "name": "EGFR Tyrosine Kinase Inhibitor Resistance"}, {"id": "WP4871", "name": "Kisspeptin-kisspeptin receptor system in the ovary"}, {"id": "WP4928", "name": "MAPK pathway in congenital thyroid cancer"}, {"id": "WP51", "name": "Regulation of Actin Cytoskeleton"}, {"id": "WP673", "name": "ErbB signaling pathway"}, {"id": "WP710", "name": "DNA damage response (only ATM dependent)"}, {"id": "WP732", "name": "Serotonin Receptor 2 and ELK-SRF-GATA4 signaling"}]}, "pdb": ["1D8D", "1D8E", "1KZO", "1KZP", "1N4P", "1N4Q", "1N4R", "1N4S", "2MSC", "2MSD", "2MSE", "3GFT", "4DSN", "4DSO", "4EPR", "4EPT", "4EPV", "4EPW", "4EPX", "4EPY", "4L8G", "4LDJ", "4LPK", "4LRW", "4LUC", "4LV6", "4LYF", "4LYH", "4LYJ", "4M1O", "4M1S", "4M1T", "4M1W", "4M1Y", "4M21", "4M22", "4NMM", "4OBE", "4PZY", "4PZZ", "4Q01", "4Q02", "4Q03", "4QL3", "4TQ9", "4TQA", "4WA7", "5F2E", "5KYK", "5MLA", "5MLB", "5O2S", "5O2T", "5OCG", "5OCO", "5OCT", "5TAR", "5TB5", "5UFE", "5UFQ", "5UK9", "5UQW", "5US4", "5USJ", "5V6S", "5V6V", "5V71", "5V9L", "5V9O", "5V9U", "5VBM", "5VP7", "5VPI", "5VPY", "5VPZ", "5VQ0", "5VQ1", "5VQ2", "5VQ6", "5VQ8", "5W22", "5WHA", "5WHB", "5WHD", "5WHE", "5WLB", "5WPM", "5XCO", "5YXZ", "5YY1", "6ARK", "6ASA", "6ASE", "6B0V", "6B0Y", "6BOF", "6BP1", "6CC9", "6CCH", "6CCX", "6CU6", "6E6F", "6E6G", "6EPL", "6EPM", "6EPN", "6EPO", "6EPP", "6F76", "6FA1", "6FA2", "6FA3", "6FA4", "6GJ5", "6GJ6", "6GJ7", "6GJ8", "6GOD", "6GOE", "6GOF", "6GOG", "6GOM", "6GQT", "6GQW", "6GQX", "6GQY", "6H46", "6H47", "6JTN", "6JTO", "6JTP", "6M9W", "6MBQ", "6MBT", "6MBU", "6MNX", "6MQG", "6MQN", "6MS9", "6MTA", "6N2J", "6N2K", "6O36", "6O46", "6O4Y", "6O4Z", "6O51", "6O53", "6OB2", "6OB3", "6OIM", "6P0Z", "6P8W", "6P8X", "6P8Y", "6P8Z", "6PGO", "6PGP", "6PQ3", "6PTS", "6PTW", "6QUU", "6QUV", "6QUW", "6QUX", "6T5B", "6T5U", "6T5V", "6TAM", "6TAN", "6USX", "6USZ", "6UT0", "6V5L", "6V65", "6V6F", "6VC8", "6VJJ", "6W4E", "6W4F", "6WGN", "6WS2", "6WS4", "6XGU", "6XGV", "6XHA", "6XHB", "6YR8", "6YXW", "6ZL5", "6ZLI", "7A1W", "7A1X", "7A1Y", "7A47", "7ACA", "7ACF", "7ACH", "7ACQ", "7C40", "7C41", "7EW9", "7EWA", "7EWB", "7EYX", "7F0W", "7KFZ", "7KMR", "7KYZ", "7LC1", "7LC2", "7LGI", "7LZ5", "7MDP", "7MQU", "7NY8", "7O70", "7OK3", "7OK4", "7OO7", "7Q9U", "7R0M", "7R0N", "7R0Q", "7ROV", "7RP2", "7RP3", "7RP4", "7RPZ", "7RSC", "7RSE", "7RT1", "7RT2", "7RT3", "7RT4", "7RT5", "7SCW", "7SCX", "7STF", "7T1F", "7T47", "7TLE", "7TLG", "7TLK", "7U8H", "7VVB", "7W5R", "7YCC", "7YCE", "7YUZ", "7YV1", "8AFB", "8AFC", "8AFD", "8AQ5", "8AQ7", "8AZR", "8AZV", "8AZX", "8AZY", "8AZZ", "8B00", "8B69", "8B6I", "8B78", "8CX5", "8DGS", "8DGT", "8DNI", "8DNJ", "8DNK", "8DVG", "8EBZ", "8ECR", "8EDY", "8EER", "8EIE", "8EPW", "8EZG", "8F0M", "8FMI", "8FMJ", "8FMK", "8G42", "8G47", "8G4F", "8G4H", "8G9P", "8G9Q", "8I5C", "8I5D", "8I5E", "8JGD", "8JHL", "8JJS", "8ONV", "8QU8", "8QUG", "8QVU", "8QW6", "8QW7", "8STM", "8STN", "8T4V", "8T71", "8T72", "8T73", "8T74", "8T75", "8TBF", "8TBH", "8TBJ", "8TBK", "8TBL", "8TBM", "8TBN", "8TXE", "8TXG", "8TXH", "8UN3", "8UN4", "8UN5", "8X6R", "9AX6"], "pfam": "PF00071", "pharmgkb": "PA30196", "pharos": {"target_id": 4341, "tdl": "Tclin"}, "pir": ["A93311", "B93311"], "prosite": ["PS51419", "PS51420", "PS51421"], "reagent": {"GNF_Qia_hs-genome_v1_siRNA": [{"id": "GNF221062", "relationship": "is"}, {"id": "GNF252043", "relationship": "is"}, {"id": "GNF252044", "relationship": "is"}, {"id": "GNF252045", "relationship": "is"}, {"id": "GNF252046", "relationship": "is"}], "GNF_hs-ORFeome1_1_reads": [{"id": "GNF160817", "relationship": "is"}, {"id": "GNF164276", "relationship": "similar to"}], "GNF_hs-Origene": {"id": "GNF046113", "relationship": "is"}, "GNF_hs-druggable_lenti-shRNA": [{"id": "GNF092293", "relationship": "is"}, {"id": "GNF092294", "relationship": "is"}], "GNF_hs-druggable_plasmid-shRNA": [{"id": "GNF051083", "relationship": "is"}, {"id": "GNF055850", "relationship": "is"}, {"id": "GNF060540", "relationship": "is"}], "GNF_hs-druggable_siRNA": [{"id": "GNF071041", "relationship": "is"}, {"id": "GNF071042", "relationship": "is"}], "GNF_mm+hs-MGC": [{"id": "GNF007821", "relationship": "is"}, {"id": "GNF030226", "relationship": "is"}], "GNF_mm+hs_RetroCDNA": [{"id": "GNF233931", "relationship": "is"}, {"id": "GNF234951", "relationship": "is"}], "NOVART_hs-genome_siRNA": [{"id": "GNF102762", "relationship": "is"}, {"id": "GNF142416", "relationship": "is"}, {"id": "GNF156313", "relationship": "is"}]}, "refseq": {"genomic": ["NC_000012.12", "NC_060936.1", "NG_007524.2"], "protein": ["NP_001356715.1", "NP_001356716.1", "NP_004976.2", "NP_203524.1", "XP_047284782.1", "XP_054227990.1"], "rna": ["NM_001369786.1", "NM_001369787.1", "NM_004985.5", "NM_033360.4", "XM_047428826.1", "XM_054372015.1"], "translation": [{"protein": "NP_004976.2", "rna": "NM_004985.5"}, {"protein": "NP_001356715.1", "rna": "NM_001369786.1"}, {"protein": "XP_054227990.1", "rna": "XM_054372015.1"}, {"protein": "XP_047284782.1", "rna": "XM_047428826.1"}, {"protein": "NP_203524.1", "rna": "NM_033360.4"}, {"protein": "NP_001356716.1", "rna": "NM_001369787.1"}]}, "reporter": {"HG-U133_Plus_2": ["1559203_s_at", "1559204_x_at", "204009_s_at", "204010_s_at", "214352_s_at"], "HG-U95Av2": ["1940_at", "32159_at"], "HTA-2_0": "TC12001314.hg.1", "HuEx-1_0": "3447863", "HuGene-1_1": "7961865", "HuGene-2_1": "16762399"}, "summary": "This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008].", "symbol": "KRAS", "taxid": 9606, "type_of_gene": "protein-coding", "umls": {"cui": "C1537502"}, "unigene": "Hs.505033", "uniprot": {"Swiss-Prot": "P01116", "TrEMBL": ["L7RSL8", "I1SRC5", "G3V4K2", "A0A8I5KR86", "A0A8I5KQU3", "G3V5T7", "A0A8I5KYH6", "A0A8I5KQ21", "A0A8I5KUB5", "A0A8I5KXN3"]}, "wikipedia": {"url_stub": "KRAS"}}